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Abstract 
Highly active antiretroviral therapy (HAART) improves morbidity and mortality in HIV-1-infected 
patients yet reversal of immune dysfunction remains incomplete. The study objective was to 
determine the impact of immunomodulatory agents on T-cell function and phenotype in treated, 
chronic HIV-1 infection. Recombinant human growth hormone (rhGH) was administered daily to 
patients at a pharmacological dose for 12 weeks. Proliferative CD4 and IFN-γ-producing CD8 HIV-
1-specific T-cell responses were induced, however these responses declined with less frequent 
dosing. In a further study, patients that received a lower, physiological dose of rhGH for 40 weeks 
demonstrated increased IFN-γ ELISpot responses to pools of both MHC Class I and MHC Class II 
restricted HIV-1 Gag peptides at week 40. T-cell phenotypes showed a trend toward a reduction in 
the expression of activation markers. A randomised, open-label, phase I clinical trial investigated 
the effects of therapeutic immunisation, interleukin (IL)-2, granulocyte macrophage colony 
stimulating factor (GM-CSF) and rhGH in HIV-1
+
 subjects on HAART. Immunisation plus IL-2, 
GM-CSF and rhGH administration resulted in increased IFN-γ, IL-2 and perforin production in 
response to peptide pools of Gag, elevated CD4 T-cell counts and improved CD4/CD8 T-cell ratios 
at week 48. Subjects that received cytokine and hormone therapy (with or without immunisation) 
showed reduced immune activation and senescence, and for all patients, exhaustion markers were 
downregulated by week 48. Distinct Gag- and Nef- specific responses were not found to correlate 
with particular immunophenotypes. Further analysis of T-cell phenotypes from healthy controls 
showed immune defects to persist in HIV-1 infection despite HAART, and notwithstanding that, 
duration of HAART positively correlated with CD4 T-cell count. Together, the data presented here 
demonstrate the beneficial effects of immunotherapy in treated chronic HIV-1 infection and 
illustrate the potential to reverse T-cell dysfunction, furthermore highlighting the necessity for the 
induction and maintenance of HIV-1-specific immune responses. 
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Chapter 1 Introduction 
1.1 T cells 
1.1.1 Early T-cell development 
T-cell-mediated immunity is an essential component of the immune response directed against 
viruses and other intracellular pathogens. T lymphocytes develop from haematopoietic progenitor 
cells, which migrate from the bone marrow to the thymus, where they differentiate into fully 
functional, self-tolerant T cells before moving to the periphery [Blom & Spits, 2006; Ciofani & 
Zuniga-Pflucker, 2007], as shown in Figure 1.1 and Figure 1.2. 
 
Figure 1.1 Schematic representation of T-cell development. 
Originating from a common lymphoid progenitor in the bone marrow, T cells migrate as immature precursors into the 
thymus via the blood stream. The thymocytes then undergo a series of maturation steps and changes in cell surface 
receptors take place. These include the CD3 signalling complex (not shown), CD4 and CD8 co-receptors and 
rearrangement of TCR genes. During maturation, thymocytes undergo positive selection (for their TCR’s compatibility 
with self-MHC molecules) and negative selection against TCRs reactive to autoantigenic peptides; during this stage 
more than 98% die by apoptosis (†). The majority of peripheral blood T cells in humans are αβ T cells and a small 
group of peripheral T cells are γδ T cells. The expression of CD4 or CD8 is lost on the αβ T cells that survive thymic 
selection, the level of the TCR increases and these cells leave the thymus and go to make up the peripheral T-cell 
repertoire. Taken from Skapenko et al., 2005 [Skapenko et al., 2005]. 
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The thymus generates two lineages of T cells, αβ and γδ, characterised by the expression of distinct 
αβ– or γδ– T-cell receptor (TCR) complexes [Ciofani & Zuniga-Pflucker, 2007]. Early T-cell 
precursors are termed double negative (DN) as they do not express the co-receptors CD4 or CD8, 
nor do they express the CD3/TCR complex [Sebzda et al., 1999; Abbey & O’Neill, 2008] and it is 
at this stage that commitment to the αβ or γδ T-cell lineage occurs [Petrie et al., 1992; Ciofani et al., 
2006]. The DN thymocytes give rise to a CD4
+
CD8
+
 double positive population from which mature 
CD4
+
CD8
-
 or CD4
-
CD8
+
 single positive (SP) cells differentiate [Ciofani & Zuniga-Pflucker, 2007; 
D’Acquisto & Crompton, 2011]. In mice, cell surface expression of CD25 and CD44 can be used to 
subdivide the immature, TCR-lacking, and DN population [Zuniga-Pflucker & Lenardo, 1996; 
D’Acquisto & Crompton, 2011]. CD44+CD25- (DN1) cells differentiate into CD44+CD25+ (DN2) 
cells and then CD44
-
CD25
+ 
and this population gives rise to CD44
-
CD25
-
 (DN4). The DN4 subset 
proliferates rapidly to generate the DP population and this is typically via an immature intermediate 
single positive (ISP) CD8 cell, as detailed in Figure 1.2 [D’Acquisto & Crompton, 2011]. Mouse 
models have provided invaluable evidence about the pathways and phenotypes involved in thymic 
development, but it is important to consider that differences exist between humans and mice, in 
terms of the ontogeny and expression of markers on the cell surface during various transitional 
phases of development, as well as differences with regard to thymic involution [Spits, 2002]. 
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Figure 1.2 Schematic representation of T-cell development in the thymus: stages of DN thymocyte differentiation. 
From the bone marrow, progenitor (PG) cells move to the thymus where they follow a natural killer cell (NK) or T-cell 
lineage. If they follow the latter, progressive differentiation occurs from double negative (DN) to double positive (DP) 
and finally to single positive CD4 or CD8 thymocytes. The expression of CD44 and CD25 distinguishes the immature 
DN thymocytes into DN1 to DN4 stages. At the DN2 / DN3 stage, the γδ lineage diverges from the αβ lineage. The 
immature CD8 single positive (ISP) is an intermediate through which progression from the DP to SP stage can occur. 
Adapted from D’Acquisto & Crompton, 2011 [D’Acquisto & Crompton, 2011]. 
 
A diverse repertoire of αβ TCR is generated in the thymus as T cells undergo rearrangement of the 
TCR α and β gene segments [Sebzda et al., 1999; Abbey & O’Neill, 2008]. The expression of the 
CD4 and CD8 co-receptors on the DP cells arise from signalling through the pre-TCR and these are 
found in the thymic cortex [Aspinall, 2006]. During the DP stage, rearrangement of the TCR α 
chain gene segments leads to expression of the mature αβ TCR and these DP T cells are selected 
through positive and negative selection as they migrate from the cortex to the medulla of the thymus 
[Aspinall, 2006; Huseby et al., 2008; Bosco et al., 2009]. The strength and duration of the TCR 
signal broadly determines the fate of the DP cell with the strongest signals leading to negative 
selection and apoptosis (for example, when TCR recognises self antigens), intermediate signals 
resulting in positive selection and very weak signals (or lack of a TCR signal) leading to death by 
neglect of the DP cell [Starr et al., 2003; von Boehmer & Kisielow, 2006; Weinreich & Hogquist, 
2008; D’Acquisto & Crompton, 2011]. It has been suggested that TCR signal duration and strength 
influence the positive selection of DP thymocytes into CD4 and CD8 T cells, with stronger TCR 
NK
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and
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CD44-
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signals tending to result in CD4 SP cells and weaker or more transient signals more likely to lead to 
a CD8 T-cell fate [Bommhardt et al., 1999]. T cells with TCR that respond to MHC Class I peptides 
become CD8 cytotoxic T lymphocytes (CTL) while those that respond to MHC Class II molecules 
become CD4 T-helper lymphocytes (TH) [Sebzda et al., 1999; Stone et al., 2009]. Of the DP 
lymphocytes, approximately 98% die during selection in the thymus and approximately 2% bear the 
appropriate TCR and are exported from the thymus to the periphery [Skapenko et al., 2005]. 
1.1.2 CD8 T cells 
CD8 T cells, when activated, differentiate into CTL, which are vital in the control of infection by 
viruses and other intracellular pathogens [Zhang et al., 2009]. They recognise foreign peptides 
presented on MHC Class I molecules [Prlic et al., 2007], and travel to the site of infection with the 
ability to destroy infected cells by lysis and by the secretion of antiviral factors [Williams & Bevan, 
2007]. Naïve T cells circulate around the body after exiting the thymus until they encounter their 
specific antigen. Following this encounter, the CTL response to infection can be divided into 
several phases. At first, antigen-specific T cells clonally expand and as they do so, they acquire 
various effector functions allowing them to eliminate infected cells. Following neutralisation of the 
pathogen, the expanded antigen-specific T-cell pool contracts via apoptosis leaving 5-10% of the 
original expansion size as long-lived memory cells [Williams & Bevan, 2007]. These cells are 
maintained for many years and their response is rapid and effective if the same pathogen is re-
encountered [Williams & Bevan, 2007; Kaech & Wherry, 2007; Wiesel et al., 2009]. The clonal 
expansion of T cells is mediated by many factors, including antigen availability, inflammatory 
stimuli, co-stimulatory molecules and secreted growth factors. It is thought that a relatively short 
exposure to antigen can lead CD8 T cells to divide and differentiate in addition to programming the 
development of a long-lived memory response [Kaech & Ahmed, 2001; van Stipdonk et al., 2003; 
Masopust et al., 2004]. CD8 T lymphocytes express a TCR that recognises a specific antigen 
peptide bound to an MHC class I molecule [Solheim, 1999; Krogsgaard & Davis, 2005] on the 
antigen-presenting cell. The TCR is a heterodimer consisting of an alpha and beta chain in the 
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majority of peripheral T cells, and a gamma and delta chain in 1-10% of circulating T cells [Beetz 
et al., 2008]. Engagement of the TCR with antigen and MHC results in activation of the T-cell 
[Stone et al., 2009; Smith-Garvin et al., 2009]. The TCR associates with other molecules, such as 
CD3, to form the TCR complex [Gil et al., 2005]. The TCR/MHC complex signal is enhanced by 
simultaneous binding of the MHC molecule to a specific co-receptor on the T-cell [Rudd et al., 
2009]. On CD8 T cells, this is the CD8 glycoprotein, which is attracted to the non-variable region of 
the MHC class I molecule (their affinity keeps the CD8 T-cell and the target cell bound closely 
together during antigen-specific activation). On CD4 TH, the co-receptor is CD4, which specifically 
binds to MHC class II molecules [Smith-Garvin et al., 2009]. 
A second signal is required, in addition to the TCR/MHC binding, on CD8 T cells in order for them 
to differentiate into effector cells [Smith-Garvin et al., 2009]. This signal is provided by a variety of 
co-stimulatory molecules present on dendritic cells (DC) and other antigen presenting cells (APC) 
which interact with those expressed on the CD8 T cells. The most well understood co-stimulatory 
pathway involves B7/CD28 interactions. DC express B7 which is up-regulated upon activation 
[Wang & Chen, 2004; Keir et al., 2008; Kaufmann & Walker, 2009]. B7 binds to its receptor, 
CD28 (expressed on T cells), promoting, in conjunction with the TCR signal, activation, expansion, 
survival and the production of IL-2 [Sharpe & Freeman, 2002; Fife & Bluestone, 2008]. Other 
important co-stimulatory molecules include 4-1BB (CD137) [Tan et al., 1999] and CD27 [Hendriks 
et al., 2000]. Signalling through one or more of these pathways is essential for CD8 T-cell 
expansion and differentiation [Bertram et al., 2004]. Which pathway is used and when varies 
depending on the pathogen as well as the TCR stimulation, and it is possible that the different 
pathways can elicit distinct functional responses [Williams & Bevan, 2007]. Further, it is thought 
that CD4 T-cell help is required to generate a memory CTL response [Wodarz & Jansen, 2003; 
Shedlock & Shen, 2003]. The role of direct CD4 T-lymphocyte help remains to be fully elucidated 
but could be required for the programming and differentiation of CD8 T-cell during a primary 
response [Shedlock & Shen, 2003], or for the maintenance of functionality after antigen has been 
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cleared [Sun et al., 2004]. It has been suggested that CD4 T cells interact with DC to activate CD8 
T-lymphocyte responses [Zhang et al., 2009; Castellino & Germain., 2006]. Although the exact 
mechanism is not known, it is clear that without CD4 T-cell help an effective CTL memory 
response is not generated [Janssen et al., 2003]. The optimal development of CTL responses also 
requires signalling from IL-12 [Curtsinger et al., 1999] and type I interferons [Zhang et al., 2009; 
Marrack et al., 1999]. 
Preformed effector proteins within the CTL can be rapidly released upon recognition of the target 
cell, triggering cell-mediated cytotoxicity and consequently apoptosis [Russell & Ley, 2002]. An 
example of such an effector protein is perforin, found in modified lysosomes, which when released 
polymerises to form a pore in the membrane of the target cell [Pipkin & Lieberman, 2007]. Perforin 
damages the integrity of the cell membrane and upsets the osmotic and salt equilibria, as well as 
facilitating the entry of serine proteases called granzymes (other CTL effector proteins) into the 
target cell where they trigger apoptosis [Lieberman et al., 2002; Gupta et al., 2008; Chattopadhyay 
et al., 2009]. A perforin-independent pathway can also cause the death of infected target cells by the 
ligation of the Fas-ligand (Fas-L), expressed on CTL, with Fas, expressed on the target cell. Death 
domains within the cytoplasm of the target cell are brought together, activating caspases which 
remove caspase-activated deoxyribonuclease (CAD) from an inactive complex with the inhibitory 
protein I-CAD, allowing CAD to enter the nucleus of the target cell where it cleaves DNA [Russell 
& Ley, 2002; Gupta et al., 2008]. CTL can regulate the immune response by means other than 
direct cytotoxicity. They can produce antiviral cytokines such as interferon-gamma (IFN-γ) and 
tumour necrosis factor alpha (TNF-α), chemokines such as macrophage inflammatory proteins 
(MIP-1α and MIP-1β) and RANTES (Regulated upon Activation, Normal T-cell Expressed and 
Secreted; CCL5), and CD8 T-cell antiviral factors (CAF) [Jassoy et al., 1993; Yang & Walker, 
1997; Geiben-Lynn, 2002]. Following elimination of the pathogen, most CTL generated in the 
initial ‘burst’ die through apoptosis, leaving memory cells [Prlic et al., 2007; D’Cruz et al., 2009]. 
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1.1.3 Memory CD8 T cells 
Mouse models have given insight into the dynamics of CTL responses [Zimmerman et al., 1996], 
however, longitudinal analysis in humans is more difficult. The phenotype and function of human 
peripheral blood subsets have been examined and several models have been proposed for the 
differentiation of naïve CD8 T cells. Three distinct populations of CD8 T cells were described in 
1997; in addition to naïve cells, memory- and effector- type T cells with distinct functional and 
phenotypic properties were defined [Hamann et al., 1997]. The memory cells had a CD45RA
-
CD45RO
+
 phenotype, and this subset was found to have the ability to produce IL-2, IFN-γ, TNF-α 
and IL-4, in addition to having a low cytolytic activity ex vivo [Hamann et al., 1997]. The terms 
central memory (CM) and effector memory (EM) have since been used to describe memory T-
lymphocyte subsets [Sallusto et al., 2004; Romero et al., 2007]. According to this model, in 
response to an encounter with antigen, effector memory T lymphocytes (TEM) migrate to inflamed 
peripheral tissue and perform immediate effector functions, whereas central memory T cells (TCM) 
home to secondary lymphoid organs where they rapidly proliferate and differentiate into effector 
cells [Sallusto et al., 1999]. TCM and TEM can be further defined based on their phenotype and 
effector functions. TCM are CD45RO
+
 cells that constitutively express chemokine receptor-7 
(CCR7) and CD62L [D’Cruz et al., 2009]. These molecules, also expressed by naïve T cells, are 
required for homing to T-cell compartments of secondary lymphoid organs. TCM have a higher 
sensitivity to antigenic stimulation than naïve cells and following TCR ligation they produce mainly 
IL-2 but then proliferate and differentiate into cells that produce large amounts of IFN-γ or IL-4. 
TEM do not express CCR7 and are heterogeneous in their expression of CD62L; they are 
characterised by their rapid effector function and CD8 TEM contain large amounts of perforin. Both 
CD8 and CD4 TEM produce IFN-γ, IL-4 and IL-5 rapidly after antigenic stimulation [D’Cruz et al., 
2009]. A proposed vaccine strategy is one in which TEM responses are prolonged at the viral entry 
site, with the hopes of halting viral replication in its initial stages [Hansen & Bouvier, 2009]. There 
has been some question as to the use of CCR7 to distinguish between TCM and TEM, and studies 
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have found no functional differences between CCR7
+
 and CCR7
-
 cells [Unsoeld et al., 2002], and it 
has been shown that CCR7 can be induced upon activation [Sallusto et al., 1999]; nevertheless, 
CCR7 remains a widely used marker in defining T-cell memory subsets. 
The expression of CD27 and CD28 have also been used to define memory T-cell subsets [Hamann 
et al., 1997], and these studies have shown sequential down-regulation of, first, CD28 and then 
CD27 (on CD8 T cells) during differentiation from naïve to memory [Romero et al., 2007; Downey 
and Imami, 2010]. Thus, CD8 T-cell differentiation may be described in terms of naïve 
(CCR7
+
CD45RA
+
), TCM (CCR7
+
CD45RA
-
), TEM (CCR7
-
CD45RA
-
), and terminally differentiated 
(TEMRA; CCR7
-
CD45RA
+
) stages, or early (CD27
+
CD28
+
), intermediate (CD27
+
CD28
-
) and late 
(CD27
-
CD28
-
) differentiation states [Downey & Imami, 2010]. A transitional memory phenotype 
(TTM) that is intermediary between TCM and TEM has been described in the literature, classified 
according to the markers used to define this transitional memory state for CD4 T cells (thus, CCR7
-
CD45RA
-
CD27
+
) [Killian et al., 2011], and also categorised using a different panel (CCR7
-
CD45RO
+
CD28
+
) [Freel et al., 2010]. 
Although the nomenclature may differ depending on the study and the surface markers used, Figure 
1.3 summarises the expression of a number of markers that have been found to be associated with 
different CD8 T-lymphocyte differentiation/maturation states, and these include the expression of 
CD57, CD11a, and granzymes A and B [Appay & Rowland-Jones, 2004; Appay et al., 2008; Wood 
et al., 2009], in addition to those already described. It is important to note that the descriptions of 
the memory subsets in Figure 1.3 may not apply to cells actively responding to antigen, only those 
in a resting state. In addition, the response to different viruses will vary in terms of phenotype, 
frequency and function of responders [Appay et al., 2002]. The level of antigen has also been 
shown to influence the differentiation of CD8 CTL [Tussey et al., 2003; Papagno et al., 2004]. 
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Figure 1.3 CD8 T-cell differentiation/maturation subsets. 
The post-thymic development of six subsets of CD8 T cells are shown here, characterised by the expression of CD27, 
CD28, CCR7, CD45RA, CD57, CD11a, perforin, and granzymes A and B. Adapted from [Appay & Rowland-Jones, 
2004; Appay et al., 2008]. 
 
1.1.4 CD4 T cells 
CD4 T cells have the ability to orchestrate an immune response; they can mobilize and co-ordinate 
a variety of other cell types leading to the clearance of a pathogen [Zhu & Paul 2008]. They express 
the TCR/CD3 complex, like all T cells, but the TCR on CD4 T lymphocytes is specific for MHC 
class II [Munz, 2009]. Similarly to CD8 T cells, following maturation, the naïve CD4 T cells leave 
the thymus and circulate the body. Activation occurs when they recognise the antigen that they are 
specific for, in the context of presentation on MHC class II [Munz, 2006]. Class II molecules are 
found on the cell surface of professional APC such as DC, macrophages and B cells [Crotzer & 
Blum, 2009]. In addition to the TCR/Class II interactions, CD4 T lymphocytes require further 
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signals through the binding of CD28 with its ligand CD80 or CD86 [Dubey et al., 1995], and 
signalling by specific cytokines for activation [O’Garra, 1998]. The differentiation of the CD4 T-
cell is determined by the strength of the signal [Obst et al., 2005; Lanzavecchia & Sallusto, 2002]. 
Once a CD4 T-lymphocyte has been activated, it can differentiate into different functional subsets 
such as TH1 and TH2 [Mosmann et al., 1986; Mosmann et al., 2005]; others include TH17, TH9, T-
follicular helper (TFH) and T-regulatory cells (Treg) [Luckheeram et al., 2012; Tan & Gery, 2012]. 
TH1 cells secrete IL-2, IFN-γ, TNF-α and -β, while TH2 cells secrete IL-4, IL-5, IL-6, IL-9 and IL-
13 [Agnello et al., 2003]. TH1 cells are thought to be protective against intracellular infection and 
TH2 responses are associated with extracellular immunity and act as more potent helpers for T-cell 
dependent antibody production [O’Garra et al., 1998]. More recently, the TH17 subset was 
identified; these cells produce IL-17 and are highly pro-inflammatory [Zhu & Paul, 2008; Dong, 
2006]. As previously described (in section 1.1.2), CD4 T-helper cells assist in the development of 
CTL memory responses. CD4 T lymphocytes can provide help to other cells of the immune system 
including APC and B cells via cell-bound receptors such as CD40 [Zhang et al., 2009; Wodarz & 
Jansen, 2001], and by the secretion of cytokines such as IFN- γ. 
Despite similar post-thymic differentiation pathways between CD4 and CD8 T cells (namely, the 
loss of CD27, CD28 and CCR7 expression, the gain of CD57 and perforin expression, and reduced 
IL-2 production and proliferative capacity) [Appay & Rowland-Jones, 2002], and the ability to sub-
divide CD4 T-cell subsets into early, intermediate and late differentiated states, it is the sequence of 
these events that differ between the two populations [Appay et al., 2008; Amyes et al., 2003]. CD4 
T cells lose expression of CD27 before CD28 (whereas the opposite is true for CD8 T cells), thus 
the differentiation states of CD4 T cells using these markers are as follows: early (CD27
+
CD28
+
), 
intermediate (CD27
-
CD28
+
) and late (CD27
-
CD28
-
) [Appay et al., 2008; Downey & Imami, 2010]. 
More recently, however, a transitional memory (TTM) T-cell subset has been described that has an 
intermediate phenotype between TCM and TEM and is characterised based on the expression of 
CCR7, CD45RA and CD27 (where TCM are CCR7
+
CD45RA
-
CD27
+
, TTM are CCR7
-
CD45RA
-
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CD27
+
, and TEM are CCR7
-
CD45RA
-
CD27
-
) [Riou et al., 2007; Chomont et al., 2009]. Only highly 
differentiated CD4 T cells begin to express perforin whereas for CD8 T cells, acquisition of lytic 
capacity and expression of perforin occurs early after the priming of naïve cells [Appay & 
Rowland-Jones, 2004]. The differentiation of CD4 T lymphocytes as compared to CD8 T 
lymphocytes is otherwise very similar with regard to markers such as CCR7, CD45RA and CD57 
[Appay et al., 2008]. Figure 1.4 illustrates the differentiation pattern of CD4 T cells. Functional 
differences between CD4 and CD8 T cells seem to be focused in the early differentiation states and 
eventually highly differentiated cytotoxic CD4 T cells have a remarkably similar phenotype to late 
differentiated CD8 T cells. This similar differentiation status seems more likely to occur in 
instances of chronic activation, such as during HIV-1 infection [Appay & Rowland-Jones, 2002; 
Appay et al., 2008]. 
 
Figure 1.4 CD4 T-cell differentiation/maturation subsets. 
The post-thymic development of five subsets of CD4 T cells are shown here, characterised by the expression of CD27, 
CD28, CCR7, CD45RA, CD57, CD11a, perforin, and granzymes A and B. Adapted from [Appay et al., 2008]. 
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1.2 Human Immunodeficiency Virus 
1.2.1 HIV-1 epidemiology 
Human immunodeficiency virus (HIV)-1 is a retrovirus belonging to the Retroviridia family and 
Lentivirinea subfamily. In 1983, it was shown to be the agent which causes acquired 
immunodeficiency syndrome (AIDS) [Barre-Sinoussi et al., 1983]. At the end of 2009, it was 
estimated that 33.3 million people worldwide were living with HIV, with 2.6 million new infections 
and 1.8 million AIDS-related deaths that year [UNAIDS Global Report 2010; 
http://www.unaids.org/globalreport/documents/20101123_GlobalReport_full_en.pdf]. Worldwide, 
about 7,000 people are infected with HIV each day [IAVI, International AIDS Vaccine Initiative; 
http://www.iavi.org/Pages/home.aspx]. Typically, life-saving effective antiretroviral therapy (ART) 
is required 7-10 years after becoming infected. However, at the end of 2009, only 36% 
(approximately 5.2 million) of the 15 million people in need in low- and middle- income countries 
were receiving ART [UNAIDS Global Report 2010], primarily due to its high cost, and the search 
for an effective vaccine continues [IAVI, International AIDS Vaccine Initiative; 
http://www.iavi.org/Pages/home.aspx]. In addition to the expense of current ART, there is also the 
associated high pill burden, toxicity and complex undesirable side effects [Gazzard et al., 2008]. An 
improvement in morbidity and mortality can be seen with ART, however it is not a cure and 
lifelong treatment is required [Siliciano et al., 2003]. Additionally, although ART may control viral 
replication, alternative measures are needed to address persistent viral reservoirs [Shen & Siliciano, 
2008]. 
1.2.2 Infection with HIV-1 
Infection with HIV-1 can occur via the mucosal route, via contaminated blood products or needles 
and through mother-to-child transmission. Infection with HIV-1 results in a brief acute phase 
(typically lasting around 14 days) and is associated with a high viral load, a decrease in peripheral 
blood CD4
 
T-cell counts [Pantaleo & Fauci, 1996], immune activation [Grossman et al., 2006], and 
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a massive depletion of CD4 T cells in the gastrointestinal tract [Brenchley & Douek, 2008]. A latent 
reservoir of infected CD4 T cells is established and an HIV-1-specific immune response is 
generated. This phase is followed by an asymptomatic phase, where the viral load drops and a viral 
set point is reached and is associated with a cellular immune response [Andrews & Koup, 1996]. On 
average, this chronic stage lasts for seven years during which time the peripheral CD4 T-cell count 
falls slowly, mucosal CD4 T-cell numbers remain low, and both immune activation and viraemia 
continue to increase [Grossman et al., 2006]. When peripheral CD4
 
T-cell counts decline to less 
than 200 cells per μl of blood and the number of mucosal CD4 T cells becomes very small, 
opportunistic infections and tumours that characterise AIDS occur, leading to mortality in most 
individuals [Grossman et al., 2006]; the stages of untreated HIV-1 disease progression are 
illustrated in Figure 1.5. 
 
 
Figure 1.5 The course of HIV-1 disease progression, shown in terms of both quantitative and qualitative measures. 
Quantitative parameters illustrated include: alterations in blood and mucosal CD4
 
T-cell counts and levels of viraemia 
and qualitative measures include: levels of immune activation, ‘regenerative capacity’ and ‘target-cell selectivity’. 
Taken from [Grossman et al., 2006]. 
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HIV-1 infects mainly TH cells and macrophages, and to a lesser extent, microglial cells and DC 
[Dunfee et al., 2009]. CD4 is used as the primary receptor for entry into the cells and the co-
receptor depends on the strain of the virus. R5 strains of HIV-1, the strain that is usually 
transmitted, use the CC-chemokine receptor 5 (CCR5) as their co-receptor and can enter 
macrophages, DC and T cells. X4 strains of HIV-1, which tend to emerge later in infection, use 
CXCR4 as a co-receptor and can only infect T cells [Doms & Trono, 2000; Kuritzkes, 2009]. 
Although the dynamics of the initial infection are not well understood [Goonetilleke et al., 2009], it 
is clear that HIV-1 establishes a life-long infection in the host, in long-lived memory T cells [Shen 
& Siliciano, 2008] causing immunodeficiency and AIDS. 
1.2.3 Highly Active Antiretroviral Therapy 
The introduction of Highly Active Antiretroviral Therapy (HAART) in 1996 resulted in a 
substantial decline in mortality and morbidity of AIDS-related symptoms in infected patients 
[Gulick et al., 1997; Hammer et al., 1997; Palella et al., 1998]. Treatment with HAART controls 
plasma viraemia to below the limit of detection of standard assays, and leads to an increase in CD4 
T-cell counts [Perelson et al., 1997; Shen & Siliciano, 2008], however, only 50% of the normal 
numbers of T cells in the gut are recovered, even after three years of fully suppressive HAART 
[Talal et al., 2001; Effros et al., 2008]. HIV-1 viraemia rapidly rebounds if therapy is interrupted, 
suggesting the persistence of viral reservoirs, and the requirement for life-long therapy [Burton et 
al., 2005; Shen & Siliciano, 2008]. This viral reservoir is thought to reside in long-lived, latently-
infected memory CD4 T cells; a model supported by the presence of replication-competent virus in 
peripheral blood lymphocytes and by the lack of evolution of viral cDNA [Sedaghat et al., 2007; 
Buzon et al., 2010]. The latently-infected population is thought to have a long half-life, such that it 
would take over 60 years of HAART to eliminate this population [Finzi et al., 1999; Edelstein et 
al., 2009]. The suggestion of low-level viral replication is also supported by the abnormal levels of 
immune activation and inflammation in HAART-treated HIV-1-infected individuals [Jiang et al., 
2009]. In patients who initiate therapy before CD4 T-cell counts fall below 350 cells/µl blood, as is 
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currently recommended by international guidelines, AIDS-associated malignancies and infections 
are infrequent, and it is thought that future guidelines will recommend initiation of ART even 
earlier [Kitahata et al., 2009; Sterne et al., 2009]. In fact, the latest reports from the USA 
recommend treatment for all HIV-1-infected persons, particularly those with CD4 T-cell counts 
below 500 cells/µl blood, those at risk of transmitting the virus to their partners, pregnant women, 
and those with HIV-1-related kidney disease or hepatitis B co-infection [Alcorn, 2012]. A recent 
study described a very small number of individuals (five out of thirty two) who maintained very low 
and stable levels of cell-associated HIV-1 DNA following treatment discontinuation; these patients 
had received early and prolonged treatment with HAART and did not have characteristics 
associated with elite controllers and long-term non-progressors (LTNP); none had HLA class I 
B*27 or B*57 alleles or homozygous Delta 32 deletion for the CCR5-encoding gene [Hocqueloux 
et al., 2010]. Although the authors underline the importance of determining the underlying 
mechanisms of this immunovirological control, they also reiterate that HAART treatment 
interruptions are not recommended [Hocqueloux et al., 2010; El-Sadr et al., 2006]. 
Improvements in HIV-1-specific CD8 T-cell functionality have been found to be slow and 
incomplete in progressors who initiate HAART during the chronic stage of infection, even when 
therapy is given for a prolonged period of time [Migueles et al., 2009; Rehr et al., 2008]. Similarly, 
HAART initiated during chronic infection does not recover polyfunctionality, proliferative capacity 
or cytotoxic ability to the extent that these functions are found in LTNP [Migueles et al., 2009; 
Hersperger et al., 2010]. (Long-term non-progressive HIV-1 infection is discussed in detail in 
section 1.3.6.) The initiation of HAART has been found to rapidly reduce the numbers of HIV-1-
specific CD8 T cells [Janbazian et al., 2012]. A study investigating the residual CD8 T-cell 
population revealed antigen decay (either by administration of HAART or by the emergence of 
epitope escape mutations) to be accompanied by alterations in the TCR repertoire, increased 
expression of CD45RA and CD127, decreased expression of programmed death-1 (PD-1), and the 
emergence of polyfunctional HIV-1-specific CD8 T cells [Janbazian et al., 2012]. Initiation of 
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HAART in early HIV-1 infection has been associated with significant reductions in proviral DNA 
to levels comparable to those found in LTNP, suggesting early HAART may lessen the viral 
reservoir [Pires et al., 2004a; Cellerai et al., 2011]. Early and prolonged HAART has been 
associated with an HIV-1-specific CD4 and CD8 T-cell polyfunctional profile (as assessed by IFN-
γ, IL-2, TNF-α production, and perforin expression) that is similar to that found in LTNP, indicating 
early HAART may preserve these virus-specific responses [Cellerai et al., 2011]. Furthermore, 
early initiation of HAART is thought to lower the activation state of monocytes and macrophages, 
as measured by a decrease in CD163 shedding [Burdo et al., 2011]. In a study of serodiscordant 
couples (HPTN 052), early initiation of HAART reduced the rate of sexual transmission to the HIV-
1 negative partner by 96%, as compared with delayed therapy, highlighting the benefit of early 
treatment both for the individual and in terms of public health [Cohen et al., 2011]. 
In 1987, the nucleoside reverse transcriptase inhibitor (NRTI) Azidothymidine/zidovudine (AZT) 
was introduced as a monotherapy for HIV-1 [Broder, 2010] until the introduction of HAART in 
1996 [De Clercq, 2010; Ray et al., 2010]. To date, there are over twenty antiretroviral drugs 
available, which target different steps of the HIV-1 life cycle, and can be distributed into six major 
classes: 1) nucleoside-analog reverse transcriptase inhibitors (NRTI), 2) non-nucleoside reverse 
transcriptase inhibitors (NNRTI), 3) protease inhibitors, 4) fusion inhibitors, 5) entry inhibitors – 
co-receptor antagonists, and 6) integrase inhibitors [De Clercq, 2010; Lobritz et al., 2010], as 
detailed in Table 1.1, and as illustrated in Figure 1.6. Combinations of antiretroviral therapy drugs 
can thus be optimised for the HIV-1-infected individual providing, in most cases, viral suppression, 
a degree of immune reconstitution, and almost normal life-expectancy [Hawkins, 2010; Ries et al., 
2012]. 
There is evidence that not all HIV-1-infected persons benefit from HAART and a portion of treated 
patients do not see restoration of CD4 T-cell counts after five to seven years of treatment [Moore & 
Keruly, 2007; Kaufmann et al., 2003]. Significant increases in non-AIDS –associated morbidities 
are found in patients with persistently low CD4 T-cell counts and the mechanisms for incomplete 
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CD4 T-cell recovery are thought to include thymic dysfunction, failure of naïve T-cell expansion 
and persistent immune activation [Jiang et al., 2009]. Even for individuals that do not have 
complications, in terms of CD4 T-cell recovery, immune inflammation and activation persist at 
abnormal levels and long-term HAART-treated patients still have an increased risk of death as a 
result of non-AIDS complications that are usually associated with aging, such as cardiovascular 
disease, osteoporosis, and end-organ failure [Deeks, 2011]. In these individuals, the prevalence of 
non-AIDS-associated malignancies is also rising, and these include Epstein-Barr virus-associated 
Hodgkin lymphoma and human papilloma virus-associated anal neoplasia [Palefsky, 2008; Ries et 
al., 2012]. 
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Table 1.1 FDA approved therapeutics for the treatment of HIV-1 infection. 
NRTI – nucleoside reverse transcriptase inhibitor, NtRTI – nucleotide reverse transcriptase inhibitor; NNRTI – non-
nucleoside reverse transcriptase inhibitor, PI – protease inhibitor. Taken from [Lobritz et al., 2010]. * Single asterisks 
indicate where drugs are also licensed in the European Union (EU), or where they have a different brand/trade name. 
Brand/Trade Name Generic Name Class Approval year 
Emtriva* emtricitabine, FTC NRTI 2003 
Epivir* Lamivudine, 3TC NRTI 1995 
Hivid* Zalcitabine, ddC NRTI 1992 
Retrovir* Zidovudine, AZT NRTI 1987 
Videx* Didanosine, ddI NRTI 1991 
VidexEC* 
Didanosine, ddI 
(extended release) 
NRTI 2000 
Viread* Tenofovir, TFV/TDF NtRTI 2001 
Zerit* Stavudine, d4T NRTI 1994 
Ziagen* Abacavir, ABC NRTI 1998 
Edurant* Rilpivirine NNRTI 2011 
Intelence* Etravirine, ETV/ETR NNRTI 2008 
Rescriptor Delavirdine, DLV NNRTI 1997 
Sustiva* Efavirenz, EFV NNRTI 1998 
Viramune* Nevirapine, NVP NNRTI 1996 
Viramune XR* 
(extended release) 
Nevirapine, NVP NNRTI 2011 
Combivir* 3TC/AZT NRTI 1997 
Kivexa* 
Epzicom 
3TC/abacavir NRTI 2004 
Trizivir* 3TC/abacavir/AZT NRTI 2000 
Truvada* FTC/tenofovir NRTI/NtRTI 2004 
Atripla* FTC/tenofovir/efavirenz NRTI/NtRTI/NNRTI 2006 
Complera 
Eviplera* 
FTC/TDF/rilpivirine NRTI/NtRTI/NNRTI 2011 
Agenerase* Amprenavir, APV PI 1999 
Aptivus* Tipranavir, TPV PI 2005 
Crixivan* Indinavir, IDV PI 1996 
Invirase* Saquinavir, SQV PI 1995 
Kaletra Aluvia* Lopinavir, LOP/ritonavir PI 2000 
Lexiva 
Telzir* 
Fosamprenavir, APV PI 2003 
Norvir* Ritonavir, RTV PI 1996 
Prezista* Darunavir, DRV PI 2006 
Reyataz* Atazanavir, ATV/ATZ PI 2003 
Viracept* Nelfinavir, NFV PI 1997 
Fuzeon* Enfuviritide, T-20 Fusion inhibitor 2003 
Selzentry 
Celsentri* 
Maraviroc, MVC CCR5/entry inhibitor 2007 
Isentress* Raltegravir, RTV Integrase inhibitor 2007 
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Figure 1.6 HIV-1 viral life cycle and antiretroviral drug targets. 
There are currently six classes of antiretroviral drugs that target five steps of the HIV-1 life cycle (binding, fusion, 
reverse transcription, integration, and proteolytic cleavage). The drugs shown here are those most commonly used in 
resource-rich settings. The complex three-step process, by which extracellular virions enter the target cell are: 1) 
attachment to the CD4 receptor, 2) binding to the CCR5 or CXCR4 co-receptors, or both, and 3) membrane fusion. 
Maraviroc blocks CCR5 binding and enfuviritide blocks fusion. The HIV-1 reverse transcriptase enzyme catalyses the 
transcription of HIV-1 RNA into double stranded HIV-1 DNA, and nucleoside analogues, and non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) interfere with this step. The HIV-1 integrase enzyme facilitates the incorportation of 
the HIV-1 DNA into the host chromosomes and raltegravir and other integrase inhibitors obstruct this process. 
Following transcription and translation of the HIV-1 genome, immature virions are produced and bud from the cell 
surface. The HIV protease enzyme cleaves polypeptide chains, allowing the virus to mature, and protease inhibitors 
prevent this final stage. Taken from [Volberding & Deeks, 2010]. 
 
Topical and oral tenofovir-based pre-exposure prophylaxis (PrEP) has been shown in four recent 
clinical trials to be efficacious, and greater adherence to PrEP has been associated with greater 
efficacy [Celum, 2011; van der Straten et al., 2012]. The studies were as follows: 1) the CAPRISA 
004 trial showed a 39% efficacy in reducing the risk of HIV acquisition in young women following 
pericoital administration of a 1% tenofovir gel, 2) the iPrEx study demonstrated a 44% efficacy in 
reducing the risk of HIV acquisition among high-risk men who have sex with men (MSM) 
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subsequent to daily oral emtricitabine/tenofovir, 3) the Partners PrEP Study in African HIV 
serodiscordant couples where the HIV-seronegative partner received daily oral tenofovir or 
emtricitabine/tenofovir showed 62% and 73% efficacy, respectively, and 4) the TDF2 trial found 
62% efficacy after daily administration of oral emtricitabine/tenofovir in young heterosexual men 
and women in Botswana [Celum, 2011]. 
1.3 Immune Response to HIV-1 
The immune system controls most viral infections, including those which establish chronic 
infection. In HIV-1 infection, the immune system appears to respond appropriately to prevent viral 
spread. There is evidence that antibodies, CD8
 
CTL and CD4 TH responses all play a role in 
containing HIV-1. However, HIV-1, unlike other persistent viruses, progressively destroys the 
immune system resulting in AIDS and death. HIV-1 has evolved a number of strategies to evade the 
host immune system [Alcami & Koszinowski, 2000; Kawashima et al., 2009]; however, the 
mechanisms by which immune function is lost remain highly controversial. Factors that may 
contribute to the loss of immune function include: continuous adaptive mutation of the virus 
[Barouch & Letvin, 2002], destruction or impairment of cells necessary for optimal immune 
response (CD4 T cells and APC) [Kalams & Walker, 1998], decreased thymic output [Douek et al., 
2001], continuous production of virus from stable reservoirs [Shen & Siliciano, 2008], and chronic 
immune activation [Appay & Sauce, 2008]. 
The deterioration of the T-cell response during HIV-1 infection follows a characteristic pattern: 
proliferative capacity, the ability to produce IL-2 and cytotoxic capacity are lost early, whereas the 
production of IFN-γ is more long-lasting. Eventually, even the ability to produce IFN-γ is impaired 
as the majority of T cells continually exposed to HIV-1 antigens enter into a state of dysfunction, 
resulting in disease progression [Appay et al., 2000; Kostense et al., 2002; Roos et al., 2000; 
Gamadia et al., 2002; Ostrowski et al., 2000; Jones et al., 2008]. 
Although this thesis focuses on the impact of HIV-1 infection on CD4 and CD8 T cells, and 
methods to reverse T-cell dysfunction, it is important to note that pathogenic HIV-1 infection also 
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disrupts other immune subsets, such as DC, B cells, macrophages, natural killer cells, and γδ T cells 
[Grossman et al., 2006; Brenchley et al., 2006]. 
1.3.1 CTL response 
HIV-1 infection results in virus-specific CTL responses against both structural and regulatory genes 
of HIV-1 [Walker et al., 1987; Addo et al., 2001]. These responses may control HIV-1 by more 
than one mechanism [Gupta et al., 2008; Yang & Walker, 1997]. CTL may recognise and lyse cells 
which present viral peptides on MHC I [Yang et al., 1996] in addition to secreting β chemokines 
which bind to HIV-1 co-receptors on target cells, thus blocking HIV-1 entry [Hadida et al., 1998; 
Wagner et al., 1998]. 
Evidence exists that CTL do control HIV-1 infection. In acute infection, clearance of primary 
viraemia correlates with the appearance of HIV-1-specific CTL [Andrews & Koup, 1996; Borrow et 
al., 1994]. In vitro experiments have shown that CTL taken from infected patients are able to inhibit 
viral replication in autologous CD4 T cells [Yang et al., 1996]. This role for CD8
 
T-cell control is 
supported by studies in rhesus macaques (RM) infected with simian immunodeficiency virus (SIV). 
In animals with depleted CD8 T cells, there was an increase in viral load and as CD8 T cells were 
restored, viraemia was controlled [Lieberman et al., 2002]. Despite high frequencies of HIV-1-
specific CTL present during infection (as determined by tetramer staining), it is possible that such 
CD8 T cells either are or become defective [Lieberman et al., 2001]. In addition, it has been found 
that HIV-1 specific CTL contain less perforin and have diminished cytotoxicity compared to other 
virus specific CTL [Appay et al., 2000]. There is also the possibility that the maturation of HIV-1 
specific memory CD8 T cells is skewed, which may lead to an ineffective response [Champagne et 
al., 2001; Garber et al., 2004]. 
1.3.2 T-cell differentiation and memory subsets during infection 
The T-cell differentiation and maturation subset patterns described in section 1.1.3 are skewed in 
HIV-1 infection. In Figure 1.7A, three models of CD8 T-cell differentiation in the human system 
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are shown, and classifications differ according to the surface markers used to characterise the 
subsets [Garber et al., 2004]. The top row shows naïve (CCR7
+
CD45RA
+
) CD8 T cells which 
differentiate into TCM (CCR7
+
CD45RA
-
), then into TEM (CCR7
-
CD45RA
-
), and finally into 
terminally differentiated effectors or CD45RA
+
 effector memory cells (TEMRA; CCR7
-
CD45RA
+
) 
[Champagne et al., 2001]. Appay et al., use CD28 and CD27 to characterise these subsets and the 
terminology differs; early- (CD28
+
CD27
+
), intermediate- (CD28
-
CD27
+
), and late- (CD28
-
CD27
-
) 
primed CD8 T-lymphocyte stages are depicted in the second row [Appay et al., 2002]. In the third 
row, naïve CD8 T cells differentiate into several stages of memory cells before becoming effector T 
cells, and this process is defined using a combination of CD28, CD27, CCR7, and CD45RA/RO 
[van Baarle et al., 2002]. Figure 1.7B illustrates the defects in maturation and differentiation that 
occur in HIV-1-specific CD8 T cells in HIV-1-infected individuals, according to each of the three 
models. The bold arrows indicate increased or excessive production, and broken arrows indicate 
defective differentiation/maturation [Garber et al., 2004]. Regardless of the markers used to 
characterise these subsets, all three models depict a disproportionate shift from central memory or 
early-primed CD8 T cells (shown in green) to an effector memory or intermediate primed (shown in 
yellow) state, with further defects in the differentiation pathway to TEMRA/late-primed/effectors 
(shown in orange and red; Figure 1.7B). 
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Figure 1.7 CD8 T-cell differentiation/maturation pathways compromised during chronic viral infection. 
A) Several models of CD8 T-cell differentiation have been described in the human system. In the first row, naïve CD8 
T cells differentiate into central memory (CM), then effector memory (EM) T cells, and finally into terminally 
differentiated effectors/CD45RA
+
 effector memory cells (TEMRA). In the second row, naïve (non-primed) CD8 T cells 
differentiate into early-primed, intermediate-primed, and late-primed cells. In the third row, naïve CD8 T cells 
differentiate into several stages of memory cells, and finally into effector T cells. B) Defective 
maturation/differentiation of HIV-1-specific CD8 T cells in HIV-1-infected individuals. Bold arrows indicate 
increased/excessive production; broken arrows indicate defective differentiation/maturation; CK –cytokine production. 
Taken from [Garber et al., 2004]. 
 
CD8 TCM preferentially localise in the lymph nodes, secrete IL-2 following antigen stimulation, yet 
show reduced cytotoxicity and limited immediate effector capabilities [Sallusto et al., 1999]; 
whereas TEM preferentially localise in non-lymphoid peripheral tissue, have reduced proliferative 
potential, yet possess cytolytic capabilities and can exhibit immediate effector functions, such as 
IFN-γ production [Ahlers & Belyakov, 2010]. 
Similar panels of markers have been used to characterise differentiation and memory subsets for 
CD4 T lymphocytes, although, as described in section 1.1.3, these differ slightly, particularly with 
regard to the expression of CD27 and CD28. As CD4 T cells progress from early to intermediate 
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and late stages of differentiation, they lose CD27 first [Downey & Imami, 2010]. Experiments in a 
mouse model have suggested that CD4 TCM have a superior capacity to reconstitute the memory T-
cell pool and to mediate protective immunity compared to TEM, and this was due to a greater 
proliferative capacity and ability to persist in vivo [Wu et al., 2002; Zaph et al., 2004]. The 
induction of CD4 TCM following SIV challenge in non-human primates has been found to correlate 
with prolonged survival [Letvin et al., 2006]. Furthermore, CD4 TCM analysed ex vivo demonstrated 
the capacity to resist apoptosis and to persist in a stable manner in the host, thus providing 
protective immunity against re-infection [Riou et al., 2007]. It is of utmost importance to consider 
how these populations are skewed or dysregulated in HIV-1 infection and therapies to target and 
reverse these defects are warranted. 
A transitional memory phenotype (TTM; CCR7
-
CD45RA
-
CD27
+
) has been described for the CD4 T-
lymphocyte compartment which was shown to have functional and transcriptional characteristics 
intermediary between those of TCM and TEM cells [Riou et al., 2007]. CD4 TCM and TTM were found 
to be the major cellular reservoirs for HIV-1, with this viral persistence mainly in the TCM 
compartment for patients that show CD4 T-cell reconstitution with HAART, and mainly in the TTM 
for aviraemic subjects with low CD4 T-lymphocyte counts [Chomont et al., 2009]. The TTM 
phenotype has also been described for the CD8 T-cell compartment using the same markers (CCR7
-
CD45RA
-
CD27
+
) [Killian et al., 2011], and using a slightly different panel (CCR7
-
CD45RO
+
CD28
+
) [Freel et al., 2010]. More recently, a long-lived memory cell population was 
described that has an enhanced capacity for self-renewal and from which central memory, effector 
memory and effector T cells can be derived [Gattinoni et al., 2011]. These cells were characteristic 
of naïve T cells (CD45RO
-
CCR7
+
CD45RA
+
CD62L
+
CD27
+
CD28
+
IL-7Rα+) but showed functional 
characteristics typically attributed to memory cells and expressed large amounts of CD95, IL-2Rβ, 
CXCR3, and LFA-1 [Gattinoni et al., 2011]. The relevance of this T-cell subset in HIV-1 infection 
remains to be elucidated but may play a crucial role in vaccine development or T-cell therapies. 
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A possible explanation for the CD8 T-cell defects seen in HIV-1 infection (described above) could 
be a lack of CD4 T-cell help [Williams & Bevan, 2007]. Depletion of CD4 T-cell counts is a 
hallmark of HIV-1 infection; however the mechanisms by which this occur remains elusive 
[Rowland-Jones, 1999; McCune, 2001]. It is clear that HIV-1 infects and kills CD4 T cells 
[Lenardo et al., 2002], however, this cytopathicity alone does not account for CD4 T-cell loss and 
the progress of the disease. In late stage AIDS, this decline is associated with a decline in CTL 
activity [Wherry et al., 2007]. Even in early stages of HIV-1 infection, specific CD4 T cells have 
been shown to be functionally defective [Rosenberg et al., 1997; Musey et al., 1999; Sun et al., 
2007]. 
1.3.3 Regulatory T cells and TH17 cells 
Regulatory T (Treg) cells are important immunoregulators; they control excessive immune 
activation which may reduce immune-mediated tissue damage but which may also suppress 
antigen-specific immune responses against pathogens [Angin et al., 2012]. To this effect, reports on 
the role of Treg cells in HIV-1 infection have been mixed. Some studies have found increased 
frequencies [Andersson et al., 2005; Nilsson et al., 2006], which normalise with effective ART 
[Montes et al., 2011; Presicce et al., 2011], while others have documented decreased frequencies in 
HIV-1-infected individuals [Tsunemi et al., 2005; Eggena et al., 2005; Burton et al., 2011]. HIV-1 
infection and subsequent PD-1 up-regulation and increased immune activation was determined to be 
associated with decreased Treg cell proliferation [Sachdeva et al., 2010]. 
The possibility that these Treg cells might be detrimental in HIV-1 infection was supported by data 
from a phase III clinical trial which showed that IL-2 therapy preferentially expanded the Treg cell 
population in HIV-1
+
 subjects, and that the individuals with the greatest expansion of this subset 
were more likely to progress to AIDS [Abrams et al., 2009; Weiss et al., 2010]. Further to this 
finding, a recent study has demonstrated that CTL that are restricted by protective HLA-alleles 
(HLA-B*27 and HLA-B*B57) up-regulate less TIM-3 and more granzyme B upon recognition of 
their cognate epitopes; these cells are less susceptible to Treg cell-mediated suppression, instead 
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killing the Treg cells that they encounter [Elahi et al., 2011]. The authors postulate that in contrast, 
the majority of HIV-1-specific CD8 CTL will up-regulate TIM-3 when they encounter their cognate 
epitopes, which leads to suppression by Treg cells [Elahi et al., 2011]. 
However, it has also been suggested that Treg cells may have the ability to directly inhibit HIV-1 
replication in activated T cells [Moreno-Fernandez et al., 2011]. One study has recently reported 
that Treg cell frequencies and numbers in elite controllers are not different to uninfected controls, 
but that in chronically infected subjects, the absolute number of Treg cells in the blood and tissue 
are diminished [Angin et al., 2012]. Furthermore, the ex vivo analysis of Treg cells from chronically 
infected HIV-1
+
 patients found preservation of suppressive function which did not differ from that 
of Treg cells from elite controllers or seronegative donors [Angin et al., 2012]. A role for Treg cells 
in the reduction of residual immune activation in patients on suppressive ART has been proposed 
[Weiss et al., 2010]. The proportion of Treg cells was found to negatively correlate with the 
proportion of CD8
+
HLA-DR
+
 T cells in treated HIV-1
+
 patients, and following treatment 
interruption, while the proportion of Treg cells increased, absolute numbers decreased [Weiss et al., 
2010]. Following treatment interruption, the numbers of activated cells (CD8
+
CD38
+
HLA-DR
+
) 
also significantly increased, but the original correlation with Treg cells was lost, suggesting an 
insufficient increase in the proportion and/or decrease in the absolute number of Treg, leading to an 
inability to control immune activation after ART is interrupted [Weiss et al., 2010]. 
Treg cells are capable of suppressing the immune response through competition with proliferating T 
cells for IL-2, which enhances the growth and differentiation of Treg cells. Thus the use of IL-2 
immunotherapy could expand the Treg cell population and blunt the anticipated immune benefits 
[Macatangay & Rinaldo, 2010]. HIV-1-infected subjects that received IL-2 in addition to ART were 
found to have an increased Treg cell population compared to patients that received ART alone and 
modest but significant decreases in Gag-specific CD4 and CD8 T-cell counts following IL-2 
therapy [Ndhlovu et al., 2010]. IL-7 immunotherapy, however, was not associated with an increase 
in Treg cell frequencies, but with an increase in T-cell activation [Sereti et al., 2009]. It is therefore 
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crucial to consider the impact of immunotherapies, such as cytokine (IL-2, IFN-α, IL-7) 
administration, inhibitory receptor blockade, and therapeutic vaccination, on the induction of Treg 
cells, and strategies to control this cell type may be warranted [Macatangay & Rinaldo, 2010]. 
One potential confounding factor in such approaches, and in fact, a possible reason for such 
conflicting data on the role of Treg cells in HIV-1 infection may be the different markers that are 
used to identify these cells. Commonly used markers such as CD25 and FoxP3 are also found on 
other T-cell subsets [Macatangay & Rinaldo, 2010]. Abnormal expression of CD27 and CD127 
have been described during HIV-1 disease, rendering these markers unreliable to identify Treg 
cells, and the CD3
+
CD4
+
CD25
high
CD45RO
+
 phenotype was found to correlate with FoxP3 
expression in both HIV-1
+
 patients and uninfected individuals [Burton et al., 2011]. 
CD4 TH17 cells are effector cells which secrete interleukin-17A (IL-17A), and may also secrete IL-
17F, IL-22, and CCL20; they have been shown to induce and regulate inflammatory responses, thus 
playing a crucial role in host defence [Ndhlovu et al., 2008; Yue et al., 2008; Milner et al., 2008; 
Steinman, 2008; Guillot-Delost et al., 2012]. During HIV-1 infection, the frequency of TH17 cells is 
found to be decreased in both the peripheral blood and gut-associated lymphoid tissue (GALT); a 
depletion which appears to be unfavourable in terms of HIV-1 control [Macal et al., 2008; 
Prendergast et al., 2010; Ndhlovu et al., 2010]. The depletion of TH17 cells from the gut mucosa 
after HIV-1 infection may lead to microbial translocation and increased immune activation 
[Brenchley & Douek, 2008; Aujla et al., 2007]. IL-2 has been found to induce the proliferation of 
TH17 cells, and in combination with IL-1β thought to drive CD4
+
CD25
+
 Treg cells into a TH17 
phenotype [Deknuydt et al., 2009], although when used alone, IL-2 has also been reported to block 
IL-17 production and inhibit TH17 cell development [Laurence et al., 2007; Downey & Imami, 
2010]. In one study, administration of IL-2 to HIV-1
+
 patients on ART did not alter the numbers of 
peripheral blood TH17 cells [Ndhlovu et al., 2010]. Another group reported TH17 numbers to be 
greater in long-term non-progressors (LTNP) compared to typical progressors, and HIV-1 RNA 
inversely correlated with IL-17 receptor expression and TH17 cell numbers [Salgado et al., 2011]. 
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CD4 TH17 cells have been described as having a CD45RO
+
CCR6
+
CD161
+
 phenotype, and IL-17 
producing cells have been detected in a minor population of CD8 T cells; these were found to be 
CD27
+/-
CD28
+
CD45RA
-
CCR6
+
CCR5
+ 
and
 
to produce IFN-γ [Guillot-Delost et al., 2012]. CD90 
was recently described to be a marker of a subset of TH17 cells (both CD4 and CD8) that are 
depleted during HIV-1 infection [Guillot-Delost et al., 2012]. Thus, TH17 cells represent an 
important cell type to consider, particularly in the case of immune-based therapies in the context of 
treated HIV-1 infection. 
1.3.4 Chronic immune activation 
Increasing evidence shows that high levels of immune activation are associated with disease 
progression in HIV-1 infection [Hazenberg et al., 2003; Giorgi, 1993; Sousa et al., 2002], although 
the precise mechanisms for this remain unclear [Hunt et al., 2003]. One study reported an 
association between the level of activation and the differentiation state of T cells; HIV-1 induces the 
activation of cells, both directly and indirectly, resulting in the differentiation of CD8 T cells toward 
replicative senescence [Papagno et al., 2004]. During HIV-1 infection, the immunosuppression that 
occurs may lead to increased replication of other viruses present in the host such as 
cytomegalovirus (CMV) and Epstein-Barr Virus (EBV), leading to further immune activation 
[Doisne et al., 2004]. One study found significantly higher levels of CMV-specific effector CD8 T 
cells in HIV-1
+
 patients compared to HIV-1 seronegative, CMV seropositive controls, and these 
levels were comparable to those typically found in much older individuals [Naeger et al., 2010]. A 
recent study of ART-treated HIV-1
+
 CMV seropositive patients with low CD4 T-cell counts 
reported that daily administration of valganciclovir for eight weeks resulted in CMV DNA levels 
becoming undetectable and significant reductions in CD8 T-cell activation (as measured by co-
expression of CD38 and HLA-DR) compared to placebo-treated patients [Hunt et al., 2011]. 
Moreover, hepatitis C virus (HCV) co-infection has been associated with progression to 
AIDS/death during HAART [Greub et al., 2000; Kovacs et al., 2010]. The translocation of 
microbial products from the damaged gut may be another mechanism for increased immune 
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activation [Brenchley et al., 2006; Douek et al., 2009]. The elevated and chronic stimulation 
induced by HIV-1 may result in the exhaustion of the capacity to generate new T cells [Hazenberg 
et al., 2003]. In addition to a direct effect of HIV-1 on the thymus, decreased thymic output and T-
cell renewal may originate from thymic involution [Kalayjian et al., 2003], as well as the failure of 
the bone marrow and a reduction of primitive haematopoietic stem cell subsets [Marandin et al., 
1996; Moses et al., 1998], as observed in HIV-1
+
 individuals. 
CD8 T-cell activation levels, in terms of CD38 and HLA-DR co-expression, decline with lower 
levels of viral replication, with even further decreases seen with ART-mediated viral suppression; 
however, even in aviraemic, treated HIV-1
+
 patients, abnormal levels of T-cell activation persist 
(compared to levels found in HIV-1 seronegative controls) [Hunt et al., 2003; Bartovska et al., 
2011; Hunt et al., 2008]. Additionally, high levels of CD8 T-cell activation have been shown to 
correlate with incomplete CD4 T-cell recovery following initiation of ART [Hunt et al., 2003]. 
Microbial translocation has been shown to correlate with immune activation, and to have an inverse 
correlation with immune reconstitution following the initiation of HAART [Jiang et al., 2009]. 
Additionally, microbial translocation (as measured by levels of plasma LPS) decreases with 
HAART but remains significantly higher than uninfected controls [Jiang et al., 2009]. Microbial 
translocation is thought to have a profound impact on both immune activation and inflammation, 
which may result in HIV-1 disease progression, non-AIDS defining co-morbidities, and early aging 
[Volberding & Deeks, 2010]. Non-AIDS events were found to be more common in HIV-1 disease, 
even after adjustment for age, HAART exposure, and traditional risk factors, further indicating 
persistent inflammation and activation may play a role in the premature aging of the immune 
system of HIV-1-infected individuals [Deeks & Phillips, 2009]. Activation levels on cells of the 
innate immune system are also important to consider; levels of soluble CD163 in the plasma of 
HIV-1-infected subjects have been associated with disease progression, and HAART does not 
normalise these levels to those seen in healthy persons [Burdo et al., 2011]. One 
immunomodulatory agent that has been shown to reduce levels of immune activation in therapy-
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naïve HIV-1
+
 patients is atorvastatin (a drug typically used to lower cholesterol levels); subjects that 
received atorvastatin for eight weeks demonstrated significant reductions in both CD4 and CD8 T-
cell activation compared to placebo-treated patients, although HIV-1 RNA levels were unaffected 
[Ganesan et al., 2011]. 
Key insights into HIV-1 pathogenesis may be derived from studies investigating non-progressive 
SIV infection in natural hosts such as sooty mangabeys or African green monkeys [Pandrea et al., 
2008]. In contrast with pathogenic HIV-1 infection and SIV infection in rhesus macaques, the 
hallmarks of non-progressive SIV infection include lower levels of immune activation and 
apoptosis, a lack of excessive T-cell proliferation, and normal levels of LPS during acute and 
chronic infection, suggestive of an intact intestinal barrier, despite massive CD4 T-cell loss and 
viral replication during primary infection [Silvestri et al., 2003; Pandrea et al., 2008]. 
1.3.5 Co-inhibitory receptors and immune exhaustion 
A balance between co-stimulatory signals that activate T cells and inhibitory signals that minimise 
harmful inflammatory responses is crucial in terms of regulating virus-specific memory CD4 and 
CD8 T cells that are necessary to control viral replication [Pitcher et al., 1999; Addo et al., 2007; 
Chen, 2004; Crawford & Wherry, 2009; Kassu et al., 2010]. T-cell activation, proliferation and 
differentiation occur following binding of the TCR to the cognate MHC-peptide complex and 
simultaneous binding of CD28 to CD80/CD86; whereas cell cycle arrest, decreased function and 
death occur when ligation of an inhibitory receptor accompanies the TCR MHC-peptide interaction 
[Chen, 2004; Crawford & Wherry, 2009]. The balance between excitatory and inhibitory signals is 
skewed in chronic viral infections toward a negative regulatory pathway, in such a way that virus-
specific T-cell function is compromised and ongoing viral replication and/or persistence occurs 
[Crawford & Wherry, 2009; Virgin et al., 2009; Kaufmann & Walker, 2008; Kaufmann & Walker, 
2009; El-Far et al., 2008]. Virus-specific CD4 T cells become exhausted during HIV-1 infection 
and lose effector function, and HIV-1-specific CD8 T cells have impaired cytolytic function and 
skewed differentiation patterns, leading to ineffective T-cell responses [Crawford & Wherry, 2009; 
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Virgin et al., 2009; El-Far et al., 2008; Addo et al., 2007]. It has been suggested that signalling 
through inhibitory receptors, such as programmed death 1 (PD-1), cytotoxic T-lymphocyte antigen-
4 (CTLA-4), and T-cell immunoglobulin and mucin domain-containing molecule 3 (TIM-3) may 
play a role in the T-cell dysfunction seen in HIV-1 infection, contributing to what has been termed 
T-cell exhaustion [Kaufmann & Walker, 2008; Kaufmann & Walker, 2009; El-Far et al., 2008; Day 
et al., 2006; D’Souza et al., 2007; Jones et al., 2008; Kaufmann et al., 2007; Petrovas et al., 2006; 
Trautmann et al., 2006]. 
PD-1 was first described as a surface receptor involved in apoptosis [Ishida et al., 1992]; it is a 
negative regulator of T cells, and engagement of PD-1 with its ligands PD-L1 and PD-L2 leads to 
an inhibition of T-cell proliferation and cytokine production [Greenwald et al., 2005]. PD-1 
expression on CTL has been found to correlate with viral load and disease progression in untreated 
HIV-1-infected subjects [Kaufmann & Walker, 2009]. Control of viral load following the initiation 
of ART resulted in reduced PD-1 expression on HIV-1-specific CTL, and in vitro blockade of the 
PD-1 pathway with an anti-PD-L1 antibody leads to enhanced HIV-1-specific T-cell proliferation 
[Day et al., 2006; Trautmann et al., 2006; Kaufmann & Walker, 2009]. PD-1 was found to be 
similarly up-regulated on the total CD4 T-lymphocyte population in HIV-1-infected subjects, and 
levels of PD-1 correlated directly with viral load and inversely with CD4 T-cell count [Day et al., 
2006]. CD4 T-cell proliferative responses were found to be improved when the PD-1 pathway was 
blocked in vitro with an anti-PD-L1 antibody, and a strong correlation was described between PD-1 
levels in CD4 and CD8 Gag-specific T cells [Day et al., 2006; D’Souza et al., 2007]. HIV-1 
controllers and LTNP were found to have lower PD-1 expression compared to patients with high 
levels of viral replication and disease progression [Zhang et al., 2007]. Recently, PD-1 has been 
proposed as a marker to identify individuals failing reconstitution despite viral suppression with 
ART and a reduction in the expression of markers associated with immune activation [Grabmeier-
Pfisterhammer et al., 2011]. Examination of PBMC from HIV-1-infected persons found PD-L1 
expression to be significantly elevated on monocytes and B cells compared with healthy controls, 
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and PD-L1 levels correlated directly with viral load and inversely with CD4 T-cell count 
[Trabattoni et al., 2003]. Although PD-1 expression was found to be normalised in aviraemic 
patients on ART, levels of PD-L1 remained elevated compared to healthy seronegative controls 
[Rosignoli et al., 2007]. 
CTLA-4 binds to B7 molecules with a higher affinity than does CD28 [Curran et al., 2010]; it is 
rapidly up-regulated following T-cell activation, and its inhibitory mechanism works by reducing 
IL-2 production and by arresting cell cycle progression [Greenwald et al., 2005]. CTLA-4 
expression is increased on total and virus-specific CD4 T cells during chronic HIV-1 infection 
[Kaufmann et al., 2007; Zaunders et al., 2006; Leng et al., 2002], although it is not highly 
expressed on HIV-1-specific CTL [Kaufmann & Walker, 2009]. Even after four years of ART, CD4 
T cells from HIV-1
+
 individuals have raised levels of CTLA-4 expression, in addition to a higher 
number of cells that contain low levels of CD28, suggestive of a population of cells that are unable 
to respond to antigen [Downey & Imami, 2010]. Moreover, increased HIV-1-specific CD4 T-cell 
proliferative responses were reported following inhibition of CTLA-4 in vitro [Kaufmann & 
Walker, 2009]. 
TIM-3 was identified as a cell surface marker of mouse Th1 CD4 T cells [Monney et al., 2002]; 
mouse TIM-3 interacts with its ligand, galectin-9, and promotes the death of IFN-γ-producing Th1 
cells, thus regulating this response [Zhu et al., 2005]. TIM-3 expression was found to be increased 
on CD8 T cells from treatment naïve HIV-1-infected persons compared to healthy seronegative 
controls, and levels correlated with HIV-1 viral load and CD38 expression and inversely with CD4 
T-cell count [Jones et al., 2008]. Furthermore, initiation of ART only reduced TIM-3 expression in 
some individuals [Jones et al., 2008]. Progressive HIV-1 infection was shown to be marked by 
increased expression of TIM-3 on HIV-1-specific CD8 T cells, and in vitro blockade of the TIM-3 
signalling pathway restored proliferative capacity and increased cytokine production to virus-
specific T cells [Jones et al., 2008]. A recent report postulates that CD8 T cells that are restricted by 
protective HLA alleles, such as HLA B*27 and B*57, up-regulate less TIM-3 but more granzyme B 
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upon recognition of their cognate epitopes, and are thus less susceptible to regulatory T-cell-
mediated suppression and instead kill the regulatory T cells that they encounter, and subsequently 
control HIV-1 replication [Elahi et al., 2011]. 
One study used a combination of these co-inhibitory markers and found that ART-treated HIV-1-
infected patients had significantly lower percentage expression of PD-1, CTLA-4 and TIM-3–
expressing, IFN-γ-producing CD4 T cells compared with untreated viraemic subjects [Kassu et al., 
2010]. Further elucidation of the mechanisms of action of these negative regulatory molecules may 
lead to a better understanding of the role that these receptors and their ligands play in HIV-1-
specific T-cell dysfunction. This may provide a novel therapeutic target to reverse HIV-1 induced 
anergy and enhance immune reconstitution after HAART [Kaufmann & Walker, 2009]. 
1.3.6 Long-term non-progressors, HIV-1-controllers and exposed seronegatives 
Long-term control of HIV-1 infection in the absence of therapy is only achieved by a small number 
of infected individuals, and the mechanisms by which this control is achieved remain debatable 
[Dembek et al., 2010]. HIV-1
+
 patients who are able to maintain stable CD4 T-lymphocyte counts 
within the normal healthy range for a prolonged period of time, and remain asymptomatic without 
ART, are termed long-term non-progressors (LTNP), and account for approximately 5% of 
individuals infected with HIV-1 [Mandalia et al, 2012; Okulicz et al., 2009]. HIV-1 controllers 
(HIC), or elite controllers, make up less than 1% of the infected population, and are additionally 
able to supress HIV-1 replication below the limit of detection of most standard clinical assays (<50-
75 HIV-1 RNA copies per ml plasma), again in the absence of ART [Deeks & Walker, 2007]. 
Insights into the mechanisms of control in the absence of therapeutic interventions may be gleaned 
from the study of such patients [Imami et al., 2002]. Reports have suggested that disease 
progression in LTNP is inevitable and the rate of disease progression may be associated with 
virological, immunological and genetic factors [Easterbrook, 1994; Lefrere et al., 1997; Mandalia et 
al., 2012]. These same factors are believed to be responsible for the control exhibited by these 
individuals, and both LTNP and HIC have demonstrated durable and broad HIV-1-specific CD4 
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and CD8 T-cell responses [Imami et al., 2002; Deeks & Walker, 2007]. Particular MHC class I 
alleles have been shown to correlate with delayed disease progression in HIV-1
+
 subjects [Migueles 
et al., 2000; Carrington et al., 1999]; in Europeans, HLA-alleles B*5701, B*2701, B*14/Cw*0802, 
B*52 and A*25 have been associated with protection, and B*35 and B*07 associated with more 
rapid HIV-1 disease progression [Carrington & Walker, 2012]. Many LTNP possess the HLA-B*57 
allele which has been associated with enhanced peptide presentation on the surface of CD4 T cells 
to cytotoxic CD8 T cells [Pereyra et al., 2010; Migueles et al., 2008]. HLA-B*5701
+
 LTNP/elite 
controllers were found to have oligoclonal HLA-B*5701-restricted p24-specific CD8 T-cell 
responses with similar levels of diversity to HLA-matched progressors, and both groups had few 
public clonotypes [Mendoza et al., 2012]. Thus, immunologic control is unlikely to be mediated by 
variations in the TCR repertoire of immunodominant HIV-1-specific CD8 T-cell populations 
[Mendoza et al., 2012]. Furthermore, high levels of HLA-C expression have been suggested to be 
advantageous in terms of host genetic control [Carrington & Walker, 2012], and recently, the MHC 
class III sub-region has been described as a major marker of the LTNP phenotype [Guergnon et al., 
2012]. 
HIV-1-specific CD8 T-cell proliferation and perforin production have been described in non-
progressors; attributes which have been found to be lacking in aviraemic patients on suppressive 
ART [Migueles et al., 2002]. Non-progressors have also been demonstrated to have enhanced CD8 
T-cell polyfunctionality in the blood [Betts et al., 2006; Zimmerli et al., 2005], and in the mucosa 
[Ferre et al., 2009], with the ability to suppress HIV-1 infection ex vivo [Saez-Cirion et al., 2007]. 
In HLA-B*27/B*57
+ 
LTNP, cell-associated HIV-1 DNA was found to be lower in the CD4 TCM 
cells compared to levels in the same T-cell compartment for LTNP without these protective alleles 
[Descours et al., 2012]. Further, TCM counts were preserved in patients with these protective alleles, 
and this correlated positively with the magnitude of the HIV-1 Gag-specific CD8 T-cell response 
[Descours et al., 2012]. In terms of immune activation, elite controllers were found to have lower 
frequencies of activated CD8 T cells (in terms of CD38 and HLA-DR co-expression) compared to 
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progressors, yet these levels were still significantly higher than those seen in uninfected persons 
[Brenchley et al., 2006; Kamya et al., 2011]. One study found activation levels in such patients to 
be associated with slow CD4 T-cell depletion [Hunt et al., 2008], while another reported that 
elevated activation levels in elite controllers did not correlate with a faster rate of CD4 T-cell 
decline [Kamya et al., 2011]. 
Another group of individuals from which important insights may be garnered, particularly in terms 
of correlates of protection against HIV-1, are individuals that do not get infected despite high 
exposure to HIV-1. These individuals are referred to as highly exposed seronegatives (HESN) and 
have been identified among intravenous drug users, children born to seropositive mothers, 
discordant couples, and commercial sex workers [Songok et al., 2012]. Only a fraction of these 
HESN have genotypes associated with protective HLA-alleles, TRIM5α, specific KIR-HLA 
associations, and APOBEC3G [MacDonald et al., 2000; Carthagena et al., 2008; Boyton & 
Altmann, 2007; Valcke et al., 2006]. Microarray analysis suggests that HIV-1 resistance occurs as a 
result of a down-regulation of genes that are involved in key signalling pathways that HIV-1 
depends on for infection, such as natural killer cell cytotoxicity and TCR signalling [Songok et al., 
2012]. Examination of samples from the genital mucosa of HESN commercial sex workers 
implicated lower T-cell activation/recruitment at the mucosal compartment as a means of reducing 
the number of HIV-1 target cells, which may play a role in natural protection from HIV-1 infection 
[Lajoie et al., 2012]. Moreover, it was found that the protective HLA-allele A*01:01 only 
recognises three Gag epitopes whereas B*07:02, an allele associated with susceptibility, binds thirty 
epitope variants, and it is this binding of more epitopes that is thought to be associated with 
susceptibility in HIV-1 infection [Luo et al., 2012]. 
1.4 Immunotherapy in treated HIV-1 infection 
Immune-based therapeutic interventions in chronic treated HIV-1 infection have the potential to 
reverse T-cell dysfunction and modify immune responses to mirror those seen in LTNP or HIC 
[Imami et al., 2001; Imami et al., 2007]. Ideal immunotherapeutic approaches would induce and 
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maintain HIV-1-specific responses, increase polyfunctionality, enhance thymic function, reduce 
levels of immune activation, reverse T-cell anergy/exhaustion, and improve skewed 
differentiation/maturation pathways [Imami et al., 2007]. A number of immunotherapeutic 
strategies in HIV-1 infection are described in the literature; however, this section will focus 
primarily on the immunomodulatory agents that are investigated in this thesis, namely recombinant 
human growth hormone (rhGH), the cytokines interleukin-2 (IL-2) and granulocyte-macrophage 
colony-stimulating factor (GM-CSF), and therapeutic immunisation. 
1.4.1 Recombinant human growth hormone 
Growth hormone (GH) secretion and subsequent insulin-like growth factor-1 (IGF-1) release is 
essential for human growth and development, and it has been implicated to play a role in 
lymphocyte development and function [Welniak et al., 2002]. Early research indicated a role for 
GH in the improvement of a variety of immune functions, including B-cell responses [Kimata & 
Yoshida, 1994; Kimata & Fujimoto, 1994], macrophage activity and T-cell functions [Stephenson 
et al., 1991]. In vitro studies in mice have demonstrated the ability of GH to enhance T-cell 
functions, stimulate thymic growth, and improve the function of thymic epithelial cells [Snow et al., 
1981; Knyszynski et al., 1992; Yamada et al., 1994]. GH administration in humans has also been 
linked with improvements in immune function, especially in elderly men and women [Khorram et 
al., 1997]. The role of the thymus in immune function is critical [Ho Tsong Fang et al., 2008], yet 
the mechanism by which GH affects the thymus in humans is unclear. It is possible that there is a 
direct effect, or an effect through IGF-1, which has been shown to have anti-apoptotic properties 
[Kooijman, 2006; Sabharwal & Varma, 1996]. It is also possible that GH could promote the 
production of IL-7 or stem cell factor from thymic epithelial cells. GH deficiency in humans, 
however, is not associated with thymic defects or T-cell deficiencies [Welniak et al., 2002], 
possibly representing redundancy. 
In addition to the effects on the thymus, GH can affect T cells directly in the periphery; GH and 
IGF-1 have been shown to increase T-cell functions in vitro [Taub et al., 1994]. In accordance with 
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this effect on the periphery, up to 10% of peripheral blood lymphocytes secrete active GH [Varma 
et al., 1993; Hattori et al., 1990], and B cells contain the majority of GH mRNA [Hattori et al., 
2001], indicating that GH can be produced and act locally. The GH receptor has been found to be 
expressed on activated T cells [Thellin et al., 1998] and at varying levels on peripheral T cells, B 
cells and neutrophils [Hattori et al., 2001]. IGF-1 and its receptor are also expressed by leukocytes; 
human leukocytes are capable of producing IGF-1 on stimulation with GH [Baxter et al., 1991], the 
main source of which are macrophages [Kirstein et al., 1992]. It is currently unclear which memory 
subsets of T cells express GH or IGF-1 receptors, and the direct effect that GH has on T cells. 
During HIV-1 infection, naïve T cells are progressively depleted [Roederer et al., 1997] and their 
maintenance may depend on the thymus [Douek et al., 2003]. However it is likely that thymic 
function is impaired during HIV-1 infection [Douek et al., 2001; Dion et al., 2004]. It has been 
suggested that a role for GH in the immune response could be to counteract the immnosuppressive 
effects of immunological stress [Welniak et al, 2002]. As HIV-1 infection puts the immune system 
under stress, GH can potentially be used to enhance the effects of HAART on thymic recovery. A 
study in HIV-1 infected children indicated a role for GH in thymic and post-thymic pathways; 
growth hormone-deficient children show different percentages of effector and memory T-cell 
subsets, as well as smaller thymic volume and lower IL-7 levels in serum [Vigano et al., 2004]. 
Recombinant human growth hormone (rhGH) has been used to treat HIV-1-associated wasting and 
HIV-1-associated lipodystrophy [Gelato et al., 2007; Sivakumar et al., 2011], and was found to 
restore lean body mass and improve physical function, body weight, body composition and quality 
of life for HIV-1
+
 patients with HIV-1-associated wasting [Moyle et al., 2004]. Furthermore, HIV-
1-infected individuals with abdominal fat accumulation who received daily, low-dose rhGH 
demonstrated significant reductions in visceral fat, truncal obesity, and triglycerides [Lo et al., 
2008]. A number of studies have shown that in vivo administration of rhGH to HIV-1-infected 
subjects may be associated with thymopoietic effects; circulating naïve CD4 T cells were found to 
be increased [Pires et al., 2004b; Napolitano et al., 2002], recent thymic emigrants (as measured by 
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T-cell receptor excision circle (TREC) content in PBMC) were found to be elevated [Napolitano et 
al., 2008; Smith et al., 2010], and thymic involution was shown to be reversed [Napolitano et al., 
2002; Napolitano et al., 2008; Hansen et al., 2009; Smith et al., 2010]. Moreover, rhGH has been 
shown to promote the restoration of T-cell responses against HIV-1 [Pires et al., 2004b; 
Herasimtschuk et al., 2008], and to reduce the levels of T-cell surface markers that are associated 
with immune activation and senescence [Napolitano et al., 2008]. rhGH has not been associated 
with reductions in levels of HIV-1 proviral DNA [Herasimtschuk et al., 2008], although this 
parameter has not been widely assessed in such studies. Additionally, rhGH has been shown to 
reverse NK cell dysfunction that is seen in treated chronic HIV-1 infection [Goodier et al., 2003]. 
1.4.2 Interleukin-2  
Interleukin-2 (IL-2) was discovered in 1975 as a growth factor for bone marrow derived T cells and 
has since been extensively studied and found to have diverse effects on different cell types of the 
immune system [Oppenheim, 2007]. IL-2 belongs to a family of cytokines (that includes IL-4, IL-7, 
IL-9, IL-15 and IL-21), and signals through a receptor complex consisting of a specific IL-2 
receptor alpha (CD25), IL-2 receptor beta (CD122) and a common gamma chain (γc) which is 
shared by all members of this family of cytokines [Wang et al., 2009]. Binding of IL-2 activates the 
Ras/MAPK, JAK/Stat and PI 3-kinase/Akt signalling molecules [Ellery & Nicholls, 2002]. Antigen 
binding to the TCR stimulates the secretion of IL-2, and the expression of IL-2 receptors and 
production of IL-2 is normally seen during an immune response [Smith et al., 1988]. IL-2 promotes 
the differentiation, growth and survival of antigen-selected T cells by the activation of specific 
genes [Beadling et al., 1993; Beadling & Smith, 2002], allowing the rapid selective expansion of 
naïve T cells, and the development of memory T cells [Smith, 1988; Hoyer et al., 2008]. This 
proliferation occurs via both pro-proliferative and anti-apoptotic signals [Ellery & Nicholls, 2002; 
Nelson et al., 1994]. 
Levels of IL-2 fall during HIV-1 infection, and low levels have been associated with disease 
progression [Johnson & Parkin, 1997]. The use of IL-2 as an immunotherapy in HIV-1 infection has 
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been widely studied and found to increase the number of circulating CD4 T cells, however despite 
sustained elevated levels of CD4 T cells, no clinical benefit was found following the administration 
of IL-2 in addition to ART in HIV-1-infected patients [Marchetti et al., 2008; Abrams et al., 2009]. 
In one study, IL-2 immunotherapy was not found to alter the number of peripheral TH17 cells in 
ART-treated HIV-1
+
 patients, but it did expand the Treg cell population, which might suppress 
HIV-1-specific responses [Ndhlovu et al., 2010], although reports on the effect of Treg cells in 
HIV-1 infection have been mixed [Elahi et al., 2011]. Furthermore, IL-2 therapy was not associated 
with reductions in the HIV-1 viral reservoir [Pett et al., 2010], nor was it found to alter the 
proportion or activation state of CD4 T cells in the gut mucosa [Read et al., 2011]. IL-2 has been 
suggested as a candidate molecule to use in conjunction with therapeutic immunisation to increase 
HIV-1-specific responses and to control viral load, but results to date have been conflicting [Levy et 
al., 2005; Hardy et al., 2007]. These divergent reports may be due in part to differences in the 
patient cohorts studied, and the stage of HIV-1 disease, length of time on ART, CD4 T-cell count 
and nadir CD4 T-cell count are important parameters to consider in such trials [Hardy et al., 2007]. 
1.4.3 Granulocyte macrophage colony stimulating factor 
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a haematopoeitic growth factor 
and immune modulator; it promotes the differentiation and mobilisation of myeloid cells in vivo 
[King et al., 2010]. It was initially defined by its ability to generate granulocytes and macrophage 
colonies from precursor cells [Burgess & Metcalf, 1980], and it can enhance the number and 
function of various cell types including neutrophils, monocytes and lymphocytes [Shi et al., 2006]. 
It is primarily produced by activated T and B cells but also by macrophages, fibroblasts, 
eosinophils, epithelial, and endothelial cells [Griffin et al., 1990]. GM-CSF production is minimal 
under normal conditions and one study found only low levels in the sera of half of individuals tested 
[Cebon & Layton, 1994]. GM-CSF acts in an autocrine and paracrine fashion on target cells 
expressing its receptor. The receptor is expressed on neutrophils, eosinophils, monocytes, 
macrophages, as well as granulocyte-macrophage progenitors and signalling through the receptor 
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induces changes in the activation state and function of cells [Hansen et al., 2008]. In addition to its 
function as a growth factor, it has been suggested that GM-CSF is a pro-inflammatory cytokine 
[Hamilton, 2002]. It has been found at raised levels in sera in response to LPS [Sheridan & Metcalf, 
1972] and in the joints of patients with arthritis [Williamson et al., 1988]. It may have a role in 
various human inflammatory diseases such as rheumatoid arthritis and pathological changes follow 
its over-expression [Hamilton & Anderson, 2004]. mRNA for the GM-CSF receptor has been found 
on T cells indicating a possibility that it is expressed on T lymphocytes [al-Aoukaty et al., 1994]. In 
vitro studies have shown that GM-CSF can augment the induction of a lymphokine-activated killer 
(LAK) response to IL-2 and also IL-2 induced proliferation [Stewart-Akers et al., 1993; Santoli et 
al., 1988]. In vitro studies have shown GM-CSF to enhance the activity of antiretroviral agents, 
suggesting a role for GM-CSF in the purging of viral reservoirs when used in conjunction with 
HAART [Hammer et al., 1990], while in vivo studies have indicated a lower frequency of 
antiretroviral drug-resistant HIV-1 mutants in subjects receiving GM-CSF in addition to zidovudine 
(AZT) [Brites et al., 2000]. It is unknown whether administration of GM-CSF results in a Th1 or 
Th2 T-cell response, although it has been suggested that it is capable of inducing both, depending 
on the conditions [Shi et al., 2006]. A mouse model study using a bicistronic HIV-1 DNA vaccine 
expressing gp120 and GM-CSF reported a greater than 7-fold increase in the CD4 T-cell response 
in terms of IFN-γ production [Barouch et al., 2002]. Another study in mice showed complete 
protection from viral challenge with a recombinant vaccinia virus expressing HIV-1 gp160 co-
administered with GM-CSF, IL-12, and TNF-α; and in these experiments, GM-CSF was found to 
enhance antigen presentation [Ahlers et al., 2001]. Thus, GM-CSF has been shown to alter T-cell 
responses directly, as well as indirectly, and to provide a link between innate and adaptive immune 
responses [Shi et al., 2006]. 
The potential for the use of GM-CSF as an immune-based therapy in HIV-1 infection has been 
considered and it has been the subject of a number of phase III clinical studies [Brown & Angel, 
2005]. GM-CSF production is significantly reduced in HIV-1 infection [Esser et al., 1996; Esser et 
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al., 1998], and replacement therapy in treated HIV-1
+
 individuals has been shown to significantly 
increase the number of CD4 T cells [Angel et al., 2000], reduce viral load and improve clinical 
outcome [Brites et al., 2000], although these results have not been universally observed [Brown & 
Angel, 2005]. Clinical benefit has been attributed to the co-administration of IL-2 and GM-CSF in 
HIV-1-infected patients on effective ART with mycobacterial immune reconstitution inflammatory 
syndrome (IRIS), suggesting the potential for such therapy in later stages of HIV-1 disease [Imami 
et al., 1999; Pires et al., 2005]. 
1.4.4 Therapeutic immunisation 
Further to the cytokines and hormones mentioned above, HIV-1-specific T-cell responses can be 
induced by therapeutic immunisation [Heath & Kilby, 2006]. The introduction of exogenous HIV-1 
antigens promotes protective immune responses by steering T cells to react to conserved HIV-1 
epitopes [McMichael, 2006]. Antigen-specific immunity can be achieved through HIV-1-specific 
DNA immunisation: one or multiple HIV-1 genes are cloned into a mammalian expression plasmid, 
which is delivered to the host. The host in turn expresses the DNA encoded antigen within its own 
cells [Ulmer et al., 1993]. As genetic vaccines are endogenously processed through the cellular 
machinery they are capable of producing CTL clones as well as inducing neutralizing antibodies 
[Donnelly et al., 2005]. 
Therapeutic vaccinations in rhesus macaques have shown that immunity can be stimulated and viral 
loads reduced [Lu et al., 2003], and SIV-specific responses were enhanced when a DNA vaccine 
encoding SIV structural proteins was given in conjunction with plasmids expressing IL-12 or IL-15 
to chronically infected rhesus macaques treated with anti-retrovirals [Halwani et al., 2008]. Studies 
in HIV-1-infected individuals have shown reductions in plasma viraemia and evidence of improved 
HIV-1-specific T-cell responses following immunisation [Lu et al., 2004; Levy et al., 2005; 
MacGregor et al., 2005; Moss et al., 2000]. In a recent study, therapeutic vaccination with LFn-
p24C, a detoxified anthrax-derived polypeptide fused to the subtype C HIV Gag p24 protein, was 
shown to be well-tolerated with HIV-1 RNA levels remaining undetectable after three 
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immunisations, increased CD4 T-cell counts in the vaccine group compared to the placebo-treated 
group after 12 months, and HIV-1-specific responses associated with higher CD4 T-cell gains 
[Kityo et al., 2011]. Following a 30-day treatment interruption, eight out of twenty four individuals 
showed no evidence of viral rebound during this period, and for all subjects, viral load was quickly 
suppressed once ART was resumed [Kityo et al., 2011]. 
The vaccine used in the study (GTU®-MulltiHIV B Clade) was provided by FIT Biotech (Finland). 
It is comprised of both regulatory and structural HIV-1 proteins (Rev, Nef, Tat, Gag p17, Gag p24 
and a stretch of 11 cytotoxic T lymphocyte (CTL) epitope clusters from Pol and Env), representing 
the B clade, cloned into a DNA vector termed the Gene Transport Unit (GTU®). The GTU® also 
codes for a nuclear anchoring protein (bovine papilloma virus E2) in order to maintain the vector 
and to keep the expression level of the selected immunogens high [Krohn et al., 2005; Blazevic et 
al., 2006]. E2 is a transcriptional regulator derived from bovine papilloma virus (BPV) [Ustav et al., 
1991] which has a dual function within the vector: it enhances the transcription and expression of 
the cloned MultiHIV antigen, and also binds simultaneously to stretches of BPV origin present in 
the vector, and to chromatin, thus assuring that the plasmid is not lost during mitosis in the dividing 
cells [Ilves et al., 1999]. The stability of the vector is enhanced and prolonged expression of the 
cloned antigen is facilitated. Figure 1.8 shows a schematic representation of the plasmid vector. 
This construct is expected to induce a broad immune response against several HIV proteins, 
producing a vaccine that might be effective in treated HIV-1
+
 individuals with high baseline CD4 
T-cell counts (400 cells/µl blood) in conjunction with immune-based therapy (IBT) [Imami et al., 
2007; Krohn et al., 2005]. 
The investigational vaccine has been tested in Phase I clinical trials in non-infected individuals and 
HAART-treated individuals in Finland and was found to be safe and well tolerated [Malm et al., 
2005; Blazevic et al., 2006]. A Phase II clinical trial in treatment naïve HIV-1 infected individuals 
in South Africa is currently ongoing. 
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Figure 1.8 The GTU

-MultiHIV-B (B-clade specific) plasmid construct. 
(A) The construct consists of a strong cytomegalovirus promoter, the intron/poly A sequence and an additional 
expression cassette for E2 with an additional viral promoter (such as RSV LTR or a CMV promoter). Also present are 
multimeric E2 protein binding sites (typically ten copies of BPV1 binding sites are added to the vector). In the Auxo-
GTU
 
variant, the antibiotic resistance gene has been replaced with the Ara D gene thus allowing production in 
bacterial cells without an antibiotic selection system (adapted from [Krohn et al., 2005]. (B) The MultiHIV-B antigenic 
insert consists of a fusion of the full-length regulatory proteins Rev, Nef and Tat, the structural proteins p17 and p24 
and stretches of T helper (TH) and cytotoxic T lymphocyte (CTL) epitopes from the Pol and Env proteins (adapted from 
[Malm et al., 2005]). 
 
1.5 Aims and hypotheses 
The overall hypothesis, based on a large amount of preliminary data, was that rational 
immunotherapy designed to induce the types of immune responses seen in LTNPs, and to reverse 
the anergic immunological state characteristic of chronic progression, should improve long-term 
cellular functional memory responses, which would result in greater virologic control and slower 
disease progression in treated chronic HIV-1 infection. Efficacious immune-based therapy may 
eventually enable chronically infected individuals to stop, or at least interrupt, HAART for 
prolonged periods of time. The central questions that I wished to address were ‘how can we induce 
or enhance protective HIV-1-specific immune responses, such as those observed in LTNP, in 
chronic progressors?’, and ‘how can we reverse persistent disrupted immunophenotypes that are 
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seen in treated HIV-1-infected subjects compared to healthy seronegative controls?’ Studies 
described in this thesis aim to pursue immune-based therapeutic approaches in chronically infected, 
HAART-treated HIV-1
+
 subjects, in order to evaluate both the quality and the quantity of the T-cell 
response. The main hypotheses for each chapter were as follows: 
1. Chapter 3 
a) Daily dosing with rhGH in addition to suppressive ART was hypothesised to boost HIV-
1-specific T-cell responses, and these responses subsequently maintained following 
cessation of rhGH therapy.  
b) Low-dose, longer term treatment with rhGH in ART-treated HIV-1+ patients was 
predicted to similarly enhance HIV-1-specific T-cell responses, and reduce the 
expression of T-cell markers associated with chronic immune activation and exhaustion.  
c) In vitro culture of PBMC with rhGH was hypothesised to result in improved 
immunophenotype, and characterisation of the GH receptor expected to reveal down-
regulation with HIV-1 infection (as compared to seronegative donors). 
2. Chapter 4 
a) Administration of therapeutic immunisation was hypothesised to result in boosted HIV-
1-specific T-cell responses, while concomitant administration of IL-2, GM-CSF and 
rhGH postulated to maintain these responses, and the administration of cytokines and 
hormone alone (or with therapeutic immunisation) was predicted to result in increased 
CD4 T-cell counts, improved functionality and phenotype at the final study time point 
compared to baseline.  
b) It was also hypothesised that this treatment schedule would be safe and well-tolerated. 
3. Chapter 5 
a) It was hypothesised that immune defects would persist in HIV-1+ patients despite 
suppressive ART compared to healthy control subjects, in terms of T-cell surface 
expression of markers of immune activation, exhaustion and senescence. 
64 
 
b) HIV-1 Gag- and Nef-specific functional responses were predicted to correlate with 
particular immunophenotpyes and successfully treated patients with low responses to 
these peptides predicted to have elevated levels of markers associated with immune 
activation, exhaustion, senescence and apoptosis on CD4 and CD8 T cells. 
To this effect, rhGH was administered to HIV-1-infected patients on suppressive ART, both at a 
supraphysiological/pharmacological dose and at a lower physiological dose. Additionally, 
therapeutic immunisation of HAART-treated HIV-1
+
 patients in conjunction with the administration 
of the cytokines IL-2, GM-CSF and rhGH was assessed. The primary aim was to investigate the 
effects of these immunomodulators and HAART on the immune system. The clinical implications 
of such immune-based therapeutic approaches in terms of patient benefit are immense, and would 
ideally result in slower disease progression, improved quality of life, and the potential for 
maintained virologic control during HAART interruption. Harnessing the plethora of current 
detailed scientific knowledge of the immune system and its role in controlling viral infections 
including HIV-1, and translating such knowledge into useful immunotherapy for patient benefit is 
extremely challenging; it is of immediate importance and addresses a substantial unmet clinical 
need. Although viral eradication from the infected host must remain the ultimate goal; enabling the 
host to co-exist with the virus may be a more realistic immediate goal. 
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Chapter 2 Materials and Methods 
2.1 Overview 
All work with HIV-1
+
 samples was carried out in the Containment Level III laboratory in the 
Department of Immunology at the Chelsea and Westminster Hospital, London, UK. All blood 
samples were processed immediately after collection and all phenotypic and functional assays 
carried out on fresh PBMC, unless otherwise detailed. 
2.2 Seronegative controls 
HIV-1 seronegative control individuals were recruited from the Department of Immunology 
following Imperial College London Occupational Health guidelines on sampling procedures.  
2.3 Patient cohort and ethical approval 
Patient samples acquired for the in vitro studies described in this report were obtained from the 
>5000 HIV-1
+ cohort from the St Stephen’s Centre at the Chelsea and Westminster Hospital 
[Mandalia et al., 2012]. Informed consent was obtained and all in vitro work was carried out under 
the ethical approval of the Riverside Research Ethics Committee (RREC1108).  
The rhGH study was approved by the RREC (REC reference number: 04/Q0406/119) and by the 
Chelsea and Westminster Hospital NHS Trust, and the patients’ informed consent was obtained. 
The low-dose rhGH study was registered at ClinicalTrials.gov (NCT 00119769) and the trial was 
approved by the regional scientific ethical committee, the Danish Medicines Agency, and the 
Danish Data Protection Agency 2004. Good Clinical Practice (GCP) standards were monitored and 
approved by the GCP Unit at the Copenhagen University Hospital, Denmark, and the Danish 
Medicines Agency. Ethics committee approval for the shipment of samples to the UK and approval 
from the Data Protection Agency was obtained prior to the shipment of the cryopreserved PBMC. 
The IMIRC 1003 study was registered with EudraCT (reference number 2008-000575-24) and 
experiments carried out on ex vivo clinical trial samples were approved by the relevant regulatory 
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authorities, including local and national ethical committees: the Genetic Therapy Advisory 
Committee (GTAC; reference number 145); the Medicines and Healthcare products Regulatory 
Agency (MHRA; reference number 19174/0262/001-0004); and the Research and Development 
office at the Chelsea and Westminster Healthcare NHS Trust (Research and Development study 
reference number 08IMM001). This study was also registered at ClinicalTrials.gov 
(NCT01130376). 
2.4 Sample collection 
Venous blood was drawn into Vacutainer™ 6ml lithium heparin (ref. 367885) and 10ml EDTA (ref. 
367873) blood collection tubes (Becton Dickinson, Oxford, UK). 
2.5 Viral load quantification 
Plasma viral load was determined by the use of the Versant HIV-1 RNA 3.0 bDNA assay (Siemens 
Healthcare Diagnostics, Camberley, UK). The assay was carried out according to the 
manufacturer’s instructions and had a detection range of 50 to 500,000 copies/ml plasma. 
Monitoring of viral load was performed as part of the patients’ routine care by St Mary’s Hospital, 
Department of Virology, Imperial College London Healthcare NHS Trust. A substantial protocol 
amendment for the IMIRC 1003 study was approved by GTAC and the MHRA (on the 13
th
 April 
2010) to change the laboratory which processed the HIV-1 viral load from St Mary’s Hospital, 
Imperial College London Healthcare NHS Trust to Barts and the London NHS Trust (for economic 
reasons within the Chelsea and Westminster Hospital NHS Trust).  
2.6 Lymphocyte subset analysis 
Murine anti-human monoclonal antibodies to CD3, CD4, CD8, CD56, CD19 and CD45 (Tetra One, 
Beckman Coulter, High Wycombe, UK) were used to mark lymphocytes within whole blood. 
Lymphocyte numbers were then evaluated using a Cytomics FC 500 flow cytometer (Beckman 
Coulter) and Tetra CXP (version 2.2) software [Burton et al., 2011]. This was carried out routinely 
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within the Clinical Laboratory in the Department of Immunology at the Chelsea and Westminster 
Hospital. 
2.7 Preparation of human male AB serum 
Frozen human male AB serum (50ml, Sigma Aldrich, Poole, UK, catalogue number H4522), 
screened for HIV-1 and -2, Hepatitis B and C, and CMV by the supplier, was heat inactivated by 
heating to 56˚C in a water bath for 30 minutes, inverting every ten minutes. This procedure 
inactivated complement but did not affect other essential components within the AB serum. The 
resulting 50ml of heat inactivated human male AB serum was then separated into 4ml aliquots in a 
sterile environment and stored at -20°C until required. 
2.8 Preparation of media and solutions 
Standard tissue culture medium (TCM) was made by adding Penicillin/Streptomycin (final 
concentration 100IU/ml and 100μg/ml respectively) and L-glutamine (final concentration 2mM) 
(+PSG) to RPMI-1640 (all from Sigma), and mixing gently. Freezing medium was prepared by 
supplementing foetal calf serum (FCS) with 10% dimethyl sulfoxide (DMSO) (both from Sigma). 
2.9 Separation of plasma 
Blood samples collected in EDTA or heparinised Vacutainers
TM
 were centrifuged at 1500rpm for 
ten minutes to separate the plasma. Plasma was aspirated and stored in 1ml aliquots at -80°C for 
future use. The volume of plasma removed was replaced with the same volume of Dulbecco’s 
Phosphate Buffered Saline (PBS; Sigma) and the sample processed further. 
2.10 Separation of peripheral blood mononuclear cells (PBMC) from whole blood 
Whole blood was diluted in a 1:1 ratio with PBS and mixed gently. Generally, heparinised whole 
blood was used for functional studies and EDTA whole blood used for phenotypic and genetic 
studies unless otherwise specified.  
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Density gradient centrifugation utilising Histopaque (Sigma) was used to separate PBMC from 
whole blood. In a sterile 50ml tube 20ml of the whole blood/PBS mix was overlaid onto 20ml of 
Histopaque and centrifuged at 2000rpm for 20 minutes at room temperature without the use of 
centrifuge brakes. A sterile Pasteur pipette was used to aspirate the resulting interface layer 
(PBMC) into a new sterile 50ml tube. The PBMC were washed once with RPMI-1640+PSG (for 
functional experiments) or PBS and centrifuged at 1800rpm for 10 minutes at room temperature 
with brakes on full to remove any Histopaque. The PBMC were then washed two more times with 
RPMI-1640+PSG (for functional experiments) or PBS and centrifuged at 1500rpm for 10 minutes 
at room temperature. 
Cell count and viability was measured using 25μl of the 50ml cell suspension stained with 25μl of 
0.4% Trypan blue (Sigma) . A KOVA Glasstic
®
 slide (Hycor Biomedical Inc., Edinburgh, UK) and 
microscope with magnification x 40 was used to count the cells. Live cells (those that did not stain 
blue) in two of the large squares were counted and the average number of cells per large square was 
used. 
The total number of cells present in the sample was calculated using the following formula: 
Total number of cells: 
Average number of cells in large square x chamber factor x dilution factor x total volume 
= Average number of cells in large square x 10
4
 x 2 x 50 
Only cell samples with cell viability greater than 70% were used. This was particularly important 
with HIV-1
+
 samples as virus-specific PBMC may be disproportionately lost. In one study, PBMC 
preparations from HIV-1
+
 subjects with viability greater than or equal to 70% demonstrated 
consistent lympoproliferative responses and were found to be suitable for functional analysis 
[Weinberg et al., 2000]. 
2.11 Cryopreservation and thawing of PBMC 
Freezing medium and a Nalgene® box (Nalge Nunc International, Hereford, UK) filled with 
isopropanol (Sigma) were cooled to 4°C. Cryotubes (Nalge Nunc International) were labelled and 
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placed in the box. PBMC were resuspended in the cold FCS/DMSO freezing medium to give a 
concentration of 5 x 10
6
 – 1 x 107 cells/ml. One ml of the cell suspension was transferred 
immediately to each cold cryotube and kept at 4°C. The Nalgene® box containing the cryotubes 
was then placed at -80°C for 24 hours. After 24 hours the cells were quickly transferred to liquid 
nitrogen (-170°C) for long-term storage. 
Cells were thawed as rapidly as possible at 30°C and resuspended in 50ml ice cold PBS (Sigma), 
added dropwise initially, then at a quicker rate. They were then immediately centrifuged at 1800rpm 
for 10 minutes, the supernatant discarded and centrifugation repeated to wash the cells. Thawed cell 
number and viability was then established using the method described in section 2.10. 
2.12 Surface staining of PBMC for flow cytometric analysis 
Specific antibodies for surface staining were aliquoted into labelled FACS tubes (Greiner Bio-One 
Ltd., Stonehouse, UK) as shown in the original panel (Table 2.1), in the expanded panel (Table 2.2) 
and in the panel used to characterise growth hormone receptor (GHR) expression (Table 2.3). 7μl of 
fluorescein isothiocyanate (FITC), phycoerythrin (PE), allophyocyanin (APC) and phycoerythrin 
(PE)-Cy7 – conjugated antibody were added to each tube. The volumes of peridinin chlorophyll 
protein (PerCp)-Cy5.5 and allophyocyanin (APC)-H7 were 5μl and 3μl respectively per tube. Table 
2.4 details the antibody, the fluorochrome conjugate, the clone, and the source, for all antibodies 
used in the experiments described in this thesis. 
The washed pellet of 1 x 10
7
 PBMC was resuspended in 600μl of PBS and this was divided 
between the tubes on the panel in Table 2.2 (giving approximately 100μl and 1.7 x 106 cells per 
tube). Incubation was carried out in the dark, at room temperature for 30 minutes. Cells were then 
washed by adding 2ml PBS to each tube and centrifuging at 1500rpm (600g) for 5 minutes. The 
supernatant was discarded and the cells resuspended in 200μl of BD Stabilizing Fixative (buffered 
solution containing 3% paraformaldehyde; prepared by diluting the 3x concentrate 1:2 with 
deionized water) and stored in the dark at 4°C. 
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Acquisition was carried out on a BD six-colour LSRII flow cytometer (BD Biosciences, Oxford, 
UK). Fifty thousand gated lymphocyte events were acquired per sample (ten thousand for the 
isotype controls) and these were analysed using FACSDiva™ Software version 6.1.2 (BD 
Biosciences, San Jose, CA, USA).  
 
Table 2.1 Original antibody combinations designed for six-colour immunophenotyping. 
The panel consists of one isotype control tube (1) and three experimental tubes (2-4). Each antibody and its conjugated 
fluorochrome are detailed. All antibodies in the panel were obtained from BD Biosciences (Oxford, UK) except CCR7 
which was sourced from R&D Systems (Abingdon, UK). 
Tube FITC PE APC PE-Cy7 
PerCP-
Cy5.5 
APC-H7 
1 IgG1 IgG1 IgG1 IgG1 CD3 CD8 
2 CD57 CD38 CD95 HLA-DR CD3 CD8 
3 CD27 CD25 CD28 CD45RO CD3 CD8 
4 PD-1 CCR7 CD45RA PD-L1 CD3 CD8 
 
Table 2.2 Expanded antibody panel used for six-colour immunophenotyping. 
The panel consists of one isotype control tube (1) and five experimental tubes (2-6). Each antibody and its conjugated 
fluorochrome are detailed. All antibodies in the panel were obtained from BD Biosciences (Oxford, UK) except CCR7 
and TIM-3 which were sourced from R&D Systems (Abingdon, UK) and PTK-7 which was obtained from Miltenyi 
Biotech Ltd (Bisley, UK). 
Tube FITC PE APC PE-Cy7 
PerCP-
Cy5.5 
APC-H7 
1 IgG1 IgG1 IgG1 IgG1 CD3 CD8 
2 CD57 CD38 CD95 HLA-DR CD3 CD8 
3 CD27 CD25 CD28 CD45RO CD3 CD8 
4 PD-1 CCR7 CD45RA PD-L1 CD3 CD8 
5 HLA-DR CD31 PTK-7 CD45RA CD3 CD8 
6 CD4 TIM-3 CTLA-4 CD69 CD3 CD8 
 
Table 2.3 Antibody panel for assessment of growth hormone receptor (GHR) on T cells. 
The panel consists of one isotype control tube and one experimental tube. Three different GHR antibodies were tested 
and these are detailed in Table 2.4. The GHR antibodies and FITC control are from Santa Cruz Biotechnology 
(Heidelberg, Germany), CCR7 is from R&D Systems (Abingdon, UK) and all other antibodies are from BD 
Biosciences (Oxford, UK). 
Tube FITC PE APC PE-Cy7 
PerCP-
Cy5.5 
APC-H7 
1 IgG1 IgG1 IgG1 IgG1 CD3 CD8 
2 GHR CCR7 CD45RA HLA-DR CD3 CD8 
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Table 2.4 Monoclonal antibodies used in six-colour flow cytometric analysis. 
This table shows the antibody, its fluorochrome, clone, and isotype. All antibodies in the panel were obtained from BD 
Biosciences (Oxford, UK) except CCR7 and TIM-3 which were sourced from R&D Systems (Abingdon, UK), PTK-7 
which was obtained from Miltenyi Biotech Ltd (Bisley, UK) and the GHR antibodies, and respective isotype control, 
which were from Santa Cruz Biotechnology (Heidelberg, Germany).  
NA – not aplicable; the company does not have a specific clone name for this product. 
Antibody Fluorochrome Clone Isotype 
IgG1 FITC MOPC-21 IgG1, κ 
IgG1 PE G18-145 IgG1, κ 
IgG1 APC MOPC-21 IgG1, κ 
IgG1 PE-Cy7 X40 IgG1, κ 
CD3 PerCP-Cy5.5 SK7 IgG1, κ 
CD8 APC-H7 SK1 IgG1, κ 
CD57 FITC HNK-1 IgM, κ 
CD38 PE HB7 IgG1, κ 
CD95 APC DX2 IgG1, κ 
HLA-DR PE-Cy7 L243 IgG2a, κ 
CD27 FITC M-T271 IgG1, κ 
CD25 PE 2A3 IgG1, κ 
CD28 APC CD28.2 IgG1, κ 
CD45RO PE-Cy7 UCHL1 IgG2a, κ 
PD-1 FITC MIH4 IgG1, κ 
CCR7 PE 150503 IgG2a, κ 
CD45RA APC HI100 IgG2b, κ 
PD-L1 PE-Cy7 MIH1 IgG1, κ 
HLA-DR FITC L243 (G46-6) IgG2a, κ 
CD31 PE WM59 IgG1, κ 
PTK-7 APC 188B IgG2a, κ 
CD45RA PE-Cy7 L48 IgG1, κ 
CD4 FITC SK3 IgG1, κ 
TIM-3 PE 344823 IgG2a, κ 
CTLA-4 APC BNI3 IgG2a, κ 
CD69 PE-Cy7 FN50 IgG1, κ 
IgM FITC G255-228 IgM, κ 
GHR FITC MAB1 IgG1, κ 
GHR FITC 3H2186 IgG1, κ 
GHR FITC MAB263 IgG1, κ 
IgG1 FITC NA IgG1, κ 
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2.13 Gating strategies for flow cytometric analysis 
Forward scatter (FSC) and side scatter (SSC) properties were used to determine the lymphocyte 
population. A dot plot displaying lymphocytes was then used to define the CD4
+
 T cells (these were 
CD3
+
CD8
-
) and CD8
+
 T cells (CD3
+
CD8
+
). Further characterisation of the CD4
+
 and CD8
+
 T cells 
was carried out by looking at these populations on dot plots with percentage expression of each of 
the markers determined using quadrant gates. The quadrants were set based on logical gating of 
distinct populations (confirmed with density plots), CD3 back-gating and verified with isotype 
matched controls that were run for each tube (as described in section 2.12, and Table 2.1 and Table 
2.2). Histograms were also plotted for each marker to elucidate the expression of each of the 
markers in terms of mean fluorescence intensity (MFI). A representative example of the gating 
strategy, looking at the expression of the activation markers CD38 and HLA-DR on CD4 and CD8 
T cells is shown in Figure 2.1. In order to determine the differentiation/maturation state of both T-
cell subsets, surface expression of CD45RA and the lymph-node homing CCR7 were used (Figure 
2.2). Cells positive for both markers were defined as naïve T cells (CCR7
+
CD45RA
+
), with the loss 
of CD45RA expression resulting in a central memory phenotype (TCM; CCR7
+
CD45RA
-
), double 
negatives were the effector memory T cells (CCR7
-
CD45RA
-
; TEM), and terminally differentiated T 
cells were those re-expressing CD45RA (CCR7
-
CD45RA
+
; TEMRA). This was done for both CD4 
and CD8 T cells (Figure 2.2B and Figure 2.2C, respectively). The histograms represent expression 
of PD-1 on each of the T-cell subsets; this gating strategy and analysis was also used to determine 
PD-L1 expression according to differentiation/maturation status. 
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Figure 2.1 Gating strategy for flow cytometric analysis. 
Forward and side scatter properties were used to gate tightly around the lymphocyte population (A). CD4
+
 and CD8
+
 T 
cells were defined based on their expression of CD3 and CD8, with CD4 T cells CD3
+
CD8
-
 and CD8 T cells CD3
+
CD8
- 
(B). In this example, the activation markers CD38 and HLA-DR were quantified on both the CD4 and CD8 T-cell 
populations (C), as was the expression of the senescence marker CD57 and the apoptosis marker CD95 (D). Other 
surface markers were assessed similarly with percentage expression in the quadrant gates noted. These plots show the 
PBMC profile from an HIV-1 infected individual (O523, screen visit). 
A B 
C D
D 
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Figure 2.2 Gating strategy for differentiation/maturation of T-cell subsets. 
A lymphocyte gate was set and used to assess CD3
+
CD8
-
 (CD4) and CD3
+
CD8
+
 (CD8) T cells (A). The 
differentiation/maturation state of the CD4 (B) and CD8 (C) T cells was assessed using surface expression of the 
markers CCR7 and CD45RA. Double positives are naïve T cells (CCR7
+
CD45RA
+
), CCR7
+
CD45RA
-
 are central 
memory (TCM), double negatives (CCR7
-
CD45RA
-
) are effector memory (TEM), and CCR7
-
CD45RA
+
 are terminally 
differentiated T cells (TEMRA). The histograms represent PD-1 expression in each of the subsets and this gating was also 
used to determine PD-L1 expression. These plots show the PBMC profile from an HIV-1
+
 patient (K087).  
 
2.14 PBMC culture 
Isolated and washed PBMC were cultured in duplicate in a 24-well, flat-bottom plate at a 
concentration of 2 x 10
6
 cells/ml in RPMI-1640+PSG and 10% human male AB serum. rhGH 
(ImmunoTools, Friesoythe, Germany) re-suspended in TCM was added at a final concentration of 
1μg/ml. Duplicate wells were also run in parallel with TCM without rhGH. Cultures were incubated 
at 37°C and 5% CO2 for 72 hours. Following culture, the cells (and TCM) were collected into 
sterile 15ml tubes. The wells were rinsed with 2ml PBS and this was transferred to the tubes prior to 
washing. Cells were counted and viability was assessed. After two washes with PBS, the pelleted 
cells were resuspended in 500μl PBS and phenotyping was carried out as described in section 2.12. 
A 
B C 
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Preliminary experiments were also set up using recombinant human insulin-like growth factor 1 
(rhIGF-1; ImmunoTools, Friesoythe, Germany). The protocol was carried out as detailed above, 
testing the following concentrations of rh-IGF-1: 1ng, 10ng, 100ng and 1µg/ml. Cultures were left 
for 72 hours and phenotypic analysis was carried out, as previously described.  
2.15 Lymphoproliferation assays 
Triplicate cultures of PBMC (10
5
 per well) in 10% human male AB serum/RPMI-1640+PSG were 
set up in 96-well round-bottomed microtiter plates (Greiner, Stonehouse, UK). These were 
stimulated with HIV-1 recombinant antigens and peptides obtained from the Medical Research 
Council Centralised Facility for AIDS Reagents (NIBSC, Potters Bar, UK), and used as previously 
described [Imami et al., 2002]. On day five, each well was pulsed with 1µCi 
3
H-methyl thymidine 
(
3
H-TdR; Amersham International, Amersham UK) and after 16 hours, the cells were harvested 
onto glass fibre filtermats (Wallac Oy, Turku, Finland). Liquid scintillation spectroscopy using a 
1205 Betaplate counter (Wallac) was used to evaluate proliferation, as measured by 
3
H-TdR 
incorporation. Wells containing PBMC in AB serum and TCM only were used as a control to 
calculate background activity. Results are expressed as stimulation index (SI) scores; calculated by 
dividing the experimental result by the background result. An SI score of five or more is defined as 
a positive response. 
2.16 Preparation of peptides and antigens 
2.16.1 Preparation of HIV-1 antigens, peptides and recombinant vaccinia vectors (rVV) 
Cells were cultured with recombinant antigen at a final concentration of 10µg/ml [Imami et al., 
1999; Herasimtschuk et al., 2008]. Inactivated, gp120-deleted, HIV-1 immunogen (Remune™), and 
its constituent Gag p24 antigen (‘native’ p24: clade G; both from Immune Response Corp. 
Carlsbad, San Diego, CA) were used at 3µg/ml [Moss et al., 1999]. Gag p24 peptides were used at a 
final concentration of 4µg/ml each in a pool of 22; these were 20mers with a 10 amino acid overlap 
covering p24 Gag (aa 133-363 of HIV-1 SF2, ARP 788.1-.22). Pol reverse transcriptase (RT) 
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peptides were used at a final concentration of 1µg/ml each in a pool of 110. These peptides were 
15mers overlapping by 10 amino acids and covered RT (HIV-1 LAI, ARP 7010.1-.110). The 
recombinant vaccinia virus (rVV) constructs encoded Gag, Pol or PB2 (influenza A virus basic 
polymerase 2 subunit as a negative control; kindly gifted by G. Smith) proteins were obtained 
through the NIH AIDS Research and Reference Reagent Program (Rockville, MD, USA) and from 
the MRC AIDS reagent project (NIBSC).  
2.16.2 Preparation of peptide pools for low-dose rhGH study 
Pools of overlapping Gag 20mer and Gag 9mer peptides were prepared at a concentration of 
10µg/ml in culture medium (RPMI-1640+PSG), and used at a final concentration of 5µg/ml. Table 
2.5 details the Gag 20mer peptides with a 10 amino acid overlap (from the National Institute for 
Biological Standards and Control [NIBSC], Potters Bar, Herts, UK) that were used in these 
experiments, and Table 2.6 shows the Gag 9mer peptides used (obtained from both Sigma Genosys 
and NIBSC). 
 
Table 2.5 Sequences of the NIBSC (Potters Bar, Herts, UK) Gag 20mer peptides (with a 10 amino acid overlap). 
Rep. Ref. Protein Peptide Sequence Length Virus Strain 
ARP788.1 Gag p24 g1 PIVQNLQGQMVHQAISPRTL 20 1SF2 
ARP788.2 Gag p24 g2 VHQAISPRTLNAWVKVVEEK 20 1SF2 
ARP788.3 Gag p24 g3 NAWVKVVEEKAFSPEVIPMF 20 1SF2 
ARP788.4 Gag p24 g4 AFSPEVIPMFSALSEGATPQ 20 1SF2 
ARP788.5 Gag p24 g5 SALSEGATPQDLNTMLNTVG 20 1SF2 
ARP788.6 Gag p24 g6 DLNTMLNTVGGHQAAMQMLK 20 1SF2 
ARP788.7 Gag p24 g7 GHQAAMQMLKETINEEAAEW 20 1SF2 
ARP788.8 Gag p24 g8 ETINEEAAEWDRVHPVHAGP 20 1SF2 
ARP788.9 Gag p24 g9 DRVHPVHAGPIAPGQMREPR 20 1SF2 
ARP788.10 Gag p24 g10 IAPGQMREPRGSDIAGTTST 20 1SF2 
ARP788.11 Gag p24 g11 GSDIAGTTSTLQEQIGWMTN 20 1SF2 
ARP788.12 Gag p24 g12 LQEQIGWMTNNPPIPVGEIY 20 1SF2 
ARP788.13 Gag p24 g13 NPPIPVGEIYKRWIILGLNK 20 1SF2 
ARP788.14 Gag p24 g14 KRWIILGLNKIVRMYSPTSI 20 1SF2 
ARP788.15 Gag p24 g15 IVRMYSPTSILDIRQGPKEP 20 1SF2 
ARP788.16 Gag p24 g16 LDIRQGPKEPFRDYVDRFYK 20 1SF2 
ARP788.17 Gag p24 g17 FRDYVDRFYKTLRAEQASQD 20 1SF2 
ARP788.18 Gag p24 g18 TLRAEQASQDVKNWMTETLL 20 1SF2 
ARP788.19 Gag p24 g19 VKNWMTETLLVQNANPDCKT 20 1SF2 
ARP788.20 Gag p24 g20 VQNANPDCKTILKALGPAAT 20 1SF2 
ARP788.21 Gag p24 g21 ILKALGPAATLEEMMTACQG 20 1SF2 
ARP788.22 Gag p24 g22 LEEMMTACQGVGGPGHKARV 20 1SF2 
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Table 2.6 Sequences of the Gag 9mer MHC Class I restricted peptides obtained from Sigma, Genosys (peptides 1-29) 
and NIBSC (peptides 30-35). 
Peptide 
number 
HLA 
restriction 
Protein & 
Position 
Amino Acid 
Sequence 
Short 
Code 
Antigen 
1 B*0702 (B7) p24 (16-24) SPRTLNAWV SV9 Gag 
2 A*0101 (A1) p17 (71-79) GSEELRSLY GY9 Gag 
3 B*5701 (B57) p24 (108-117) TSTLQEQIGW TW10 Gag 
4 B*5501 (B55) p24 (83-92) VHPVHAGPIA VA10 Gag 
5 A*2402 (A24) p17 (28-36) KYKLKHIVW KW9 Gag 
6 B*5701 (B57) p24 (176-184) QASQEVKNW QW9 Gag 
7 B*5701 (B57) p24 (30-40) KAFSPEVIPMF KF11 Gag 
8 B*5701 (B57) p24 (32-40) FSPEVIPMF FF9 Gag 
9 B*5701 (B57) p24 (15-23) ISPRTLNAW IW9 Gag 
10 A*2601 (A26) p24 (35-43) EVIPMFSAL EL9 Gag 
11 B*0801 (B8) p24 (197-205) DCKTILKAL DL9 Gag 
12 B*0801 (B8) p17 (72-82) ELRSLYNTV EV9 Gag 
13 B*0801 (B8) p17 (93-101) EIKDTKEAL EL9 Gag 
14 B*0801 (B8) p17 (24-32) GGKKKYKLK GK9 Gag 
15 B*4402 (B44) p24 (174-184) AEQASQDVKNW AW11 Gag 
16 A*0201 (A2) p17 (17-85) SLYNTVATL SL9 Gag 
17 B*3501 (B35) p17 (36-44) WASRELERF WF9 Gag 
18 B*3501 (B35) p17 (124-132) NSSKVSQNY NY9 Gag 
19 B*3501 (B35) p24 (122-130) PPIPVGDIY PY9 Gag 
20 B*2705 (B27) p24 (131-140) KRWIILGLNK KK10 Gag 
21 A*1101 (A11) p24 (217-227) ACQGVGGPGHK AK11 Gag 
22 A*2501 (A25) p24 (71-80) ETINEEAAEW EW10 Gag 
23 A*2501 (A25) p24 (13-23) QAISPRTLNAW QW11 Gag 
24 B*3901 (B39) p24 (61-69) GHQAAMQML GL9 Gag 
25 B*5701 (B57) p24 (108-117) TSTLQEQIGN TN10 Gag 
26 A*1101 (A11) p17 (84-92) TLYCVHQRI TI9 Gag 
27 B*4001 (B60) p17 (92-101) IEIKDTKEAL IL10 Gag 
28 B*4001 (B60) p24 (44-52) SEGATPQDL SL9 Gag 
29 A*0301 (A3) p17 (20-28) RLRPGGKKK RK9 Gag 
30 B*0801 (B8) p17 (24-31) GGKKKYKL GL8 Gag 
31 B*0702 (B7) p24 (48-56) TPQDLNTML TL9 Gag 
32 (A2) p24 (78-86) AEWDRLHPV AV9 Gag 
33 (A3, A11) p24 (135-143) ILGLNKIVR IR9 Gag 
34 (A2) p24 (143-151) RMYSPTSIL RL9 Gag 
35   p24 (150-158) ILDIKQGPK IK9 Gag 
 
Peptides were identified from the NIH HIV Molecular Immunology Database website (http://www.hiv.lanl.gov). 
References for each peptide are available at this website. 
2.16.3 Preparation of peptide pools for IMIRC 1003 clinical trial 
Pools of Gag p24, Gag p17, Rev, Tat and Nef peptides from NIBSC (9mers, 15mers overlapping by 
5 and 20mers overlapping by 10) were prepared at a concentration of 10µg/ml in culture medium 
(RPMI+PSG) and used at a final concentration of 5µg/ml. The lyophilised peptides were originally 
resuspended in RPMI+PSG to a concentration of 1mg/ml before being pooled. Pooled peptides 
were carefully aliquoted, 1.8ml into 2ml cryotubes and stored at -80°C. 
A second set of peptides was obtained from FIT Biotech (Tartu, Estonia; kindly provided by Rein 
Sikut) and consisted of: Gag p17/p24, Rev, Tat, Nef and CTL epitope-stretch peptides (15mers with 
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an 11 amino acid overlap) for the MultiHIV-B consensus antigen [Molder et al., 2009]. Additional 
peptides needed to cover the MultiHIV-Han2 antigen were custom synthesised by ProImmune 
(Oxford, UK). These were also 15mers overlapping by 11 and pooled with the FIT Biotech peptides 
to a concentration of 20µg/ml. As per the manufacturer’s instructions, peptides were diluted to a 
concentration of 4µg/ml and used at a final concentration of 2µg/ml. Peptides were aliquoted and 
stored as described for the NIBSC peptide pools above. 
The sequences of the overlapping peptides from both sources can be found in Table 2.7 and Table 
2.8.  
Phytohaemagglutinin (PHA) (Sigma) was diluted in RPMI-1640+PSG to a concentration of 
10μg/ml to be used at a final concentration of 5μg/ml as a mitogen positive control. 
 
Table 2.7 Peptides obtained from NIBSC (Potters Bar, Herts, UK). 
The sequences of the overlapping Gag, Rev, Tat and Nef peptides used in pools to stimulate T cells are detailed. 
Rep. Ref. Protein Peptide Sequence Length 
Virus 
Strain 
ARP703.1 Gag p17 m1 MGARASVLSGGELDK 15 SF2 
ARP703.2 Gag p17 m2 GELDKWEKIRLRPGG 15 SF2 
ARP703.3 Gag p17 m3 LRPGGKKKYKLKHIV 15 SF2 
ARP703.4 Gag p17 m4 LKHIVWASRELERFA 15 SF2 
ARP703.5 Gag p17 m5 LERFAVNPGLLETSE 15 SF2 
ARP703.6 Gag p17 m6 LETSEGCRQILGQLQ 15 SF2 
ARP703.7 Gag p17 m7 LGQLQPSLQTGSEEL 15 SF2 
ARP703.8 Gag p17 m8 GSEELRSLYNTVATL 15 SF2 
ARP703.9 Gag p17 m9 TVATLYCVHQRIDVK 15 SF2 
ARP703.10 Gag p17 m10 RIDVKDTKEALEKIE 15 SF2 
ARP703.11 Gag p17 m11 LEKIEEEQNKSKKKA 15 SF2 
ARP703.12 Gag p17 m12 SKKKAQQAAAAAGTG 15 SF2 
ARP703.13 Gag p17 m13 AAGTGNSSQVSQNY 15 SF2 
ARP789.1 Gag p17 m3b LRPRGKKRYKLKHIV 15 RF 
ARP789.2 Gag p17 m3c LRPGGKKQYRLKHIV 15 CD41 
ARP789.3 Gag p17 m3d LRPGGKKKYQLKHIV 15 MAN 
ARP789.4 Gag p17 m3e LRPGGKKKYALKHLI 15 NDK 
ARP788.1 Gag p24 g1 PIVQNLQGQMVHQAISPRTL 20 1SF2 
ARP788.2 Gag p24 g2 VHQAISPRTLNAWVKVVEEK 20 1SF2 
ARP788.3 Gag p24 g3 NAWVKVVEEKAFSPEVIPMF 20 1SF2 
ARP788.4 Gag p24 g4 AFSPEVIPMFSALSEGATPQ 20 1SF2 
ARP788.5 Gag p24 g5 SALSEGATPQDLNTMLNTVG 20 1SF2 
ARP788.6 Gag p24 g6 DLNTMLNTVGGHQAAMQMLK 20 1SF2 
ARP788.7 Gag p24 g7 GHQAAMQMLKETINEEAAEW 20 1SF2 
ARP788.8 Gag p24 g8 ETINEEAAEWDRVHPVHAGP 20 1SF2 
ARP788.9 Gag p24 g9 DRVHPVHAGPIAPGQMREPR 20 1SF2 
ARP788.10 Gag p24 g10 IAPGQMREPRGSDIAGTTST 20 1SF2 
ARP788.11 Gag p24 g11 GSDIAGTTSTLQEQIGWMTN 20 1SF2 
ARP788.12 Gag p24 g12 LQEQIGWMTNNPPIPVGEIY 20 1SF2 
ARP788.13 Gag p24 g13 NPPIPVGEIYKRWIILGLNK 20 1SF2 
ARP788.14 Gag p24 g14 KRWIILGLNKIVRMYSPTSI 20 1SF2 
ARP788.15 Gag p24 g15 IVRMYSPTSILDIRQGPKEP 20 1SF2 
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ARP788.16 Gag p24 g16 LDIRQGPKEPFRDYVDRFYK 20 1SF2 
ARP788.17 Gag p24 g17 FRDYVDRFYKTLRAEQASQD 20 1SF2 
ARP788.18 Gag p24 g18 TLRAEQASQDVKNWMTETLL 20 1SF2 
ARP788.19 Gag p24 g19 VKNWMTETLLVQNANPDCKT 20 1SF2 
ARP788.20 Gag p24 g20 VQNANPDCKTILKALGPAAT 20 1SF2 
ARP788.21 Gag p24 g21 ILKALGPAATLEEMMTACQG 20 1SF2 
ARP788.22 Gag p24 g22 LEEMMTACQGVGGPGHKARV 20 1SF2 
EVA7046.18 Gag p24 g23 TLRAEQATQEVKNWMTETLL 20 Subtype A 
EVA7080.51 Gag p24 Cg204 TINEEAAEWDRLHPV 15 C/B(CN54) 
EVA7080.52 Gag p24 Cg208 EAAEWDRLHPVHAGP 15 C/B(CN54) 
EVA7080.69 Gag p24 Cg276 MYSPTSILDIKQGPK 15 C/B(CN54) 
ARP7074.1 Nef n1 GGKWSKSSVVGWPTVRERMR 20 BRU 
ARP7074.2 Nef n2 GWPTVRERMRRAEPAADGVG 20 BRU 
ARP7074.3 Nef n3 RAEPAADGVGAASRDLEKHG 20 BRU 
ARP7074.4 Nef n4 AASRDLEKHGAITSSNTAAT 20 BRU 
ARP7074.5 Nef n5 AITSSNTAATNAACAWLEAQ 20 BRU 
ARP7074.6 Nef n6 NAACAWLEAQEEEEVGFPVT 20 BRU 
ARP7074.7 Nef n7 EEEEVGFPVTPQVPLRPMTY 20 BRU 
ARP7074.8 Nef n8 PQVPLRPMTYKAAVDLSHFL 20 BRU 
ARP7074.9 Nef n9 KAAVDLSHFLKEKGGLEGLI 20 BRU 
ARP7074.10 Nef n10 KEKGGLEGLIHSQRRQDILD 20 BRU 
ARP7074.11 Nef n11 HSQRRQDILDLWIYHTQGYF 20 BRU 
ARP7074.12 Nef n12 LWIYHTQGYFPDWQNYTPGP 20 BRU 
ARP7074.13 Nef n13 PDWQNYTPGPGVRYPLTFGW 20 BRU 
ARP7074.14 Nef n14 GVRYPLTFGWCYKLVPVEPD 20 BRU 
ARP7074.15 Nef n15 CYKLVPVEPDKVEEANKGEN 20 BRU 
ARP7074.16 Nef n16 KVEEANKGENTSLLHPVSLH 20 BRU 
ARP7074.17 Nef n17 TSLLHPVSLHGMDDPEREVL 20 BRU 
ARP7074.18 Nef n18 GMDDPEREVLEWRFDSRLAF 20 BRU 
ARP7074.19 Nef n19 EWRFDSRLAFHHVARELHPE 20 BRU 
ARP7074.20 Nef n20 HHVARELHPEYFKNC 15 BRU 
EVA7081.2 Nef Cn842 KRQEILDLWVYHTQG 15 C/B(CN54) 
EVA7081.44 Nef Cn1010 GFPVRPQVPLRPMTY 15 C/B(CN54) 
EVA7086.6 Nef Nef 137-145 LTFGWCFKL 15 C/B(CN54) 
EVA779.1 Tat t1 EPVDPRLEPWKHPGSQPKTA 20 LAI 
EVA779.2 Tat t2 KHPGSQPKTACTTCYCKKCC 20 LAI 
EVA779.3 Tat t3 CTTCYCKKCCFHCQVCFTTK 20 LAI 
EVA779.4 Tat t4 FHCQVCFTTKALGISYGRKK 20 LAI 
EVA779.5 Tat t5 ALGISYGRKKRRQRRRPPQG 20 LAI 
EVA779.6 Tat t6 RRQRRRPPQGSQTHQVSLSK 20 LAI 
EVA779.7 Tat t7 SQTHQVSLSKQPTSQPRGD 19 LAI 
EVA779.8 Tat t8 QPTSQPRGDPTGPKE 15 LAI 
EVA7084.1 Tat  Tat aa24-32 NCYCKKCCL 9 HXB2 
EVA7084.2 Tat  Tat aa35-43 QVCFTRKGL 9 HXB2 
EVA7084.3 Tat Tat aa61-69 DSQTHQVSL 9 HXB2 
EVA780.1 Rev r1 AGRSGDSDEDLLKAVRLIKF 20 LAI 
EVA780.2 Rev r2 LLKAVRLIKFLYQSNPPPNP 20 LAI 
EVA780.3 Rev r3 LYQSNPPPNPEGTRQARRNR 20 LAI 
EVA780.4 Rev r4 EGTRQARRNRRRRWRERQRQ 20 LAI 
EVA780.5 Rev r5 RRRWRERQRQIHSISERILS 20 LAI 
EVA780.6 Rev r6 IHSISERILSTYLGRSAEPV 20 LAI 
EVA780.7 Rev r7 TYLGRSAEPVPLQLPPLERL 20 LAI 
EVA780.8 Rev r8 PLQLPPLERLTLDCNEDCGT 20 LAI 
EVA780.9 Rev r9 TLDCNEDCGTSGTQGVGSPQ 20 LAI 
EVA780.10 Rev r10 SGTQGVGSPQILVESPTVLE 20 LAI 
EVA780.11 Rev r11 ILVESPTVLESGTKE 15 LAI 
EVA7085.1 Rev Rev aa14-22 KTVRLIKFL 9 HXB2 
EVA7085.2 Rev Rev aa56-64 SERILSTFL 9 HXB2 
EVA7085.3 Rev Rev aa67-75 PAEPVPLQL 9 HXB2 
 
 
Table 2.7 continued 
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Table 2.8 Peptide sub-pools supplied by FIT Biotech and ProImmune. 
Overlapping sequences (15mers with an 11 amino acid overlap) are detailed. Asterisks * indicate where peptide 
synthesis failed. 
Sub-pool Peptide Code Sequence Peptide Code Sequence 
Gag p17/p24 HAN-106  GARASVLSGGELDKW  FIT.1-152  TMLNTVGGHQAAMQM  
 HAN-107  SVLSGGELDKWEKIR  FIT.1-153  TVGGHQAAMQMLKET  
 HAN-108  GGELDKWEKIRLRPG  FIT.1-154  HQAAMQMLKETINEE  
 HAN-109  DKWEKIRLRPGGKKK  FIT.1-155  MQMLKETINEEAAEW  
 HAN-110  KIRLRPGGKKKYQLK  FIT.1-156  KETINEEAAEWDRLH  
 HAN-111  RPGGKKKYQLKHIVW  FIT.1-157  INEEAAEWDRLHPVHA  
 HAN-112  KKKYQLKHIVWASRE  FIT.1-158  AEWDRLHPVHAGPIA  
 HAN-113  QLKHIVWASRELERF  FIT.1-159  RLHPVHAGPIAPGQM  
 FIT.1-114  IVWASRELERFAVNP  FIT.1-160  VHAGPIAPGQMREPR  
 FIT.1-115  SRELERFAVNPGLLE  FIT.1-161  PIAPGQMREPRGSDI  
 FIT.1-116  ERFAVNPGLLETSEG  FIT.1-162  GQMREPRGSDIAGTT  
 FIT.1-117 VNPGLLETSEGCRQI FIT.1-163  EPRGSDIAGTTSTLQ  
 HAN-118  LLETSEGCRQIMGQL  FIT.1-164  SDIAGTTSTLQEQIG  
 HAN-119  SEGCRQIMGQLQPSL  FIT.1-165  GTTSTLQEQIGWMTN  
 HAN-120  RQIMGQLQPSLQTGS  FIT.1-166  TLQEQIGWMTNNPPI  
 FIT.1-121  GQLQPSLQTGSEELR  FIT.1-167  EQIGWMTNNPPIPVGE  
 FIT.1-122  PSLQTGSEELRSLYN  FIT.1-168  MTNNPPIPVGEIYKR  
 FIT.1-123  TGSEELRSLYNTVAT  FIT.1-169  PPIPVGEIYKRWIIL  
 FIT.1-124 ELRSLYNTVATLYCV  FIT.1-170  VGEIYKRWIILGLNK  
 FIT.1-125  LYNTVATLYCVHQKI  FIT.1-171  YKRWIILGLNKIVRM  
 FIT.1-126  VATLYCVHQKIEVKD  FIT.1-172  IILGLNKIVRMYSPT  
 FIT.1-127  YCVHQKIEVKDTKEA FIT.1-173  LNKIVRMYSPTSILD  
 HAN-128  HQKIEVKDTKEALDKV   HAN-174  VRMYSPTSILDIKQG  
 HAN-129  VKDTKEALDKVEEEQ  HAN-175  SPTSILDIKQGPKEP  
 HAN-130  KEALDKVEEEQNNSK  HAN-176  ILDIKQGPKEPFRDY  
 HAN-131  DKVEEEQNNSKKKAQ  HAN-177  KQGPKEPFRDYVDRF  
 HAN-132  EEQNNSKKKAQQEAA  FIT.1-178  KEPFRDYVDRFYKTL  
 HAN-133  NSKKKAQQEAADAGN  FIT.1-179  RDYVDRFYKTLRAEQ  
 HAN-134  KAQQEAADAGNRNQV  HAN-180  DRFYKTLRAEQATQE  
 HAN-135  EAADAGNRNQVSQNY  HAN-181  KTLRAEQATQEVKNW  
 HAN-136  AGNRNQVSQNYPIVQ HAN-182  AEQATQEVKNWMTET  
 FIT.1-137  SQVSQNYPIVQNLQG  HAN-183  TQEVKNWMTETLLVQ  
 FIT.1-138  SQNYPIVQNLQGQMVH  FIT.1-184  KNWMTETLLVQNANP  
 FIT.1-139  IVQNLQGQMVHQAIS  FIT.1-185  TETLLVQNANPDCKT  
 FIT.1-140  LQGQMVHQAISPRTL  FIT.1-186  LVQNANPDCKTILKA  
 FIT.1-141  MVHQAISPRTLNAWV  FIT.1-187  ANPDCKTILKALGPA  
 FIT.1-142  AISPRTLNAWVKVVE  FIT.1-188  CKTILKALGPAATLE  
 FIT.1-143  RTLNAWVKVVEEKAF  FIT.1-189  LKALGPAATLEEMMT  
 FIT.1-144  AWVKVVEEKAFSPEV  FIT.1-190  GPAATLEEMMTACQG  
 FIT.1-145  VVEEKAFSPEVIPMF  FIT.1-191  TLEEMMTACQGVGGP  
 FIT.1-146  KAFSPEVIPMFSALS  FIT.1-192  MMTACQGVGGPGHKA  
 FIT.1-147  PEVIPMFSALSEGAT  FIT.1-193  CQGVGGPGHKARVLP  
 FIT.1-148  PMFSALSEGATPQDL    
 FIT.1-149  ALSEGATPQDLNTML    
 FIT.1-150  GATPQDLNTMLNTVG    
 FIT.1-151  PQDLNTMLNTVGGHQA    
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Sub-
pool 
Peptide 
Code 
Sequence Sub-pool 
Peptide 
Code 
Sequence 
Nef  HAN-30  TSVGKWSKCSGWPTV  Tat FIT.1-81  EPVDPRLEPWKHPGS 
 HAN-31 KWSKCSGWPTVRERM   HAN-82  PRLEPWKHPGSQPRT  
 HAN-32  CSGWPTVRERMKQAE   HAN-83  PWKHPGSQPRTPCTN  
 HAN-33  PTVRERMKQAEPEPA   HAN-84  PGSQPRTPCTNCYCK  
 HAN-34  ERMKQAEPEPAADGV   HAN-85  PRTPCTNCYCKKCCL  
 HAN-35  QAEPEPAADGVGAAS   HAN-86  CTNCYCKKCCLHCQV  
 HAN-36  EPAADGVGAASRDLE   HAN-87  YCKKCCLHCQVCFTR  
 HAN-37  DGVGAASRDLEKHGA   HAN-88  CCLHCQVCFTRKGLG  
 HAN-38 AASRDLEKHGAITSS   HAN-89  CQVCFTRKGLGISYG  
 HAN-39  DLEKHGAITSSNTAT   HAN-90  FTRKGLGISYGRKKR  
 HAN-40  HGAITSSNTATNNAA    FIT.1-91  GLGISYGRKKRRQRR  
 HAN-41  TSSNTATNNAACAWL    FIT.1-92  SYGRKKRRQRRRAPQ  
 HAN-42  TATNNAACAWLEAQE   FIT.1-93  KKRRQRRRAPQDSQT  
 FIT.1-43  CAWLEAQEEEEVGFP   FIT.1-94  RQRRRAPQDSQTHQVS 
 HAN-44  AWLEAQEEEEVGFPV   HAN-95  APQDSQTHQVSLPKQ  
 HAN-45  AQEEEEVGFPVRPQV   HAN-96  SQTHQVSLPKQPSSQ  
 HAN-46  EEVGFPVRPQVPLRP   HAN-97  HQVSLPKQPSSQQRGD   
 HAN-47  FPVRPQVPLRPMTYK   HAN-98  PKQPSSQQRGDPTGP  
 HAN-48  PQVPLRPMTYKGALD   HAN-99  SSQQRGDPTGPKKSK  
 HAN-49  LRPMTYKGALDLSHF   HAN-100  RGDPTGPKKSKKKVE  
 HAN-50  TYKGALDLSHFLKEK   HAN-101  TGPKKSKKKVERETE  
 HAN-51  ALDLSHFLKEKGGLE   HAN-102  KSKKKVERETEADPF  
 HAN-52  SHFLKEKGGLEGLIY   HAN-103  KVERETEADPFDAAV  
 HAN-53  KEKGGLEGLIYSPKR     
 HAN-54  GLEGLIYSPKRQEIL     
 HAN-55  LIYSPKRQEILDLWV     
 HAN-56  PKRQEILDLWVYHTQ     
* FIT.1-56  RQDILDLWVYHTQGYF    
 HAN-58  LWVYHTQGYFPDWQN     
 HAN-59  HTQGYFPDWQNYTPG     
 HAN-60  YFPDWQNYTPGPGVR     
 HAN-61  WQNYTPGPGVRYPLT     
 HAN-62  TPGPGVRYPLTFGWC     
 HAN-63  GVRYPLTFGWCFKLV     
 HAN-64  PLTFGWCFKLVPVEP     
 HAN-65  GWCFKLVPVEPDEEE     
 HAN-66  KLVPVEPDEEENSSL     
* HAN-67  VEPDEEENSSLLHPA     
* HAN-68  EEENSSLLHPASLHG    
 HAN-69  SSLLHPASLHGTEDT     
 HAN-70  HPASLHGTEDTEREV     
 HAN-71  LHGTEDTEREVLKWK     
 HAN-72  EDTEREVLKWKFDSH     
* FIT.1-74  EVLVWKFDSRLAFHH    
 HAN-74  KWKFDSHLAFHHKAR     
 HAN-75  DSHLAFHHKARELHP     
 HAN-76  AFHHKARELHPEYYK     
 HAN-77  KARELHPEYYKDCKL     
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Sub-pool 
Peptide 
Code 
Sequence Sub-pool 
Peptide 
Code 
Sequence 
Rev FIT.1-1  AGRSGDSDEELLKTV  CTL FIT.1-197  ITLWQRPLVTIKIGG  
 FIT.1-2  GDSDEELLKTVRLIK  Epitope HAN-203  ALIEICTEMEKEGKIS  
 FIT.1-3 EELLKTVRLIKFLYQ  Stretch FIT.1-204  CTEMEKEGKISKIGP  
 FIT.1-4  KTVRLIKFLYQSNPP  HAN-207  AGLKKKKSVTVLDVG  
 HAN-5  LIKFLYQSNPPPSNE   HAN-208  KKKSVTVLDVGDAYF 
 HAN-6  LYQSNPPPSNEGTRQ   FIT.1-209  VTVLDVGDAYFSVPL  
 HAN-7  SNPPPSNEGTRQARRN   FIT.1-210  DVGDAYFSVPLDKDF  
 HAN-8  SNEGTRQARRNRRRR   FIT.1-211  AYFSVPLDKDFRKYT  
 FIT.1-9  TRQARRNRRRRWRER   FIT.1-212  VPLDKDFRKYTAFTI  
 FIT.1-10  RRNRRRRWRERQRQI   FIT.1-213  KDFRKYTAFTIPSIN  
 FIT.1-11  RRRWRERQRQIRSIS  FIT.1-218  WKGSPAIFQSSMTKI  
 HAN-12 RERQRQIRSISERIL   FIT.1-223  KQNPDIVIYQYMDDL  
 HAN-13  RQIRSISERILSTFL   FIT.1-224  DIVIYQYMDDLYVGS  
 HAN-14  SISERILSTFLGRPA   FIT.1-228  TVQPIVLPEKDSWTV  
 HAN-15  RILSTFLGRPAEPVP  FIT.1-233  LVGKLNWASQIYAGI  
 FIT.1-16  TYLGRPAEPVPLQLP   FIT.1-234  LNWASQIYAGIKVKQ  
 FIT.1-17  RPAEPVPLQLPPLER   FIT.1-240  REILKEPVHGVYYDP  
 FIT.1-18  PVPLQLPPLERLTLD  FIT.1-244  EKEPIVGAETFYVDG  
 HAN-19  LQLPPLERLTLDCSED   FIT.1-245 IVGAETFYVDGAANR  
 HAN-20  LERLTLDCSEDCGNS   HAN-250  AGNLWVTVYYGVPV  
 HAN-21  TLDCSEDCGNSGTQG   FIT.1-251 LWVTVYYGVPVWKEA  
 HAN-22  CSEDCGNSGTQGVGSP   FIT.1-252  VYYGVPVWKEATTTL  
 HAN-23  GNSGTQGVGSPQVLV   HAN-258  VERYLRDQQLLGIWGCA  
 HAN-24  TQGVGSPQVLVESPA   FIT.1-263  INQMLRGPGRAFVTI  
 HAN-25  GSPQVLVESPAVLEP     
 HAN-26  VLVESPAVLEPGTKE     
 
2.17 IFN-γ, IL-2, IL-4 and perforin ELISpot assays for virus-specific T cells 
ELISpot assays were carried out to detect IFN-γ (IL-2, IL-4 and perforin) by first coating a 96 well 
Polyvinylidene Difluoride (PVDF) backed plate (Millipore, catalogue no. MAIP S45 10) with 
100µl per well of capture antibody (MabTech AB, Nacha Strand, Sweden) diluted to a 
concentration of 10µg/ml in sterile PBS followed by overnight incubation at 4°C. The wells were 
then washed six times with 200µl of sterile PBS. The PVDF membrane-backed plate was then 
blocked by adding 100µl of TCM supplemented with 10% human male AB serum and incubated for 
60 minutes at room temperature. After removal of the blocking AB medium, 2.5 x 10
5 
PBMC 
(suspended in 100µl of 20% human male AB serum/TCM; at a concentration of 2.5 x 10
6 
cells/ml), 
were added per well. 
100µl of the relevant peptide pool from either NIBSC or FIT Biotech (at a final concentration of 
5μg/ml or 2μg/ml respecively), PHA (positive control; at a final concentration of 5μg/ml) or TCM 
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(negative control) was added to each well in duplicate as shown in Figure 2.3. The ELISpot plate 
was then incubated at 37˚C in 5% CO2 for 24 hours. 
Following the removal of the contents of the plate, each well was washed six times with 200µl of 
PBS. All non-sterile washes were carried out using an ELISpot plate washer (Multiwash 
Advantage, TriContinent, California, USA). 100µl of detection antibody (Ab); biotinylated anti-
human IFNγ Ab (MabTech), in PBS at a concentration of 1µg/ml was added per well. The plate was 
then incubated for 24 hours at 4°C (or for 2 hours at room temperature). 
The detection antibody was then removed and the plate washed, as described above, six times with 
200µl PBS per well. Streptavidin-alkaline phosphatase conjugate (MabTech) was diluted in PBS, in 
the dark, to a concentration of 1/2000, 100µl of which was then added per well, followed by a 1 
hour incubation at room temperature. 
The plate was then washed six times with 200µl of PBS per well immediately followed by addition 
of 100µl of freshly prepared chromogen to each well. 10ml of the chromogen was prepared (per 
plate) by using the AP Conjugate Substrate Kit (BioRad, Catalogue no. 170-6432) and mixing 
9.6ml deionised water with 400 l Development Buffer™, followed by the addition of 50µl of 
Reagent A™ and 50µl of Reagent B™. 
The plate was then left to develop in the dark for approximately 15 minutes (dependent on ambient 
temperature) and then washed with water. The plate was left to dry overnight and stored at room 
temperature, away from direct sunlight, until reading was carried out on a Zeiss KS ELISpot system 
(KS Elispot, Carl Zeiss MicroImaging GmbH, Jena, Germany). 
Responses in the IFN-γ, IL-2 and IL-4 ELISpot assays were considered significant if more than 50 
spot forming cells (SFC) were present per million PBMC after background (TCM stimulation) was 
subtracted, and the results were at least twice the background. Responses in the perforin ELISpot 
assay were considered significant if the result was more than 100 SFC per million PBMC and at 
least twice the background (TCM stimulation) after the background was subtracted (this higher cut-
off is due to higher background in perforin ELISpot assays).  
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Figure 2.3 ELISpot plate layout for the IMIRC 1003 clinical trial samples. 
 
2.18 Recombinant vaccinia virus construct based ELISpot assay for enumeration of 
IFN-γ-producing HIV-1-specific CD8 T cells 
PBMC were infected with recombinant vaccinia (rVV) virus constructs expressing either HIV-1 
Gag or Pol protein. It has been previously demonstrated that CD8 T cells produce >90% of the IFN-
γ release in response to rVV stimulation of PBMC [Larsson et al., 1999]. rVV Gag, rVV Pol and 
rVVPB2 were used to infect PBMC for one hour at 37°C in 5% AB plasma using 20 infectious 
units per cell. Cells were washed twice in RPMI-1640+PSG containing 5% AB plasma before being 
resuspended in 10% AB plasma/RPMI-1640+PSG and plated out in duplicate with 2.5 x 10
5
 PBMC 
per well directly onto ELISpot plates. rVVPB2 was used as a negative control and PHA at 5µg/ml 
as a positive control. Detection and enumeration of SFC was carried out as described in the 
previous section. A positive result is defined as at least twice the background, and a score of 5 or 
more above background, which was always <20 SFC/10
6
 PBMC. Data represent mean values of 
duplicate wells at each point with variation among duplicates <10%. 
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2.19 Viral sequencing 
The HIV-1 viral subtypes of the patients enrolled on the IMIRC 1003 clinical trial were determined 
by Maarja Adojaan at FIT Biotech LTD, Tartu, Estonia. Two proviral DNA regions, gag/pol/pr and 
gp41, were sequenced and genotyped from cryopreserved PBMC (5 x 10
6
). Briefly, samples were 
shipped and proviral DNA was extracted from PBMC (Quattromed HTI Laborid OÜ) before nested 
PCR of gp41, gag-pol and pr regions of HIV-1 was performed according to the laboratory’s 
standard operating procedure (SOP). Samples were prepared for sequencing according to the SOP 
and sequencing electrophoresis was run in Estonian Biocentre Sequencing Centre with ABI 3730x1 
DNA Analyzer. Two proviral genomic regions were analysed: gag/pol/pr and envelope (gp41); the 
sequencing of two regions located in different parts of the viral genome allows possible 
recombination events to be traced. Both regions contain nucleotide divergence that is sufficient for 
subtype determination, yet both are conserved enough to allow the design of consensus primers and 
to create the DNA sequence alignments. In order to overcome HIV-1 variability, a set of different 
primers was prepared which enabled amplification of samples from various subtypes. Positive 
control samples of different viral subtypes (A, B, C, D, G, CRF-06.cpx) were successfully amplified 
and sequenced to test primers. 
BioEdit Sequence Alignment Editor version 7.0.9.0 software, Clone Manager 9 Professional 
Edition software and subtyping tools available at HIV database websites were used to perform the 
sequencing analysis [Adojaan et al., 2005]. Two genomic regions were sequenced in all 12 samples 
and if sequence data was available for both of these regions, it was merged as amplified fragments 
of gag/pol and protease partly overlap. Details on the methodology and analysis and interpretation 
of the results were taken from a study report kindly generated by Maarja Adojaan. 
2.20 Genomic DNA extraction 
Genomic DNA extraction was carried out on 3 x 10
6
 – 1 x 107 PBMC using the Nucleon™ BACC2 
Genomic DNA Extraction Kit (GE Healthcare Life Sciences, Buckinghamshire, UK). 
Cryopreserved PBMC from IMIRC 1003 patient screen visits were thawed as described previously 
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(in section 2.11). The thawed cells were washed and collected by centrifugation at 600g and 4°C for 
5 minutes. Once the supernatant was discarded, the pellet was resuspended in 1.0ml of Reagent A 
and left on ice for 5 minutes. A further centrifugation was carried out at 1300g for 5 minutes at 4°C 
and the supernatant discarded.  
For cell lysis and RNA digestion, 2ml of Reagent B was added to the pellet (ensuring the detergent 
was fully dissolved) and this was vortexed briefly to resuspend the pellet. The resulting suspension 
was transferred to a screw-cap polypropylene centrifuge tube (max internal diameter 12mm) and 
150µl/ml RNAse A solution was added and this was incubated for 30 minutes at 37°C.  
For the deproteinisation steps, 500µl of sodium perchlorate was added and this was mixed by 
inverting ten times by hand. Following this, 2ml of chloroform was added and this was inverted 10 
times by hand to emulsify the phases. This was centrifuged for 1 minute at 1300g. Once it was 
ensured that the Nucleon resin was well suspended, 300µl was added to the tube. Without re-mixing 
the phases, this was centrifuged at 1300g for 4 minutes.  
To precipitate the DNA, the upper phase was first transferred to a fresh (at least 10ml) tube, without 
disturbing the [orange] Nucleon resin layer. If any resin was carried over, a brief centrifugation was 
carried out at 1300g to pellet the resin and the upper phase again transferred to a fresh tube. Two 
volumes of cold (-20°C) absolute ethanol were added and the tube inverted several times to 
precipitate the DNA. The precipitated DNA was ‘hooked out’ and placed directly into an eppendorf 
tube containing 200µl of RNAse/DNAse free water. Where ‘hooking out’ was not possible, the 
DNA was washed as described below. 
The DNA washing required centrifugation at 5000g for 5 minutes to pellet the DNA. The 
supernatant was discarded and 2ml of cold (-20°C) absolute ethanol was added and the tube 
inverted several times to wash. Re-centrifugation was carried out as above and the supernatant 
discarded. The pellet was allowed to air dry for ten minutes, ensuring all the ethanol was removed 
and the sample was resuspended in 200µl of RNAse/DNAse free water. 
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2.21 HLA-typing 
HLA-typing for each patient was carried out on baseline samples at the Clinical Immunology 
Laboratory, Department of Histocompatibility and Immunogenetics, Hammersmith Hospital. 
Sequencing of HLA was performed using Invitrogen SeCore® kits. The class I (A, B and Cw 
Locus) kits use primers that sequence exons 2, 3 & 4, whilst the DRB1 locus kit uses primers that 
sequence exon 2 only as these are significant sites of HLA polymorphism. The sequencing involves 
locus specific amplification for class I and group specific amplification for class II, in conjunction 
with the use of Taq DNA Polymerase and sample genomic DNA. Prior to carrying out sequencing 
reaction all unincorporated primers and free nucleotides are treated with ExoSAP-ITTM. The 
nucleotides and resulting HLA subtype is determined using multicolour sequence analyser. Based 
on the sequence data, the HLA type is assigned using SBT software [Turner et al., 1998]. Details on 
the methodology were kindly provided by Ruhena Sergeant. 
2.22 Study design 
2.22.1 Impact of rhGH on HIV-1-specific T-cell responses 
Twelve chronically infected, ART-treated, HIV-1
+
 individuals with lipodystrophy were enrolled 
onto a randomised, double-blinded, placebo-controlled study to receive 4mg rhGH (Serostim, 
Serono International, Geneva, Switzerland) daily for 12 weeks. The patients were then randomised 
into one of three groups to receive: (A) placebo, (B) alternate-day dosing, or (C) twice-per-week 
dosing of rhGH for a further 12 weeks, after which the subjects went back to receiving ART alone 
with no immunotherapy. Samples were collected at baseline, at weeks 12 and 24 of the study, and at 
a 48-week follow up visit.  
Patients were eligible to participate in the study if they had CD4 T-cell counts greater than 200 
cells/µl blood and if they had been on stable highly active ART (HAART) for more than a year. A 
schematic of the study design and the treatment schedule is illustrated in Figure 2.4. 
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Figure 2.4 Schematic representation of study design and treatment schedule. 
PBMC from 12 HIV-1-infected individuals with lipoatrophy, on long-term successful ART receiving rhGH (Serostim, 
Serono International, Geneva, Switzerland), were assessed for CD4 T-cell proliferation and IFN-γ production by CD8 T 
cells. rhGH administration: given at 4mg/day for 12 weeks. After 12 weeks, patients were randomised into three groups: 
placebo; alternate day dosing; or twice weekly dosing for a further twelve weeks. Weeks 24-48, patients received ART 
alone (no immunotherapy). Samples were collected at baseline and weeks 12, 24 and 48 of the study. ELISpots were 
carried out at each time point to assess the ability of CD8 T cells to recognise HIV-1 peptides or proteins and produce 
IFN-γ. 
 
2.22.2 Low-dose rhGH study 
Samples were obtained from a randomised, placebo-controlled, double-blinded, clinical, single-
centre study (carried out at the Department of Infectious Diseases, Copenhagen University Hospital, 
Hvidovre, Denmark). Caucasian, male subjects on effective ART received either 0.7mg/day rhGH 
(n = 21) or placebo (n = 15) subcutaneously for 40 weeks (Genotropin or placebo obtained from 
Pfizer A/S, DK2750 Ballerup, Denmark).  
IFN-γ ELISpot assays were carried out (as described in section 2.17) on cryopreserved PBMC from 
baseline (week 0) and week 40, stimulated with peptide pools of HIV-1 Gag 20mers and Gag 9mers 
(as detailed section 2.16.2, in Table 2.5 and Table 2.6, respectively) to assess the virus-specific CD4 
and CD8 T cells recognising antigenic peptide in the context of MHC class II or class I, 
respectively.  
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Flow cytometric, phenotypic analysis was carried out on T cells from the most robust responders (n 
= 4). The panel included markers used to determine maturation/differentiation (CCR7, CD45RA, 
CD27, CD28), activation (CD25, HLA-DR, CD38), exhaustion (PD-1, PD-L1), senescence (CD57) 
and apoptosis (CD95) as well as assessing markers associated with regulatory T cells 
(CD4
+
CD45RO
+
CD25
high
). The panel of antibodies was prepared as described in section 2.12, 
Table 2.1. 
 
Figure 2.5 Schematic of low-dose rhGH treatment schedule. 
From a study of ART-treated HIV-1-infected men, samples were investigated from subjects randomised to receive 
either 0.7mg/day rhGH (n=21) or placebo (n=15) (Genotropin or placebo, obtained from Pfizer A/S, DK-2750 Ballerup, 
Denmark), administered as daily subcutaneous injections for 40 weeks. Patients were 21-60 years of age, on ART for at 
least 12 months, with less than 1000 copies/ml HIV-1 RNA and greater than 200 CD4
+
 T cells. IFN-γ ELISpot assays 
were performed on these samples at baseline and at week 40 to determine responses to overlapping Gag 20mer and Gag 
9mer peptides following treatment with rhGH or placebo. 
2.22.3 Novel interventions in HIV-1 infection – IMIRC 1003 clinical trial 
Out of 93 patient referrals and 21 screen visits, 12 patients that met the eligibility criteria were 
enrolled onto the trial. Patients had to be chronically infected with HIV-1, on stable ART (for at 
least 6 months), have plasma viral loads <50 copies/ml, with nadir CD4 T-cell counts >200 cells/µl, 
current CD4 T-cell counts >400 cells/µl, and could not be receiving or have received 
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immunomodulatory drugs. Patients were randomised into one of three arms of the trial: in the first, 
patients received the GTU®-MultiHIV DNA Clade B vaccine (FIT Biotech, Tampere, Finland) at 
baseline, followed by administration of IL-2 (Aldesleukin, Proleukin) and GM-CSF (Sargramostim, 
Leukine™) for five days during week 1 of the trial, and rhGH (Somatropin, Saizen™) for five days 
during week 2 of the trial, with vaccine further administered at weeks 6 and 12 of the trial (n = 3); 
in the second arm, patients received vaccine alone (n = 4); and in the third arm, patients received 
cytokine and hormone alone (n = 5), all at the aforementioned time points. Blood was drawn at two 
screen visits, at baseline (week 0) and at weeks 1, 2, 4, 6, 8, 12, 24 and 48, and the treatment 
schedule is detailed in Table 2.9, with a more detailed patient visit schedule shown in Table 2.10. 
The vaccine was administered at a dose of 1mg/ml as 10 intradermal injections (five 100µl 
injections per arm); the IL-2 given twice daily, 5 x 10
6
 Units, administered by subcutaneous 
injection, 8 hours apart; the GM-CSF, 150µg, was administered subcutaneously once daily, 4 hours 
from the IL-2; and the rhGH self-administered subcutaneously daily at a dose of 4mg/day. Nurses 
provided training on how to use the Saizen
®
 click.easy
®
 cartridges and the cool.click
®
 needle-free 
rhGH delivery device (Merck Serono Ltd). 
For each patient visit and blood draw, 10ml EDTA blood and 30ml heparinised (lithium heparin; 
LH) blood was obtained. The samples were centrifuged, the plasma collected and frozen at -80°C 
and the PBMC separated by density gradient centrifugation over Histopaque as described in section 
2.10. 
IFN-γ, IL-2, IL-4 and perforin ELISpots were carried out at each time point to assess functional 
responses to peptide pools of Gag p17, Gag p24, Nef, Rev, and Tat (as detailed in section 2.17). 
Phenotypic analysis of the CD4 and CD8 T cells was also carried out and the panel included 
markers for activation (CD38, HLA-DR), exhaustion (CTLA-4, TIM-3, PD-1, PD-L1), senescence 
(CD57), and differentiation (CCR7, CD45RA, CD27, CD28), as well as markers associated with 
regulatory T cells (CD3
+
CD4
+
CD45RO
+
CD25
high
), and the panel is shown in Table 2.2. 
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Table 2.9 IMIRC 1003 overview of treatment schedule. 
Patients were randomised into one of three arms of the trial: to receive therapeutic immunisation (GTU®-MultiHIV 
DNA Clade B vaccine), in addition to IL-2, GM-CSF and rhGH (Arm 1); vaccine alone (Arm 2); or cytokines and 
hormone alone (Arm 3). 
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Table 2.10 IMIRC 1003 Patient visit schedule. 
The study ran for 52 weeks with two screen visits, two weeks apart, followed by 48 weeks of the study. 
 
*Pregnancy test (women of child bearing potential only). **When recommended by the physician, with the exception of 
the first screen when compulsory. ***HIV-1 viral load, lymphocyte subsets, biochemistry (urea, creatinine, glucose, 
total bilirubin, alkaline phosphatise, AST (SGOT), ALT (SGPT), albumin, globulin, fasting cholesterol triglycerides, 
sodium, potassium, amylase, calcium and phosphate), and haematology (haemoglobin, platelets, total WBC, and 
neutrophils). †Vaccine, GTU®-MultiHIV B (Han-2 isolate), FIT Biotech Plc (1mg/ml) administered at 0, 6 and 12 
weeks as ten intradermal injections (100µl/injection volume) with five injections per each arm. ‡Cytokines: Aldesleukin 
(IL-2), Proleukin, Novartis, UK (BD; 8 hours apart) 5 x 10
6
 Units administered for five days by SC injection on days 7, 
8, 9, 10 and 11 after first vaccination. Sargramostim (GM-CSF), Leukine™, Berlex, Seattle, USA 150µg SC once daily 
four hours from rhIL-2 injections. ‡‡Hormone, rhGH (Serono International, Geneva, Switzerland) 4mg/day self-
administered by SC injection for five days on days 14, 15, 16, 17 and 18 following first vaccination. 
 
  
9
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Figure 2.6 Trial sample flow chart. 
The steps in the immediate processing of the IMIRC 1003 clinical trial samples are detailed. All experiments were carried out in accordance with standard operating procedures, as 
described in full in this chapter of the thesis. 
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2.23 Data and statistical analysis 
Data analysis was performed using Microsoft Excel 2007 (Microsoft, Redmond, WA) and 
GraphPad Prism Software version 5.0 (GraphPad Software, San Diego, CA, USA).  A professional 
on-site statistician, Ms Sundhiya Mandalia (Imperial College London, Kobler Clinic St Stephen’s 
AIDS Trust) was consulted regarding statistical analysis. Where data sets were not normally 
distributed, inter-group statistical significance was calculated using a Mann-Whitney U test and 
intra-group statistical significance was calculated by comparing the medians of the paired data 
using the Wilcoxon signed rank test. Results are presented as p values, and considered significant 
where p  0.05. 
For the IMIRC 1003 clinical trial analysis, a random intercept model using MIXED procedure in 
SAS was generated by fitting all functional, phenotypic, immunological and virological results as 
dependent variables by study time point visits, stratified by the three randomised treatment arms. 
Mean changes from baseline in all functional, phenotypic, immunological and virological results are 
presented as point estimates, presented with a 95% confidence interval (CI). For the graphs, where 
the 95% CI does not cross the line of origin, a statistically significant difference can be inferred 
(above – a statistically significant increase and below – a statistically significant decrease). 
Statistically significant differences (p ≤ 0.05) are indicated with asterisks (*) in the figures, and 
trends (0.05 < p > 0.1) described in the text. All p values and 95% CI limits for this analysis can be 
found in Appendix 2. 
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Chapter 3 Impact of rhGH on T-Cell Phenotype and Function in Treated 
HIV-1 Infection 
Human growth hormone (GH) produced by the anterior pituitary gland [Clark, 1997], mediates its 
effects either directly or through insulin-like growth factor-1 (IGF-1), and plays an important role in 
T-cell development and function [Welniak et al., 2002]. Impaired GH secretion has been described 
in HIV-1-infected individuals with visceral or central adiposity [Rietschel et al., 2001; Vigano et 
al., 2003], and recombinant human growth hormone (rhGH) has been used to successfully treat 
HIV-1-associated wasting syndrome and visceral adiposity in patients on antiretroviral therapy 
(ART) [Cominelli et al., 2002; Moyle et al., 2004; Grunfeld et al., 2007] (reviewed in [Gelato et al., 
2007]). Prolonged treatment with ART has been shown to improve morbidity and mortality 
associated with HIV-1 infection, reduce HIV-1 replication and normalise CD4 T-cell counts, as 
well as stabilising naive/memory cell ratios and reducing levels of activated cells [Guihot et al., 
2011]. However, ART does not eradicate HIV-1 or facilitate immune control of the virus, and 
immune restoration is functionally incomplete with levels of activation markers remaining elevated 
in a significant subset of individuals [Kauffman et al., 2011]. While GH is not believed to exert 
direct effects on the peripheral T cells, it is critical for T-cell development in the thymus [Welniak 
et al. 2002; Napolitano et al., 2002]. There appears a role for rhGH as an immunomodulator, 
complimentary to the benefits of effective combination ART in HIV-1 infection. Studies of rhGH in 
treated HIV-1 infection have shown a reversal of thymic involution, increased numbers of 
peripheral naive CD4 T cells [Napolitano et al., 2002, Pires et al., 2004b], increased numbers of 
total CD4 T cells [Napolitano et al., 2008; Smith et al., 2010], and a reduction in the expression of 
markers associated with immune activation (CD38, HLA-DR) and apoptosis (CD95) [Napolitano et 
al., 2008].  
This chapter explores the effects of rhGH in treated HIV-1 infection using ex vivo samples from two 
clinical trials: one investigating the impact of short term administration of a ‘supra-physiological’ 
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dose of rhGH (4mg/day), and the other the effect of a ‘physiological’ low dose of rhGH 
(0.7mg/day) given for 40 weeks, according to the schematics in Figures 2.4 and 2.5 respectively. In 
vitro PBMC cultures were set up to assess the impact of rhGH directly on CD4 and CD8 T cells and 
experiments set up to elucidate the expression of the growth hormone receptor (GHR) on both T-
cell subsets. 
3.1 Effect of rhGH on HIV-1-specific T-cell responses in HIV-1+ individuals on ART 
Twelve chronically HIV-1-infected individuals with lipodystrophy were enrolled onto a 
randomised, double-blind, placebo-controlled study to receive 4mg/day rhGH subcutaneously 
(Serostim, Serono International, Geneva Switzerland) for 12 weeks. Patients were then randomised 
into one of three groups: to receive placebo (A), to receive alternate day dosing (B), or to receive 
twice-per-week dosing of rhGH (C), and this continued for a further 12 weeks. At week 24 of the 
study, patients went back to receiving ART alone (with no immunotherapy) for 24 weeks. HIV-1-
specific proliferative CD4 and IFN-γ-producing CD8 T-cell responses were assessed at baseline, 
weeks 12 and 24 of the study and at a follow-up week 48 visit. Patients’ informed consent and 
Ethics Committee approval were obtained for this study [Herasimtschuk et al., 2008]. Patients were 
eligible to participate in the study if they had a CD4 T-cell count >200 cells/µl blood and if they had 
been receiving stable HAART for >1 year. 
3.1.1 Patient characteristics 
The twelve HIV-1-infected individuals enrolled on the trial had all been receiving ART for >4 
years, median age was 41 years (IQR 40-47 years), viral load was undetectable (<50 copies/ml 
plasma) in ten out of twelve patients, and median baseline CD4 and CD8 T-cell counts were 467 
(IQR 313-626) and 1068 (IQR 675-1251) cells/µl blood, respectively (Table 3.1). CD4 and CD8 T-
cell numbers and viral load did not change significantly between the sample time points. Viral load 
remained detectable in only one individual throughout the course of the study, and for all patients 
and study time points, CD4 and CD8 T-cell counts and viral load remained significantly unchanged. 
HIV-1-specific CD4 T-cell responses were measured using the conventional lymphoproliferative 
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assay, while pools of overlapping peptides and rVV constructs were used in ELISpot assays to 
evaluate HIV-1-specific CD8 T-cell responses. 
3.1.2 HIV-1-specific CD4 and CD8 T-cell responses following daily administration of rhGH 
In eleven out of twelve individuals, HIV-1-specific CD4 and CD8 T-cell responses were absent at 
baseline despite stable numbers of both T-cell subsets. Following 12 weeks of daily administration 
of rhGH in combination with successful HAART, HIV-1-specific CD4 T-cell proliferative 
responses increased significantly (anti-recombinant p24 p = 0.0059, anti-native p24 p = 0.014, anti-
Remune immunogen p = 0.0090; Figure 3.1). This increase was focussed on Gag-specific and 
whole HIV-1 antigen (Remune)-specific CD4 T-cell responses and these were found to be positive 
in nine out of the twelve patients. These HIV-1-specific T-cell responses were not maintained at 
week 24 following less frequent dosing of rhGH and by week 48 follow-up, they were undetectable 
in the majority of individuals. 
Daily administration of rhGH in the context of HAART-treated HIV-1 infection resulted in a 
significant increase in HIV-1-specific CD8 T-cell responses to rVV constructs (Gag rVV p = 0.059, 
Pol rVV p = 0.049) and whole peptide pools of Gag and Pol proteins (p = 0.049 and p = 0.0025, 
respectively). At week 24, these virus-specific CD8 T-cell responses were maintained in all 
patients, including those that did not receive further rhGH. At the week 48 follow-up visit, virus-
specific CD8 T-cell responses had significantly declined, except those directed at the pools of Pol 
and Gag peptides (Figure 3.2). 
Daily injections of a ‘supra-physiological’ dose (4mg/day) of rhGH for 12 weeks, in addition to 
HAART, resulted in significant increases in both proliferative CD4 and IFN-γ-producing CD8 HIV-
1-specific T-cell responses. This increase was predominantly seen for HIV-1 Gag-specific T-cell 
responses. Subsequent randomisation into different dosing regimens lead to a decline in HIV-1-
specific proliferative CD4 T-cell responses in patients receiving less frequent dosing of rhGH, while 
virus-specific IFN-γ-producing CD8 T-cell responses were maintained for longer periods of time. 
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Table 3.1 Patient characteristics at baseline (week 0), and weeks 12, 24 and 48 of the study. 
 
   Baseline Week 12 Week 24 Week 48 
Patient
a
 
Age 
(years) 
CD4 
T-cell 
count 
(cells/µl 
blood) 
CD8 
T-cell 
count 
(cells/µl 
blood) 
HIV-1 
RNA 
(copies/
ml 
plasma) 
CD4 
T-cell 
count 
(cells/µl 
blood) 
CD8 
T-cell 
count 
(cells/µl 
blood) 
HIV-1 
RNA 
(copies/
ml 
plasma) 
CD4 
T-cell 
count 
(cells/µl 
blood) 
CD8 
T-cell 
count 
(cells/µl 
blood) 
HIV-1 
RNA 
(copies/
ml 
plasma) 
CD4 
T-cell 
count 
(cells/µl 
blood) 
CD8 
T-cell 
count 
(cells/µl 
blood) 
HIV-1 
RNA 
(copies/
ml 
plasma) 
1 B  40 823 1239 <50 714 1218 <50 688 1027 <50 745 956 <50 
2 C  32 436 555 <50 422 735 <50 456 667 <50 418 567 <50 
3 C  38 636 1235 1555 616 1209 5017 676 1179 2027 518 737 2788 
4 B  39 604 1613 <50 425 1137 <50 371 899 <50 415 980 <50 
5 A  45 667 553 <50 697 680 <50 647 559 <50 540 557 <50 
6 A  58 320 421 <50 431 837 <50 393 917 <50 364 750 <50 
7 C  41 257 884 <50 269 747 <50 375 986 <50 443 954 <50 
8 B  40 622 1602 17089 435 776 <50 609 1202 <50 577 942 <50 
9 B  53 211 1074 <50 217 1336 <50 844 1369 <50 241 884 <50 
10 C  40 293 715 <50 262 791 <50 286 708 <50 ND ND ND 
11 A  52 374 1288 <50 563 1624 <50 713 2357 <50 599 1364 <50 
12 A  43 498 1061 <50 375 980 <50 421 908 <50 341 709 <50 
Median  41 467 1068  428 909  533 952  443 884  
IQR  40-47 
313- 
626 
675-
1251 
 
349- 
576 
769-
1211 
 
389- 
679 
851-
1185 
 
390- 
559 
723- 
955 
 
a 
Randomisation group at week 12 to 24: A – placebo recipients; B – alternate day dosing; and C – twice weekly dosing. Changes in CD4 and CD8 T-cell numbers and viral load 
between different time points are all non-significant. <50 = undetectable. ND – Not Done. 
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Figure 3.1 Proliferative CD4 T-cell responses to HIV-1 antigens in ART-treated HIV-1-infected patients before and 
after rhGH immunotherapy. 
PBMC from 12 HIV-1-infected patients were cultured in the presence of various HIV-1 antigens in triplicate for 6 days 
and 
3
H-thymidine incorporation was measured. Patient visits are depicted at baseline, weeks 12, 24 and 48. Results are 
expressed as the mean stimulation index of triplicate cultures with percentage error of the mean <15%. The positive 
threshold of an SI ≥ 5 is indicated. Box plots show the median and IQR, and whiskers represent the 10th and 90th 
percentiles. Symbols are specific to each patient according to Table 3.1. Randomisation into three groups at week 12 is 
represented by different colours. Group A (red) received placebo, group B (purple) received alternate day dosing of 
rhGH and group C (blue) received twice weekly dosing of rhGH. Significant p values of ≤0.05 are shown.  
 
 
 
Figure 3.2 IFN-γ production by CD8 T cells in response to rVV HIV-1 constructs and peptide pools in ART-treated 
HIV-1
+
 patients before and after rhGH therapy. 
Patient visits are depicted at baseline and at weeks 12, 24 and 48. Results are expressed as the mean number of SFC per 
10
6
 PBMC of duplicate cultures with <10% variation among duplicates. The positive threshold of ≥20 SFC per 106 
PBMC is indicated. Box plots show the median and IQR, and whiskers represent the 10
th
 and 90
th
 percentiles. Symbols 
are specific to each patient according to Table 3.1. Randomisation into three groups performed at week 12 is 
represented by different colours. Group A (red) received placebo, group B (purple) received alternate day dosing of 
rhGH and group C (blue) received twice weekly dosing of rhGH. Significant p values of ≤0.05 are shown. 
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3.2 Long-term, low-dose rhGH in treated HIV-1 infection 
HIV-1-specific T-cell responses were investigated from a study in which a low-dose of rhGH 
(0.7mg) was administered daily for 40 weeks in chronically infected individuals on ART.  
Samples were obtained from a randomised, placebo-controlled, double-blind, clinical, single-centre 
study (carried out at the Department of Infectious Diseases, Copenhagen University Hospital, 
Hvidovre, Denmark). Caucasian, male subjects on effective ART received either 0.7mg/day rhGH 
(n = 21) or placebo (n = 15) subcutaneously for 40 weeks (Genotropin or placebo, obtained from 
Pfizer A/S, DK-2750 Ballerup, Denmark). Subjects were eligible to participate in the study if they 
were male, Caucasian, aged between 21 and 60 years, on a HAART regimen for at least 12 months, 
with HIV-1-associated lipodystrophy syndrome (HALS) or not (classification according to the 
clinical definition applied in The Lipodystrophy Definition Case Study [Carr et al., 2003]), <1000 
copies/ml plasma HIV-1 RNA and >200 CD4 T cells/µl blood [Hansen et al., 2009]. 
IFN-γ ELISpot assays were carried out on cryopreserved PBMC from baseline (week 0) and week 
40, stimulated with peptide pools of Gag 20mers and Gag 9mers (section 2.17, Table 2.5 and Table 
2.6, respectively) to assess the virus-specific CD4 and CD8 T cells recognising antigenic peptides in 
the context of MHC class II or class I, respectively. Flow cytometric, phenotypic analysis was 
carried out on T cells from the most robust responders (n = 4) in the IFN-γ ELISpot assays. The 
panel included markers used to determine maturation/differentiation (CCR7, CD45RA, CD27, 
CD28), activation (CD25, HLA-DR, CD38), exhaustion (PD-1, PD-L1), senescence (CD57) and 
apoptosis (CD95), as well as assessing markers associated with regulatory T cells 
(CD4
+
CD45RO
+
CD25
high
), panel as per section 2.12 and Table 2.1. 
Flow cytometry data was analysed using FACS DIVA™ software and statistical analysis carried 
out using GraphPad Prism. For analysis of data between patient groups at baseline, the Mann-
Whitney U test was used and for intra-group analysis, comparing the paired samples at baseline 
(week 0) and week 40, the Wilcoxon signed rank test was performed. Results are presented as p 
values and considered significant where p ≤0.05. 
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3.2.1 Patient characteristics  
Subjects were well matched between the two groups with a median age of 44 years (interquartile 
range, IQR, 41-51 years) and median CD4 T-cell count of 633 cells/µl blood (IQR 493-902 cells/µl 
blood) for the entire study group (Table 3.2). Median duration of HIV-1 infection for the whole 
study population was 14 years (IQR 9-19 years) and median ART duration was 8 years (IQR 6-8 
years). Table 3.2 shows patient characteristics with median and IQR calculated for each treatment 
group (rhGH or placebo) and for the entire data set. For sample identification, ‘H’ and ‘NH’ refer to 
HALS (HIV-1-associated lipodystrophy syndrome) and non HALS, respectively. The patients 
depicted with an open symbol in Table 3.2 (H17, H20, H22 and H25) indicate individuals who 
showed the most robust responses at week 40 following daily administration of rhGH and were 
further characterised phenotypically. 
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Table 3.2 Baseline characteristics for patients on the low-dose rhGH study. 
rhGH- (n=21) and placebo- (n=15) treated patients are shown here in the upper and lower part of the table respectively, 
with the median and IQR for each group shown below the appropriate dataset, and with the median and IQR for the 
entire dataset at the bottom of the table. For the sample ID, ‘H’ and ‘NH’ refer to HALS and non HALS, respectively. 
Symbols depict patients that were further analysed phenotypically. 
Treatment 
Sample 
ID 
 
Age 
(years) 
Viral 
Load 
(copies/ml) 
CD4 T-
cell 
count 
(cells/µl) 
CD8 T-
cell 
count 
(cells/µl) 
HIV-1 
duration 
(years) 
ART 
duration 
(years) 
rhGH H01/0  53 <40 924 730 13 8 
 H03/0  58 <40 1213 3088 12 8 
 H05/0  55 <40 413 1022 14 8 
 H07/0  44 <40 740 1531 13 8 
 H09/0  46 <40 619 929 19 6 
 H10/0  59 <40 672 710 8 8 
 H11/0  46 43 507 681 7 7 
 H13/0  37 <40 1296 1399 14 8 
 H15/0  41 <40 779 1335 19 8 
 H17/0  41 <40 276 1771 20 9 
 H20/0  50 <40 552 1355 10 5 
 H21/0  48 <40 519 1037 20 7 
 H22/0  61 <40 347 469 19 10 
 H25/0  59 <40 589 498 14 11 
 NH04/0  43 102 654 2623 3 3 
 NH07/0  38 40 843 1265 10 7 
 NH08/0  58 <40 1556 1282 22 8 
 NH09/0  42 <40 527 1060 21 10 
 NH16/0  44 <40 1355 1396 11 9 
 NH17/0  42 <40 1113 1254 7 7 
 NH21/0  29 <40 345 953 2 2 
Median   46  654 1254 13 8 
IQR   42-55  519-924 929-1396 10-19 7-8 
         
Placebo H02/0  55 <40 941 1141 6 6 
 H04/0  38 <40 1108 918 11 7 
 H06/0  41 <40 761 1131 16 7 
 H08/0  49 <40 404 951 16 8 
 H12/0  41 <40 894 1253 9 8 
 H14/0  39 <40 618 995 3 2 
 H18/0  55 <40 208 709 8 8 
 H19/0  46 <40 524 1550 21 6 
 H24/0  46 <40 698 1101 16 9 
 NH03/0  28 <40 401 952 1 1 
 NH06/0  37 <40 647 1175 18 9 
 NH10/0  50 <40 547 1207 20 5 
 NH11/0  42 <40 449 837 20 3 
 NH18/0  43 <40 216 800 20 10 
 NH20/0  37 <40 1018 1657 19 8 
Median   42  618 1101 16 7 
IQR   39-47  427-828 935-1191 9-19 6-8 
Overall 
Median 
 
 
44  633 1116 14 8 
Overall IQR   41-51  493-902 926-1340 9-19 6-8 
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3.2.2 IFN-γ production in response to peptide stimulation 
At baseline (week 0), there was no statistically significant difference in IFN-γ production in 
response to peptide pools of overlapping HIV-1 Gag 20mers or Gag 9mers between the rhGH-
treated and the placebo-treated groups (p = 0.6188 and p = 0.6512, respectively). At week 40, 
patients who received placebo showed no significant difference in their response to Gag 20mers or 
Gag 9mers compared to baseline (Figure 3.3B and 3.3D, respectively). However, patients that 
received 0.7mg rhGH/day showed increased responses to both pools of peptides at week 40, 
compared to baseline. Responses to the MHC class II restricted peptides increased but did not reach 
statistical significant (p = 0.0559; Figure 3.3A), whilst responses to MHC class I restricted peptide 
pools increased significantly (p = 0.0355; Figure 3.3C). 
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Figure 3.3 IFN-γ production by T cells in response to Gag 20mer and Gag 9mer peptide stimulation in patients 
receiving low-dose rhGH or placebo. 
IFN-γ production at baseline and at week 40 was assessed in ART-treated patients receiving daily administration of 
rhGH (n = 21), shown here in solid black squares () and open shapes, or placebo (n = 15), shown here in solid black 
circles (). PBMC were stimulated with pools of overlapping Gag 20mer (A and B) or Gag 9mer (C and D) peptides 
overnight and IFN-γ production determined. The robust responders at week 40 (n = 4), from which PBMC were further 
characterised phenotypically at baseline and at week 40, are depicted with the open shapes:  H17,  H20,  H22,  
H25. Results are expressed on a log transformed scale as mean spot forming cells (SFC) per million PBMC of duplicate 
cultures with <10% variation among duplicates. Individual data points, the median and interquartile range are illustrated 
for each graph. Statistical analysis was carried out in GraphPad Prism 5.0 and changes from baseline were determined 
using the Wilcoxon signed rank test, with significant p values (≤ 0.05) and those approaching statistical significance 
(0.05<p<0.1) shown.  
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3.2.3 Phenotypic characterisation of the strongest responders 
CD4 and CD8 T-cell phenotypes of the most robust responders in terms of IFN-γ production at 
week 40 (n = 4) were characterised (these patients are depicted with open symbols in Table 3.2 and 
Figures 3.3A and 3.3C). Statistical analyses were not performed on these results due to the small 
sample number. Immunophenotyping, performed at baseline and at week 40 on these samples, 
demonstrated a trend toward a reduction in the percentage expression of the activation markers 
HLA-DR and CD38 within both T-cell subsets following administration of low-dose rhGH for 40 
weeks (Figure 3.4). This reduction was more pronounced when looking at CD38 expression, for 
both percentage expression and mean fluorescence intensity (MFI; Figure 3.4C and Figure 3.4E, 
respectively). The MFI of the apoptotic marker CD95 was also reduced on CD4 and CD8 T cells 
following 40 weeks of rhGH (Figure 3.5E) whereas there were no other apparent trends in the 
expression of senescent (CD57) or apoptotic markers (CD95; Figure 3.5).  
Markers associated with a regulatory T-cell phenotype (CD4
+
CD45RO
+
CD25
high
) were assessed at 
baseline and week 40 and did not reveal any distinct trends (two patients showed an increase in the 
percentage expression of these markers, and two patients showed a decrease; Figure 3.6A). For all 
four patients, however, there was a decrease in the expression of CD25, on both T-cell subsets, in 
terms of both percentage expression and MFI (Figure 3.6B and Figure 3.6C, respectively).  
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Figure 3.4 The effect of low-dose rhGH on the expression of activation markers. 
Flow cytometric analysis was carried out at baseline (week 0) and at week 40, following daily administration of 0.7mg 
rhGH, for the most robust responders in the IFN-γ ELISpot assays at week 40 (n = 4; symbols for each patient 
correspond to the symbols used in Figure 3.3). CD4 and CD8 T cells (open symbols and dotted lines, and closed 
symbols and solid lines, respectively) were assessed for the percentage expression of HLA-DR and CD38 (A), HLA-
DR (B), CD38 (C) and the MFI of both of these markers (D and E, respectively). 
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Figure 3.5 The effect of low-dose rhGH on the expression of markers of senescence and apoptosis. 
Flow cytometric analysis was carried out at baseline and at week 40, following daily administration of 0.7mg rhGH, for 
the most robust responders in the IFN-γ ELISpot assays at week 40 (n = 4; symbols for each patient correspond to the 
symbols used in Figure 3.3). CD4 and CD8 T cells (open symbols and dotted lines, and closed symbols and solid lines, 
respectively) were assessed for the percentage expression of CD57 and CD95 (A), CD57 (B), CD95 (C) and the MFI of 
both of these markers (D and E, respectively). 
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Figure 3.6 Regulatory T-cell markers following long-term, low-dose rhGH. 
Flow cytometric analysis was carried out at baseline and at week 40, following daily administration of 0.7mg rhGH, for 
the most robust responders in the IFN-γ ELISpot assays at week 40 (n = 4; symbols for each patient correspond to the 
symbols used in Figure 3.3). CD4 and CD8 T cells (open symbols and dotted lines, and closed symbols and solid lines, 
respectively) were assessed for the percentage expression of markers associated with a regulatory T-cell phenotype 
(CD4
+
CD45RO
+
CD25
high
; (A), and CD25 expression both in terms of percentage expression (B) and MFI (C). 
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Administration of low-dose rhGH for 40 weeks resulted in a shift from an early T-cell phenotype to 
an intermediate and late phenotype, as determined by the expression of CD27 and CD28 (Figure 
3.7) for both T-cell subsets. When differentiation status was assessed using CCR7 and CD45RA 
expression, the trend was similar, with a reduction in naive CD4 and CD8 T cells following rhGH 
therapy (Figure 3.8A) and an increase in CD8 TCM (Figure 3.8B) and CD4 TEM (Figure 3.8C). There 
was no apparent effect on the markers associated with a TEMRA phenotype (Figure 3.8D). Following 
40 weeks of low-dose rhGH, no apparent trends in the percentage expression of PD-1 or PD-L1 
were observed on the differentiation/maturation subsets of CD4 and CD8 T cells (Figure 3.9 and 
Figure 3.10, respectively). Similarly, the MFI of PD-1 and PD-L1 on both T-cell subsets did not 
appear to be altered by rhGH therapy (Figure 3.11A and 3.11B, respectively). However, there was a 
trend towards a reduction in the percentage expression of PD-L1 on total lymphocytes following 
daily administration of 0.7mg rhGH for 40 weeks (Figure 3.11C). 
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Figure 3.7 Early, intermediate and late T cells as determined by expression of CD27 and CD28. 
Flow cytometric analysis was carried out at baseline and at week 40, following daily administration of 0.7mg rhGH, for 
the most robust responders in the IFN-γ ELISpot assays at week 40 (n = 4; symbols for each patient correspond to the 
symbols used in Figure 3.3). CD4 and CD8 T cells (open symbols and dotted lines, and closed symbols and solid lines, 
respectively) were assessed for the percentage expression of markers associated with early (CD27
+
CD28
+
) T cells (A), 
intermediate (CD4
+
CD27
-
CD28
+
 or CD8
+
CD27
+
CD28
-
) T cells (B) or late (CD27
-
CD28
-
) T cells (C).  
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Figure 3.8 CD4 and CD8 T-cell differentiation defined by expression of CCR7 and CD45RA. 
Flow cytometric analysis was carried out at baseline (week 0) and at week 40, following daily administration of 0.7mg 
rhGH, for the most robust responders in the IFN-γ ELISpot assays at week 40 (n = 4; symbols for each patient 
correspond to the symbols used in Figure 3.3). CD4 and CD8 T cells (open symbols and dotted lines, and closed 
symbols and solid lines, respectively) were assessed for the percentage expression of markers associated with a naive 
(CCR7
+
CD4RA
+
; A), TCM (CCR7
+
CD45RA
-
; B), TEM (CCR7
-
CD45RA
-
; C) and a TEMRA (CCR7
-
CD45RA
+
; D) 
phenotype.  
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Figure 3.9 PD-1 expression on differentiated subsets of CD4 and CD8 T cells following low-dose rhGH. 
Flow cytometric analysis was carried out at baseline (week 0) and at week 40, following daily administration of 0.7mg 
rhGH, for the most robust responders in the IFN-γ ELISpot assays at week 40 (n = 4; symbols for each patient 
correspond to the symbols used in Figure 3.3). CD4 and CD8 T cells (open symbols and dotted lines, and closed 
symbols and solid lines, respectively) were assessed for the percentage expression of PD-1 on naive (A), TCM (B), TEM 
(C) and TEMRA (D) subsets, defined as previously described by the expression of CCR7 and CD45RA.  
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Figure 3.10 PD-L1 expression on differentiated subsets of CD4 and CD8 T cells following low-dose rhGH. 
Flow cytometric analysis was carried out at baseline (week 0) and at week 40, following daily administration of 0.7mg 
rhGH, for the most robust responders in the IFN-γ ELISpot assays at week 40 (n = 4; symbols for each patient 
correspond to the symbols used in Figure 3.3). CD4 and CD8 T cells (open symbols and dotted lines, and closed 
symbols and solid lines, respectively) were assessed for the percentage expression of PD-L1 on naive (A), TCM (B), TEM 
(C) and TEMRA (D) subsets, defined as previously described by the expression of CCR7 and CD45RA. 
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Figure 3.11 Expression of PD-1 and PD-L1 on CD4 and CD8 T cells and on total lymphocyte subset. 
Flow cytometric analysis was carried out at baseline (week 0) and at week 40, following daily administration of 0.7mg 
rhGH, for the most robust responders in the IFN-γ ELISpot assays at week 40 (n = 4; symbols for each patient 
correspond to the symbols used in Figure 3.3). CD4 and CD8 T cells (open symbols and dotted lines, and closed 
symbols and solid lines, respectively) were assessed for the expression in terms of MFI of PD-1 (A) and PD-L1 (B). 
The percentage expression of PD-1 (C; blue symbols and solid blue lines) and PD-L1 (grey symbols and dotted lines) 
and the MFI (D) were also determined. 
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+
 subjects on HAART for 40 weeks 
resulted in increased IFN-γ production in response to overlapping peptide pools of HIV-1 Gag 
20mers and Gag 9mers; the increase in response to the latter being significant. There were no 
significant changes in IFN-γ production in response to these peptide pools for patients who had 
received placebo for 40 weeks. Phenotypic characterisation of CD4 and CD8 T cells from the four 
rhGH-treated patients with the most robust responses (in terms of IFN-γ production) at week 40 
showed a decrease in markers associated with chronic immune activation at this time point, 
compared to baseline. 
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3.3 rhGH in vitro culture studies 
To elucidate further the impact of rhGH on T-cell phenotype, PBMC from HIV-1-infected 
individuals (n =10) and from healthy donors (n = 6) were cultured with rhGH at a concentration of 
1µg/ml (corresponding to the pharmacological dose) for 72 hours (as described in section 2.14). 
Immunophenotyping was carried out at baseline and following in vitro culture to assess the effect of 
rhGH on the surface markers of T cells using the panel of markers described in section 2.12, Table 
2.1. The Wilcoxon signed rank test was used for statistical analysis. P values are shown where there 
is a significant difference between the means (p ≤ 0.05). As a control, cells from each donor were 
also cultured with AB media alone (no rhGH) for 72 hours and phenotyped.  
3.3.1  Patient characteristics 
HIV-1
+
 donors were all male, had a median age of 46 years (IQR 43 – 51 years), median CD4 T-
cell count of 621 cells/µl blood (IQR 533-658 cells/µl blood) and HIV-1 RNA was <50 copies/ml 
plasma in 9/10 individuals. The duration of infection, duration of ART, treatment regimen and nadir 
CD4 T-cell count are detailed in Table 3.3. The healthy control samples had a median age of 29 
years (IQR 27-32 years) and included three male and three female donors. 
Table 3.3 Patient characteristics for HIV-1
+
 samples and seronegative controls used in rhGH culture experiments. 
NA – not applicable; patient was not on HAART. 
Patient 
short  
code 
Age 
(years) 
Gender 
Viral load 
(copies/ml) 
ART regimen 
Duration 
of ART 
(months) 
CD4  
T-cell 
count 
(cells/µl) 
Nadir 
CD4  
T-cell 
count 
(cells/µl) 
Duration 
of HIV-1 
infection 
(months) 
Healthy 
controls 
(n = 6) 
Median 
29 
IQR: 
27-32   
3M, 3F       
B732 51 M <50 NA NA 554 418 36.66 
W693 37 M <50 TFV+FTC+EFV 29.84 526 203 49.77 
K560 51 M <50 ABC+3TC+SQV+RTV 128.33 617 113 135.77 
N374 45 M 81 TFV+3TC+NVP 17.15 1039 733 229.28 
Z171 38 M <50 TFV+FTC+EFV 64.66 641 182 65.41 
J567 57 M <50 TFV+FTC+RTV+LOP 152.56 625 27 153.21 
L061 44 M <50 FTC+TFV+ATZ+RTV 130.03 218 48 164.07 
C828 43 M <50 FTC+TFV+RTV+ATZ 50.33 664 235 80.49 
E760 46 M <50 TFV+FTC+EFV 87.34 513 64 87.61 
G201 51 M <50 ABC+3TC+NVP 144.56 975 7 222.16 
Median 46    87.34 621 148 111.69 
IQR 43-51    
50.33-
130.03 
533 
-658 
52- 
227 
69.18-
161.35 
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3.3.2 Immunophenotyping before and after culture with rhGH 
PBMC from seronegative healthy donors (n = 6) generally showed no significant difference in the 
percentage expression of surface markers before and after culture with either rhGH or AB TCM 
alone. Figure 3.12 illustrates percentage co-expression of the activation markers HLA-DR and 
CD38 on CD4 and CD8 T cells (Figure 3.12 A and B, respectively). Only a statistically significant 
reduction in the percentage expression of CD38 on CD4 T cells was seen following 72-hour culture 
either with rhGH or TCM alone (Figure 3.12 E). Statistically significant reductions in the 
percentage expression of senescence and apoptosis markers on CD8 T cells was seen following 72-
hour culture with TCM (Figures 3.13 B, C and D). The phenotypic changes for all other markers 
investigated on the panel (Table 2.1) were minimal (data not shown). 
Following 72-hour culture with rhGH, a significant reduction in activation, senescence and 
apoptosis markers was seen compared to baseline in HIV-1
+
 donors (n = 10). Figure 3.14 shows 
representative flow cytometry plots for one individual, before and after culture with rhGH. 
However, when a control was added, and cells were cultured in parallel in the presence of TCM 
alone for 72 hours, these markers were similarly reduced. This was true for markers of immune 
activation (Figure 3.15), markers of senescence and apoptosis (Figure 3.16) and other markers in 
the panel, and this down-regulation was also seen on PBMC from HIV-1
+
 patients cultured with 
varying concentrations of rhIGF-1 (data not shown). The Wilcoxon signed rank test was used as 
data sets were not normally distributed and changes following culture were being observed (within 
patient changes). 
T-cell surface markers were significantly down-regulated following 72-hour culture of PBMC from 
HIV-1
+
 individuals, and this occurred both in the presence and absence of rhGH. This decreased 
surface marker expression was not seen following culture of PBMC from healthy donors in the 
same way. 
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Figure 3.12 Changes in the expression of activation markers in healthy donors following culture with rhGH and TCM. 
Percentage co-expression of HLA-DR and CD38 was assessed on CD4 (A) and CD8 (B) T cells from healthy control 
individuals (n = 6). Percentage expression of HLA-DR and CD38 was assessed on both T-cell subsets (C and E show 
expression on CD4 T cells, and D and E show expression on CD8 T cells). Symbols represent results from individual 
donors and are consistent throughout the plots. Box plots show the median and IQR and whiskers represent the 10
th
 and 
90
th
 percentiles. 
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Figure 3.13 Changes in the expression of senescence and apoptosis markers in healthy donors following culture with 
rhGH and TCM. 
Percentage co-expression of CD57 and CD95 was assessed on CD4 (A) and CD8 (B) T cells from healthy control 
individuals (n = 6). Percentage expression of CD57 and CD95 was assessed on both T-cell subsets (C and E show 
expression on CD4 T cells, and D and E show expression on CD8 T cells). Symbols represent results from individual 
donors and are consistent throughout the plots. Box plots show the median and IQR and whiskers represent the 10
th
 and 
90
th
 percentiles. 
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Figure 3.14 Representative example of changes in extracellular surface staining following culture with rhGH. 
The lymphocyte population was determined (A) as described previously and in this example, markers of activation 
(CD38 and HLA-DR; top panel) and markers of senescence and apoptosis (CD57 and CD95, lower panel) were 
assessed in an HIV-1-infected donor (K087) both before (B) and after (C) 72-hour culture with rhGH.  
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Figure 3.15 Changes in the expression of activation markers on PBMC from HIV-1
+
 donors following culture with 
rhGH and TCM. 
Percentage co-expression of HLA-DR and CD38 was assessed on CD4 (A) and CD8 (B) T cells from HIV-1-infected 
individuals (n =10). Percentage expression of HLA-DR and CD38 was assessed on both T-cell subsets (C and E show 
expression on CD4 T cells, and D and E show expression on CD8 T cells). Symbols represent results from individual 
donors and are consistent throughout the plots. Box plots show the median and IQR and whiskers represent the 10
th
 and 
90
th
 percentiles. 
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Figure 3.16 Changes in the expression of senescence and apoptosis markers on PBMC from HIV-1
+
 donors following 
culture with rhGH and TCM. 
Percentage co-expression of CD57 and CD95 was assessed on CD4 (A) and CD8 (B) T cells from HIV-1-infected 
individuals (n =10). Percentage expression of CD57 and CD95 was assessed on both T-cell subsets (C and E show 
expression on CD4 T cells, and D and E show expression on CD8 T cells). Symbols represent results from individual 
donors and are consistent throughout the plots. Box plots show the median and IQR and whiskers represent the 10
th
 and 
90
th
 percentiles. 
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3.4 Growth hormone receptor expression on CD4 and CD8 T cells 
In order to elucidate further the impact of GH in the context of HIV-1 infection, characterisation of 
the growth hormone receptor (GHR) on CD4 and CD8 T cells was carried out using PBMC from 
HIV-1 infected individuals and healthy control subjects. The FITC-conjugated GHR antibodies, and 
appropriate isotype-matched control, were obtained from Santa Cruz Biotechnology (Heidelberg, 
Germany) as detailed in Table 2.4. A panel was set up as detailed in Table 2.3 with all three GHR 
antibodies (which differed by clone) tested. Flow cytometric analysis was carried out and 100,000 
gated lymphocytes were acquired in order to detect the GHR expression. The panel was designed to 
determine GHR expression on differentiation/maturation subsets of both T-cell subsets using the 
markers CCR7 and CD45RA. Although all three GHR antibodies gave similar results in terms of 
percentage expression of the GHR on CD4 and CD8 T cells, the MAB1 clone produced more 
consistent results in preliminary experiments and was used for all subsequent experiments which 
are described in this section. PBMC from eight ART-treated HIV-1
+
 individuals (patient 
characteristics for these individuals can be found in Table 5.2, and their short codes are as follows: 
F810, G739, M160, O523, P087, R771, S648, W097), and four healthy seronegative donors were 
assessed. GHR expression was found to be significantly lower in HIV-1
+
 subjects compared to 
healthy controls on both CD4 and CD8 T cells (Figure 3.17). There was no significant difference 
between the MFI of GHR on either T-cell subset between HIV-1
+
 and healthy persons and 
expression of the GHR on CD4 T cells did not differ significantly from expression on CD8 T cells 
in either group (data not shown). 
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Figure 3.17 Growth hormone receptor (GHR) expression on CD4 and CD8 T cells. 
Percentage expression of GHR on both CD4 (A) and CD8 (B) T cells was determined using PBMC from seronegative 
healthy controls (shown here in blue circles, n = 4) and HIV-1
+
 patients (shown here in red circles, n = 8). Box plots 
show the median and IQR while whiskers represent the 10
th
 and 90
th
 percentiles. Statistical analysis was carried out 
using the Mann-Whitney U Test and P values are shown where there is a statistically significant difference between the 
means (p ≤ 0.05). 
 
3.5 Discussion 
In order to determine the biological significance of GH in the immune system, it is important to 
consider which cells produce GH and which cells express GHR. GH, identical to pituitary GH, has 
been found to be synthesised and secreted by lymphocytes [Varma et al., 1993; Hattori et al., 2001]. 
PBMC have also been shown to bear GHR with almost all monocytes and close to 90% of B cells 
positive for GHR [Bresson et al., 1999]. Studies using flow cytometric analysis of healthy control 
PBMC have described percentage expression of GHR on peripheral T cells to range from 2-6% 
[Bresson et al., 1999] and from 2-20% [Rapaport et al., 1995]; with less than 5% of activated 
tonsillar T-cell sub-populations (CD4 and CD8 T cells) possessing GHR [Thellin et al., 1998]. An 
extensive literature search revealed no previous characterisation of GHR expression on T cells in 
the context of HIV-1 infection. Here CD4 and CD8 T-cell subsets from healthy control individuals 
showed higher expression of GHR compared to HIV-1-infected persons. No significant differences 
were seen in GHR expression in terms of MFI for either T-cell subset between the two groups and 
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study groups separately, and this concurs with a previous report which found no difference in 
expression between CD4 and CD8 tonsillar T-cell populations [Thellin et al., 1998]. GHR 
expression levels in both subject groups were low and ranged from 0.2 – 1.3% which did not agree 
with previous reports. These found GHR expression to be higher on peripheral T cells than found 
here at 5% [Bresson et al., 1999] and between 2-20% [Rapaport et al., 1995]. Further elucidation of 
the percentage expression on T-cell maturation/differentiation subsets was not carried out as 
percentage expression on the T cells was so low. The supplier of the GHR antibodies was contacted 
for information on positive and negative control staining (using these antibodies on human cells), 
and references reporting on the use of these antibodies to characterise GHR expression in flow 
cytometric analysis, however, this could not be provided. As the validity of these antibodies was 
questioned, further experiments using these reagents were not carried out. 
Using the methodology described here, further experiments to characterise GHR expression on T 
cells in the context of HIV-1 infection are warranted. In one study, GHR expression on PBMC from 
female individuals was found to be lower than age-matched males, and expression differed between 
different age groups [Bresson et al., 1999]. It would be of interest to investigate GHR expression on 
T cells from HIV-1
+
 persons and to look at the effect of ART, and perhaps even in the context of 
immune-based therapy, such as before and after administration of rhGH. Characterisation of the 
prolactin receptor could yield important findings as this receptor is found on all GHR positive 
peripheral T cells [Welniak et al., 2002], and prolactin has been shown to promote T-cell function 
in vitro and in vivo [Clevenger et al., 1990; Welniak et al., 2002]. The expression of GHR on T-cell 
differentiation/maturation (naïve vs memory) subsets has yet to be addressed and it is not known 
whether GH-mediated effects, following administration of rhGH for example, are due to GH 
binding directly to T cells or as a result of indirect stimulation of monocytes and APC [Welniak et 
al., 2002]. Future experiments could employ the use of a GHR antibody clone (and conjugate) that 
has been previously published and validated [Rapaport et al., 1995; Bresson et al., 1999]. 
Alternatively, GHR expression on T cells could be assessed using RT-PCR [Hattori et al., 2001]. 
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Administration of rhGH in treated HIV-1 infection has been shown to significantly reduce the 
expression of markers associated with immune activation (HLA-DR and CD38 on CD4 and CD8 T 
cells) and apoptosis [Napolitano et al., 2008], with effects on memory T-cell subsets [Pires et al., 
2004b].To ascertain the direct effect of rhGH on peripheral T cells, cultures were set up with PBMC 
from healthy controls and HIV-1-infected individuals and incubated for 72 hours with rhGH. 
Cultures with PBMC in TCM alone were set up as negative controls. Preliminary 
lymphoproliferation assays showed that rhGH did not result in the proliferation of T-lymphocytes. 
Phenotypic analysis was carried out before and after culture with rhGH and markers of activation, 
exhaustion, senescence, apoptosis and differentiation/maturation assessed. PBMC from healthy 
donors showed little change in terms of percentage expression of these markers whether cultured 
with rhGH or TCM alone. Preliminary experiments using PBMC from HIV-1-infected individuals, 
however, showed promising results, with a down-regulation in markers associated with immune 
activation (HLA-DR and CD38), senescence (CD57) and apoptosis (CD95). When negative control 
wells were run in parallel, these also produced a down-regulation of the same markers, suggesting 
that this decrease was an effect of culture. The provider of the rhGH for the clinical trial (Merck 
Serono Ltd, Feltham, UK) was contacted in order to use the same rhGH given to patients in this 
culture system, however this was unavailable. These rhGH culture experiments may be optimised 
by ensuring the use of carrier/adjuvant-free rhGH and by resting the cells overnight prior to 72-hour 
culture which might improve cell viability. IL-2 was not added to these cultures as an observation 
of the direct effect of rhGH on T cells was the main objective and IL-2 is known to induce 
proliferation in vitro [Mookerjee et al., 1989; Besser et al., 2009], and may alter the expression of 
surface markers. 
Daily administration of a ‘supra-physiological’ dose of rhGH (4mg/day) for 12 weeks in HAART-
treated HIV-1-infected individuals resulted in significant increases in HIV-1-specific CD4 and CD8 
T-cell responses. At week 24, when patients had received less frequent dosing of rhGH, a decline 
was observed in HIV-1-specific CD4 T-cell responses (this was the case for all patients and also 
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noted at week 48). The increased HIV-1-specific CD8 T-cell responses measured at week 12 were 
maintained at week 24 (regardless of randomisation group) and despite a lack of virus-specific CD4 
T-cell responses. At the week 48 follow-up visit, when patients had received HAART alone for a 
further 24 weeks, only HIV-1-specific CD8 T-cell responses to Gag and Pol remained whereas 
responses to other HIV-1 antigens had significantly declined and virus-specific CD4 T-cell 
responses remained undetectable. These findings support previously published data investigating 
the role of rhGH in HIV-1 infection, not only for the treatment of lipodystrophy [Lo et al., 2001; 
Sivakumar et al., 2011] but as an immunomodulator to reverse T-cell dysfunction in combination 
with effective HAART. Administration of rhGH in treated HIV-1-infected adults has been shown to 
increase thymic density [Napolitano et al., 2002; Napolitano et al., 2008; Hansen et al., 2009; Smith 
et al., 2010], increase numbers of circulating naïve CD4 T cells [Napolitano et al., 2002; Pires et 
al., 2004b; Napolitano et al., 2008; Hansen et al., 2009; Smith et al., 2010], increase TREC 
frequency [Napolitano et al., 2008; Hansen et al., 2009; Smith et al., 2010], and reduce expression 
of markers associated with immune activation (HLA-DR and CD38) and senescence (Fas) 
[Napolitano et al., 2008], whereas it has not been shown to have a discernible effect on viral load. A 
report by Smith et al., investigating rhGH administration in treated HIV-1
+
 patients did not find 
improvements in HIV-1-specific responses (in terms of lymphoproliferative responses to recall, neo 
or HIV-1 antigens) [Smith et al., 2010]. This could be due to the lower dose of rhGH used in their 
study (1.5mg/3.0mg). Additionally, their patient demographics differed with a median baseline CD4 
T-cell count of 219 cells/µl blood, compared to 467 cells/µl blood in this study, although duration 
of ART was similar for both (>4 years). Differences in nadir CD4 T-cell counts between the two 
study groups might also explain the variation, in terms of recovery of virus-specific responses, 
although these data were not available for comparison. The decrease of the CD4 T-cell response 
following withdrawal of rhGH suggests that cells may require a stronger or more sustained signal 
from rhGH to recover and provide help to the CD8 T cells. CD8 T-cell responses have been shown 
to be maintained for a limited amount of time without help from CD4 T cells [Williams and Bevan, 
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2007], but eventually diminished following discontinuation of rhGH therapy. The responses at week 
48; the absence of HIV-1-specific CD4 T-cell responses and decline in virus-specific CD8 T-cell 
responses may reflect exhaustion or a lack of CD4 T-cell help to facilitate the complete function of 
effective CD8 T cells [Shedlock & Shen, 2003; Sun & Bevan, 2003; Janssen et al., 2003]. This 
immunomodulatory therapy, however, has provided adequate help to HIV-1-specific CD4 T cells 
which have in turn induced the appropriate effective anti-HIV-1 CD8 T cells [Herasimtschuk et al., 
2008] and these findings suggest that stronger or prolonged treatment with rhGH may be needed to 
further maintain these virus-specific responses. 
Low ‘physiological’ dosing of rhGH provided findings that were consistent with short-term high-
dose studies. The robust and durable responses seen following 40 weeks of rhGH suggest that this 
treatment may improve key defects in both MHC Class I and II presentation and appropriate T-cell 
function, and show a reversal of T-cell anergy that is greater than seen with ART alone. Clinical 
observations showed long-term, low-dose rhGH to be well tolerated and to significantly increase 
thymic density and thymic index, as well as significantly increasing the number of total CD8 T cells 
with a trend towards an increase in both the number of total CD4 T cells and the number of naïve T 
cells (in the rhGH group compared to the placebo) [Hansen et al., 2009]. Few studies have 
investigated such a low dose of rhGH in the context of treated HIV-1 infection. A study by Lo et 
al., investigated long-term (18 months), low-dose rhGH (average dose 0.33mg/day) in GH-deficient 
treated HIV-1
+
 individuals and did not find an increase in CD4 T-cell numbers following rhGH 
administration. However, patient demographics differed considerably to this study in terms of 
baseline CD4 T-cell counts, plasma HIV-1 RNA, length of time on ART and duration of infection, 
and the effect on the thymus was not determined [Lo et al., 2008]. Further studies into the 
phenotype of both total peripheral and HIV-1-specific T cells following treatment with rhGH are 
warranted. High levels of chronic immune activation have been associated with HIV-1 disease 
progression [Hazenberg et al., 2003] and although these levels are lowered with effective ART 
[Bartovska et al., 2011], they are not normalised. These experiments provide additional evidence 
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that even at a low dose rhGH may provide a means of further lowering the levels of expression of 
activation and apoptotic markers which concurs with other (high-dose) studies [Napolitano et al., 
2008]. Additionally, a shift towards a central memory phenotype in the CD8 T-cell compartment 
following rhGH administration may be beneficial as an accumulation of effector memory CD8 T 
cells has been described in chronic HIV-1 infection [Downey & Imami, 2010]. Interestingly, the 
four samples that showed the most robust IFN-γ ELISpot responses at week 40, and were 
characterised phenotypically, were all from patients presenting with HIV-1-associated 
lipodystrophy syndrome (HALS). This is perhaps not unexpected as patients with HIV-1 
lipodystrophy have been found to have abnormalities in GH secretion that are strongly associated 
with body composition and metabolic irregularities [Stanley & Grinspoon, 2009], and thus these 
patients may show the most benefit not only clinically (in terms of reduced visceral fat and lipid 
parameters) but also immunologically. Similarly, the study by Smith et al., found that subjects with 
low baseline TREC had the greatest increase in TREC, suggesting rhGH had the most benefit for 
those with poor thymopoiesis at baseline [Franco et al., 2002; Smith et al., 2010]. The down-
regulation of surface markers seen in the low-dose rhGH study may be an effect of an additional 40 
weeks of ART. Phenotypic characterisation of PBMC samples from placebo-treated individuals and 
non HALS rhGH-treated patients would give a clearer indication of the effect of rhGH on 
immunophenotype in HIV-1 infection. Long-term, low-dose rhGH also has the added benefit of 
being associated with fewer treatment-related adverse events such as peripheral edema, arthralgias 
and increased blood glucose [Kotler et al., 2004; Grunfeld et al., 2007], although it should be noted 
that this was not an issue in the high-dose rhGH study presented here. Withdrawal of low-dose 
rhGH in the study by Lo et al., saw a rapid rebound in visceral adipose tissue (VAT) to a level 
significantly above initial baseline values within 6 months of crossover to placebo [Lo et al., 2010] 
however, immunological parameters were not ascertained and again, the population studied 
presented with abdominal fat accumulation and relative GH deficiency. It would be of interest to 
assess the phenotype of the non-HALS individuals from this study but samples were limited. 
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IGF-1 treatment in HIV-1 infection was not shown to have any impact on visceral adiposity [Rao et 
al., 2010]. However, immunological parameters were not investigated. Immunological changes 
following administration of a molecule upstream of GH in treated HIV-1
+
 individuals has not been 
investigated. The growth hormone releasing factor analogue, tesamorelin (hypothesised to induce 
endogenous GH secretion), was found to significantly reduce visceral adipose tissue in ART-treated 
HIV-1
+
 patients with excess fat accumulation [Falutz et al., 2010], and the function of this molecule 
on the function and phenotype of HIV-1-specific T cells has yet to be discerned. 
In summary, the results from the two clinical trials presented here, demonstrate the ability of rhGH 
at a high- or low- dose to induce HIV-1-specific T-cell responses in chronically infected patients on 
effective HAART, with the potential to improve the dysfunctional immunophenotype observed in 
chronic HIV-1 infection. These findings clearly illustrate the importance of the development and 
further study of new and current immune-based therapeutic approaches in the context of HAART-
treated chronic HIV-1 infection. 
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Chapter 4 Novel Interventions in HIV-1 Infection: IMIRC 1003 Clinical Trial 
The development of new, and modification of existing, immune-based therapeutic approaches in the 
context of treated HIV-1 infection are needed. Effective HAART controls HIV-1 infection and 
improves morbidity and mortality in infected patients [Montaner et al., 2006], however, it cannot 
eradicate HIV-1 and does not improve the immune system’s ability to control the virus [Pires et al., 
2004a; Imami et al., 2007]. ART-treated HIV-1-infected persons are at a higher than normal risk for 
certain age-associated diseases, which may be due in part to irreversible virus-associated 
immunological damage [Deeks, 2011]. Studies have sought to optimise the timing and duration of 
ART; initiation of ART in early HIV-1 infection has been shown to result in lower residual viral 
reservoirs [Pires et al., 2004a; Cellerai et al., 2011], lower levels of immune activation and 
improved polyfunctionality of HIV-1-specific T-cell responses [Cellerai et al., 2011]. Although it 
appears that a very small number of individuals, treated at the time of primary HIV-1 infection, 
maintain immunovirological control following treatment interruption [Hocqueloux et al., 2010], for 
the majority of individuals, cessation of ART results in viral rebound [Burton et al., 2005; 
Hocqueloux et al., 2010] and treatment interruptions are discouraged [El-Sadr et al., 2006]. Novel 
therapeutic interventions may provide a means of further depleting viral reservoirs, improving 
cellular immune responses and providing full and prolonged control of viral replication in the 
absence of ART.  
The design of this clinical trial, the immunomodulatory agents used, and the timing of their 
administration have been carefully based upon findings from previous studies and preliminary data. 
Therapeutic vaccination in conjunction with effective HAART may lead to a reversal of anergy by 
selective activation of the immune system against specific viral proteins, such that specific memory 
responses may be induced or augmented. Administration of IL-2, GM-CSF and rhGH may lead to 
the in vivo expansion of useful T-cell subsets [Imami et al., 2007]. A brief summary of the rationale 
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for the study is shown in Table 4.1, with more detailed information on each of the treatments 
described in detail in the introduction of this thesis. 
Table 4.1 Rationale for the treatments given in the IMIRC 1003 clinical trial. 
Treatment Immunological effect 
Therapeutic 
vaccination 
Induce/boost HIV-1-specific (new and memory) responses in functional cells 
[Imami et al., 2007] 
IL-2 
Growth, survival, differentiation/maturation; de-anergise; increase in frequency 
and function of effector T cells and regulatory T cells (particularly HIV-1-
specific CD4 T cells) 
[Imami et al., 1999; Imami et al. 2001; Levy et al., 2003] 
GM-CSF 
De-anergise; increase effector T cells; increase HIV-1-specific CD4 and CD8 T-
cell, APC and NK cell function 
[Imami et al., 1999; Pires et al., 2005; Brown & Angel, 2005] 
rhGH 
Increase thymic activity and differentiation/maturation of T cells, increased NK 
cell function 
[Pires et al., 2004b; Goodier et al., 2003] 
 
Approaches using therapeutic vaccination or immunotherapy with cytokines appear to result in 
greater benefits, than seen with ART alone, when viral load is undetectable (when patients are on 
effective HAART) [Pires et al., 2004b; Imami et al., 2007]. The duration of ART-induced viral 
control and nadir CD4 T-cell counts have been shown to be important factors for CD4 T-cell 
recovery [Koegl et al., 2009], thus patient eligibility criteria were strictly defined. Enhanced 
responses were predicted through the induction/re-introduction of specific cellular immune 
responses by priming with therapeutic immunisation, sustaining these responses through the 
administration of cytokines/hormones and boosting memory responses with further immunisations 
[Imami et al., 2007]. Previous animal models have shown that administration of IL-2 during the 
antigen-specific T-cell contraction phase of the immune response, approximately 8-15 days 
following vaccination, may result in the preservation and maintenance of clinically relevant 
responses [Blattman et al., 2003; Nacsa et al., 2005]. IL-2 administration pre-vaccination in HIV-1
+
 
HAART-treated patients did not result in an increase in specific T-cell proliferation [Levy et al., 
2003, Valdez et al., 2003]. However, IL-2 administered following tetanus vaccination in HIV-1-
infected persons was found to better sustain the tetanus-specific responses than IL-2 administered 
together with or before vaccination [Hardy et al., 2004]. Further immune reconstitution may occur 
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in the periphery, via enhanced antigen presentation to fully functional HIV-1-specific CD4 and CD8 
T cells as a result of GM-CSF administration [Pires et al., 2005; Brown & Angel, 2005], and via the 
thymus, following treatment with rhGH [Pires et al., 2004b; Napolitano et al., 2002; Napolitano et 
al., 2008; Smith et al., 2010]. 
To this effect, patients were recruited with CD4 T-cell counts >400 cells/µl blood, nadir CD4 T-cell 
counts >200 cells/µl blood and HIV-1 RNA <50 copies/ml plasma. They had to be on suppressive 
HAART for at least 6 months prior to study initiation and could not be receiving or have received 
immunomodulatory drugs. 
4.1 Patient characteristics and HLA-typing 
The baseline characteristics of the twelve patients enrolled on the trial are detailed in Table 4.2. Of 
these individuals, eleven were male, infected with HIV-1 clade B, and one was female, infected 
with HIV-1 clade C. The median age of those enrolled was 48 years (IQR 42-51 years), with a 
median CD4 T-cell count at baseline of 757 cells/µl blood (IQR 567-886 cells/µl blood). The 
majority of patients had nadir CD4 T-cell counts >200 cells/µl blood (median 219; IQR 177-289 
cells/µl blood) and for all patients HIV-1 RNA at baseline was <50 copies/ml plasma. Median 
duration of HIV-1 infection was 142.92 months (IQR 89.04-186.98 months) and median duration of 
ART was 93.07 months (IQR 58.63-143.89 months). Three individuals were randomised into group 
1, four into group 2 and five into group 3 (Table 4.2). 
The HLA-type and ethnicity of the twelve enrolled patients is given in Table 4.3. The majority of 
individuals were of White/Caucasian ethnicity and there was no observable difference in protective 
or non-protective HLA Class I allele requencies between individuals in each group. 
  
  
1
3
3
 
Table 4.2 Characteristics of the twelve patients enrolled on the IMIRC 1003 clinical trial. 
IQR – interquartile range; NK – not known. 
Patient 
short 
code 
Group 
Graph 
symbol 
Date of 
birth 
Age  
(years) 
Gender 
Clade of 
infection 
Duration of 
HIV-1 
infection 
(months) 
Duration of 
ART 
(months) 
ART 
regimen 
CD4 T-cell count 
(cells/µl blood) 
Plasma viral 
load at 
baseline 
(copies/ml) 
Nadir Baseline 
R771 1  20/03/1946 64 M B 160.13 139.05 FTC+TFV+EFV 391 884 <50 
B784 1  30/05/1970 40 M B 99.25 98.95 FTC+TFV+EFV 80 1332 <50 
G739 1  28/06/1967 43 M B 141.61 113.15 FTC+TFV+EFV 227 534 <50 
P087 2  02/09/1959 50 M B 172.95 162.75 FTC+TFV+EFV 210 731 <50 
C789 2  07/01/1981 29 M B 20.75 12.20 FTC+TFV+EFV 309 535 <50 
L043 2  27/10/1963 47 M B 90.69 45.87 FTC+TFV+EFV 303 782 <50 
C319 2  04/09/1962 48 M B 229.05 80.03 FTC+TFV+ETV 93 1077 <50 
F810 3 ▲ 07/08/1959 50 M B 233.41 193.54 FTC+TFV+NVP 166 582 <50 
O523 3 ▲ 31/05/1956 53 F C 84.10 62.89 FTC+TFV+ETR 284 892 <50 
S648 3 ▲ 18/01/1957 52 M B 300.39 158.43 TFV+DRV+RTV 227 578 <50 
C241 3 ▲ 07/02/1963 47 M B 144.23 87.18 FTC+TFV+DRV+RTV 180 466 <50 
P054 3 ▲ 17/04/1978 33 M B 40.80 28.80 FTC+TFV+EFV 200 840 <50 
Median    48   142.92 93.07  219 757  
IQR    42-51   
89.04- 
186.98 
58.63- 
143.89 
 
177- 
289 
567- 
886 
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Table 4.3 Ethnicity and HLA-type of the individuals on the IMIRC 1003 clinical trial. 
Patient are grouped and colour-coded according to randomisation arm: group 1 (blue), group 2 (green) and group 3 
(red). *New HLA-type identified which is most similar to B*37:01 except that position 454 is C instead of G. 
Patient 
short code 
Ethnicity HLA-A HLA-B HLA-Cw HLA-DR 
R771 White/Caucasian 0201, 2902 3924, 4403 0701, 1601 0701, 1102 
B784 White/Caucasian 1101, 6802 1402, 1501 0102, 0802 0101, 1301 
G739 Asian 0201, 3201 4402, 5101 0501, 1502 0407, 1201 
P087 White/Caucasian 0201/09, 6801 4001, 0702 0304, 0702 0404, 1501 
C789 White/Caucasian 0101/0201 3503, 3701* 0602, 1203 0701, 1502 
L043 White/Caucasian 0205, 2601 5801, 5802 0602, 0701 0401, 1302 
C319 White/Caucasian 0301, 3201 0702, 1401 0702, 0802 0103, 0701 
F810 White/Caucasian 0101, 2402 0801, 2705 0102, 0701 0404, 1501 
O523 White/Caucasian 0101, 3201 0702, 4402 0501, 0702 0407, 1301 
S648 White/Caucasian 3101, 2402/09N 0801, 0702 0701, 0702 0301, 0404 
C241 Hispanic 0101, 2402 3905, 8102 0702, 1801/02 0301, 1402 
P054 White/Caucasian 0201, 2601 0702, 4001 0304, 0702 1302 
 
4.2 Lymphocyte subsets and plasma viral load 
The results presented in this chapter show changes from baseline in all clinical and immunological 
parameters as described in section 2.23, thus all baseline values are tabulated in Appendix 1. For the 
graphs presented herein, a statistically significant difference compared to baseline can be observed 
easily where the 95% CI does not cross the line of origin (the point where the X axis crosses the Y 
axis at zero); where it is above, a statistically significant increase can be inferred and where it is 
below, a statistically significant decrease. Where 95% CI from the groups do not overlap for an 
individual time point, there is a statistically significant difference between the means of the groups. 
All mean changes from baseline, 95% CI values and p values can be found in Appendix 2. 
Administration of IL-2 and GM-CSF for five days resulted in a mean change from baseline to week 
2 of 1307 cells/µl and 1511 cells/µl blood in groups 1 and 3, respectively (95% CI 1104-1511 
cells/µl blood, p <0.0001; and 95% CI 1353-1688 cells/µl blood, p <0.0001, respectively), and this 
was significantly higher than for group 2 (in which patients received vaccine alone; Figure 4.1A). 
At week 6, CD4 T-cell counts were elevated compared to baseline in both groups that received 
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cytokines and hormone and the mean increase was 413 cells/µl and 239 cells/µl blood in groups 1 
and 3, respectively (95% CI 210-617 cells/µl blood, p = 0.0001; and 95% CI 82-397 cells/µl blood, 
p = 0.0039, respectively), whereas for group 2 there was a marginal but statistically significant 
decrease in the mean CD4 T-cell count compared to baseline at week 6 of -191 CD4 T cells (95% 
CI -367 – -15, p = 0.0369). At the final study time point, week 48, only patients in group 1 (that had 
received therapeutic vaccination and cytokines and hormone) demonstrated an increase in mean 
CD4 T-cell count compared to baseline of 281 cells/µl blood (95% CI 78-484 cells/µl blood, p = 
0.0083; Figure 4.1A). 
A similar, though less pronounced pattern was seen when looking at the change from baseline in 
CD4 T-cell percentage. Following cytokine administration in treatment groups 1 and 3, a 
statistically significant increase in CD4 T-cell percentage was observed at week 2, with a mean 
change from baseline to week 2 of 8.3% and 8.2%, respectively (95% CI 4.5-12.1%, p <0.0001; 
95% CI 5.2-11.2%, p <0.0001, respectively; Figure 4.1B). For group 3, statistically significant 
increases in CD4 T-cell percentage from baseline values were seen again at weeks 4 and 8 with 
mean increases of 3.1% and 3.7% (95% CI 0.1-6.0%, p = 0.0453; 95% CI 0.8-6.8%, p = 0.0156, 
respectively), with a trend toward a statistically significant increase at week 48 (the mean increase 
was 2.9%, 95% CI -0.1-5.9%, p = 0.0590). Patients in group 1, however, had CD4 T-cell 
percentages which remained elevated at each time point for the remainder of the study, up until 
week 48, where the mean increase from baseline was 5% (95% CI 1.2-8.8%, p = 0.0124). 
Throughout the course of the study, the CD4 T-cell percentage did not deviate significantly from 
baseline in patients that received vaccine alone (group 2; Figure 4.1B). 
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Figure 4.1 CD4 T-cell changes from baseline to each of the study time points. 
CD4 T-cell count (A) and CD4 T-cell percentage (B) are depicted for each of the patient groups: group 1 in blue circles, 
group 2 in green squares and group 3 in red triangles. Mean change from baseline to the study time point (week) is 
plotted in each instance, with error bars displaying the 95% confidence interval. Asterisks indicate statistical 
significance, where p ≤ 0.05. 
 
Throughout the course of the 48 weeks, the CD8 T-cell counts followed a similar pattern to the CD4 
T-cell counts. Patients in groups 1 and 3 demonstrated statistically significant increases in their 
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CD8 T-cell counts at week 2, following administration of the cytokines, IL-2 and GM-CSF, 
compared to baseline and compared to group 2. The mean increase from baseline at week 2 was 634 
cells/µl and 999 cells/µl blood, respectively (95% CI 377-891 cells/µl blood, p <0.0001; and 95% 
800-1199 cells/µl blood, p <0.0001, respectively; Figure 4.2A). The increase was more prominent 
for group 3 for which CD8 T-cell counts remained elevated at weeks 4 and 6, with a mean increase 
from baseline of 248 cells/µl and 220 cells/µl blood, respectively (95% CI 49-448 cells/µl blood, p 
= 0.0168; and 95% CI 21-420 cells/µl blood, p = 0.0330, respectively). Patients in group 2 
experienced a marginal but significant reduction in the numbers of CD8 T cells at weeks 6 and 12 
with a mean decrease of -283 cells/µl and -239 cells/µl blood, respectively (95% CI -505 – -60 
cells/µl blood, p = 0.0151; and 95% CI -462 – -16 cells/µl blood, p = 0.0387, respectively). By 
week 48, there was no difference from baseline in CD8 T-cell counts for any of the groups (Figure 
4.2A). 
CD8 T-cell percentages were significantly reduced compared to baseline at weeks 2 (p = 0.0008), 6 
(p = 0.0387), 16 (p = 0.0169), 24 (p = 0.0003) and 48 (p = 0.0453) for individuals in group 1, 
whereas significant decreases in CD8 T-cell percentage were seen at weeks 2 (p <0.0001) and 4 (p 
= 0.0421) in group 3 and only at week 48 for group 2 (p = 0.0472; Figure 4.2B). 
Marked increases in CD3 T-cell counts (compared to baseline and compared to group 2) were 
observed at week 2 following cytokine administration in patients in groups 1 and 3 with mean 
increases from baseline at week 2 of 2014 cells/µl and 2510 cells/µl blood (95% CI -589-208 
cells/µl blood, p <0.0001; and 95% CI 2154-2867 cells/µl blood, p <0.0001, respectively). A less 
pronounced increase was found at week 6 (p = 0.0096 for group 1, and p = 0.0100 for group 3) 
following growth hormone treatment in these groups. At week 48, there was no significant 
difference from baseline in CD3 T-cell count for any of the treatment groups (Figure 4.3A). 
In terms of the percentage of CD3 T cells, significant increases were seen for individuals in groups 
1 and 3 at week 2 with mean increase from baseline of 4.2% and 3.9% (95% CI 1.2-7.2%, p = 
0.0075; and 1.6-6.2%, p = 0.0014, respectively). CD3 T-cell percentages remained elevated for 
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individuals in group 1 but by week 48, there was no statistically significant difference from baseline 
in CD3 T-cell counts for any of the groups (Figure 4.3B). 
 
Figure 4.2 CD8 T-cell changes from baseline to each of the study time points. 
CD8 T-cell count (A) and CD8 T-cell percentage (B) are depicted for each of the patient groups: group 1 in blue circles, 
group 2 in green squares and group 3 in red triangles. Mean change from baseline to the study time point (week) is 
plotted in each instance, with error bars displaying the 95% confidence interval. Asterisks indicate statistical 
significance, where p ≤ 0.05. 
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Figure 4.3 CD3 T-cell changes from baseline to each of the study time points. 
CD3 T-cell count (A) and CD3 T-cell percentage (B) are depicted here for each of the patient groups: group 1 in blue 
circles, group 2 in green squares and group 3 in red triangles. Mean change from baseline to the study time point (week) 
is plotted in each instance, with error bars displaying the 95% confidence interval. Asterisks indicate statistical 
significance, where p ≤ 0.05. 
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In terms of CD19 B-cell counts (Figure 4.4A), individuals that received cytokines and hormone 
showed a mean decrease from baseline to week 4 of -131 cells/µl and -77 cells/µl blood, for group 1 
and group 3, respectively (95% CI -204 – -58 cells/µl blood, p = 0.0007; and 95% CI -134 – -21 
cells/µl blood, p = 0.0085, respectively). Both groups also showed a mean decrease from baseline to 
week 8 of the study of -78 cells/µl and -63 cells/µl blood, in groups 1 and 3 respectively (95% CI -
151 – -6.0 cells/µl blood, p = 0.0376; and 95% CI -119 – -6.3 cells/µl blood, p = 0.0321, 
respectively). Again, by week 48, there were no statistically significant differences from baseline in 
CD19 B-cell counts in any of the three randomisation groups (Figure 4.4A). 
The profile of CD19 B-cell percentage change from baseline over the time course of the trial was 
somewhat different. There was a mean decrease from baseline at week 2 of -6.3% and -5.5% in 
groups 1 and 3, respectively (95% CI -8.3 – -4.4%, p <0.0001; and 95% CI -7.1 – 4.0%, p <0.0001, 
respectively). This CD19 B-cell percentage remained statistically lower than baseline for these two 
groups until week 16 but by week 48, there was no statistically significant difference in CD19 B-
cell percentage in any of the treatment groups compared to baseline (Figure 4.4B). 
Looking at CD56 NK-cell count, there was a mean increase from baseline to week 2 of 235 cells/µl 
and 511 cells/µl blood in groups 1 and 3, respectively (95% CI 82.7-387 cells/µl blood, p = 0.0033; 
and 95% CI 393-629 cells/µl blood, p <0.0001, respectively). The more pronounced increase for 
group 3 in CD56 NK-cell declined at the following study time points but remained significantly 
elevated compared to baseline until week 8. By week 48 of the study, no statistically significant 
differences in CD56 NK-cell count were seen regardless of treatment group (Figure 4.5A). In terms 
of C56 NK-cell percentage, the mean change from baseline to each of the study time points did not 
reveal any statistically significant findings regardless of randomisation group (Figure 4.5B). 
Changes in ISUM (total number of lymphocytes; CD3 T cells, CD19 B cells, and CD56 NK cells) 
and CD4/CD8 T-cell ratios are shown in Figure 4.6. There is a statistically significant increase in 
ISUM for patients in groups 1 and 3 with a mean increase from baseline to week 2 of 2254 cells/µl 
and 3063 cells/µl blood, respectively (95% CI 1665-2843 cells/µl blood, p <0.0001; and 95% CI 
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2606-3516 cells/µl blood, p <0.0001, respectively). At week 6, there was a statistically significant 
increase in ISUM for these two groups compared to baseline although it was less prominent and by 
week 48, no statistically significant changes from baseline were seen in either group (Figure 4.6A). 
CD4/CD8 T-cell ratios were elevated at week 2 for individuals in groups 1 and group 3 with a mean 
increase from baseline of 0.43 and 0.34, respectively (95% CI 0.26-0.61, p <0.0001; and 0.21-0.47, 
p <0.0001, respectively). This increased CD4/CD8 T-cell ratio was maintained for all of the other 
time points for patients randomised to group 1 with a mean increase from baseline to week 48 of 
0.27 (95% CI 0.09-0.44, p = 0.0033; Figure 4.6B). 
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Figure 4.4 CD19 B-cell changes from baseline to each of the study time points. 
CD19 cell count (A) and CD19 cell percentage (B) are shown here for each of the patient groups: group 1 in blue 
circles, group 2 in green squares and group 3 in red triangles. Mean change from baseline to the study time point (week) 
is plotted in each instance, with error bars displaying the 95% confidence interval. Asterisks indicate statistical 
significance, where p ≤ 0.05. 
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Figure 4.5 CD56 NK-cell changes from baseline to each of the study time points. 
CD56 cell count (A) and CD56 cell percentage (B) are shown here for each of the patient groups: group 1 in blue 
circles, group 2 in green squares and group 3 in red triangles. Mean change from baseline to the study time point (week) 
is plotted in each instance, with error bars displaying the 95% confidence interval. Asterisks indicate statistical 
significance, where p ≤ 0.05. 
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Figure 4.6 ISUM and CD4/CD8 ratio changes from baseline to each of the study time points. 
ISUM (A) and CD4/CD8 ratio (B) are shown here for each of the patient groups: group 1 in blue circles, group 2 in 
green squares and group 3 in red triangles. Mean change from baseline to the study time point (week) is plotted in each 
instance, with error bars displaying the 95% confidence interval. Asterisks indicate statistical significance, where p ≤ 
0.05. 
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Plasma viral load was <50 copies/ml for all individuals at both screen visits and at baseline (Table 
4.4). Patients from each treatment group experienced detectable viraemia throughout the course of 
the study and this was not attributable to a particular treatment or time point, although one 
individual in group 1 and one individual in group 3 demonstrated the most pronounced increases in 
plasma viral load (G739 at week 2, and O523 at week 8, with viral loads of 345 and 588 copies/ml 
plasma, respectively). 
 
Table 4.4 Plasma viral load (in copies/ml) for all twelve patients, for all study time points. 
ND – not done. Values in bold indicate where plasma viral load was detectable.  
Study visit 
(week) 
Group 1 Group 2 Group 3 
R771 B784 G739 P087 C789 L043 C319 F810 O523 S648 C241 P054 
-4 (Screen) <50 <50 <50 <50 <50 <50 <50 <50 <50 <50 <50 <50 
-2 (Screen) <50 <50 <50 <50 <50 <50 ND <50 <50 <50 <50 ND 
0 (Baseline) <50 <50 <50 <50 <50 <50 <50 <50 <50 <50 <50 <50 
1 <50 <50 69 <50 <50 <50 <50 <50 <50 <50 <50 <50 
2 <50 <50 345 <50 <50 <50 <50 <50 <50 <50 <50 <50 
4 <50 <50 <50 <50 88 <50 53 <50 <50 <50 <50 <50 
6 <50 <50 <50 <50 <50 <50 <50 <50 <50 <50 <50 <50 
8 <50 <50 <50 <50 <50 <50 <50 <50 588 <50 <50 <50 
12 80 <50 62 <50 <50 <50 <50 77 <50 <50 <50 <50 
16 <50 <50 <50 <50 <50 <50 <50 <50 <50 <50 <50 <50 
24 <50 <50 <50 <50 57 <50 <50 <50 <50 <50 <50 <50 
48 <50 <50 <50 <50 <50 <50 <50 <50 <50 <50 <50 <50 
 
4.3 Toxicology and patient compliance 
In terms of clinical chemistry, very few values were outside the normal limits throughout the course 
of the study. The majority of patients had high triglyceride levels at one of the screen visits or at the 
baseline visit (9/12). After week 2, plasma chloride levels were higher for patients in group 1 (who 
received therapeutic immunisation and IL-2, GM-CSF and rhGH). Following cytokine 
administration, patient C241 showed an acute peak in ALT and AST at week 2. Throughout the 
course of the study, patient G739 showed a degree of hypophosphataemia, patients B784 and S648 
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had consistently raised ALT levels, and patient F810 had raised alkaline phosphatase (toxicology 
data not shown). 
The adverse events documented were mostly mild and included erythema at the injection site and 
slightly more severe reactions in patients that failed to take ibuprofen and paracetamol prophylaxis 
the evening prior to IL-2 and GM-CSF administration. The protocol deviations that arose were 
discussed with the principle investigator, study clinician and on-site statistician and the majority 
deemed minor: five study visits were performed outside of the schedule (the trial team decided that 
these were within a timeframe that would not impact the immunological relevance of the 
subsequent time points); subject O523 did not administer rhGH on day 16 but took it on day 19 
instead; F810 did not receive rhGH day 8 dose due to problems with reconstitution; and for P087, 
the on-site clinical team were only able to administer 8 x 0.1 ml instead of 10 x 0.1 ml of the 
vaccine on day one (they confirmed that the vial was not dropped or drawn up incorrectly). There 
was only one major protocol deviation which occurred for patient C241; this subject was admitted 
to the hospital with headaches following the first administration of rhGH on day 14. It was agreed 
that due to this serious adverse event (SAE) the individual should receive no further rhGH but 
continue on the study on an observational basis. A more comprehensive look at the adverse events 
can be found in Appendix 4 (Appendix Tables 37 and 38). 
4.4 IFN-γ, IL-2, IL-4 and perforin production in response to peptide stimulation 
Preliminary ELISpot assays were run using PBMC from seronegative donors and from HIV-1-
infected individuals (prior to initiation of the study) in order to confirm that the aliquoted NIBSC 
and FIT Biotech peptides were of a high quality and not cross-reactive. Details of the results from 
these assays can be found in Appendix 3. The baseline responses to each of the peptide pools and to 
TCM and PHA can be found in Appendix 1. Graphs presented here are as previously for the clinical 
data and mean changes from baseline are presented with 95% CI and significant p values (p ≤0.05) 
shown. Changes from baseline in IFN-γ production in response to stimulation with peptide pools 
from two sources (NIBSC and FIT Biotech) are shown in Figure 4.7 and Figure 4.8 respectively. 
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Following treatment with IL-2 and GM-CSF (in the absence of therapeutic immunisation), group 3 
individuals showed a statistically significant reduction in IFN-γ production in response to peptide 
pools of Gag p17 and Gag p 24 from NIBSC (Figures 4.7A and B, respectively) and a reduction 
was seen in response to the Gag p17/p24 sub-pool from FIT Biotech (Figure 4.8A). The mean 
decrease from baseline to week 2 was -148 SFC/10
6
 PBMC (95% CI -242 – -54, p = 0.0027) for 
Gag p17 NIBSC, -260 SFC/10
6
 PBMC (95% CI -419 – -100 SFC/106 PBMC, p = 0.0020) for Gag 
p24 NIBSC, and -285 SFC/10
6
 PBMC (95% CI -470 – -100 SFC/106 PBMC, p = 0.0034) for Gag 
p17/p24 FIT Biotech sub-pool (Figures 4.7A and B, and Figure 4.8A, respectively). This reduction 
in IFN-γ production was also seen at week 24 for individuals randomised to group 3 to all three Gag 
peptide pools although by week 48, there was no significant difference from baseline in IFN-γ 
production for this group. Group 2 (vaccine only) showed moderate increases in IFN-γ response to 
the NIBSC Gag p17 peptide pool at weeks 12 and 24, but these were not maintained by week 48 
(Figure 4.7A). Patients in group 1 (who received vaccine in addition to IL-2, GM-CSF and rhGH), 
however, showed a statistically significant increase in IFN-γ production in response to the Gag 
p17/p24 peptide pool from FIT Biotech at week 48. The mean increase from baseline to week 48 
was 312 SFC/10
6
 PBMC (95% CI 73-551 SFC/10
6
 PBMC, p = 0.0122; Figure 4.8A). This was 
reflected in the group 1 response to Gag p24 from NIBSC at week 48, although statistical 
significance was not reached (p = 0.0589). IFN-γ production in response to peptide pools of Nef 
from the two sources revealed a reduction in responsiveness from patients in group 3 at week 2 
(following administration of cytokines). The mean decrease from baseline was -114 SFC/10
6
 
PBMC for NIBSC Nef and -107 SFC/10
6
 PBMC for the FIT Biotech sub-pool (95% CI -211 – -17 
SFC/10
6
 PBMC, p = 0.0244; and -205 – -9 SFC/106 PBMC, p = 0.0353; Figures 4.7C and 4.8B, 
respectively). At week 12, patients in group 2 (vaccine alone) showed a statistically significant 
increase in IFN-γ production in response to the NIBSC peptide pool of Nef (Figure 4.7C). The 
mean increase from baseline to week 12 was 123 SFC/10
6
 PBMC (95% CI 14-232 SFC/10
6
 PBMC, 
p = 0.0297). By week 48, no statistically significant differences were observed in any of the three 
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groups compared to baseline in terms of IFN-γ response to peptide pools of Nef from either source. 
IFN-γ responses to Tat stimulation were consistent between the two peptide sources for individuals 
in group 2 which show no statistically significant difference from baseline to any of the study time 
points. Responses from individuals in group 3 demonstrated significantly reduced responses from 
baseline at weeks 2, 6, 8, 12, 16 and 24 of the study in response to the NIBSC peptide pool (Figure 
4.7D) whereas no significant differences from baseline were seen in response to the sub-pool from 
FIT Biotech (Figure 4.8C). Responses to Tat from both peptide sources also differed for patients 
randomised into group 1 and a significant increase in IFN-γ production was seen at week 48 
compared to baseline in response to NIBSC Tat (Figure 4.7D) whereas a significant decrease was 
seen in response to the Tat peptide pool from FIT Biotech (Figure 4.8C). IFN-γ production in 
response to peptide pools of Rev from both sources was very similar across the board. For 
individuals that received therapeutic immunisation only (group 2) or therapeutic immunisation in 
conjunction with cytokines and hormone (group 1), no significant differences were detected in IFN-
γ production at any of the study time points compared to baseline for either NIBSC or FIT Biotech 
peptide pools (Figures 4.7E and 4.8D, respectively). Statistically significant reductions in IFN-γ 
production in response to Rev were seen for both peptide providers, at week 2 compared to baseline 
(Figures 4.7E and 4.8D) for individuals in group 3 (who received cytokine and hormone only with 
no vaccine). This was the case at week 24 for both peptide sources but only maintained statistical 
significance for the FIT Biotech peptide pool, which saw a significant reduction in IFN-γ 
production in response to the Rev sub-pool at week 48. Mean decrease from baseline to week 48 
was -41 SFC/10
6
 PBMC (95% CI -70 – -13, p = 0.0059; Figure 4.8D). Responses to the CTL sub-
pool from FIT Biotech showed reduced IFN-γ production in response to peptide stimulation at week 
12 compared to baseline and this significant reduction was maintained until week 48 (Figure 4.8E). 
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Figure 4.7 Changes from baseline to each of the study time points in IFN-γ production in response to NIBSC peptide 
stimulation. 
Plots show mean change from baseline with error bars representing a 95% confidence interval. PBMC were stimulated 
with peptides from NIBSC: Gag p17 (A), Gag p24 (B), Nef (C), Tat (D) and Rev (E), and IFN-γ production determined 
by calculating the number of SFC per million PBMC. This was done for each study time point and the treatment groups 
are as previous: group 1 in blue circles, group 2 in green squares and group 3 in red triangles. Asterisks indicate 
statistical significance, where p ≤ 0.05.  
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Figure 4.8 Changes from baseline to each of the study time points in IFN-γ production in response to FIT Biotech 
peptide stimulation. 
Plots show mean change from baseline with error bars representing a 95% confidence interval. PBMC were stimulated 
with peptides from FIT Biotech: Gag p17/p24 (A), Nef (B), Tat (C), Rev (D) and CTL (E) and IFN-γ production 
determined by calculating the number of SFC per million PBMC. This was done for each study time point and the 
treatment groups are as previous: group 1 in blue circles, group 2 in green squares and group 3 in red triangles. 
Asterisks indicate statistical significance, where p ≤ 0.05. 
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IL-2 production in response to peptide pools of Gag p17 and p24 from NIBSC showed a trend 
towards an increase compared to baseline at week 48 for patients in group 1 (Figures 4.9A and 
4.9B, respectively). The mean increase from baseline to week 48 was 115 SFC/10
6
 PBMC (95% CI 
-4 – 235 SFC/106 PBMC, p = 0.0621) and 42 SFC/106 PBMC (95% CI -5 – 89 SFC/106 PBMC, p = 
0.0817), respectively. Responses to the FIT Biotech sub-pool of Gag p17/p24 at week 48 for 
individuals that received therapeutic vaccine in addition to cytokines and hormone were 
significantly increased compared to baseline (Figure 4.10A). The mean increase from baseline to 
week 48 was 79 SFC/10
6
 PBMC (95% CI 31-127 SFC/10
6
 PBMC, p = 0.0017; Figure 4.10A). At 
week 2, following administration of IL-2 and GM-CSF, patients in group 3 showed significantly 
increased responses to peptide pools of Nef from both sources, compared to baseline. In response to 
NIBSC Nef, mean change from baseline to week 2 was 31 SFC/10
6
 PBMC (95% CI 11-51 SFC/10
6
 
PBMC, p = 0.0030) and in response to FIT Biotech Nef, mean change from baseline to week 2 was 
32 SFC/10
6
 PBMC (95% CI 12-52 SFC/10
6
 PBMC, p = 0.0022; Figures 4.9C and 4.10B, 
respectively). IL-2 production in response to peptide pools of Nef remained statistically unchanged 
compared to baseline for all remaining time points for group 3 and no changes were seen at any of 
the study time points for individuals in groups 1 and 2 (Figures 4.9C and 4.10B, respectively). 
Stimulation with peptide pools of Tat from both sources resulted in significantly increased 
responses at week 2 compared to baseline for individuals in group 3. Mean increase from baseline 
to week 2 in response to NIBSC Tat was 35 SFC/10
6
 PBMC (95% CI 18-53 SFC/10
6
 PBMC, p = 
0.0002) and mean increase in response to FIT Biotech Tat was also 35 SFC/10
6
 PBMC (95% CI 17-
53, p = 0.0003; Figures 4.9D and 4.10C, respectively). No other statistically significant changes 
were seen in terms of IL-2 production in response to Tat for any of the other study groups at any of 
the study time points. Patients that received IL-2 and GM-CSF, both with and without vaccine, 
showed increased IL-2 responses following stimulation with NIBSC Rev at week 2 compared to 
baseline (Figure 4.9E). Mean change from baseline to week 2 was 30 SFC/10
6
 PBMC for patients 
in group 1 (95% CI 7-53, p = 0.0130) and it was 36 SFC/10
6
 PBMC for individuals in group 3 (95% 
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CI 18-57 SFC/10
6
 PBMC, p = 0.0001; Figure 4.9E). For the FIT Biotech sub-pool, only patients in 
group 3 showed a significantly increased response to the sub-pool of Rev at week 2. The mean 
change from baseline to week 2 was 35 SFC/10
6
 PBMC (95% CI 18-52 SFC/10
6
 PBMC, p = 
0.0001; Figure 4.10D). Patients that received IL-2 and GM-CSF showed increased IL-2 production 
in response to the CTL sub-pool from FIT Biotech, with the mean change from baseline to week 2 
of the study 34 SFC/10
6
 PBMC (95% CI 16-52 SFC/10
6
 PBMC, p = 0.0003; Figure 4.10E). There 
were no significant changes for individuals in groups 1 and 2 at any of the study time points 
compared to baseline, and IL-2 responses to the CTL sub-pool was statistically unchanged 
compared to baseline for patients in group 3 at all other time points (Figure 4.10E). 
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Figure 4.9 Changes from baseline to each of the study time points in IL-2 production in response to NIBSC peptide 
stimulation. 
Plots show mean change from baseline with error bars representing a 95% confidence interval. PBMC were stimulated 
with peptides from NIBSC: Gag p17 (A), Gag p24 (B), Nef (C), Tat (D) and Rev (E), and IL-2 production determined 
by calculating the number of SFC per million PBMC. This was done for each study time point and the treatment groups 
are as previous: group 1 in blue circles, group 2 in green squares and group 3 in red triangles. Asteriks indicate 
statistical significance, where p ≤ 0.05. 
-200
-100
0
100
200
300
0 1 2 4 6 8 1612 24 48
*
Baseline
Vaccine
IL-2/GM-CSF
rhGH Vaccine Vaccine
Study Week
C
h
a
n
g
e
 f
ro
m
 b
a
s
e
li
n
e
 i
n
IL
-2
 p
ro
d
u
c
ti
o
n
 t
o
 G
a
g
 p
1
7
,
S
F
C
/1
0
6
 P
B
M
C
-150
-100
-50
0
50
100
0 1 2 4 6 8 1612 24 48
* *
Study Week
C
h
a
n
g
e
 f
ro
m
 b
a
s
e
li
n
e
 i
n
IL
-2
 p
ro
d
u
c
ti
o
n
 t
o
 G
a
g
 p
2
4
,
S
F
C
/1
0
6
 P
B
M
C
-40
-20
0
20
40
60
0 1 2 4 6 8 1612 24 48
*
Study Week
C
h
a
n
g
e
 f
ro
m
 b
a
s
e
li
n
e
 i
n
IL
-2
 p
ro
d
u
c
ti
o
n
 t
o
 N
e
f,
S
F
C
/1
0
6
 P
B
M
C
-40
-20
0
20
40
60
0 1 2 4 6 8 1612 24 48
*
Study Week
C
h
a
n
g
e
 f
ro
m
 b
a
s
e
li
n
e
 i
n
IL
-2
 p
ro
d
u
c
ti
o
n
 t
o
 T
a
t,
S
F
C
/1
0
6
 P
B
M
C
-40
-20
0
20
40
60
0 1 2 4 6 8 1612 24 48
**
Study Week
C
h
a
n
g
e
 f
ro
m
 b
a
s
e
li
n
e
 i
n
IL
-2
 p
ro
d
u
c
ti
o
n
 t
o
 R
e
v
,
S
F
C
/1
0
6
 P
B
M
C
A
B
C
D
E
154 
 
 
Figure 4.10 Changes from baseline to each of the study time points in IL-2 production in response to FIT Biotech 
peptide stimulation. 
Plots show mean change from baseline with error bars representing a 95% confidence interval. PBMC were stimulated 
with peptides from FIT Biotech: Gag p17/p24 (A), Nef (B), Tat (C), Rev (D) and CTL (E), and IL-2 production 
determined by calculating the number of SFC per million PBMC. This was done for each study time point and the 
treatment groups are as previous: group 1 in blue circles, group 2 in green squares and group 3 in red triangles. 
Asterisks indicate statistical significance, where p ≤ 0.05. 
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IL-4 production in response to Gag p17 from NIBSC was significantly increased at week 12 and at 
week 24 compared to baseline for patients that received vaccine alone (group 2; Figure 4.11A). At 
week 24, patients in group 3 also had a significantly increased IL-4 response following stimulation 
with NIBSC Gag p17 but by week 48, these responses were statistically unchanged compared to 
baseline. It was only individuals in group 1 that received cytokine and hormone in addition to 
therapeutic vaccine that showed increased IL-4 production in response to NIBSC Gag p17 at week 
48 compared to baseline. Mean change from baseline to week 48 was 111 SFC/10
6
 PBMC (95% CI 
16-206 SFC/10
6
 PBMC, p = 0.0240; Figure 4.11A). In response to NIBSC Gag p24, patients that 
received vaccine in addition to cytokines and hormone (group 1) and those that received vaccine 
alone (group 2) showed increased IL-4 responses at week 48 compared to baseline. Mean increase 
from baseline to week 48 was 11 SFC/10
6
 PBMC for patients in group 1 (95% CI 0.3-21 SFC/10
6
 
PBMC, p = 0.0475) and 11 SFC/10
6
 PBMC for individuals in group 2 (95% CI 2-19 SFC/10
6
 
PBMC, p = 0.0248; Figure 4.11B). In response to Gag p17/p24 from FIT Biotech, only patients in 
group 2 showed a significant increase at week 48 compared to baseline; mean increase from 
baseline to week 48 was 38 SFC/10
6
 PBMC (95% CI 18-58 SFC/10
6
 PBMC, p = 0.0003; Figure 
4.12A). Looking at IL-4 production in response to the Nef sub-pool from FIT Biotech, there are no 
significant differences from baseline to any of the study visit time points for any of the treatment 
groups (Figure 4.12B). However, stimulation with the NIBSC Nef peptide pool resulted in a 
significant reduction in IL-4 production at week 1 and week 16 compared to baseline for individuals 
in group 1 and significant reductions at weeks 1 to 48 for individuals in group 3 (Figure 4.11C). IL-
4 production in response to the Tat peptide pool from NIBSC was increased at week 2 for patients 
that received vaccine, IL-2 and GM-CSF (group 1); mean change from baseline to week 2 was 78 
SFC/10
6
 PBMC (95% CI 44-112 SFC/10
6
 PBMC, p <0.0001; Figure 4.11D). The production of IL-
4 in response to FIT Biotech Tat only showed a significant increase at week 48 for individuals that 
received vaccine alone (group 2) with a mean increase from baseline to week 48 of 9 SFC/10
6
 
PBMC (95% CI 2-16 SFC/10
6
 PBMC, p = 0.0164; Figure 4.12C). PBMC stimulation with the 
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overlapping peptide pool of Rev from NIBSC showed significant reductions compared to baseline 
for all study time points from week 1 to week 48 for patients in group 1. Mean decrease in IL-4 
production at week 48 compared to baseline was -19 SFC/10
6
 PBMC (95% CI -28 – -9 SFC/106 
PBMC, p = 0.0002; Figure 4.11E). IL-4 production in response to the Rev peptide pool from FIT 
Biotech for individuals in group 1 showed a trend towards a reduction at week 48 compared to 
baseline with a mean decrease from baseline to week 48 of -7 SFC/10
6
 PBMC (95% CI -14 – 0.8, p 
= 0.0839; Figure 4.12D). The increase in IL-4 production in response to Rev from FIT Biotech at 
week 48 compared to baseline for individuals in group 2 (who received vaccine alone) did not reach 
statistical significance (Figure 4.12D), however, responses to NIBSC Rev for this treatment group 
were significantly elevated at week 48 compared to baseline. The mean increase from baseline to 
week 48 was 10 SFC/10
6
 PBMC (95% CI 2-18 SFC/10
6
 PBMC, p = 0.0185; Figure 4.11E). Only 
patients in group 2 showed significantly increased responses to the CTL sub-pool from FIT Biotech 
at week 48 compared to baseline with a mean increase at week 48 of 7.5 SFC/10
6
 PBMC (95% CI 
2-13 SFC/10
6
 PBMC, p = 0.0089). All other IL-4 responses to this overlapping CTL peptide pool 
remained statistically unchanged compared to baseline for all other study time points and for all 
other treatment groups (Figure 4.12E). 
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Figure 4.11 Changes from baseline to each of the study time points in IL-4 production in response to NIBSC peptide 
stimulation. 
Plots show mean change from baseline with error bars representing a 95% confidence interval. PBMC were stimulated 
with peptides from NIBSC: Gag p17 (A), Gag p24 (B), Nef (C), Tat (D) and Rev (E), and IL-4 production determined 
by calculating the number of SFC per million PBMC. This was done for each study time point and the treatment groups 
are as previous: group 1 in blue circles, group 2 in green squares and group 3 in red triangles. Asterisks indicate 
statistical significance, where p ≤ 0.05. 
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Figure 4.12 Changes from baseline to each of the study time points in IL-4 production in response to FIT Biotech 
peptide stimulation. 
Plots show mean change from baseline with error bars representing a 95% confidence interval. PBMC were stimulated 
with peptides from FIT Biotech: Gag p17/p24 (A),  Nef (B), Tat (C), Rev (D) and CTL (E), and IL-4 production 
determined by calculating the number of SFC per million PBMC. This was done for each study time point and the 
treatment groups are as previous: group 1 in blue circles, group 2 in green squares and group 3 in red triangles. 
Asterisks indicate statistical significance, where p ≤ 0.05. 
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Stimulation with overlapping Gag p17 peptides from NIBSC resulted in a significant increase in 
perforin production at week 4 compared to baseline for patients in group 1; mean increase at week 4 
compared to baseline was 271 SFC/10
6
 PBMC (95% CI 54-488 SFC/10
6
 PBMC, p = 0.0166; Figure 
4.13A). Individuals in group 3, however, demonstrated a modest but significant increase in their 
perforin response to Gag p17 at week 24 with mean change at this time point compared to baseline 
of 172 SFC/10
6
 PBMC (95% CI 4-340 SFC/10
6
 PBMC, p = 0.0487; also Figure 4.13A). Only 
individuals in group 3 showed a marked increase in perforin production at week 8 in response to 
Gag p24 stimulation compared to baseline. Mean change in perforin production compared to 
baseline was 276 SFC/10
6
 PBMC (95% CI 156-395 SFC/10
6
 PBMC, p <0.0001; Figure 4.13B). For 
the FIT Biotech Gag p17/p24 peptide pool, only patients in group 1, who received vaccine in 
addition to cytokines and hormone, showed an increase in perforin production at week 48 compared 
to baseline; with a mean change of 95 SFC/10
6
 PBMC (95% CI 11-179 SFC/10
6
 PBMC, p = 
0.0287; Figure 4.14A). Perforin production in response to Nef, Tat and Rev from NIBSC was 
significantly increased at week 8 compared to baseline for individuals in group 3 but these 
responses were only transient (Figures 4.13C, 4.13D and 4.13E, respectively). Perforin production 
in response to Tat and CTL sub-pools from FIT Biotech showed increased responses at week 8 
compared to baseline for patients in group 3 (Figures 4.14C and 4.14E, respectively). Mean increase 
from baseline was 164 SFC/10
6
 PBMC (95% 39-288 SFC/10
6
 PBMC, p = 0.0120) and 136 SFC/10
6
 
PBMC (95% CI 20-252 SFC/10
6
 PBMC, p = 0.0241; Figures 4.14C and 4.14E, respectively). No 
changes were observed for any of the treatment groups between baseline and any of the study time 
points in terms of perforin production in response to the Rev sub-pool from FIT Biotech (Figure 
4.14D). Responsiveness to the Nef sub-pool decreased slightly but significantly at week 24 
compared to baseline for patients in group 3 (mean change from baseline -85 SFC/10
6
 PBMC; 95% 
CI -169 – -2 SFC/106 PBMC, p = 0.0488) but by week 48 there was no significant change in 
perforin production in response to this peptide pool compared to baseline (Figure 4.14B). 
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Figure 4.13 Changes from baseline to each of the study time points in perforin production in response to NIBSC 
peptide stimulation. 
Plots show mean change from baseline with error bars representing a 95% confidence interval. PBMC were stimulated 
with peptides from NIBSC: Gag p17 (A), Gag p24 (B), Nef (C), Tat (D) and Rev (e), and perforin production 
determined by calculating the number of SFC per million PBMC. This was done for each study time point and the 
treatment groups are as previous: group 1 in blue circles, group 2 in green squares and group 3 in red triangles. 
Asterisks indicate statistical significance, where p ≤ 0.05. 
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Figure 4.14 Changes from baseline to each of the study time points in perforin production in response to FIT Biotech 
peptide stimulation. 
Plots show mean change from baseline with error bars representing a 95% confidence interval. PBMC were stimulated 
with peptides from FIT Biotech: Gag p17/p24 (A) ,Nef (B), Tat (C), Rev (D) and CTL (E), and perforin production 
determined by calculating the number of SFC per million PBMC. This was done for each study time point and the 
treatment groups are as previous: group 1 in blue circles, group 2 in green squares and group 3 in red triangles. 
Asterisks indicate statistical significance, where p ≤ 0.05. 
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4.5 Phenotypic characterisation of CD4 and CD8 T cells 
Following administration of IL-2 and GM-CSF, there was a marked increase in the percentage co-
expression of the activation markers CD38 and HLA-DR on CD4 T cells. The mean increase from 
baseline to week 2 was 18.3% (95% CI 15.2-21.3%, p <0.0001) and 18.1% (95% CI 15.7-20.4%, p 
<0.0001) for patients in groups 1 and 3 respectively (Figure 4.15A). The co-expression of these two 
markers was also significantly increased at week 2, but to a lesser extent, for individuals that 
received vaccine alone (group 2) with a mean increase from baseline of 4.9% (95% CI 2.3-7.5%, p 
= 0.0005; Figure 4.15A). CD38 and HLA-DR co-expression on CD8 T cells at week 2 was also 
significantly higher in all groups, with the greatest increase noted for individuals in group 1, with a 
mean increase from baseline to week 2 of 30.9% (95% CI 26.1-35.7%, p <0.0001; Figure 4.16A). 
By week 48, co-expression of these activation markers had normalised and there were no 
statistically significant differences compared to baseline for either T-cell subset (Figures 4.15A and 
4.16A). Percentage expression and MFI of HLA-DR on CD4 and CD8 T cells from the trial 
participants followed a similar pattern, with notable increases in the HLA-DR expression at week 2 
which was normalised by week 48 of the study (Figures 4.15B and 4.15D show percentage 
expression and MFI on CD4 T cells and Figures 4.16B and 4.16D depict percentage expression and 
MFI on CD8 T cells). Elevated expression of HLA-DR (in terms of MFI) was only seen for 
individuals in group 2 at week 48, with a marginal yet significant increase from baseline of 3407 
(95% CI 446-6368, p = 0.0268; Figure 4.15D). CD38 percentage expression was also increased at 
week 2 for all study groups on both T-cell subsets, with more pronounced increases for individuals 
that received IL-2 and GM-CSF (Figures 4.15C and 4.16C). By week 4, CD38 expression on the 
CD4 T cells had normalised for patients in all study groups and by week 6, there was a significant 
reduction in the percentage expression of CD38 on CD4 T cells for individuals that received 
cytokine and hormone and this decline was maintained up to and including the final study time 
point (week 48). At week 48, the mean decrease from baseline was -8.3% (95% CI -15.1 – 1.5%, p 
= 0.0194) and -6.1% (95% CI -11.4 – -0.9%, p = 0.0254; Figure 4.15C). At week 24, individuals in 
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groups 1 and 3 showed a significant reduction in the percentage expression of CD38 on their CD8 T 
cells, and this was only maintained for individuals in group 3, with a mean decrease from baseline 
to week 48 of -8.8% (95% CI -15.6 – -1.9%, p = 0.0139), although there was a trend towards a 
decrease in this markers for individuals in group 1 with a mean decline from baseline of -8.4% 
(95% CI -17.3 – 0.4%, p = 0.0651; Figure 4.16C). In terms of CD38 MFI, only CD4 T cells from 
patients in groups 1 and 3 showed marginal but significant reductions at week 48 compared to 
baseline with mean decreases of -468 (95% CI -905 – -31, p = 0.0387) and -346 (95% CI -684 – -8, 
p = 0.0484) for groups 1 and 3 respectively (Figure 4.15E). 
CD69 expression was also assessed on both CD4 and CD8 T lymphocytes and no significant 
changes from baseline were observed in percentage expression of this marker in any of the study 
groups. MFI of CD69 on CD4 T cells revealed significantly increased expression at weeks 16 and 
24 for patients in groups 1 and 3, with elevated levels at week 48 for individuals in group 3. CD8 T-
cell expression of CD69 in terms of MFI showed similar elevations at weeks 16 and 24 for patients 
in groups 1 and 3 but these values had normalised by week 48, with increased levels measured on 
CD8 T cells from patients in group 2 at the final study time point (graphs not shown but mean 
change from baseline, 95% CI and p values are detailed in Appendix 2). 
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Figure 4.15 Changes from baseline to each of the study time points in CD4 T-cell activation. 
Plots show mean change from baseline with error bars representing a 95% confidence interval. PBMC were assessed for 
surface expression of markers associated with immune activation: shown here are percentage co-expression of HLA-DR 
and CD38 (A), and HLA-DR (B) and CD38 (C) individually. The MFI of both of these markers was also determined (D 
and E, respectively). This was done for each study time point and the treatment groups are as previous: group 1 in blue 
circles, group 2 in green squares and group 3 in red triangles. Asterisks indicate statistical significance, where p ≤ 0.05. 
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Figure 4.16 Changes from baseline to each of the study time points in CD8 T-cell activation. 
Plots show mean change from baseline with error bars representing a 95% confidence interval. PBMC were assessed for 
surface expression of markers associated with immune activation: shown here are percentage co-expression of HLA-DR 
and CD38 (A), and HLA-DR (B) and CD38 (C) individually. The MFI of both of these markers was also determined (D 
and E, respectively). This was done for each study time point and the treatment groups are as previous: group 1 in blue 
circles, group 2 in green squares and group 3 in red triangles. Asterisks indicate statistical significance, where p ≤ 0.05. 
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Percentage co-expression of markers of immune senescence (CD57) and apoptosis (CD95) showed 
a significant decrease on CD4 T cells at week 4 for individuals that received cytokines and 
hormone. Mean reduction from baseline to week 4 was -3.5% (95% CI -6.6 – 0.5, p = 0.0261) and -
3.2% (95% CI -5.6 – 0.8%, p = 0.0097) for groups 1 and 3 respectively (Figure 4.17A). Co-
expression of these markers was reduced for patients in groups 2 and 3 by week 48, with a trend 
towards a decrease for individuals in group 1 (Figure 4.17A). Expression of CD57 on CD4 T cells 
followed a similar pattern (Figure 4.17B). At week 2, all study groups showed a significant increase 
in the percentage expression of CD95 compared to baseline but this was more pronounced for 
individuals that received IL-2 and GM-CSF, and expression of the apoptotic marker had normalised 
by week 48 (Figure 4.17C). CD4 T-cell MFI of CD95, however, was significantly reduced by week 
48, despite a significant increase at week 2, and mean decrease from baseline was -1562 (95% CI -
2682 – -442, p = 0.0077) and -1675 (95% CI -2542 – -808, p = 0.0003) for groups 1 and 3 
respectively (Figure 4.17E). CD95 expression in terms of MFI followed the same pattern on the 
CD8 T cells, with a significant increase at week 2 compared to baseline for individuals that received 
IL-2 and GM-CSF and a significant reduction by week 48 for patients in group 3, with a trend 
towards a reduction for those in group 1 (Figure 4.18E). Co-expression of CD57 and CD95 on CD8 
T cells was significantly reduced at weeks 2, 8 and 48 for patients in group 3 with a mean reduction 
from baseline of -10.5% (95% CI -16.2 – -4.8, p = 0.0005; Figure 4.18A). A similar pattern 
emerged when looking at the single expression of CD57 on the CD8 T cells but by week 48, 
patients in group 2 also demonstrated a reduction in this marker although this was less pronounced 
(Figure 4.18B). MFI of CD57 on the CD8 T-cell subset was significantly reduced by week 48 for 
patients that received cytokine and hormone, although more so for those in group 3 (Figure 4.18D). 
Percentage expression of CD95 did not deviate significantly from baseline for any group at any 
study time point except for a marginal but significant increase at week 24 for patients in group 3 
with a mean increase from baseline of 5.0% (95% CI 0.2-9.8%, p = 0.0460; Figure 4.18C). 
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Figure 4.17 Changes from baseline to each of the study time points in CD4 T-cell senescence and apoptosis. 
Plots show mean change from baseline with error bars representing a 95% confidence interval. PBMC were assessed for 
surface expression of markers associated with senescence and apoptosis: shown here are percentage co-expression of 
CD57 and CD95 (A), and CD57 (B) and CD95 (C) individually. The MFI of both of these markers was also determined 
(D and E, respectively). This was done for each study time point and the treatment groups are as previous: group 1 in 
blue circles, group 2 in green squares and group 3 in red triangles. Asterisks indicate statistical significance, where p ≤ 
0.05. 
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Figure 4.18 Changes from baseline to each of the study time points in CD8 T-cell senescence and apoptosis. 
Plots show mean change from baseline with error bars representing a 95% confidence interval. PBMC were assessed for 
surface expression of markers associated with senescence and apoptosis: shown here are percentage co-expression of 
CD57 and CD95 (A), and CD57 (B) and CD95 (C) individually. The MFI of both of these markers was also determined 
(D and E, respectively). This was done for each study time point and the treatment groups are as previous: group 1 in 
blue circles, group 2 in green squares and group 3 in red triangles. Asterisks indicate statistical significance, where p ≤ 
0.05. 
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At week 6, markers associated with an early T-cell phenotype (CD27
+
CD28
+
) were elevated 
moderately on CD4 T cells for individuals in group 3, but by week 48 no significant changes 
compared to baseline were observed for any of the treatment groups (Figure 4.19A). The 
intermediate phenotype (CD27
-
CD28
+
) was significantly increased at week 2 for patients that 
received IL-2 and GM-CSF, and this was more pronounced for patients that received vaccine in 
addition to the cytokines (Figure 4.19B). Mean increase from baseline to week 2 was 5.3% (95% CI 
3.8-6.8%, p <0.0001) and 2.2% (95% CI 1.0-3.4%, p = 0.0004) for groups 1 and 3 respectively. 
These increases were maintained, but to a lesser degree, at week 4 for both groups and only 
significantly elevated for patients in group 1 by week 6, and by week 48, no significant differences 
were seen compared to baseline for any of the treatment groups (Figure 4.19B). CD4 T-cell 
expression of markers associated with a late differentiation state were significantly reduced at 
weeks 2 and 6 for patients in group 3 and at week 24 for patients in group 1 but no significant 
changes compared to baseline were observed at week 48 (Figure 4.19C). Co-expression of CD27 
and CD28 on CD8 T cells was significantly increased for patients in group 2 at weeks 4, 8 and 24 
whereas patients in group 3 showed an initial decrease in these early T-cell markers at week 1 
followed by significant increases at weeks 6, 12 and 48 (Figure 4.20A). Mean increase from 
baseline to week 48 was 6.7% (95% CI 1.2-12.3%, p = 0.0196) for patients in group 3. The 
percentage expression of markers associated with an intermediate CD8 T-cell phenotype were 
reduced at weeks 1, 2, 4, 8, 12, 16, 24 and 48 of the study for patients that received vaccine alone 
(Figure 4.20B). Markers associated with a late CD8 T-cell differentiation state were found to be 
significantly reduced at weeks 2, 6, 8 and 12 for individuals in group 3 with a trend towards a 
reduction at week 48 for these patients that received cytokine and hormone only (Figure 4.20C). 
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Figure 4.19 Changes from baseline to each of the study time points in early, intermediate and late CD4 T cells. 
Plots show mean change from baseline with error bars representing a 95% confidence interval. PBMC were assessed for 
percentage expression of CD27 and CD28 and early (CD27
+
CD28
+
; A), intermediate (CD27
-
CD28
+
; B) and late (CD27
-
CD28
-
; C) CD4 T cells were determined. This was done for each study time point and the treatment groups are as 
previous: group 1 in blue circles, group 2 in green squares and group 3 in red triangles. Asterisks indicate statistical 
significance, where p ≤ 0.05. 
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Figure 4.20 Changes from baseline to each of the study time points in early, intermediate and late CD8 T cells. 
Plots show mean change from baseline with error bars representing a 95% confidence interval. PBMC were assessed for 
percentage expression of CD27 and CD28 and early (CD27
+
CD28
+
; A), intermediate (CD27
+
CD28
-
; B) and late (CD27
-
CD28
-
; C) CD8 T cells were determined. This was done for each study time point and the treatment groups are as 
previous: group 1 in blue circles, group 2 in green squares and group 3 in red triangles. Asterisks indicate statistical 
significance, where p ≤ 0.05. 
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Characterisation of the expression of markers associated with a regulatory T-cell phenotype 
revealed a significant increase at week 2 following administration of IL-2 and GM-CSF for patients 
in groups 1 and 3, with a more pronounced increase for patients in group 3 (Figure 4.21A). The 
mean increase from baseline to week 2 was 7.0% (95% CI 4.4-9.6%, p <0.0001) and 11.0% (95% 
CI 9.0-13.0%, p <0.0001) for groups 1 and 3 respectively, and by week 48, expression of these 
markers had normalised and no significant changes compared to baseline were found for any of the 
treatment groups (Figure 4.21A). A similar increase at week 2 was seen when looking at the 
CD45RO
+
CD25
+
 CD4 T cells for patients that received IL-2 and GM-CSF, however by week 48, 
all study treatment groups demonstrated elevated co-expression of these markers (Figure 4.21B). 
Single expression of these markers followed the same pattern with marked increases at week 2 for 
those that received IL-2 and GM-CSF, but by week 48 only patients in group 2 showed a significant 
increase in CD25 expression with a mean increase from baseline of 8.3% (95% CI 1.5-15.2%, p = 
0.0198; Figure 4.21C). Individuals in groups 1 and 3 showed elevated levels of CD45RO at week 
48 with mean increases from baseline of 9.0% (95% CI 3.3-14.6%, p = 0.0025) and 6.6% (95% CI 
2.3-11.0%, p = 0.0038; Figure 4.21D). 
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Figure 4.21 Changes from baseline to each of the study time points in markers associated with a regulatory T-cell 
phenotype. 
Plots show mean change from baseline with error bars representing a 95% confidence interval. PBMC were assessed for 
percentage expression of markers associated with a regulatory T-cell phenotype (CD4
+
CD45RO
+
CD25
high
; A), as well 
as looking at co-expression of CD45RO and CD25 (B) and expression of CD25 (C) and CD45RO (D). This was done 
for each study time point and the treatment groups are as previous: group 1 in blue circles, group 2 in green squares and 
group 3 in red triangles. Asterisks indicate statistical significance, where p ≤ 0.05. 
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Using CCR7 and CD45RA to determine T-lymphocyte subsets, decreased expression of markers 
associated with a naïve CD4 T-cell phenotype were observed at weeks 2 and 4 for patients that 
received IL-2 and GM-CSF but by week 48, only patients in group 1 demonstrated reduced 
percentage expression of naïve T-cell markers. Mean decrease from baseline to week 48 was -5.8% 
(95% CI -10.7 – 0.8%, p = 0.0242; Figure 4.22A).In terms of CD4 TCM, patients that received 
vaccine alone showed significant increases in this population at weeks 2 and 48 of the study, with 
individuals in group 1 showing a trend towards an increase by week 48 (Figure 4.22B). Patients that 
received cytokines demonstrated a significant increase in CD4 TEM at week 2 with mean increases 
from baseline of 8.7% (95% CI 3.3-14.1%, p = 0.0023) and 4.7% (95% CI 0.5-8.9%, p = 0.00306) 
for groups 1 and 3 respectively (Figure 4.22C). The elevation in CD4 TEM was maintained for 
patients in group 1 until week 6 but by week 48, there were no significant changes compared to 
baseline for any of the treatment groups (Figure 4.22C). Despite moderate fluctuations in the 
percentage expression of markers associated with a differentiated T-cell phenotype, there were no 
significant changes in CD4 TEMRA for any of the study time points for any of the study groups 
(Figure 4.22D). The expression of the differentiation markers on the CD8 T-cell subsets showed a 
very different profile change over the course of the study (Figure 4.23) with patients in group 3 
demonstrating significantly elevated levels of markers associated with a naïve T-cell phenotype 
from week 1 and this was maintained until week 48 of the study. The mean increase in naïve CD8 T 
cell markers was 10.6% (95% CI 3.2-11.1%, p = 0.0065; Figure 4.23A) and this was reflected by a 
significant reduction in TEMRA markers from week 2 until week 48 of the study, with a mean 
decrease from baseline to week 48 of -10.6% (95% CI -19.0 – -2.2%, p = 0.0158; Figure 4.23D). 
For group 3 individuals, increases in TEM were reflected by decreases in TCM at various study time 
points but these changes rarely reached statistical significance when compared to baseline (Figures 
4.23B and 4.23C, respectively). Patients in group 2 that received vaccine alone showed significant 
reductions in the expression of TEM markers at weeks 2, 12, 16 and 24 but by week 48, there were 
no significant changes from baseline in TEM cells for any of the treatment groups (Figure 4.23C). 
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Figure 4.22 Changes from baseline to each of the study time points in CD4 T-cell differentiation, as determined by 
CCR7 and CD45RA expression. 
Plots show mean change from baseline with error bars representing a 95% confidence interval. PBMC were assessed for 
percentage expression of markers associated with a naive profile (CCR7
+
CD45RA
+
; A), a TCM profile (CCR7
+
CD45RA
-
; B), a TEM phenotype (CCR7
-
CD45RA
-
; C) and a TEMRA profile (CCR7
-
CD45RA
+
; D). This was done for each study 
time point and the treatment groups are as previous: group 1 in blue circles, group 2 in green squares and group 3 in red 
triangles. Asterisks indicate statistical significance, where p ≤ 0.05. 
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Figure 4.23 Changes from baseline to each of the study time points in CD8 T-cell differentiation, as determined by 
CCR7 and CD45RA expression. 
Plots show mean change from baseline with error bars representing a 95% confidence interval. PBMC were assessed for 
percentage expression of markers associated with a naive profile (CCR7
+
CD45RA
+
; A), a TCM profile (CCR7
+
CD45RA
-
; B), a TEM phenotype (CCR7
-
CD45RA
-
; C) and a TEMRA profile (CCR7
-
CD45RA
+
; D). This was done for each study 
time point and the treatment groups are as previous: group 1 in blue circles, group 2 in green squares and group 3 in red 
triangles. Asterisks indicate statistical significance, where p ≤ 0.05. 
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PD-1 expression was investigated on each of the CD4 T-cell subsets as determined by CCR7 and 
CD45RA surface markers. Individuals in group 1 showed a significant reduction in percentage PD-
1 expression at week 6 compared to baseline for all CD4 T-cell differentiation states: naïve, TCM, 
TEM and TEMRA (Figures 4.24A, 4.24B, 4.24C and 4.24D, respectively). By week 48, all study 
groups, regardless of randomisation and subsequent treatment schedule, showed a significant 
decrease in the percentage of PD-1 expressed on each of the CD4 T-cell differentiation/maturation 
subsets (Figure 4.24). Assessment of PD-1 expression on the CD8 T-cell subsets revealed an early 
reduction of PD-1 on CD8 TEM cells (Figure 4.25C) but by week 48, all patient groups showed a 
significant decline in the percentage expression of PD-1, regardless of treatment group for each of 
the differentiation states: naïve, TCM, TEM and TEMRA (Figures 4.25A, 4.25B, 4.25C and 4.25D, 
respectively).  
PD-L1 expression on naïve CD4 T cells for patients in group 2 increased significantly at week 2 
with a mean increase from baseline of 6.0% (95% CI 0.8-11.2%, p = 0.0266; Figure 4.26A) with a 
trend towards an increase at week 2 on CD8 TCM and TEMRA (Figures 4.26B and 4.26D, 
respectively). Individuals that received cytokine and hormone alone (group 3) showed a significant 
reduction in percentage PD-L1 expression at week 16 for all CD4 T-cell differentiation states and 
by week 48, no significant changes compared to baseline were observed for any of the treatment 
groups (Figure 4.26A-D). PD-L1 expression on the CD8 T-cell subsets for the individuals in group 
3 demonstrated a significant increase at week 2 for all subsets but this was normalised by week 48 
(Figure 4.27A-D). CD8 TEM for patients in group showed elevated levels of PD-L1 at week 1 
following administration of the therapeutic immunisation with a mean increase from baseline of 
12.5% (95% CI 1.6-23.4%, p = 0.0270) and this remained increased (but not significantly at week 
2) but PD-L1 expression on TEM for group 1 individuals was not significantly different from 
baseline by week 48 (Figure 4.27C). 
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Figure 4.24 Changes from baseline to each of the study time points in PD-1 expression on differentiated CD4 T-cell 
populations. 
Plots show mean change from baseline with error bars representing a 95% confidence interval. PBMC were assessed for 
percentage PD-1 expression on naive (CCR7
+
CD45RA
+
; A), TCM (CCR7
+
CD45RA
-
; B), TEM (CCR7
-
CD45RA
-
; C) and 
TEMRA (CCR7
-
CD45RA
+
; D) subsets. This was done for each study time point and the treatment groups are as previous: 
group 1 in blue circles, group 2 in green squares and group 3 in red triangles. Asterisks indicate statistical significance, 
where p ≤ 0.05. 
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Figure 4.25 Changes from baseline to each of the study time points in PD-1 expression on differentiated CD8 T-cell 
populations. 
Plots show mean change from baseline with error bars representing a 95% confidence interval. PBMC were assessed for 
percentage PD-1 expression on naive (CCR7
+
CD45RA
+
; A), TCM (CCR7
+
CD45RA
-
; B), TEM (CCR7
-
CD45RA
-
; C) and 
TEMRA (CCR7
-
CD45RA
+
; D) subsets. This was done for each study time point and the treatment groups are as previous: 
group 1 in blue circles, group 2 in green squares and group 3 in red triangles. Asterisks indicate statistical significance, 
where p ≤ 0.05. 
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Figure 4.26 Changes from baseline to each of the study time points in PD-L1 expression on differentiated CD4 T-cell 
populations. 
Plots show mean change from baseline with error bars representing a 95% confidence interval. PBMC were assessed for 
percentage PD-L1 expression on naive (CCR7
+
CD45RA
+
; A), TCM (CCR7
+
CD45RA
-
; B), TEM (CCR7
-
CD45RA
-
; C) 
and TEMRA (CCR7
-
CD45RA
+
; D) subsets. This was done for each study time point and the treatment groups are as 
previous: group 1 in blue circles, group 2 in green squares and group 3 in red triangles. Asterisks indicate statistical 
significance, where p ≤ 0.05. 
-15
-10
-5
0
5
10
15
0 1 2 4 6 8 1612 24 48
*
*
Baseline
Vaccine
IL-2/GM-CSF
rhGH Vaccine Vaccine
Study Week
C
h
a
n
g
e
 f
ro
m
 b
a
s
e
li
n
e
 i
n
%
 C
D
4
+
C
C
R
7
+
C
D
4
5
R
A
+
P
D
-L
1
+
-20
-10
0
10
20
0 1 2 4 6 8 1612 24 48
*
Study Week
C
h
a
n
g
e
 f
ro
m
 b
a
s
e
li
n
e
 i
n
%
 C
D
4
+
C
C
R
7
+
C
D
4
5
R
A
- P
D
-L
1
+
-15
-10
-5
0
5
10
15
0 1 2 4 6 8 1612 24 48
*
Study Week
C
h
a
n
g
e
 f
ro
m
 b
a
s
e
li
n
e
 i
n
%
 C
D
4
+
C
C
R
7
- C
D
4
5
R
A
- P
D
-L
1
+
-15
-10
-5
0
5
10
15
0 1 2 4 6 8 1612 24 48
*
Study Week
C
h
a
n
g
e
 f
ro
m
 b
a
s
e
li
n
e
 i
n
%
 C
D
4
+
C
C
R
7
- C
D
4
5
R
A
+
P
D
-L
1
+
A
B
C
D
Naive
TCM
TEM
TEMRA
181 
 
 
Figure 4.27 Changes from baseline to each of the study time points in PD-L1 expression on differentiated CD8 T-cell 
populations. 
Plots show mean change from baseline with error bars representing a 95% confidence interval. PBMC were assessed for 
percentage PD-L1 expression on naive (CCR7
+
CD45RA
+
; A), TCM (CCR7
+
CD45RA
-
; B), TEM (CCR7
-
CD45RA
-
; C) 
and TEMRA (CCR7
-
CD45RA
+
; D) subsets. This was done for each study time point and the treatment groups are as 
previous: group 1 in blue circles, group 2 in green squares and group 3 in red triangles. Asterisks indicate statistical 
significance, where p ≤ 0.05. 
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PD-1 expression on the entire CD4 T-lymphocyte population revealed a similar pattern to that 
observed looking at the individual subsets, with a significant reduction in percentage PD-1 
expression observed at week 48 for all treatment groups (Figure 4.28A). PD-L1 expression on the 
CD4 T cells showed a significant decrease in percentage expression at week 16 for individuals in 
group 3 with a mean reduction from baseline of -6.6% (95% CI -12.0 – -1.2%, p = 0.0192; Figure 
4.28B). The MFI of PD-1 and PD-L1 showed significant increases at week 2 for patients in group 3 
following cytokine administration, and significant elevations of PD-L1 at week 16 and week 24 for 
individuals in groups 1 and 3 (Figures 4.28C and 4.28D, respectively). By week 48, the MFI of PD-
1 and PD-L1 were not significantly different to baseline however patients in group 2 showed 
elevated levels of both the negative regulatory molecule and its ligand. Mean increase from baseline 
to week 48 in MFI was 123 (95% CI 40-205, p = 0.0046) and 876 (95% CI 349-1403, p = 0.0017) 
for PD-1 and PD-L1 respectively (Figures 4.28C and 4.28D, respectively). 
Percentage PD-1 expression on the whole CD8 T-lymphocyte population was significantly reduced 
compared to baseline at week 48 for all treatment groups regardless of randomisation (Figure 
4.29A). PD-L1 increased in terms of percentage expression at week 2 for patients in group 3 with a 
mean change from baseline of 18.9% (95% CI 7.8-30.1%, p = 0.0013; Figure 4.29B). The MFI of 
both PD-1 and PD-L1 was significantly higher than the baseline value for patients in group 2 with a 
mean increase from baseline of 126 (95% CI 17-235, p = 0.0265) and 833 (95% CI 100-1565, p = 
0.0286; Figures 4.29C and 4.29D, respectively). 
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Figure 4.28 Changes from baseline to each of the study time points in PD-1 and PD-L1 expression on CD4 T cells. 
Plots show mean change from baseline with error bars representing a 95% confidence interval. CD4 T cells were 
assessed for percentage PD-1 expression (A) as well as MFI (C), and percentage expression and MFI of PD-L1 was also 
assessed (B and D, respectively). This was done for each study time point and the treatment groups are as previous: 
group 1 in blue circles, group 2 in green squares and group 3 in red triangles. Asterisks indicate statistical significance, 
where p ≤ 0.05. 
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Figure 4.29 Changes from baseline to each of the study time points in PD-1 and PD-L1 expression on CD8 T cells. 
Plots show mean change from baseline with error bars representing a 95% confidence interval. CD4 T cells were 
assessed for percentage PD-1 expression (A) as well as MFI (C), and percentage expression and MFI of PD-L1 was also 
assessed (B and D, respectively). This was done for each study time point and the treatment groups are as previous: 
group 1 in blue circles, group 2 in green squares and group 3 in red triangles. Asterisks indicate statistical significance, 
where p ≤ 0.05.  
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Percentage co-expression of CTLA-4 and TIM-3 on CD4 T cells was significantly increased for 
patients in group 1 at weeks 2, 4 and 6, and reduced for patients in group 2 at weeks 8, 16 and 24. It 
was only patients in group 3 that showed a significant reduction in the co-expression of these 
markers at week 48 with a mean decrease from baseline of -0.06% (95% CI -0.1 – -0.01%, p = 
0.0153; Figure 4.30A). At week 48, patients that received cytokine and hormone immunotherapy 
demonstrated significant reductions in the co-expression of these markers on CD8 T lymphocytes at 
week 48 with mean decreases from baseline of -0.1 (95% CI -0.2 – -0.05%, p = 0.0015) and -0.08% 
(95% CI -0.1 – -0.02%, p = 0.0126; Figure 4.30B). 
Looking at single percentage expression of CTLA-4, there was no change from baseline regardless 
of randomisation group at week 48 on CD4 or CD8 T lymphocytes, and also for the MFI of CTLA-
4 on CD8 T cells at week 48. The MFI of CTLA-4 on the CD4 T cells, however, was significantly 
reduced compared to baseline for all three groups at week 12 and at the final study time point (week 
48). TIM-3 percentage expression at week 48 did not differ significantly from baseline for any of 
the study groups in the CD4 T-cell compartment but the CD8 T cells showed a trend towards a 
reduction in the expression of this marker at week 48 for patients in group 3. The MFI of TIM-3 on 
both CD4 and CD8 T cells was significantly reduced for individuals in group 2 at week 48, with a 
trend towards a reduction for patients in group 1 at this study time point (graphs not shown but 
mean change from baseline, 95% CI and p values are given in Appendix 2). 
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Figure 4.30 Changes from baseline in co-expression of CTLA-4 and TIM-3 on CD4 and CD8 T cells. 
Plots show mean change from baseline with error bars representing a 95% confidence interval. CD4 (A) and CD8 (B) T 
cells were assessed for percentage co-expression of CTLA-4 and TIM-3. This was done for each study time point and 
the treatment groups are as previous: group 1 in blue circles, group 2 in green squares and group 3 in red triangles. 
Asterisks indicate statistical significance, where p ≤ 0.05. 
 
Following cytokine administration, the percentage co-expression of CD45RA and CD31 on CD4 T 
cells was significantly reduced at week 2 compared to baseline for patients in groups 1 and 3 
(Figure 4.31A). By week 48, only patients in group 1 showed a significant decrease in the 
expression of these markers on CD4 T cells with a mean change from baseline of -4.7% (95% CI -
8.0 – -1.4%, p = 0.0060; Figure 4.31A). Percentage expression of CD31 on CD4 T lymphocytes 
was significantly reduced for patients in groups 1 and 3 at weeks 2, 6 and 48, while expression for 
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study participants in group 2 was significantly elevated at weeks 8 and 12 with a mean increase 
from baseline of 6.5% (95% CI 0.3-12.8%, p = 0.0437) and 10.1% (95% CI 3.9-16.3%, p = 0.0021) 
for week 8 and week 12, respectively (Figure 4.31B). CD31 percentage expression on CD8 T cells 
increased significantly at week 2 for patients in group 3 with a mean change from baseline of 10.8% 
(95% CI 6.1-15.4%, p <0.0001) and decreased marginally but significantly at week 16, but by week 
48 there were no changes from baseline in CD31 expression for any of the treatment groups (Figure 
4.31C). MFI of CD31 on both CD4 and CD8 T cells from patients in groups 1 and 3 showed 
significant increases at week 2 following administration of IL-2 and GM-CSF but these were 
normalised by week 48 (graphs not shown but mean changes from baseline, CI and p values are 
detailed in Appendix 2). PTK-7 percentage expression on CD4 T cells was significantly reduced at 
weeks 2, 4, 6, 12, 16, 24 and 48 for patients in group 1, and significantly increased on CD8 T cells 
at weeks 2 and 6 for patients in the same treatment group. MFI of PTK-7 on CD4 T cells was 
significantly reduced at week 48 compared to baseline for patients in groups 1 and 3, while there 
was no change compared to baseline in PTK-7 expression (MFI) on CD8 T cells for patients in any 
of the treatment groups, although patients in group 3 showed significant increases compared to 
baseline at weeks 2 and 8 (graphs not shown but mean changes from baseline, CI and p values are 
detailed in Appendix 2). 
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Figure 4.31 Changes from baseline to each of the study time points in CD31 expression. 
Plots show mean change from baseline with error bars representing a 95% confidence interval. CD4 T cells were 
assessed for percentage co-expression of CD45RA and CD31 (A), and percentage expression of CD31 measured on 
CD4 (B) and CD8 (C) T cells. This was done for each study time point and the treatment groups are as previous: group 
1 in blue circles, group 2 in green squares and group 3 in red triangles. Asterisks indicate statistical significance, where 
p ≤ 0.05. 
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4.6 Discussion 
It had been intended to recruit 30 patients in total for this study; ten per randomisation arm. 
However, out of 93 patient referrals and 21 screens, only 12 individuals were enrolled. This 
discrepancy (between the number screened and number enrolled, and why so few referred patients 
were screened) was primarily due to individuals not meeting the required nadir CD4 T-cell count of 
200 cells/µl blood. In actuality four out of the twelve patients had nadir CD4 T-cell counts of less 
than the requirement. Two of these were only moderately below (F810 had a nadir CD4 T-cell 
count of 166 cells/µl blood and C241 had 180 cells/µl blood); these individuals were approved by 
the recruiting clinician as these were determined to be ‘blips’ in otherwise stable and high CD4 T-
lymphocyte numbers. The other two patients were recruited onto the trial once the enrolment 
criteria had been amended and nadir CD4 T-cell requirements removed; these were B784 (group 1) 
and C319 (group 2) with 80 cells/µl and 93 cells/µl blood respectively. All patients on the study met 
the requirement of greater than 400 cells/µl blood at baseline, and all were aviraemic at baseline. 
These carefully selected characteristics are of utmost importance in the context of assessing the 
impact of immune-based therapies in treated HIV-1-infection. CD4 T-cell recovery has been shown 
to be influenced by the duration of ART-induced aviraemia and nadir CD4 T-lymphocyte counts 
[Koegl et al., 2009], Moreover, nadir CD4 T-cell counts have been found to inversely correlate with 
levels of HIV-1 proviral DNA in the circulating CD4 T cells of ART-treated HIV-1-infected 
individuals [Boulassel et al., 2012], which implies that the timing of ART initiation and its duration 
have an effect on immune reconstitution [Cellerai et al., 2011]. Earlier initiation of ART and higher 
nadir CD4 T-cell counts have also been shown to be associated with functional responses to 
immunisation [Lange et al., 2002]. In a pilot study investigating IL-2 administration and 
immunisation with the therapeutic HIV-1 vaccine Remune™, functional responses were not 
boosted in ART-treated HIV-1-infected patients that had low pre-ART CD4 T-cell counts [Hardy et 
al., 2007]. This lack of immune recovery was postulated to be due to protracted immunosuppression 
and/or clonal dysfunction [Hardy et al., 2007] and differed from previous Remune™ studies which 
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demonstrated proliferative responses in patients that had higher pre-ART CD4 T-cell counts 
[Robbins et al., 2003]. 
In terms of functional responses following administration of the therapeutic DNA vaccine, no 
apparent increases in functionality were seen at the time points immediately following any of the 
three immunisations. Administration of IL-2 and GM-CSF following the first immunisation for 
individuals in group 1 did not boost these responses, to either the NIBSC or FIT Biotech peptide 
pools. The timing of the immunotherapy was designed based on previous reports which found IL-2 
administered following immunisation to be associated with improved antigen-specific responses 
[Imami et al., 2001; Hardy et al., 2004]. The clinical parameters for patients in group 2, who 
received the DNA vaccine alone, did not show any striking changes at any of the study time points. 
There was a moderate but significant decrease in the percentage of CD8 T cells at week 48, which 
was also observable for patients in group 1 (who received cytokine and hormone in addition to 
immunisation). 
The delivery route of the immunisation may influence the resulting antigen-specific responses. The 
FIT Biotech DNA vaccine was delivered via ten intradermal injections (five per arm), whereas 
another study reported enhanced HIV-1-specific CD8 T-cell responses following immunisation on 
the skin with DNA plasmids (although this was not associated with viral control during treatment 
interruption) [Gudmundsdotter et al., 2011]. In vivo electroporation (EP) delivery of a DNA vaccine 
was found to significantly improve cellular immune responses in terms of rate, magnitude, duration 
and breadth of response to a number of antigens [Vasan et al., 2011] which concurred with results 
from animal models that demonstrated improved responses with EP [Hallengard et al., 2011]. 
Patients that received IL-2 and GM-CSF showed elevated levels of CD4 T cells at week two, but 
only patients who also received vaccine (group 1) demonstrated CD4 T-lymphocyte numbers that 
were significantly higher than baseline values at week 48, and increased CD4/CD8 T-cell ratios at 
this time point (these ratios were raised from week 2 of the study). These individuals also 
demonstrated increased IFN-γ, IL-2 and perforin production in response to the FIT Bitoech peptide 
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pools at the final study time point (week 48). Increased functionality, and specifically 
polyfunctionality, is a characteristic attributed to LTNP or HIV controllers [Makedonas and Betts, 
2011] and the induction of these responses suggests that immunotherapy may serve as a means of 
reversing T-cell anergy, in addition to HAART. The increased CD4/CD8 T-cell ratios may reflect 
improved immune reconstitution, and be influenced in part by the increased CD4 T-lymphocyte 
numbers in these patients, but studies have suggested that CD4/CD8 T-cell ratios in patients on 
suppressive ART negatively correlate with HIV-1 proviral DNA levels [Chun et al., 2002; 
Boulassel et al., 2012] which proposes a role for immunotherapy in the depletion of the viral 
reservoir. It has been suggested that ART leads to a reduction in the latent viral reservoir, and in one 
study, decreased levels of HIV-1 proviral DNA were seen in HAART-treated individuals (these 
were still higher than, but not significantly different from, levels seen in elite controllers) [Julg et 
al., 2010]. In another study, early initiation of ART resulted in levels of proviral DNA similar to 
those found in LTNP [Pires et al., 2004a]. Thus, for future work, it would be of added benefit to 
carry out HIV-1 proviral DNA analysis on cryopreserved samples from these twelve individuals, at 
baseline and at week 48, to determine the impact of immunotherapy on this parameter. 
The expression of markers associated with a regulatory T-cell phenotype and those linked to 
immune activation were both significantly increased at week 2 for patients that had received IL-2 
and GM-CSF. The administration of IL-2 to patients on ART has been shown to induce regulatory 
T-cell populations [Ndhlovu et al., 2010]. A previous study suggested a role for T-regulatory cells 
in controlling residual immune activation and/or spontaneous T-cell proliferation in vivo for patients 
on suppressive ART [Weiss et al., 2010], which may explain why both of these T-cell subsets were 
found to be increased at this time point and why there was no increase in plasma viraemia. Only by 
taking samples at more time points subsequent to cytokine administration would it be possible to 
elucidate whether an initial rise in T-cell activation was followed by this rise in Treg. Reports on 
this particular T-cell subset in the context of HIV-1 infection have been varied; the levels of 
regulatory T cells have been found to be unaffected, elevated and decreased with regard to disease 
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progression [Weiss et al., 2010], although a study which found Treg in the periperhal blood of elite 
suppressors to be preserved indicates a beneficial role for Treg in HIV-1
+
 patients that control viral 
replication [Chase et al., 2008]. It is important to note that in these studies, markers used to assess 
the Treg population have differed and although intracellular FoxP3 staining was not carried out, the 
CD3
+
CD4
+
CD45RO
+
CD25
high 
phenotype has been found to correlate with FoxP3 expression in 
HIV-1-infected individuals and in healthy seronegative donors [Burton et al., 2011]. Chronic 
immune activation has been associated with disease progression and although the expression of 
HLA-DR and CD38 was lowered with ART (compared to untreated HIV-1 infection) [Bartovska et 
al., 2011], abnormal T-cell activation persists even in patients on suppressive ART [Hunt et al., 
2003; Hunt et al., 2008]. In the present study, treatment with IL-2, GM-CSF and rhGH (with or 
without therapeutic immunisation) significantly reduced the expression of CD38 on CD4 T cells 
(both in terms of percentage expression and MFI) at week 48 compared to baseline, and at this time 
point, patients in group 3 (that received cytokine and hormone therapy alone) showed a reduction in 
the percentage expression of CD38 on CD8 T cells, with a trend towards a reduction for patients 
that also received the DNA vaccine. These findings suggest that immune-based therapy in the 
context of treated HIV-1 infection may serve to further reverse T-cell dysfunction, and to this 
effect, GH therapy in addition to ART has been shown to reduce T-cell activation [Napolitano et 
al., 2008]. Treatment with valganciclovir was found to reduce CD8 T-cell activation in patients 
with CMV co-infection and incomplete CD4 T-cell recovery on ART [Hunt et al., 2011]. Coupled 
with this decrease in immune activation, reductions in markers associated with immune senescence 
and apoptosis were seen at the final study time point (week 48), particularly for patients that 
received IL-2, GM-CSF and rhGH alone. One study found that treated HIV-1-infected adults had a 
CD8
+
CD57
+
CD28
-
 phenotype that was similar to much older uninfected controls [Desai & Landay, 
2010], suggesting a role for immunotherapy in the reversal of immune senescence and the 
premature aging that is seen in chronic, treated HIV-1 infection [Deeks, 2011]. 
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The expression of PD-1 on both CD4 and CD8 T cells was found to be reduced at week 48 
compared to baseline for all treatment groups regardless of randomisation, which may be an effect 
of prolonged HAART. A study by Kassu et al., found the percentage of HIV-1-specific CD4
+
IFN-
γ+PD-1+ T cells to be significantly lower in ART treated patients compared to untreated viraemic 
subjects [Kassu et al., 2010] and PD-1 has even been proposed as a marker to identify individuals 
on long-term suppressive ART for whom immune reconstitution is incomplete [Grabmeier-
Pfisterhammer et al., 2011]. Co-expression of CTLA-4 and TIM-3 was significantly reduced at 
week 48 compared to baseline for patients that had received IL-2, GM-CSF and rhGH, suggesting a 
benefit of immunotherapy for treated HIV-1-infected patients over the reduction seen in these 
markers with suppressive ART alone [Kassu et al., 2010]. 
Assessment of T-cell differentiation/maturation showed that patients in group 1 (who received IL-2, 
GM-CSF and rhGH in addition to therapeutic immunisation) had fewer naïve CD4 T cells at week 
48 (as measured by the co-expression of CCR7 and CD45RA, and single expression of CD31) 
compared to baseline, but that the number of TCM at this time point was increased (although not 
significantly). Chronic progressive HIV-1 infection has been shown to result in depletion of the 
naïve and TCM cells and accumulation of TEM and TEMRA (for the CD8 T-cell compartment) [Ladell 
et al., 2008]. To this effect, patients in group 3 (that received cytokine and hormone alone), 
demonstrated a significant reduction in CD8 TEMRA from week 2 of the study, and a significant 
increase in the expression of markers associated with a naïve CD8 T-cell phenotype from week 1, 
and both of these phenotypic changes were maintained at week 48 of the study. 
The primary endpoint of this phase I study was to determine the safety profile of this treatment 
schedule and overall, it was found to be safe and well-tolerated. The majority of beneficial clinical 
and immunological parameters were observed in patients that received IL-2, GM-CSF and rhGH, 
with or without therapeutic immunisation. Due to the complexities of the treatment schedule, there 
was no placebo group but the changes from baseline give a clear representation of the benefits of 
immunotherapy in addition to suppressive ART. rhGH has been shown to induce T-cell 
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thymopoeisis and improve T-cell functionalitiy [Napolitano et al., 2008; Herasimtschuk et al., 
2008] but here, the beneficial effects of rhGH were either masked due to prior administration of IL-
2 and GM-CSF, or it is possible that a longer duration of rhGH treatment is needed for 
immunological improvements to be seen. The results from the SILCAAT and ESPRIT studies 
found no clinical benefit when IL-2 was administered in addition to ART in HIV-1-infected 
patients, despite substantial and maintained increases in CD4 T-lymphocyte counts [Abrams et al., 
2009], while another study described no effect on the proportion of CD4 T cells in the gut mucosa 
of patients treated with IL-2 in addition to ART compared to ART alone [Read et al., 2011]. 
However, this does not rule out IL-2 as a candidate molecule to be used in conjunction with other 
immunomodulators. Combination IL-2 and GM-CSF immunotherapy was associated with improved 
antigen-specific T-cell responses and clinical recovery in patients with advanced HIV-1 infection 
presenting with mycobacterial immune reconstitution inflammatory syndrome [Pires et al., 2005]. 
The focus of future work investigating immune-based therapeutic approaches in treated HIV-1 
infection will be to find the optimal therapeutic strategy that will not only induce, but maintain, 
increased T-cell functionality, improve immunophenotypes and result in beneficial clinical 
characteristics. 
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Chapter 5 Functional and phenotypic assessment of T-cell anergy in HIV-1 
infection 
T-cell dysfunction is a well-known characteristic of HIV-1 infection. Markers of chronic immune 
activation, exhaustion and senescence are up-regulated and differentiation/maturation pathways are 
skewed, particularly in acute infection [Papagno et al., 2004; Day et al., 2006; Rosignoli et al., 
2009; Jones et al., 2008; Garber et al., 2004, Appay et al., 2008]. Treatment with ART has been 
found to reduce the expression of markers associated with immune activation [Shou et al., 2011] 
and reverse disrupted maturation states, especially when initiated in early HIV-1 infection [Bisset et 
al., 1998], as well as lowering the expression of co-inhibitory and exhaustion markers [Kassu et al., 
2010]. However, other reports suggest that levels of peripheral T-cell activation are not normalised 
with ART [Rueda et al., 2012], nor are the expression levels of markers such as PD-L1 [Rosignoli 
et al., 2007] and CTLA-4 [Rueda et al., 2012]. The functionality of PBMC from HIV-1
+
 patients on 
ART is important to consider in addition to immunophenotype. Increased polyfunctionality has 
been described in LNTP; they demonstrated a greater proportion of HIV-1-specific CD8 T cells that 
were able to perform five functions simultaneously (including the secretion of IL-2, IFN-γ, TNF-α, 
CD107a and MIP-1β) compared to chronically infected individuals [Betts et al., 2006]. 
Furthermore, HIV-1-specific CD8 T cells from LTNP were found to be more cytotoxic against 
autologous HIV-1-infected CD4 T cells, and to have a greater proliferative capacity than CD8 T 
lymphocytes from chronic progressors [Migueles et al., 2008; Horton et al., 2006]. 
It is important to consider the frequency with which the protective MHC class I alleles (HLA-B*27, 
B*57, B*5801) are represented in these LTNP populations and how this might influence the quality 
of the CD8 T-cell response; these HLA types have been associated with robust HIV-1-specific CD8 
T-lymphocyte responses and viral control [Migueles et al., 2000; O’Brien et al., 2001; Kiepiela et 
al., 2004; Tang et al., 2010; Xie et al., 2010]. Investigations into CD8 T-cell antigen specificity 
have revealed Gag-specific T cells to be more protective [Kiepiela et al., 2007; van Baalen et al., 
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1997; Lichterfeld et al., 2004] with higher cell avidity, polyfunctionality and clonal turnover 
described for Gag-specific CD8 T cells from HLA-B*27
+
 individuals [Almeida et al., 2007]. 
Whereas HLA-B*27 only presents an immunodominant epitope in Gag, but not Nef, to CD8 T 
cells, HLA-B*57/5801 present a number of Gag and Nef epitopes [Altfeld et al., 2006; Bailey et al., 
2009]. In a study by Xie et al., IFN-γ-producing Gag-specific CD8 T cells from HLA-B*57/5801+ 
patients had a higher proportion of CD27
+
 central memory cells compared to Nef-specific CD8 T 
lymphocytes from the same individuals [Xie et al., 2010]. Moreover, it was only the Gag-specific 
CD27
+
 central memory cells from these individuals with the protective HLA allele that showed a 
negative correlation with cell-associated HIV-1 DNA, suggesting that better control can be 
conferred by Gag-specific T cells [Xie et al., 2010]. Another group reported HIV-1 controllers to 
have higher functional avidities of their Gag-specific and HLA-B-restricted responses, compared to 
non-controllers; and these responses were not restored following the initiation of ART in HIV-1 
non-controllers [Berger et al., 2011]. Other studies have reinforced the idea that Gag-specific 
responses are better able to control viral replication [Kiepiela et al., 2007; Mendiratta et al., 2011] 
but Nef-specifity has been shown to be maintained in HLA-B*57/B*5801 non progressors [Navis et 
al., 2008], and a population of Nef-specific effector CD8 T cells (CD8
+
CD45RA
+
IFN-γ-MIP-1β+) 
was shown to be associated with non-progressive HIV-1 infection [Dembek et al., 2010]. 
This chapter investigates the immunophenotypic differences between PBMC from HIV-1-infected 
individuals and healthy seronegative donors. From a subset of HIV-1
+
 patients with carefully 
matched characteristics (undetectable plasma viraemia and high CD4 T-cell counts), the phenotype 
of functionally defined Gag- and/or Nef- specific responders is characterised. Again, comparisons 
are made to samples from healthy, uninfected controls. Finally, using data from all of the patients 
described in this chapter, correlations are drawn between CD4 T-cell count and the surface 
expression of markers associated with immune dysregulation, as well as investigating other 
parameters, such as the influence of the nadir CD4 T-lymphocyte count and the length of time on 
ART on discordant immunophenotypes. 
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5.1 T-cell phenotype in HIV-1+ persons compared to seronegative donors 
The phenotype of CD4 and CD8 T cells from HIV-1
+
 (n = 24) and HIV-1
-
 (n = 13) donors was 
compared using the panel of antibodies described in section 2.12, Table 2.1 and patient 
characteristics are displayed in Table 5.1. Due to limitations with blood volumes, not all subjects 
were analysed using all antibody panels, and the number of samples run for each experiment can be 
found in the figure legends. Statistical analysis was carried out using the Mann-Whitney U Test and 
p values are shown where there was a statistically significant difference between the medians of the 
two groups (p ≤ 0.05). 
5.1.1 Patient characteristics 
The majority of patients were male (23/24) with a median age of 47 years (IQR 41-51 years), a 
median CD4 T-cell count of 434 cells/µl blood (IQR 247-619 cells/µl blood) and a median nadir 
CD4 T-lymphocyte count of 122 cells/µl blood (IQR 53-211 cells/µl blood; Table 5.1). Only three 
subjects had detectable viraemia (N374, B887 and S803 with 81, 106 and 2734 HIV-1 RNA 
copies/ml plasma, respectively) and the rest had HIV-1 RNA of <50 copies/ml plasma. The median 
duration of ART was 50.33 months (IQR 7.97-110.10 months) and the median duration of HIV-1 
infection was 153.21 months (IQR 72.95-171.64 months). Only three of the twenty four patients 
were not on ART therapy (two with HIV-1 RNA <50 copies/ml plasma) and they are indicated with 
an asterisk in Table 5.1. Of the subjects in the table, PBMC from 23 were run for each of the three 
phenotypic panels and all were the same between panels except for the two patients at the end; J565 
was used for assessment of T-cell differentiation subsets using CCR7 and CD45RA and W309 was 
used for panels looking at activation, senescence and apoptosis, as well as CD27 and CD28 
expression (as per panel in section 2.12, Table 2.1). This was due to limitations in the blood 
volumes available from these particular patients. 
The healthy control subjects had a median age of 29 years (IQR 26-32 years), with near even 
numbers of males and females (n = 7 and n = 6, respectively). The number of these donors tested 
for each of the phenotype panels is indicated in the figure legends and range from 9-13. 
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Table 5.1 HIV-1
+
 patient characteristics. 
Patients are indicated by their short code, and all patients were on ART except those marked with an asterisk (*). The top panel shows information for healthy seronegative control 
subjects. NA – not applicable, ND – not done, NK – not known. 
Patient short 
code 
Age 
(years) 
Gender 
Viral load 
(copies/ml) 
Duration of 
ART  
(months) 
ART 
regimen 
CD4 T-cell 
count 
(cells/µl 
blood) 
Nadir CD4 
T-cell count 
(cells/µl 
blood) 
Duration of 
HIV-1 
infection 
(months) 
Healthy donors 
(n = 13) 
Median: 29 
IQR: 26-32 
6F 
7M 
NA NA NA ND NA NA 
B732* 51 M <50 NA NA 554 418 36.66 
C806 48 M <50 159.84 ABC+3TC+TFV+NVP 301 3 179.21 
W693 37 M <50 29.84 FTC+TFV+EFV 526 203 49.77 
K560 51 M <50 128.33 ABC+3TC+SQV+RTV 617 113 135.77 
N374 45 M 81 17.15 TFV+3TC+NVP 1039 733 229.28 
Z171 38 M <50 64.66 FTC+TFV+EFV 641 182 65.41 
J567 57 M <50 152.56 FTC+TFV+RTV+LOP+RTV 625 27 153.21 
L061 44 M <50 130.03 FTC+TFV+ATZ+RTV 218 48 164.07 
W080 41 M <50 7.97 FTC+TFV+NVP 250 133 NK 
C828 43 M <50 50.33 FTC+TFV+ATZ+RTV 664 235 80.49 
E760 46 M <50 87.61 FTC+TFV+RFV 513 64 87.34 
G201 51 M <50 144.56 ABC+3TC+NVP 975 7 222.16 
B671 47 F <50 4.66 ABC+3TC+EFV 150 58 115.34 
B887 33 M 106 0.75 FTC+TFV+EFV 474 55 21.93 
H202 41 M <50 37.11 FTC+TFV+DRV+RTV 144 120 217.48 
H850 45 M <50 60.98 FTC+TFV+DRV+RTV 206 22 163.21 
K087 28 M <50 4.30 FTC+TFV+DRV+RTV 367 235 NK 
M569 48 M <50 15.02 FTC+TFV+EFV 400 306 45.05 
S819 59 M <50 5.08 FTC+TFV+EFV 303 19 NK 
S881 53 M <50 0.10 NK 583 233 163.80 
T215 62 M <50 76.56 TFV+3TC+EFV 433 123 246.82 
S803* 39 M 2734 NA NA 238 156 NK 
J565 49 M <50 110.10 NVP+ABC+3TC 1489 160 164.07 
W309* 62 M <50 NA NA 228 110 NK 
Median 47   50.33  434 122 153.21 
IQR 41-51   7.97-110.10  247-619 53-211 72.95-171.64 
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5.1.2 Immunophenotype 
Percentage co-expression of the activation markers HLA-DR and CD38 on CD4 and CD8 T cells 
was significantly higher in HIV-1
+
 individuals compared to seronegative donors (p <0.0001 in both 
cases; Figures 5.1A and 5.1B, respectively). Looking at percentage of single positive cells with 
these markers, HLA-DR was significantly higher in HIV-1-infected persons compared to healthy 
controls on both T-cell subsets (p <0.0001 for both; Figure 5.1C and 5.1D, respectively) whereas no 
statistically significant difference was seen in percentage expression of CD38 (Figures 5.1E and 
5.1F). 
Evaluation of the senescence marker CD57 and the apoptotic marker CD95 on CD4 and CD8 T 
cells from HIV-1
+
 patients and seronegative donors showed significantly higher percentage 
expression of double positive (CD57
+
CD95
+
) CD4 and CD8 T cells in HIV-1-infected individuals 
compared to healthy donors (p = 0.0003 and p = 0.0001 for CD4 and CD8 T lymphocytes; Figures 
5.2A and 5.2B, respectively). For single expression of CD57, by both T-cell subsets, levels are 
significantly higher on PBMC from HIV-1
+
 individuals compared to healthy controls (p = 0.0006 
and p = 0.0001 for CD4 and CD8 T cells; Figures 5.2C and 5.2D, respectively). Single expression 
of CD95 was also significantly elevated in HIV-1
+
 patients compared to seronegative donors for 
both T-lymphocyte subsets (p = 0.0013 and p<0.0001; Figures 5.2E and 5.2F for CD4 and CD8 T 
cells, respectively). 
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Figure 5.1 CD4 and CD8 T-cell activation in HIV-1
+
 individuals and healthy donors. 
Percentage co-expression of HLA-DR and CD38 was determined on CD4 and CD8 T cells (A and B, respectively) from 
seronegative controls (n = 13; depicted with blue circles) and HIV-1-infected persons (n = 23; depicted with red 
circles). Percentage expression of HLA-DR on CD4 and CD8 T cells was also assessed (C and D) as was the percentage 
expression of CD38 on both subsets (E and F). All individual data points are shown with box plots representing the 
median and IQR, and whiskers representing the 10
th
 and 90
th
 percentiles. P values are shown where there are 
statistically significant differences between the groups.  
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Figure 5.2 CD4 and CD8 T-cell senescence and apoptosis in HIV-1
+
 individuals and healthy donors. 
Percentage co-expression of CD57 and CD95 was determined on CD4 and CD8 T cells (A and B, respectively) from 
seronegative controls (n = 13; depicted with blue circles) and HIV-1-infected persons (n = 23; depicted with red 
circles). Percentage expression of CD57 on CD4 and CD8 T cells was also assessed (C and D) as was the percentage 
expression of CD95 on both subsets (E and F). All individual data points are shown with box plots representing the 
median and IQR, and whiskers representing the 10
th
 and 90
th
 percentiles. P values are shown where there are 
statistically significant differences between the groups. 
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Early, intermediate and late differentiation states of CD4 and CD8 T cells were determined using 
percentage expression of CD27 and CD28, with early T cells defined as double positives 
(CD27
+
CD28
+
), intermediate T cells as CD4
+
CD27
-
CD28
+
 or CD8
+
CD27
+
CD28
-
, and late as 
double negatives (CD27
-
CD28
-
). For the CD4 T-lymphocyte compartment, HIV-1
+
 persons had 
significantly lower expression of markers associated with an early T-cell phenotype and 
significantly higher expression of markers associated with intermediate and late differentiation 
states (p = 0.0159, p = 0.0022 and p = 0.0105, respectively; Figure 5.3A). CD8 T cells showed 
significantly higher percentage expression of phenotypically defined late T cells in HIV-1-infected 
patients compared to healthy controls (p = 0.0159; Figure 5.3B). 
CD4 and CD8 T-cell differentiation/maturation was also assessed using the expression of CCR7 
and CD45RA. CD4 and CD8 T cells from HIV-1
+
 patients had significantly lower expression of 
markers associated with naïve T cells (p = 0.0057 and p = 0.0005; Figures 5.4A and 5.4B, 
respectively). Similarly, for both T-cell subsets, HIV-1-infected persons had higher expression of 
markers associated with terminally differentiated phenotype (TEMRA; p = 0.0420 and p = 0.0011; 
Figures 5.4A and 5.4B, respectively). 
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Figure 5.3 Early, intermediate and late CD4 and CD8 T-cell subsets in healthy control and HIV-1-infected individuals. 
Expression of CD27 and CD28 was used to determine early (CD27
+
CD28
+
), intermediate (CD4
+
CD27
-
CD28
+
 or CD8
+
CD27
+
CD28
-
) and late (CD27
-
CD28
-
) CD4 (A) and CD8 (B) 
T cells in healthy control individuals (n = 11; depicted with blue circles) and HIV-1
+
 individuals (n = 23; red circles). Box plots show the median and IQR and whiskers represent the 
10
th
 and 90
th
 percentiles. P values are shown where there is a statistically significant difference between the two groups. 
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Figure 5.4 CD4 and CD8 T-cell differentiation in healthy donors and HIV-1
+
 individuals. 
Subsets of CD4 (A) and CD8 (B) T-cell differentiation were determined using surface expression of CCR7 and CD45RA. Naive (CCR7
+
CD45RA
+
), TCM (CCR7
+
CD45RA
-
) TEM 
(CCR7
-
CD45RA
-
) and TEMRA (CCR7
-
CD45RA
+
) were defined in healthy control individuals (n = 9; shown here with blue circles) and HIV-1-infected patients (n = 23; red circles). 
All individual data points are shown with box plots representing the median and interquartile range, and whiskers representing the 10
th
 and 90
th
 percentiles. P values are shown where 
there is a statistically significant difference between the two groups. 
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5.2 Distinct HIV-1 Gag- or Nef- specific responses and their correlations with altered 
immunophenotypic profiles 
5.2.1 Patient characteristics 
The clinical characteristics of HIV-1-infected individuals (n = 17) and healthy controls (n = 11) 
used in this section are shown in Table 5.2. The majority of the HIV-1
+
 subjects were male (16/17) 
with a median age of 47 years (IQR 37-50 years), a median CD4 T-cell count of 731 cells/µl blood 
(IQR 534-884 cells/µl blood), a median nadir CD4 T-lymphocyte count of 210 cells/µl blood (IQR 
180-284 cells/µl blood) and all patients had <50 copies/ml plasma HIV-1 RNA. The median 
duration of HIV-1 infection was 142.92 months (IQR 90.40-197.48 months) and all individuals had 
been on ART for a median duration of 84.79 months (IQR 45.87-139.05 months). Table 5.2 also 
details the responder statuses of the subjects tested, the classification of which is described in 
section 5.2.2, and the symbols used for figures in this chapter. No statistically significant 
differences were found in the characteristics (age, CD4 T-cell count, nadir CD4 T-cell count, 
duration of HIV-1 infection and duration of HAART) between individuals that were responders to 
Gag, Nef, Gag and Nef, or low responders; the Kruskal-Wallis test was used to determine if there 
were significant differences between the medians (data not shown). The healthy seronegative 
donors were mostly male (7/11) with a median age of 35 years (IQR 28-44 years; Table 5.2). 
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Table 5.2 Clinical characteristics of HIV-1
+
 patient and control cohorts. 
F: female, M: male; NA: not applicable; ND: not done; NK: not known 
Patient 
short code 
Responder 
status 
Graph 
Symbol 
Age 
(years) 
Gender 
Duration 
of HIV-1 
infection 
(months) 
Duration 
of ART 
(months) 
ART 
regimen 
CD4 T-
cell 
count 
(cells/µl) 
Nadir 
CD4 
T-cell 
count 
(cells/µl) 
Plasma 
viral load 
(copies/ml) 
Healthy controls (n = 11)  
Median: 35 
IQR: 28-44 
4 F 
7 M 
NA NA NA ND NA NA 
R771 Gag ▲ 64 M 160.13 139.05 FTC+TFV+EFV 884 391 <50 
B784 Gag & Nef  40 M 99.25 98.95 FTC+TFV+EFV 1332 80 <50 
G739 Nef  43 M 141.61 113.15 FTC+TFV+EFV 534 227 <50 
P087 Low  50 M 172.95 162.75 FTC+TFV+EFV 731 210 <50 
C789 Low  29 M 20.75 12.20 FTC+TFV+EFV 535 309 <50 
L043 Gag ▲ 47 M 90.69 45.87 FTC+TFV+EFV 782 303 <50 
C319 Low  48 M 229.05 80.03 FTC+TFV+ETV 1079 93 <50 
F810 Gag ▲ 50 M 233.41 193.54 FTC+TFV+NVP 582 166 <50 
O523 Nef  53 F 84.10 62.89 FTC+TFV+ETR 892 284 <50 
S648 Gag ▲ 52 M 300.39 158.43 TFV+DRV+RTV 616 227 <50 
C241 Gag ▲ 47 M 144.23 87.18 FTC+TFV+DRV+RTV 307 180 <50 
P054 Gag & Nef  33 M 40.80 28.80 FTC+TFV+EFV 840 200 <50 
M160 Nef  35 M 120.43 36.43 FTC+TFV+DRV+RTV 397 200 <50 
C766 Low  37 M 89.54 84.79 RTV+3TC+LOP+RTV 755 136 <50 
W097 Low  30 M NK 19.41 FTC+TFV+RTV+ATZ 462 201 <50 
L765 Gag & Nef  48 M 186.95 178.95 ABC+3TC+EFV 529 275 <50 
B548 Nef  42 M 252.72 58.03 FTC+TFV+DRV+RTV 1213 444 <50 
Median   47  142.92 84.79  731 210  
IQR   37-50  
90.40- 
197.48 
45.87- 
139.05 
 
534- 
884 
180- 
284 
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5.2.2 Defining HIV-1 Gag and Nef responders 
IFN-γ production in response to peptide stimulation was used to determine HIV-1 Gag-and/or Nef- 
specific responders. Figure 5.5 shows the responses to HIV-1 Gag and Nef overlapping peptide 
pools from two sources (the overlapping peptide pools and their sources are detailed in Tables 2.7 
and 2.8 in section 2.16). The threshold for positivity in the ELISpot assays is indicated in Figure 5.5 
and Figure 5.6: a positive response is defined as >50 SFC/10
6
 PBMC and at least three times the 
background (cells cultured in TCM without peptides, the background value was always less than 25 
SFC/10
6
 PBMC for these assays; definitions on thresholds and cut offs as per Burton et al., 2006). 
Individuals with responses to the overlapping peptide pools between 51 and 250 SFC/10
6
 PBMC 
were considered ‘low responders’, and individuals with responses >250 SFC/106 PBMC were 
termed ‘responders’. Responses to the mitogen control PHA were >250 SFC/106 PBMC for all IFN-
γ ELISpot assays (median 1440, range 282-1958 SFC/106 PBMC) and >130 SFC/106 PBMC for all 
IL-2 ELISpot assays (median 400, range 136-1600 SFC/10
6
 PBMC). The lower responses to PHA 
in the IL-2 ELISpot assays were expected as the ability to produce IL-2 has been found to be 
impaired in chronic HIV-1 infection [Younes et al., 2003; Iyasere et al., 2003] and studies have 
shown that even prolonged ART is only associated with a partial recovery of HIV-1-specific T cells 
that secrete IL-2 [Day & Walker, 2003]. This dysfunction has been attributed to defects in the 
JAK/STAT signalling pathway and unrelated to expression level of the IL-2 receptor [Kryworuchko 
et al., 2004]. 
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Figure 5.5 Defining distinct HIV-1 Gag- and Nef- specific responses. 
IFN-γ responses to overlapping peptide pools of Gag (purple bars) and Nef (green bars) from two sources (NIBSC and FIT Biotech; the peptide source and corresponding bar colour 
is detailed in the figure legend). A threshold of >50 SFC/10
6
 PBMC was used to determine a positive response (with the cut off line indicated on the graph). Responses between 51-
250 SFC/10
6
 PBMC were considered ‘low responders’ and individuals with responses >250 SFC/106 PBMC were termed ‘responders’. Patient short codes are given on the X axis 
and n  = 17. 
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Figure 5.6 HIV-1 Gag- and Nef- specific responses in terms of IL-2 production. 
IL-2 responses to peptide pools of Gag (purple bars) and Nef (green bars) from two sources (NIBSC and FIT Biotech; the peptide source and corresponding bar colour is detailed in 
the figure legend). The cut off line shown here illustrates the threshold for positivity in the ELISpot assays where responses >50 SFC/10
6
 PBMC are considered positive. Patient 
short codes are given on the X axis and n = 17. 
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Using the aforementioned threshold for positivity and cut offs to determine low responders and 
responders to HIV-1 Gag, Nef, or both (Figure 5.5) five individuals were classified as ‘low 
responders’ (P087, C789, C319, C766 and W097), five as responders to Gag (R771, L043, F810, 
S648 and C241), four as responders to Nef (G739, O523, M160 and B548) and three as responders 
to both Gag and Nef (B784, P054 and L765), as shown in Table 5.2. Following characterisation of 
the patients in this manner, the corresponding phenotype at the same time point was assessed in 
order to determine if distinct functional responses are associated with a particular phenotype. 
5.2.3 Phenotypic profiles of Gag and Nef responders 
Phenotypic characterisation of the patient PBMC was carried out and the graphs depicting the 
phenotypic profiles of these individuals highlight particular types of responder. Low responders are 
shown with red circles, Gag responders with purple triangles, Nef responders with green rhombi 
and responders to both Gag and Nef with orange squares (as detailed in Table 5.2). The 
immunophenotypic profiles of healthy control individuals were also assessed and they are shown on 
the graphs with blue circles. The Kruskal-Wallis test was first used to determine if there were any 
significant differences between the medians of the phenotypic properties for the patients classified 
according to their Gag and Nef responses. No statistically significant differences between the 
groups were found for the parameters assessed, and this warranted grouping all HIV-1
+
 patients 
together. Thus, the Mann-Whitney U test was used for the statistical analysis of data between HIV-
1
+
 patients and healthy control individuals with all statistically significant differences (and 
corresponding p values) shown on the graph, and any trends, particularly with regard to Gag/Nef 
responder status, described in the text. 
The markers HLA-DR and CD38 were used to assess the immune activation status of CD4 and 
CD8 T cells (Figure 5.7 and Figure 5.8, respectively) in treated HIV-1-infected persons compared 
to healthy control individuals. Specific responses to Gag and/or Nef were also considered in these 
investigations. On both T-cell subsets, the percentage co-expression of HLA-DR and CD38 was 
significantly higher in HIV-1-infected individuals compared to healthy donors (p <0.0001 for both; 
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Figure 5.7A and Figure 5.8A, respectively). In terms of single expression of these markers, looking 
at both percentage expression and MFI, CD4 and CD8 T cells of HIV-1-infected patients had 
significantly higher expression of HLA-DR compared to healthy controls (p = 0.0002 and p 
<0.0001, respectively; Figure 5.7B and Figure 5.8B). Although no apparent differences could be 
distinguished in the phenotypes of the differently classified responders to Gag and Nef peptides 
when looking at CD8 T cells, the CD4 T-cell profile depicted a tendency for Gag responders to 
have higher percentage co-expression of HLA-DR and CD38 and the ‘low-responders’ to have a 
lower expression of these two markers (Figure 5.7A). The percentage expression of CD38 appeared 
higher on the Gag responders, whereas the Nef responders tended to have lower percentage 
expression of this marker on their CD4 T cells (Figure 5.7C). 
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Figure 5.7 CD4 T-cell activation in HIV-1
+
 patients and healthy control individuals. 
Percentage co-expression of HLA-DR and CD38 was determined on CD4 T cells from HIV-1-infected individuals (n = 
17) and healthy controls (n = 11; A). Percentage expression and MFI were also assessed for HLA-DR (B and D, 
respectively) and CD38 (C and E, respectively). For all graphs, HIV-1
+
 patients are shown in the left hand plot, with 
Gag (▲), Nef (), Gag and Nef (), or low responder () status indicated. Healthy control individuals are depicted 
with blue circles (). All individual data points are shown with box plots representing the median and interquartile 
range, and whiskers representing the 10
th
 and 90
th
 percentiles. P values are shown where there are statistically 
significant differences between the two groups. 
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Figure 5.8 CD8 T-cell activation in HIV-1+ patients and healthy control individuals. 
Percentage co-expression of HLA-DR and CD38 was determined on CD8 T cells from HIV-1-infected individuals (n = 
17) and healthy controls (n = 11; A). Percentage expression and MFI were also assessed for HLA-DR (B and D, 
respectively) and CD38 (C and E, respectively). For all graphs, HIV-1
+
 patients are shown in the left hand plot, with 
Gag (▲), Nef (), Gag and Nef (), or low responder () status indicated. Healthy control individuals are depicted 
with blue circles (). All individual data points are shown with box plots representing the median and interquartile 
range, and whiskers representing the 10
th
 and 90
th
 percentiles. P values are shown where there are statistically 
significant differences between the two groups. 
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The percentage co-expression of markers associated with immune senescence (CD57) and apoptosis 
(CD95) were significantly higher in HIV-1
+
 patients compared to healthy controls on both CD4 and 
CD8 T cells (p = 0.0030 and p = 0.0111, respectively; Figure 5.9A and Figure 5.10A). Percentage 
expression of CD57 was found to be higher for both subsets in HIV-1-infected persons compared to 
healthy donors (p = 0.0118 and p = 0.0144, respectively; Figure 5.9B and Figure 5.10B) and the 
same was found for CD95 percentage expression on CD4 and CD8 T cells (p = 0.0064 and p = 
0.0004, respectively; Figure 5.9C and Figure 5.10C). The MFI of CD57 on the CD4 T cell 
population was significantly higher in HIV-1
+
 persons compared to seronegative individuals (p = 
0.0022; Figure 5.9D). No clear pattern emerged looking at the graphs divided into type of 
responder, however, Nef responders tended to have higher percentage expression of CD95 on CD4 
T cells (Figure 5.9C) and low responders had a lower percentage expression of CD57 on their CD4 
T cells (Figure 5.9B). Responders to both Gag and Nef, tended to have higher co-expression of 
CD57 and CD95 on the CD8 T-cell population (Figure 5.10A) and higher percentage expression of 
CD57, again on CD8 T cells (Figure 5.10B). 
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Figure 5.9 CD4 T-cell senescence and apoptosis in HIV-1+ patients and healthy control individuals. 
Percentage co-expression of CD57 and CD95 was determined on CD4 T cells from HIV-1-infected individuals (n = 17) 
and healthy controls (n = 11; A). Percentage expression and MFI were also assessed for CD57 (B and D, respectively) 
and CD95 (C and E, respectively). For all graphs, HIV-1
+
 patients are shown in the left hand plot, with Gag (▲), Nef 
(), Gag and Nef (), or low responder () status indicated. Healthy control individuals are depicted with blue circles 
(). All individual data points are shown with box plots representing the median and interquartile range, and whiskers 
representing the 10
th
 and 90
th
 percentiles. P values are shown where there are statistically significant differences 
between the two groups. 
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Figure 5.10 CD8 T-cell senescence and apoptosis in HIV-1+ patients and healthy control individuals. 
Percentage co-expression of CD57 and CD95 was determined on CD8 T cells from HIV-1-infected individuals (n = 17) 
and healthy controls (n = 11; A). Percentage expression and MFI were also assessed for CD57 (B and D, respectively) 
and CD95 (C and E, respectively). For all graphs, HIV-1
+
 patients are shown in the left hand plot, with Gag (▲), Nef 
(), Gag and Nef (), or low responder () status indicated. Healthy control individuals are depicted with blue circles 
(). All individual data points are shown with box plots representing the median and interquartile range, and whiskers 
representing the 10
th
 and 90
th
 percentiles. P values are shown where there are statistically significant differences 
between the two groups. 
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The differentiation status of both CD4 and CD8 T cells was assessed using two panels of markers. 
The first used the expression of CD27 and CD28 to determine early, intermediate, and late CD4 and 
CD8 T cells (Figure 5.11A and Figure 5.11B, respectively). For both subsets, the double positives 
(CD27
+
CD28
+
) are the early T cells, intermediate T cells are characterised by the loss of CD27 on 
the CD4 T cells (CD27
-
CD28
+
), and by the loss of CD28 expression on the CD8 T cells 
(CD27
+
CD28
-
). Cells which are double negative for both markers (CD27
-
CD28
-
) are classed as 
being in a late differentiation state. Healthy control individuals had significantly more early CD4 
and CD8 T cells as determined by surface expression of these two markers (Figure 5.11A, p = 
0.0073 and Figure 5.11B, p = 0.0019, respectively). For both T-cell subsets, the HIV-1-infected 
individuals showed profiles shifted to a late differentiation status (Figure 5.11A, p = 0.0030 and 
Figure 5.11B, = 0.0035). Nef responders in particular appeared shifted toward a later differentiation 
state with noticeably lower expression of markers associated with an early phenotype and higher 
expression of markers associated with a late maturation profile on the CD4 T cells (Figure 5.11A). 
A similar pattern was seen on CD8 T cells from Gag and Nef responders, with fewer early, and 
more late, CD8 T cells (Figure 5.11B). 
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Figure 5.11 Early, intermediate and late CD4 and CD8 T-cell subsets. 
Expression of CD27 and CD28 was used to determine early (CD27
+
CD28
+
), intermediate (CD4
+
CD27
-
CD28
+
 or CD8
+
CD27
+
CD28
-
) and late (CD27
-
CD28
-
) CD4 (A) and CD8 (B) 
T cells in HIV-1
+
 individuals (n = 17) and healthy controls (n = 11). For each differentiation state (early, intermediate or late) shown, HIV-1
+
 patients are shown in the left hand plot, 
with Gag (▲), Nef (), Gag and Nef (), or low responder () status indicated. Healthy control individuals are depicted with blue circles (). All individual data points are shown 
with box plots representing the median and interquartile range, and whiskers representing the 10
th
 and 90
th
 percentiles. P values are shown where there are statistically significant 
differences between the two groups. 
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The percentage expression of CCR7 and CD45RA was also used to determine the 
maturation/differentiation profiles of both T-cell subsets (Figure 5.12A and Figure 5.12B, 
respectively). Naïve (CCR7
+
CD45RA
+
), central memory (TCM; CCR7
+
CD45RA
-
), effector memory 
(TEM; CCR7
-
CD45RA
-
) and terminally differentiated (TEMRA; CCR7
-
CD45RA
+
) CD4 and CD8 T 
cells from HIV-1-infected individuals were characterised and compared to healthy donors. Healthy, 
seronegative donors had significantly higher percentage expression of naïve CD4 and CD8 T cells 
(Figure 5.12A, p = 0.0431, and Figure 5.12B, p = 0.0016, respectively) whereas HIV-1-infected 
patients demonstrated significantly higher expression of TEMRA cells in both T-cell subsets. In the 
CD4 T-cell compartment, the Nef responders tended to have fewer naïve cells and more TEM cells 
(Figure 5.12A), and when looking at the CD8 T cells, the Gag and Nef responders tended to have 
lower expression of markers associated with a TCM phenotype and higher expression of those 
associated with a TEMRA profile (Figure 5.12B). Interestingly, the low responders tended to have 
higher expression of markers associated with a TEM phenotype and lower expression of markers 
associated with a TEMRA phenotype (Figure 5.12B). 
Regardless of the combination of markers used to determine differentiation status, healthy control 
individuals had significantly more early/naïve CD4 and CD8 T cells and HIV-1-infected individuals 
had more late/TEMRA CD4 and CD8 T cells. Parallels can also be seen in the phenotype of the Gag 
and Nef responders with Nef responders having a shift in CD4 T-cell differentiation/maturation 
from an early/naïve phenotype to a late, or TEM phenotype, and Gag and Nef responders having a 
shift from an early/TCM to a late/TEMRA profile in the CD8 T-cell compartment. 
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Figure 5.12 CD4 and CD8 T-cell differentiation. 
Subsets of CD4 (A) and CD8 (B) T-cell differentiation were determined using surface expression of CCR7 and CD45RA. Naive (CCR7
+
CD45RA
+
), TCM (CCR7
+
CD45RA
-
) TEM 
(CCR7
-
CD45RA
-
) and TEMRA (CCR7
-
CD45RA
+
) were defined in HIV-1-infected patients (n = 17) and healthy control individuals (n = 11). For each differentiation state (Naïve, TCM, 
TEM or TEMRA) depicted, HIV-1
+
 patients are shown in the left hand plot, with Gag (▲), Nef (), Gag and Nef (), or low responder () status indicated. Healthy control individuals 
are depicted with blue circles (). All individual data points are shown with box plots representing the median and interquartile range, and whiskers representing the 10th and 90th 
percentiles. P values are shown where there are statistically significant differences between the two groups. 
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In terms of PD-1 and PD-L1 expression on the differentiation/maturation subsets, according to 
expression of CCR7 and CD45RA, there were no significant differences seen in either the CD4 or 
CD8 T-cell subsets from HIV-1-infected individuals or healthy controls (Figure 5.13 and Figure 
5.14, respectively). The Nef responders tended to have higher percentage expression of PD-L1 on 
all of the subsets of CD4 T cells (Figure 5.13B) and PD-L1 expression on the naïve and TCM CD8 T 
cells was lower for Gag and Nef responders and tended to be higher for low responders (Figure 
5.14B). 
PD-1 and PD-L1 expression did not differ significantly between the CD4 and CD8 T cells of HIV-
1-infected individuals and healthy donors (Figure 5.15 and Figure 5.16, respectively). The low 
responders appeared to express a higher percentage of PD-L1 on their CD8 T cells compared to the 
other types of responder (Figure 5.16B). 
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Figure 5.13 PD-1 and PD-L1 expression on CD4 T-cell subsets. 
PD-1 (A) and PD-L1 (B) expression on CD4 T-cell differentiation/maturation subsets (according to CCR7 and CD45RA expression, as described previously) was assessed in HIV-1
+
 
patients (n = 17) and healthy control individuals (n = 11). For each differentiation state (Naïve, TCM, TEM or TEMRA) depicted, HIV-1
+
 patients are shown in the left hand plot, with 
Gag (▲), Nef (), Gag and Nef (), or low responder () status indicated. Healthy control individuals are depicted with blue circles (). All individual data points are shown with 
box plots representing the median and interquartile range, and whiskers representing the 10
th
 and 90
th
 percentiles. P values are shown where there are statistically significant 
differences between the two groups. 
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Figure 5.14 PD-1 and PD-L1 expression on CD8 T-cell subsets. 
PD-1 (A) and PD-L1 (B) expression on CD8 T-cell differentiation/maturation subsets (according to CCR7 and CD45RA expression, as described previously) was assessed in HIV-1
+
 
patients (n = 17) and healthy control individuals (n = 11). For each differentiation state (Naïve, TCM, TEM or TEMRA) depicted, HIV-1
+
 patients are shown in the left hand plot, with 
Gag (▲), Nef (), Gag and Nef (), or low responder () status indicated. Healthy control individuals are depicted with blue circles (). All individual data points are shown with 
box plots representing the median and interquartile range, and whiskers representing the 10
th
 and 90
th
 percentiles. P values are shown where there are statistically significant 
differences between the two groups. 
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Figure 5.15 PD-1 expression on CD4 and CD8 T cells. 
Percentage expression and MFI of PD-1 on CD4 (A and C, respectively) and CD8 (B and D, respectively) T cells from 
HIV-1
+
 patients (n = 17) and healthy controls (n = 11). For all graphs, HIV-1
+
 patients are shown in the left hand plot, 
with Gag (▲), Nef (), Gag and Nef (), or low responder () status indicated. Healthy control individuals are 
depicted with blue circles (). All individual data points are shown with box plots representing the median and 
interquartile range, and whiskers representing the 10
th
 and 90
th
 percentiles. P values are shown where there are 
statistically significant differences between the two groups. 
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Figure 5.16 PD-L1 expression on CD4 and CD8 T cells. 
Percentage expression and MFI of PD-L1 on CD4 (A and C, respectively) and CD8 (B and D, respectively) T cells 
from HIV-1
+
 patients (n = 17) and healthy controls (n = 11). For all graphs, HIV-1
+
 patients are shown in the left hand 
plot, with Gag (▲), Nef (), Gag and Nef (), or low responder () status indicated. Healthy control individuals are 
depicted with blue circles (). All individual data points are shown with box plots representing the median and 
interquartile range, and whiskers representing the 10
th
 and 90
th
 percentiles. P values are shown where there are 
statistically significant differences between the two groups. 
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Co-expression of the exhaustion markers TIM-3 and CTLA-4 did not differ significantly on the 
CD4 and CD8 T cells from HIV-1
+
 patients and healthy individuals (Figure 5.17 and Figure 5.18, 
respectively). TIM-3 expression on the CD4 T cells was significantly higher in HIV-1-infected 
persons compared to healthy donors (Figure 5.17B, p = 0.0077) and there was a trend toward a 
higher MFI in the HIV-1
+
 group (Figure 5.17D, p = 0.0997). The MFI of TIM-3 on the CD4 T cells 
appeared elevated in the low responders and lower for patients who responded to both Gag and Nef 
peptides (Figure 5.17D). For the CD8 T-cell compartment, only when looking at the MFI of TIM-3 
was there a statistically significant difference between the HIV-1
+
 patients and the seronegative 
controls (Figure 5.18D, p = 0.0212), and again here, the low responders appeared to have higher 
expression of TIM-3 in terms of MFI and the Gag and Nef responders had lower expression of 
TIM-3 and CTLA-4 (Figure 5.18D and Figure 5.18E, respectively). 
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Figure 5.17 CD4 T-cell expression of the exhaustion marker TIM-3 and the co-inhibitory marker CTLA-4. 
Percentage co-expression of TIM-3 and CTLA-4 (A), percentage expression and MFI of TIM-3 (B and D, respectively) 
and CTLA-4 (C and E, respectively) on CD4
+ 
T cells from HIV-1
+
 patients (n = 17) and healthy controls (n = 11). For 
all graphs, HIV-1
+
 patients are shown in the left hand plot, with Gag (▲), Nef (), Gag and Nef (), or low responder 
() status indicated. Healthy control individuals are depicted with blue circles (). All individual data points are shown 
with box plots representing the median and interquartile range, and whiskers representing the 10
th
 and 90
th
 percentiles. P 
values are shown where there are statistically significant differences between the two groups. 
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Figure 5.18 CD8 T-cell expression of the exhaustion marker TIM-3 and the co-inhibitory marker CTLA-4. 
Percentage co-expression of TIM-3 and CTLA-4  (A), percentage expression and MFI of TIM-3 (B and D, respectively) 
and CTLA-4 (C and E, respectively) on CD8
+ 
T cells from HIV-1
+
 patients (n = 17) and healthy controls (n = 11). For 
all graphs, HIV-1
+
 patients are shown in the left hand plot, with Gag (▲), Nef (), Gag and Nef (), or low responder 
() status indicated. Healthy control individuals are depicted with blue circles (). All individual data points are shown 
with box plots representing the median and interquartile range, and whiskers representing the 10
th
 and 90
th
 percentiles. P 
values are shown where there are statistically significant differences between the two groups. 
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Markers associated with a regulatory T-cell phenotype (CD4
+
CD45RO
+
CD25
high
) did not differ 
significantly between HIV-1
+
 patients and healthy controls (Figure 5.19A), although the Gag and 
Nef responders tended to have a higher percentage expression of this combination of markers 
compared to the other types of responder. Only when looking at the MFI of CD25 on the CD4 T 
cells was a significant difference seen between HIV-1-infected persons and healthy controls (Figure 
5.19D, p = 0.0482). 
 
 
Figure 5.19 Markers associated with a regulatory T-cell phenotype. 
CD4
+
CD45RO
+
CD25
high
 T cells from HIV-1 infected individuals (n =17) and healthy controls (n = 11) were compared 
(A) as was percentage expression and MFI of CD25 and CD45RO on this subset (B and D, and C and E, respectively). 
For all graphs, HIV-1
+
 patients are shown in the left hand plot, with Gag (▲), Nef (), Gag and Nef (), or low 
responder () status indicated. Healthy control individuals are depicted with blue circles (). All individual data points 
are shown with box plots representing the median and interquartile range, and whiskers representing the 10
th
 and 90
th
 
percentiles. P values are shown where there are statistically significant differences between the two groups. 
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The expression of CD45RA, CD31 and PTK-7 were used to determine recent thymic emigrants. 
Co-expression of CD45RA and CD31 on CD4 T cells did not differ significantly between HIV-1
+
 
persons and healthy donors (Figure 5.20A), nor did single expression of PTK-7 in terms of 
percentage expression (Figure 5.20C) and MFI (Figure 5.20E). However, healthy control 
individuals had significantly higher percentage expression of CD31 compared to HIV-1-infected 
patients (Figure 5.20C, p = 0.0033) with a trend toward an increased MFI of CD31 in the HIV-1
+
 
group (Figure 5.20D, p = 0.0666). The MFI of CD31 on CD8 T cells was significantly higher in 
HIV-1-infected persons compared to healthy controls (Figure 5.21C, p = 0.0482). The Nef 
responders tended to have lower percentage co-expression of CD45RA and CD31 on the CD4 T 
cells (Figure 5.20A) but higher expression of PTK-7 on the CD8 T cells (Figure 5.21B). 
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Figure 5.20 Markers associated with recent thymic emigrants on CD4 T cells. 
Co-expression of CD31 and CD45RA (A) was assessed on CD4 T cells from HIV-1
+
 individuals (n = 17) and healthy 
controls (n = 11). Percentage expression and MFI of CD31 (B and D, respectively) and PTK-7 (C and E, respectively) 
were also determined for the CD4 T-cell population. For all graphs, HIV-1
+
 patients are shown in the left hand plot, 
with Gag (▲), Nef (), Gag and Nef (), or low responder () status indicated. Healthy control individuals are 
depicted with blue circles (). All individual data points are shown with box plots representing the median and 
interquartile range, and whiskers representing the 10
th
 and 90
th
 percentiles. P values are shown where there are 
statistically significant differences between the two groups. 
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Figure 5.21 Markers of recent thymic emigrants on CD8 T cells. 
Percentage expression and MFI of CD31 (A and C, respectively) and PTK-7 (B and D, respectively) on CD8 T cells 
were determined for HIV-1-infected patients and healthy control subjects. For all graphs, HIV-1
+
 patients are shown in 
the left hand plot, with Gag (▲), Nef (), Gag and Nef (), or low responder () status indicated. Healthy control 
individuals are depicted with blue circles (). All individual data points are shown with box plots representing the 
median and interquartile range, and whiskers representing the 10
th
 and 90
th
 percentiles. P values are shown where there 
are statistically significant differences between the two groups. 
 
5.3 Correlations between clinical parameters and immunophenotype 
Correlations between clinical parameters (CD4 T-cell count, nadir CD4 T-lymphocyte count, 
duration of HIV-1 infection and duration of ART) and CD4 and CD8 T-cell phenotype were carried 
out for the 17 patients that were classified according to their IFN-γ ELISpot responses to peptide 
pools of Gag and Nef (Table 5.2). The non-parametric Spearman correlation coefficient was the 
statistical test used as the data were not normally distributed. Graphs display the correlation 
coefficient (rs), with negative values representing a negative correlation, and p value, with p values 
≤0.05 considered to be significant. For the seventeen patients, there were no significant correlations 
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CD38 on the CD4 and CD8 T lymphocytes, or with the expression of CD57 and CD95, or with PD-
1 (data not shown). There were however, significant negative correlations between CD4 T-cell 
count and percentage expression of TIM-3 on CD4 and CD8 T cells (rs = 0.6671, p = 0.0034; and rs 
= -0.5674, p = 0.0175; Figures 5.22A and 5.22B, respectively). 
 
 
Figure 5.22 Correlation between CD4 T-cell count and expression of TIM-3 on CD4 and CD8 T lymphocytes. 
A significant negative correlation was seen between CD4 T-cell count and percentage expression of TIM-3 on CD4 (A) 
and CD8 (B) T cells; all subjects were HIV-1-infected and on HAART (n = 17). The correlation coefficient (rs) and p 
value are shown for each plot.  
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CD38 (rs = -0.5941, p <0.0001; and rs = -0.3634, p = 0.0212; Figures 5.23A and 5.23B for CD4 and 
CD8 T cells, respectively). A significant negative correlation was also seen between CD4 T-
lymphocyte count and single expression of HLA-DR on CD4 T cells (rs = -0.4831, p = 0.0016; 
Figure 5.23C). Moreover, the duration of ART correlated negatively with the percentage co-
expression of the two aforementioned activation markers, but only on the CD8 T-cell population, 
and this correlation approached statistical significance (rs = -0.3090, p = 0.0524; Figure 5.23D). 
 
 
 
Figure 5.23 Correlations between clinical parameters and immune activation. 
The correlation between CD4 T-cell count and percentage co-expression of HLA-DR and CD38 on both CD4 (A) and 
CD8 (B) T cells is shown (n = 41), as well as single expression of HLA-DR on CD4 T cells (C; n =41). The way in 
which duration of ART correlates with CD8 T-cell activation is also depicted (D; n= 40). The correlation coefficient (rs) 
and p value are shown for each plot. 
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0.0088; Figure 5.24B) on CD4 T lymphocytes. Investigation of the clinical parameters and patient 
characteristics revealed significant positive correlations between CD4 T-cell count and both nadir 
CD4 T lymphocyte count (rs = 0.3680, p = 0.0179; Figure 5.25A) and duration of ART (rs = 0.3476, 
p = 0.0259; Figure 5.25B). 
 
 
 
Figure 5.24 Correlation between CD4 T-cell count and markers of terminal differentiation and apoptosis. 
The correlation between CD4 T-cell count and markers associated with a terminally differentiated T-cell phenotype 
(CCR7
+
CD45RA
+
; TEMRA) is shown (A; n = 40). The correlation between peripheral CD4 T-lymphocyte numbers and 
the apoptotic marker CD95 is also depicted (B; n = 40). The correlation coefficient (rs) and p value are shown for each 
plot. 
 
 
 
Figure 5.25 Duration of ART and nadir CD4 T-cell count correlate with peripheral CD4 T-lymphocyte numbers. 
The correlation between CD4 T-cell count and nadir CD4 T-cell count was assessed (A; n = 40), as was the correlation 
between CD4 T-lymphocyte number and duration of ART (B; n = 40). The correlation coefficient (rs) and p value are 
shown for each plot. 
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5.4 Discussion 
No differences were observed in CD38 expression on CD4 or CD8 T lymphocytes between HIV-1-
infected patients and healthy control subjects for either study group described in this chapter. This 
agrees with findings from other studies in which CD38 expression is elevated in acute HIV-1 
infection but normalises following treatment with ART [Papagno et al., 2004; Shou et al., 2011]. It 
has been suggested that the mean density of CD38 per cell (MFI) rather than the proportion of cells 
that express CD38 might provide a better indicator of activation [Liu et al., 1996; Deeks et al., 
2004]. However, even when comparing the MFI of CD38 on PBMC from HIV-1 infected 
individuals from both groups of patients and healthy controls, no significant differences were found. 
The increased co-expression of HLA-DR and CD38 on both T-cell subsets from HIV-1
+
 persons, 
and increased expression of HLA-DR, compared to healthy seronegative donors was significant 
even when the population of HIV-1
+
 individuals was more carefully regulated and the subjects had 
significantly higher baseline CD4 T-cell counts, higher nadir CD4 T-lymphocyte counts and had 
been on ART for a longer duration. This suggests that chronic immune activation persists even with 
suppressive ART, which agrees with previous findings in terms of percentage co-expression of both 
markers on CD4 and CD8 T-cell subsets [Hunt et al., 2003], although reports from other groups 
describe a reduction in HLA-DR expression on CD8 T cells to levels approaching those found in 
healthy donors following 7 years of ART [Shou et al., 2011]. It should also be noted that the 
median co-expression of these markers was lower for the seventeen patients assessed for Gag- and 
Nef- specific responses compared to the 23 patients originally phenotyped in this chapter. This 
could be due to significantly longer treatment with ART for these individuals or explained by 
higher peripheral CD4 T-lymphocyte counts and higher nadir CD4 T-cell counts; suggesting better 
immune reconstitution in these patients. 
T-cell immune activation has been linked to declines in CD4 T-lymphocyte numbers and disease 
progression [Hunt et al., 2008; Hazenberg et al., 2003] and a recent study found CD38 to be 
expressed at similar levels in LTNP and patients treated with ART in early HIV-1 infection for a 
237 
 
prolonged period of time [Cellerai et al., 2011]. Furthermore, atypical activation profiles have been 
described (in terms of CD38 and HLA-DR expression) on HIV-1-specific CD8 T cells from HIV-1 
controllers; these cells express low levels of CD38 (similar to levels observed in the total CD8 T-
lymphocyte population) but unusually high levels of HLA-DR (higher than levels observed among 
total CD8 T cells), thus this CD38
low
/HLA-DR
high
 phenotype of HIV-1-specific CD8 T cells may 
characterise cells with an ability to proliferate upon antigenic stimulation and exert effector function 
[Saez-Cirion et al., 2007]. 
HIV-1-infected patients from both groups had significantly greater co-expression of the senescence 
marker CD57 and the apoptosis marker CD95 on both CD4 and CD8 T lymphocytes compared to 
healthy control individuals and this was also true for single positive expression of both of these 
markers on both T-cell subsets. These findings agree with previously published data; the expression 
of CD57 on peripheral T cells was found to be significantly higher on PBMC from HIV-1-infected 
persons compared to healthy seronegative donors and its expression associated with a loss of 
proliferative capacity, increased apoptosis and defective cytokine production [Papagno et al., 2004; 
Brenchley et al., 2003; Palmer et al., 2005]. HIV-1-specific CD8 T cells have been described as 
having an increased sensitivity to CD95/Fas-induced death, particularly in the CD45RA
-
CD62L
-
 
effector memory compartment [Mueller et al., 2001] and the expression of CD95, similar to CD57, 
has been associated with reduced ex vivo survival [Mueller et al., 2001] and impaired cytokine 
production [Betts et al., 2006]. CD8 T cells that are sensitive to CD95/Fas-induced apoptosis may 
be unable to exert a cytotoxic response against HIV-1-infected macrophages and CD4 T cells 
expressing CD95 ligand (CD95L) [Tateyama et al., 2000]. HIV-1 has been found to induce an up-
regulation of CD95L in macrophages, T cells and DC and a role for Nef in the increased expression 
of this ligand on T cells and macrophages has been proposed [Strauss et al., 2009]. It was suggested 
that this up-regulation on APC following infection with HIV-1 may inhibit T-cell activation and 
proliferation and that this may allow HIV-1 to evade the immune response [Strauss et al., 2009]. 
Further understanding and characterisation of these markers in HIV-1 infection is of the utmost 
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importance and perhaps therapies targeting these molecules might help to improve the survival and 
differentiation of HIV-1-specific T cells, thereby enhancing viral clearance. 
CD4 and CD8 T-cell differentiation was characterised based on the expression of the co-stimulatory 
molecules CD27 and CD28 and for both groups of HIV-1
+
 patients, the percentage of expression of 
markers associated with an early T-cell phenotype (CD27
+
CD28
+
) were significantly reduced, and 
the percentage expression of those defining a late differentiation state (CD27
-
CD28
-
) were 
significantly increased, when compared to PBMC from healthy uninfected donors. It is interesting 
to note that the expression of the late phenotype is particularly elevated in the first 23 patients 
investigated; those with lower CD4 T-cell count, lower nadir CD4 T-lymphocyte counts and less 
time on ART. These findings fit with other reports in which chronic progressive HIV-1-infection is 
associated with a CD8 T-cell differentiation that is skewed toward a CD28
-
 TEM population 
[Ellefsen et al., 2002; Downey and Imami, 2010], and this population has been associated with a 
lack of proliferative capacity [Appay et al., 2008]. Similarly, examining CD4 and CD8 T-cell 
differentiation in terms of CCR7 and CD45RA expression, markers associated with a naïve T-cell 
phenotype were significantly reduced and markers associated with a terminally differentiated 
(TEMRA) phenotype were significantly increased in HIV-1
+
 persons compared to healthy controls. 
This partially correlates with previous reports, although these also describe a reduction in the 
central memory subset and an increase in the effector memory subset for CD8 T cells [Ladell et al., 
2008; Downey and Imami, 2010]. There were no significant differences found in the expression of 
PD-1 and PD-L1 on CD4 or CD8 T lymphocytes (or their differentiation subsets) between HIV-1-
infected persons and healthy control individuals. PD-1 expression has been found to correlate with 
plasma viraemia and disease progression [Kaufmann and Walker, 2009; Day et al., 2006] and 
initiation of ART and subsequent control of plasma HIV-1 RNA has been shown to reduce the 
expression of PD-1 on HIV-1-specific CD8 CTL and PD-L1 on PBMC [Kaufmann and Walker, 
2009]. However others reported that PD-L1 levels may not be normalised on ART [Rosignoli et al., 
2007]. It is important to consider that the patients involved in these studies may differ in their 
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clinical characteristics and duration of ART, and that these factors may result in discrepancies in 
such findings. 
There were no significant differences found in CTLA-4 expression on PBMC from HIV-1
+
 persons 
compared to healthy controls. CTLA-4 increases during chronic HIV-1 infection [Leng et al., 
2002], although up-regulation only occurs on CD4 T lymphocytes and has not been described at 
high levels on CTL in HIV-1 infection [Steiner et al., 1999]. Of note, PD-1 is expressed by the 
majority of CD4 T cells that express CTLA-4 [Downey and Imami, 2010] in the context of HIV-1 
infection, and suppressive ART has been found to reduce the expression of this molecule 
[Kaufmann et al., 2007] but levels remained high. Another study found decreased expression of 
PD-1, TIM-3 and CTLA-4 on virus-specific CD4 T cells in patients receiving effective ART but 
they did not look at expression on total peripheral PBMC, nor did they include analysis of healthy 
donors [Kassu et al., 2010]. Percentage expression of TIM-3 was significantly elevated on CD4 T 
cells from HIV-1 infected individuals compared to healthy donors and an increased MFI was 
observed on the CD8 T-lymphocyte population from these same subjects. TIM-3 levels have been 
found to be increased in HIV-1-infected patients with acute or chronic progressing HIV-1 infection 
and this is on both virus-specific and non-specific CD4 and CD8 T cells with impaired responses to 
stimuli; expression was found to be reduced in some, but not all, patients following initiation of 
ART [Golden-Mason et al., 2009; Jones et al., 2008; Downey and Imami, 2010]. Of note, the levels 
of TIM-3 expressed on T lymphocytes from HIV-1-infected patients and healthy donors were very 
low compared to previous publications. 
There were no significant differences in the expression of markers associated with a regulatory T-
cell phenotype in HIV-1
+
 subjects compared to healthy controls and this agrees with another report 
of largely normalized T-regulatory cell frequencies with ART [Presicce et al., 2011]. 
A significantly diminished expression of CD31 was found on CD4 T cells from HIV-1
+
 subjects 
compared to healthy donors. In one study, the proportion of CD4
+
CD45RA
+
CD31
+ 
T cells declined 
with age in both ART-treated HIV-1 infected individuals and in healthy control subjects 
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[Tanaskovic et al., 2010] and no differences were seen in the co-expression of these two markers. 
Higher single expression of CD31 on CD4 T cells from the healthy donors might be in part 
explained by the younger median age of this control group compared to the HIV-1-infected group; 
ideally the two groups would be age-matched to account for phenotypic differences that are seen 
with age [Appay and Sauce, 2008; Tenorio et al., 2009; Cao et al., 2009]. PTK-7, a marker to 
measure circulating CD4
+
 recent thymic emigrants, was found to be expressed at very low levels on 
both T-cell subsets with no significant differences between HIV-1-infected individuals and healthy 
control subjects. The frequency of PTK-7 has been found to be age-dependent with approximately 
10% of CD45RA
high
CD45RO
low
PTK-7
+ 
described in the CD4 T-cell compartment [Haines et al., 
2009] which is considerably more than the percentage expression found in these experiments. 
These results indicate that treatment with ART only serves to partially restore immunophenotypic 
dysfunction seen in chronic HIV-1-infection and that recovery of these parameters is perhaps in part 
better for individuals that have been on ART for longer, with higher CD4 T-cell counts and higher 
nadir CD4 T-lymphocyte counts. 
There were no significant differences found in the immunophenotype of patients classified as Gag- 
and/or Nef-specific responders but trends were noted, such as a tendency for the Nef-specific 
responders to express lower levels of CD38 on CD4 T cells. Increased numbers of patient samples, 
for individuals with closely matched characteristics, defined according to their Gag- or Nef- 
specificity might help to further determine any correlations between functional responses and 
immunophenotype. Understanding the impact of antigen specificity on markers associated with T-
cell dysfunction might provide further insight into targets for immune-based therapies.  
Significant negative correlations were found between CD4 T-cell count and parameters associated 
with chronic immune activation, differentiation, exhaustion and apoptosis, and significant positive 
correlations were found between CD4 T-cell count and nadir CD4 T-lymphocyte count, and 
between CD4 T-cell count and duration of ART. Nadir CD4 T-cell numbers and the duration of 
ART-induced aviraemia have been shown to be important factors for CD4 T-cell recovery [Cellerai 
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et al., 2011]. This emphasises the importance of the timing of ART initiation and duration, 
particularly in the context of immune reconstitution [Koegl et al., 2009] and may provide insights 
into the timing and duration of immune-based therapies in the context of treated HIV-1 infection. 
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Chapter 6 General Discussion 
The work presented in this thesis centres around the investigation of novel immune-based 
therapeutic approaches in treated chronic HIV-1 infection, and further assessment of known 
immunomodulators. There are three clinical trials which are described and which formulate the 
main findings of this thesis. Although there are a number of studies in which rhGH has been 
administered to HIV-1-infected patients on ART, rarely do these studies assess HIV-1-specific 
functional T-cell responses. Most other rhGH trials investigate the impact on the thymus (thymic 
density, TRECs, naïve CD4 T-cell counts), other clinical parameters, and even immune activation, 
highlighting a major strength of the experiments carried out here. 4mg/day rhGH for 12 weeks was 
found to increase proliferative CD4 and IFN-γ-producing CD8 HIV-1-specific T-cell responses, 
although these responses declined with less frequent dosing. The low-dose rhGH study is the first 
study to describe the immunological impact of low-dose, long-term rhGH in treated HIV-1 
infection. Administration of 0.7mg rhGH daily for 40 weeks resulted in increased IFN-γ production 
in response to peptide pools of HIV-1 Gag (both 9mers and 20mers), with a trend toward a 
reduction in activation markers at week 40 compared to baseline for the most robust responder in 
the ELISpot assays. The IMIRC 1003 clinical trial incorporated known immunomodulators 
(therapeutic immunisation, IL-2, GM-CSF and rhGH) in a novel treatment schedule in order to 
induce and sustain desired immunological responses. In this study, the most promising immune 
changes were seen following administration of cytokine and hormone in addition to therapeutic 
immunisation, with increased total CD4 T-cell counts, improved CD4/CD8 T-cell ratios and 
reduced immune activation seen at week 48 compared to baseline. Limitations of this particular 
study were due to problems finding patients who fit the strict enrolment criteria, and 12 were 
enrolled rather than an anticipated 30. The findings described in this thesis could have been 
improved with further investigations which include but are not limited to: HIV-1 proviral DNA 
assessment for the IMIRC 1003 clinical trial samples (to elucidate the effect on the viral reservoir), 
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pentamer/tetramer staining (using HLA-types of the twelve patients; to allow for HIV-1-specific T 
cells to be phenotyped in addition to peripheral T-cell analysis), FoxP3 staining (to further 
determine/confirm the impact of this treatment schedule on regulatory T cells), and greater numbers 
of patients defined as Gag and/or Nef responders (to allow for more accurate correlations of this 
functional parameter with immunophenotype to be made). 
The findings shown here highlight the importance of the development of new, and/or modification 
of existing, immune-based therapeutic approaches in the context of treated chronic HIV-1 infection. 
Even for a carefully defined subset of aviraemic HAART-treated patients, with high CD4 T-cell 
counts and high nadir CD4 T-lymphocyte counts, immune defects were seen to persist for both CD4 
and CD8 T cells. Expression levels of activation markers (HLA-DR, CD38), senescence (CD57), 
co-inhibition (CTLA-4), exhaustion (TIM-3), apoptosis (CD95), and a late (CD27
-
CD28
-
) or 
terminally differentiated (CCR7
-
CD45RA
+
) state were found to be significantly higher in HIV-1-
infected patients compared to healthy seronegative controls. Most HIV-1
+
 persons on ART achieve 
and maintain viral suppression to less than 50 copies/ml plasma HIV-1 RNA [Palmer et al., 2008], 
however abnormally high (CD8
+
HLA-DR
+
CD38
+
) T-cell activation levels persist, despite 
successfully suppressive antiretroviral therapy, compared to healthy controls [Hunt et al., 2003; 
Hunt et al., 2008, Robbins et al., 2009]. The increased translocation of microbial products as a 
result of the compromised gastrointestinal mucosal barrier has been proposed to be a continuous 
trigger of immune activation in chronic HIV-1 infection [Brenchley et al., 2006; Marchetti et al., 
2008]. Microbial translocation has been found to correlate positively with immune activation and 
inversely with immune reconstitution, and although levels (in terms of plasma LPS) are reduced 
with ART, they are not normalised [Brenchley et al., 2006; Jiang et al., 2009; Brenchley & Douek, 
2012]. This hyper-activation of the immune system may be associated with, and causally related to, 
the higher than expected risk of premature heart disease, kidney disease, liver disease, bone disease, 
cancer and neurocognitive dysfunction in ART-treated HIV-1-infected persons compared to healthy 
controls [Volberding & Deeks, 2010]. Interestingly, sooty mangabeys, natural hosts for SIV 
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infection, do not develop AIDS despite high levels of viral replication (and limited virus-specific 
CD8 T-cell responses), which has been attributed to lower levels of immune activation and 
senescence than that observed in pathogenic SIV or HIV infections [Silvestri et al., 2003; Pandrea 
et al., 2008]. Immune activation is reportedly lower in HIV-1-infected patients that are able to 
suppress viraemia in the absence of ART (elite controllers) when compared to non-controllers 
(patients not on ART with detectable plasma HIV-1 RNA) [Hunt et al., 2008; Owen et al., 2010], 
but this reduced activation is still higher than in seronegative controls [Hunt et al., 2008]. In one 
study, HIV-1 controllers were found to have higher levels of activated CD8 T cells (as measured by 
co-expression of HLA-DR and CD38) compared to ART-treated aviraemic patients [Hunt et al., 
2008], while another reported no difference in activation between these groups, although it is 
important to note that this second study calculated expression of CD8
+
IFN-γ+HLA-DR+CD38+ T 
cells following stimulation with HIV p55 [Owen et al., 2010]. They also reported fewer recently 
proliferated HIV-1-specific CD4 T cells from elite controllers compared to patients on suppressive 
ART, as measured by expression of CD4, IFN-γ and Ki-67 subsequent to stimulation with HIV p55 
[Owen et al., 2010]. Elite controllers are unable to completely clear HIV-1 [Hatano et al., 2009], 
and it has been suggested that these individuals, as well as those identified as LTNP, will eventually 
progress to AIDS [Deeks & Walker, 2007; Hunt et al., 2008; Mandalia et al., 2012]. Thus, there is 
evidence that even with viral control (both in the presence and absence of ART) a means of 
reducing immune activation in HIV-1 infection is required. 
Attempts have been made using ART intensification to reduce immune activation and low-level 
viraemia in ART-treated HIV-1-infected patients; however this approach did not decrease levels of 
plasma HIV-1 RNA (as measured using a single copy sensitivity assay) for efavirenz, 
lopinavir/ritonavir, or atazanavir/ritonavir intensified regimens [Dinoso et al., 2009], or following 
raltegravir intensification [Gandhi et al., 2010]. Reductions in immune activation were not observed 
when comparisons were made between patients that had received raltegravir intensification versus 
those that didn’t [Buzon et al., 2010]. Further, enfuviritide therapy (two reverse transcriptase 
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inhibitors and a ritonavir-boosted protease inhibitor) did not result in a depletion of the latent viral 
reservoir, nor did it result in a reduction in immune activation [Gandhi et al., 2010]. One study, 
however, did report a decrease in HIV-1 RNA in the ileum of subjects receiving a raltegravir-
containing intensification (with no impact on HIV-1 RNA from plasma, PBMC, duodenum, colon 
or rectum), as well as trends toward a reduction in CD4 and CD8 T-cell activation at these sites 
(although these were not statistically significant) [Yukl et al., 2010]. Optimisation of ART has 
included use of the CCR5-antagonist Maraviroc; in a phase II randomised clinical trial 
(MOTIVATE); significant increases in CD4 T-cell counts and reduced plasma HIV-1 RNA were 
observed in pre-treated patients that received Maraviroc in addition to ART [Gulick et al., 2008], 
and Maraviroc has been associated with decreased immune activation [Wilkin et al., CROI, 2010; 
Wilkin & Gulick, 2012]. 
Therapeutic approaches targeting the gut-associated lymphoid tissue (GALT), where CD4 T-cell 
numbers and TH17 cells are not restored with ART, have been proposed as a means of reversing the 
damage to the gut mucosa and minimising the translocation of microbial products, factors thought 
to play a role in the persistent inflammation and immune activation in chronic HIV-1 infection 
[Hunt, 2010]. Pigtail macaques infected with SIV were found to have increased reconstitution of 
CD4 T cells, increased polyfunctionality, and reduced T-cell turnover (as measured by Ki-67 
expression on CD4 memory T cells) in the colon when probiotics were given in combination with 
antiretroviral treatment [Klatt et al., CROI, 2012]. A phase II trial is currently recruiting ART-
treated patients with incomplete CD4 T-cell recovery in order to determine the effects of the 
antibiotic rifaximin on microbial translocation and systemic immune activation (clinicaltrials.gov, 
NCT01466595). Evidence from pigtail macaques infected with SIV that received rifaximin and (an 
anti-inflammatory drug) sulfasalazine, demonstrated that together these agents reduced microbial 
translocation (as measured by sCD14), reduced viral load, lowered levels of immune activation 
(CD8
+
HLA-DR
+
Ki-67
+
) and inflammation (IL-6 and RANTES), and decreased mucosal CD4 T-cell 
depletion during acute SIV infection (compared to untreated controls) [Pandrea et al., CROI, 2012]. 
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Patients with HIV-1 and CMV co-infection treated with valganciclovir showed undetectable levels 
of CMV DNA following eight weeks of treatment, and significantly greater reductions in CD8 T-
cell activation (in terms of percentage HLA-DR and CD38 co-expression) compared to placebo-
treated patients, although these individuals presented with incomplete CD4 T-cell recovery on ART 
and immune activation was thought to arise as a result of CMV replication [Hunt et al., 2011]. 
Administration of hydroxychloroquine to patients defined as immunologic non-responders (CD4 T-
cell counts <200 cells/µl blood, CD4 T-cell increase <5% in 12 months prior to study initiation) 
despite suppressive ART, resulted in reduced CD4 T-cell proliferation (Ki-67), decreased CD8 T-
cell activation (HLA-DR
+
, CD38
+
), lower levels of plasma LPS and a decline in pro-inflammatory 
cytokines (IL-6 and TNF-α), as well as increased CD4 T-cell percentages [Piconi et al., 2011]. In 
another study, chloroquine in untreated subjects resulted in reduced CD4 and CD8 T-cell 
proliferation (as measured by Ki-67) and reduced CD8 T-cell activation (again, as determined by 
co-expression of HLA-DR and CD38) [Murray et al., 2010], although it is thought to be more 
promising as an adjunctive therapy to ART [Ries et al., 2012]. Chloroquine interferes with 
endosomal acidification, and in cell culture it was found to reduce IFN-α production by HIV-1 and 
HIV-1-infected cells, lower the expression of CD38 on CD8 T cells, and block IDO and PD-L1, 
two negative regulators of T-cell responses [Martinson et al., 2010].  
The patients described here who received 40 weeks of low-dose rhGH showed a trend toward a 
reduction in the expression of HLA-DR and CD38 (both in terms of co-expression and single 
expression, looking at percentage expression and MFI) on both CD4 and CD8 T cells compared to 
baseline. In another study in which rhGH was administered daily to ART-treated patients for one 
year (3.0mg daily for 6 months and 1.5mg/day for 6 months), significant reductions in the 
percentage co-expression of HLA-DR and CD38 on both CD4 and CD8 T lymphocytes were seen 
compared to placebo-treated controls [Napolitano et al., 2008]. Individuals in the IMIRC 1003 trial 
who received IL-2, GM-CSF and rhGH (with or without immunisation) had marked increases in the 
percentage co-expression of HLA-DR and CD38 at week 2 following administration of the 
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cytokines. However, by week 48 these individuals showed significant reductions in the percentage 
expression of CD38 on both CD4 and CD8 T cells (and a decrease in CD38 MFI on CD4 T 
lymphocytes) compared to baseline. These results provide further evidence that immune-based 
therapy in the context of treated HIV-1 infection may serve to reduce immune activation further to 
the effects of ART alone. 
Although there was no marked impact of rhGH administration to patients in the IMIRC trial 
treatment schedule, particularly looking at the analysis of markers associated with recent thymic 
emigration (CD31 and PTK-7), it cannot be said that this immunomodulator did not contribute to 
the reduced expression of activation and senescence markers seen at week 48 in patients that 
received cytokine and hormone therapy. It is possible that the duration of rhGH treatment (five 
days) was not long enough to induce significant HIV-1-specific responses, whereas the two rhGH 
trials described in this thesis showed improved virus-specific functionality following 12 and 40 
weeks of rhGH therapy. The incomplete restoration of the immune system with ART has been 
partly attributed to thymic dysfunction and an inability to produce new CD4 T cells [Valdez, 2002; 
Douek et al., 1998]. rhGH treatment in addition to ART has been shown to increase thymic density 
[Napolitano et al., 2002; Napolitano et al., 2008; Hansen et al., 2009; Smith et al., 2010], elevate 
the frequency of circulating TREC within PBMC [Napolitano et al., 2008; Hansen et al., 2009; 
Smith et al., 2010] and increase the number of naïve CD4 T cells [Pires et al., 2004b; Napolitano et 
al., 2008]. Following 12 weeks of rhGH, there were no significant changes in TREC levels; this 
might be reflective of unaltered thymic output or it may be due to an increased division rate of the 
naïve T-cell pool [Herasimtschuk et al., 2008]. Thymic density, TREC levels and naïve T-cell 
numbers were not assessed in the IMIRC 1003 trial following rhGH administration; however, 
assessment of naïve T cells based on their immunophenotpye (using CCR7 and CD45RA co-
expression) did not show any impact at week 4. The duration of rhGH treatment may not have been 
enough to elicit an increase in the number of naïve T cells, or transient increases may have occurred 
which were then absent at week 4 (samples were not taken at week 3). Another attractive adjuvant 
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therapy in treated HIV-1 infection is recombinant human interleukin-7 (rhIL-7). IL-7 
responsiveness is largely dependent upon the presence or absence of the IL-7 receptor (IL-7R) that 
is found on most mature T cells, and it plays a crucial role in T-cell homeostasis [Park et al., 1990], 
which includes promoting the survival of naïve T cells [Schluns et al., 2000]. HIV-1-infected 
individuals have higher levels of IL-7 and reduced levels of IL-7R compared to healthy controls 
[Llano et al., 2001; Rethi et al., 2005], and these levels are not restored even after seven years of 
ART [Shou et al., 2011]. Phase I and II studies using rhIL-7 in HIV-1-infected patients described it 
to be well-tolerated but caused a transient increase in viral replication; an effect that is not seen 
when it is used in conjunction with ART [Sereti et al., 2009; Levy et al., 2009]. rhIL-7 
administration was found to significantly increase both naïve and central memory CD4 T-cell 
counts, in a dose-dependent manner, elevate levels of RTE, increase numbers of TREC, and 
increase naïve CD4 T-cell counts, an indication of enhanced thymopoiesis [Sereti et al., 2009; Levy 
et al., 2009; Sportes et al., 2008; Rosenberg et al., 2006; Okamoto et al., 2002]. Preliminary data 
from the INSPIRE 2 study indicate that IL-7 administration may increase the expression of gut-
homing receptors (α4β7 integrin) and decrease the expression of PD-1 on peripheral CD4 and CD8 
T cells [Sereti et al., CROI, 2011]. The increased homing potential may account for the induced 
expansion of CD4 T cells in the gut mucosa following treatment with IL-7, and these CD4 T 
lymphocytes were predominantly of a central memory phenotype (CD45RO
+
CD27
+
) [Sereti et al., 
CROI 2012]. 
Patients that received both the pharmacological dose and the longer term physiological dose of 
rhGH demonstrated increased HIV-1-specific T-cell responses whereas patients on the IMIRC 1003 
trial only showed occasional alterations in T-cell functionality throughout the course of the study. 
The production of IL-2 and IL-15 is defective in HIV-1-infected patients [Sirskyj et al., 2008], and 
PBMC from immunologic non-responders (where CD4 T-cell recovery does not occur with ART) 
stimulated with PHA have been shown to produce less IL-2 than PBMC from HIV-1
+
 subjects with 
higher CD4 T-lymphocyte counts [Erikstrup et al., 2010]. Data from one group found that LTNP 
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had a greater recovery of CD8 T-cell polyfunctionality, proliferation and cytotoxicity when 
compared to aviraemic subjects in which ART had been initiated in the chronic stage of infection 
[Migueles et al., 2009]. Another study found that patients treated with ART in early HIV-1 
infection had strong polyfunctional CD4 and CD8 T-cell responses with low perforin expression in 
virus-specific CD8 T cells, similar to responses from patients in their LTNP cohort; however, a 
higher breadth of response and a trend towards a higher magnitude of response was seen 
particularly for Gag-specific CD8 T cells from LTNP [Cellerai et al., 2011]. Slow, or non-
progressive HIV-1 infection has been found to be associated with polyfunctional HIV-1-specific T-
cell responses [Betts et al., 2006; Zimmerli et al., 2005; Almeida et al., 2007; Daucher et al., 2008], 
although the role of this polyfunctionality in viral control has been the subject of much debate 
[Cellerai et al., 2011]. HIV-2-infected patients, who have an overall better prognosis than subjects 
with HIV-1, have been shown to possess polyfunctional T-cell profiles [Duvall et al., 2008], 
lending weight to the idea that polyfunctionality is indeed imperative. A recent re-evaluation of the 
cellular correlates of protection [Makedonas & Betts, 2011], particularly in terms of the design of a 
prophylactic HIV-1 vaccine, and taking into consideration the results from the Merck STEP trial 
[Buchbinder et al., 2008] and the Thai RV144 trial [Rerks-Ngarm et al., 2009], has speculated on 
the parameters of CD8 T-cell phenotype and function that need to be considered. The authors 
highlight the necessity for, at the very least, a high frequency of effector CD8 T cells present at the 
site of infection (the mucosa) with moderate cytolytic ability, and they propose a panel of T-cell 
markers that may have a role, either alone or in combination, in defining a correlate of protection 
against HIV-1, and that may be used to assess potential HIV-1 vaccine candidates (Table 6.1) 
[Makedonas & Betts, 2011]. 
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Table 6.1 T-cell markers that may potentially correlate with protection against HIV-1 infection. 
(Taken from Makedonas & Betts, 2011). 
T-cell aspect Markers 
Memory phenotype CCR7, CD27, CD28, CD45RA/RO, CD57, CD62L 
Cytokine production and 
Cytotoxicity 
IFN-γ, TNF-α, IL-2, IL-4, IL-10, 1L-12, IL-17, IL-23 
Perforin (new and granule-associated) 
Granzyme A/B/K, Granulysin 
Miscellaneous 
Degranulation (CD107a exposure) 
MIP-1α/β, proliferation (CFSE dilution) 
Transcriptional control T-bet, Eomesodermin, BLIMP-1, GATA, ROR-γT 
Activation status HLA-DR, Ki-67, bcl-2, CD38, CD69, CD95 
Exhaustion PD-1, CD160, Lag-3, 2B4, TIM-3 
Tissue trafficking α4β7, CCR5, CCR9, CCR10, CD161 
Regulatory function CTLA-4, FoxP3, GITR, CD25, CD39, CD73, TGF-β 
 
Analysis of frozen PBMC from the IMIRC trial could further elucidate the impact of the 
immunotherapy treatment schedule, particularly on CD8 T-cell responses. A six-colour panel was 
designed and samples run on an LSR II for all phenotypic experiments described in this thesis. 
Another laser has since been added to the flow cytometer, allowing for the design of ten colour 
panels. Assessing multiple parameters by increasing the number of antibodies per tube allows for 
the distinctive co-expressions of markers to be determined, for example, one study compared the 
expression of CTLA-4, PD-1 and TIM-3 on HIV-1-specific T cells from treated and untreated HIV-
1-infected patients, and further determined the IFN-γ and IL-2-producing capability of these cells 
(these were significantly lower for ART-treated patients compared to viraemic untreated 
individuals) [Kassu et al., 2010]. Another group investigated the co-expression of CD38 and PD-1 
on virus-specific CD8 T cells (and found levels to be higher in HIV-1 progressors compared to 
HIV-1 controllers, and that levels decreased following initiation of ART) [Vollbrecht et al., 2010]. 
Non-progressive HIV-1 infection has been found to be associated with Nef-specific CD8 T cells 
that are CD45RA
+
 and secrete MIP-1β but not IFN-γ [Dembek et al., 2010]. Future work on the 
IMIRC 1003 cryopreserved PBMC samples could thus include the evaluation of HIV-1-specific T-
cell responses and an expanded antibody panel which includes intracellular markers in addition to 
the surface markers. HLA-typing has been performed for all twelve individuals enrolled on the trial 
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(the results of which are presented in Chapter 4), and pentamer/tetramer staining would allow for 
more concise evaluation of the HIV-1-specific T cells. A long-lived memory T-cell population with 
an enhanced capacity for self-renewal and the ability to become central memory, effector memory 
and effector T cells was recently described, and these were termed memory stem T cells (TSCM) 
[Gattinoni et al., 2011]. These TSCM cells had a phenotype characteristic of naïve T cells (CD45RO
-
CCR7
+
CD45RA
+
CD62L
+
CD27
+
CD28
+
IL-7Rα+), but displayed functional attributes of memory 
cells (they expressed large amounts of CD95, IL-2Rβ, CXCR3 and LFA-1) and compared with 
known memory populations, they had increased proliferative capacity and more efficiently 
reconstituted immunodeficient hosts, however, this profile remains to be elucidated in HIV-1 
infection and may be relevant in terms of vaccine design and T-cell therapies [Gattinoni et al., 
2011]. One emerging technology that allows a very large number of parameters to be 
simultaneously measured at a single cell level, thus making it possible to more easily evaluate these 
complex T-cell profiles, is mass cytometry. Instead of fluorescent dyes, mass cytometry joins rare-
earth metals to antibodies and eliminates the need for the calculation of spectral overlap 
(compensation) and has no issues with cell-dependent background signal [Bendall et al., 2011]. 
The viral inhibition assay, which measures CD8 T-cell-mediated inhibition of HIV-1 replication 
using autologous T cells and replication competent viruses (including primary isolates and lab-
adapted strains) and does not require knowledge of HLA-type, has been proposed as an 
immunogenicity assay to test potential HIV-1 vaccine candidates [Spentzou et al., 2010]. This cell-
mediated inhibition of HIV-1 was found to correlate with CD107a or MIP-1β expression from HIV-
1-specific T cells from chronically infected virus controllers [Freel et al., 2010]. The development 
and optimisation of assays that identify antiviral CD8 T-cell responses, is key, not only in terms of 
assessing HIV-1 prophylactic vaccines, but also in the evaluation of immune-based therapies. The 
results of such experiments on samples from ART-treated chronically HIV-1-infected persons have 
been mixed; one study found that CD8 T cells from these individuals were able to efficiently inhibit 
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viral replication [Freel et al., 2010], while another study reported that this CD8 T-cell-mediated 
viral inhibition was not preserved in treated aviraemic subjects [Spentzou et al., 2010]. 
Immune-based therapeutic approaches in treated, chronic HIV-1 infection have a number of targets, 
some of which have been discussed: improvement in the integrity of the gut mucosa and GALT, 
enhanced thymic output or reversal of thymic involution, increased production of naïve CD4 T 
cells, increased T-cell polyfunctionality, and reduced immune activation, immune senescence and 
exhaustion. A crucial parameter that must be considered is the impact of such immunotherapies on 
the latent HIV-1 reservoir. Studies of ART intensification found that it was unable to eradicate 
HIV-1 from the stable reservoir [Gandhi et al., 2010], and administration of rhGH in treated HIV-1 
infection had no impact on the levels of proviral DNA [Herasimtschuk et al., 2008]. HIV-1
+
 
patients on suppressive ART have detectable levels of HIV-1 DNA in PBMC, as well as measurable 
levels of HIV-1 DNA and HIV-1 RNA in the rectal mucosa-associated lymphoid tissue [Anton et 
al., 2003]. One study comparing HIV-1 RNA and DNA levels in the GALT found HIV-1 
controllers to have lower levels than HIV-1 non-controllers, but similar levels to subjects on 
suppressive ART, suggesting that lymphoid tissues are an active viral reservoir even for patients 
that are able to maintain low plasma viraemia in the absence of ART [Yukl et al., CROI, 2012]. 
Initiation of ART during the early stages of HIV-1 has been associated with a decrease in the 
residual viral reservoir, comparable to levels found in LTNP, an effect that is not seen when ART is 
initiated during chronic HIV-1 infection [Pires et al., 2004a]. The major cellular reservoirs for HIV-
1 have been found to be the central memory (TCM; CD45RA
-
CCR7
+
CD27
+
) and the transitional 
memory (TTM; CD45RA
-
CCR7
-
CD27
+
) CD4 T cells [Chomont et al., 2009]. The TCM cells were 
shown to primarily harbour this reservoir for ART-treated HIV-1
+
 patients with higher CD4 T-cell 
counts, whereas for aviraemic patients on ART with poor CD4 T-lymphocyte reconstitution, HIV-1 
proviral DNA resided mainly in the TTM cells, which persisted through IL-7-mediated homeostatic 
proliferation [Chomont et al., 2009]. LTNP individuals with the protective HLA-B*27/B*57 alleles 
have recently been described as having lower levels of cell-associated HIV-1 DNA in their CD4 
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TCM cells compared to LTNPs without these alleles [Descours et al., 2012]. This reduced viral 
reservoir was found to correlate with preserved CD4 TCM cell numbers, the magnitude of HIV-1 
Gag-specific CD8 T cells, and lower levels of activation on memory CD4 T cells [Descours et al., 
2012]. Thus it would be of considerable interest to elucidate the impact of immune-based therapy 
on the viral reservoir in this particular subset; to determine if there is the potential to boost the 
immune system in chronic HIV-1 infection to more closely resemble that of a LTNP. 
For patients enrolled on the IMIRC 1003 study who received IL-2, GM-CSF and rhGH in addition 
to therapeutic immunisation, significantly elevated CD4/CD8 T-cell ratios were seen at week 48 
compared to baseline. CD4/CD8 T-lymphocyte ratios in patients on suppressive ART have been 
reported to inversely correlate with levels of HIV-1 proviral DNA [Boulassel et al., 2012], 
suggesting that this combination of immunomodulatory agents in addition to ART may have 
reduced the latent viral reservoir in these patients. Future work would include assessment of 
proviral DNA levels at baseline and at week 24 (and/or at week 48) of the study, using 
cryopreserved PBMC samples, in order to determine the impact of this treatment schedule on the 
HIV-1 latent reservoir, expansion of the phenotypic panel to include markers to assess TSCM and 
TTM cells in addition to TCM and TEM profiles. To this effect, analysis of plasma samples could be 
measured for LPS or sCD14 in order to determine the effect of these immunotherapies on microbial 
translocation, especially as the levels of circulating LPS in the first years of chronic HIV-1 infection 
have been found to be a strong indicator of disease progression [Marchetti et al., 2011]. 
One compound that has been described as able to activate the latent viral reservoirs in HIV-1 
infection, without global T-cell activation, is the histone deacetylase (HDAC) inhibitor 
suberoylanilide hydroxamic acid (SAHA, vorinostat); a drug approved for the treatment of 
cutaneous T-cell lymphoma in patients with progressive, persistent, or recurrent disease [Edelstein 
et al., 2009]. Patients on fully suppressive ART that received a single dose of vorinostat 
demonstrated a marked increase in HIV-1 RNA expression in highly purified resting CD4
+
 T cells 
[Archin et al., CROI, 2012]. In vitro studies have reported that stimulation of HIV-1-specific CTL 
254 
 
may be essential for latent viral eradication, as resting CD4 T cells (in which latency had been 
reversed with SAHA), were not killed by viral cytopathic effects, nor by the host CTL response 
following viral reactivation [Shan et al., CROI, 2012]. Following the case of Timothy Ray Brown, 
the leukaemia patient who was the first person to ever be cured of HIV-1 infection [Allers et al., 
2011], new lines of investigation have opened up in search of a cure for HIV-1, and although a 
number of methodologies are being tested, it is generally believed that a combinatorial approach, 
particularly one that targets the viral reservoir, is most likely to be successful [Cairns, 2011; Cairns, 
2012]. The potential to induce a functional cure is currently being explored by treating patients in 
very early acute HIV-1 infection with a combination of three or five antiretroviral drugs for two 
years, followed by ART cessation; with the aim to induce remission at acute infection [Lafeuillade, 
2012]. 
Continued investigations into immunomodulatory agents that might purge the HIV-1 reservoir are 
warranted. The development and testing of new therapies, or the modification of existing ones to 
reduce chronic immune activation and/or inflammation, to decrease immunosenescence, and to 
reverse HIV-1-specific T-cell dysfunction have the potential to improve quality of life and delay the 
time to progression in chronic treated HIV-1 infection [Richman et al., 2009]. Such studies will 
form an essential foundation for large phase II/III immunotherapy trials with analytical treatment 
interruption, in the UK and elsewhere in the world. There is the potential for successful 
immunotherapy to be followed by the removal of ART with long periods of self-sustained low 
viraemia, and such strategies have a clear patient benefit. 
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Appendix 
Appendix 1 Baseline values for IMIRC 1003 clinical trial 
The statistical analysis for Chapter 4 (the IMIRC 1003 trial) looked at changes from baseline. Thus, 
here the baseline values are documented, and these include baseline patient characteristics, baseline 
ELISpot responses and baseline phenotypic values (both percentage expression and MFI). 
Appendix Table 1 Baseline patient characteristics for the twelve IMIRC 1003 study participants. 
Cell counts are in cells per µl blood and HIV-1 RNA is per ml plasma. 
 
Short 
code 
Group 
CD3 
count 
CD3 
% 
CD19 
count 
CD19 
% 
CD4 
count 
CD4 
% 
CD8 
count 
CD8 
% 
CD56 
count 
CD56 
% 
ISUM 
CD4: 
CD8 
Ratio 
HIV-1 
RNA  
R771 1 1652 79.7 304 14.1 884 44.4 659 33.1 88 4.1 2044 1.3 <50 
B784 1 2887 84 304 8.8 1332 39 1471 43.1 161 4.6 3352 0.9 <50 
G739 1 1107 81.6 145 10.5 534 40.1 496 37.2 86 6.3 1338 1.1 <50 
P087 2 1862 81.5 169 7.6 731 31.4 1158 49.8 225 10.1 2256 0.6 <50 
C789 2 1356 74.8 229 12.6 535 29.8 642 35.7 108 5.9 1693 0.8 <50 
L043 2 2204 91.1 76 3.2 782 31.8 1416 57.6 107 4.5 2387 0.6 <50 
C319 2 2430 80.2 375 12.9 1077 34.2 1543 49 188 6.4 2993 0.7 <50 
F810 3 1255 87.8 65 4.5 582 40.6 710 49.5 87 6.1 1407 0.8 <50 
O523 3 1514 82.4 187 10.3 892 47.6 673 35.9 116 6.4 1817 1.3 <50 
S648 3 1664 62.8 268 9.9 578 22.4 962 37.2 704 25.9 2636 0.6 <50 
C241 3 957 67.7 158 11.3 466 32.5 505 35.2 258 18.5 1373 0.9 <50 
P054 3 2066 78.6 500 18.6 840 32.8 1168 45.6 73 2.7 2639 0.7 <50 
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Appendix Table 2 Baseline ELISpot responses to peptide pools from NIBSC. 
IFN-γ, IL-2, IL-4 and perforin baseline values are shown here as spot forming cells per million PBMC, and include 
responses to TCM and PHA. 
 
Short  
code 
Group IFNg_TCM IFNg_p17 IFNg_p24 IFNg_Nef IFNg_Tat IFNg_Rev IFNg_PHA 
R771 1 0 66 466 14 52 0 1584 
B784 1 2 206 386 302 22 0 1726 
G739 1 2 24 76 204 12 2 1410 
P087 2 14 6 72 196 0 14 420 
C789 2 14 6 8 250 20 22 1600 
L043 2 0 2 676 68 0 36 414 
C319 2 0 6 22 66 0 2 792 
F810 3 12 18 334 20 0 2 1704 
O523 3 4 12 44 576 62 30 282 
S648 3 44 358 382 262 154 0 1568 
C241 3 164 162 916 166 544 98 1740 
P054 3 0 296 100 454 42 34 1762 
         
Short  
code 
Group IL-2_TCM IL-2_p17 IL-2_p24 IL-2_Nef IL-2_Tat IL-2_Rev IL-2_PHA 
R771 1 0 6 34 2 0 2 418 
B784 1 2 136 168 18 2 2 438 
G739 1 4 2 14 10 2 0 212 
P087 2 6 20 10 4 4 2 200 
C789 2 2 4 0 8 2 2 408 
L043 2 0 96 24 2 0 0 254 
C319 2 0 50 0 0 10 0 24 
F810 3 2 0 26 8 0 0 412 
O523 3 6 18 72 24 6 2 1600 
S648 3 0 6 54 10 10 0 506 
C241 3 0 4 30 8 0 4 1652 
P054 3 0 412 8 0 0 0 212 
         
Short  
code 
Group IL-4_TCM IL-4_p17 IL-4_p24 IL-4_Nef IL-4_Tat IL-4_Rev IL-4_PHA 
R771 1 0 0 26 28 18 48 212 
B784 1 6 12 0 4 6 0 394 
G739 1 0 0 10 12 34 8 770 
P087 2 8 2 2 4 10 4 374 
C789 2 0 6 4 4 6 4 418 
L043 2 0 0 2 0 0 0 56 
C319 2 0 16 0 0 0 0 2 
F810 3 0 14 14 12 8 14 462 
O523 3 10 10 12 94 4 14 904 
S648 3 0 2 0 0 2 0 232 
C241 3 0 0 2 0 0 0 1186 
P054 3 0 210 0 0 10 10 60 
         
Short  
code 
Group PER_TCM PER_p17 PER_p24 PER_Nef PER_Tat PER_Rev PER_PHA 
R771 1 22 82 74 20 66 72 236 
B784 1 8 12 6 6 22 2 210 
G739 1 4 12 2 8 106 4 50 
P087 2 6 12 10 6 300 12 6 
C789 2 200 390 210 546 232 148 414 
L043 2 0 16 38 12 24 54 2 
C319 2 0 22 0 40 40 26 0 
F810 3 56 46 74 58 48 108 850 
O523 3 12 4 14 0 32 10 6 
S648 3 122 118 34 188 158 20 24 
C241 3 60 222 104 16 226 130 186 
P054 3 152 256 156 208 172 228 220 
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Appendix Table 3 Baseline ELISpot responses to peptide pools from FIT Biotech. 
IFN-γ, IL-2, IL-4 and perforin baseline values are shown here as spot forming cells per million PBMC. 
 
Short  
code 
Group IFNg_RevSub IFNg_NefSub IFNg_TatSub IFNg_p17p24sub IFNg_CTLsub 
R771 1 0 0 4 182 2 
B784 1 2 358 724 362 120 
G739 1 16 270 12 162 10 
P087 2 6 222 6 100 122 
C789 2 54 90 24 72 164 
L043 2 8 162 10 734 0 
C319 2 0 0 2 44 4 
F810 3 14 48 8 372 72 
O523 3 16 506 28 48 6 
S648 3 68 200 240 932 160 
C241 3 154 152 116 1044 392 
P054 3 10 422 6 178 24 
       
Short  
code 
Group IL-2_RevSub IL-2_NefSub IL-2_TatSub IL-2_p17p24sub IL-2_CTLsub 
R771 1 0 2 8 6 4 
B784 1 2 56 14 74 26 
G739 1 4 0 2 2 2 
P087 2 2 2 18 14 6 
C789 2 0 4 0 2 0 
L043 2 0 4 2 28 4 
C319 2 0 0 0 0 0 
F810 3 0 0 4 18 0 
O523 3 14 12 10 30 8 
S648 3 2 6 10 134 6 
C241 3 4 12 0 10 6 
P054 3 0 0 0 0 0 
       
Short  
code 
Group IL-4_RevSub IL-4_NefSub IL-2_TatSub IL-4_p17p24sub IL-4_CTLsub 
R771 1 2 0 0 2 0 
B784 1 2 14 6 10 14 
G739 1 16 14 14 18 4 
P087 2 2 14 2 2 0 
C789 2 14 18 0 4 6 
L043 2 0 0 0 0 0 
C319 2 0 0 4 2 2 
F810 3 20 28 20 0 2 
O523 3 2 2 2 2 0 
S648 3 0 2 2 0 0 
C241 3 2 2 0 0 8 
P054 3 0 0 0 2 0 
       
Short  
code 
Group PER_RevSub PER_NefSub PER_TatSub PER_p17p24sub PER_CTLsub 
R771 1 34 68 76 48 136 
B784 1 6 16 10 2 4 
G739 1 8 4 10 2 0 
P087 2 52 24 18 26 8 
C789 2 170 244 240 192 640 
L043 2 46 44 40 56 50 
C319 2 14 12 0 10 16 
F810 3 68 70 38 40 58 
O523 3 10 2 2 12 2 
S648 3 40 26 40 4 80 
C241 3 224 202 248 14 48 
P054 3 236 266 196 280 258 
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Appendix Table 4 Baseline phenotype in terms of percentage expression. 
 
Short  
code 
Group 
CD4+ 
HLADR+ 
CD38+ 
CD4+ 
HLADR+ 
CD4+ 
CD38+ 
CD4+ 
CD57+CD95+ 
CD4+ 
CD57+ 
CD4+ 
CD95+ 
R771 1 4.6 10 71.8  4.6 42 
B784 1 4.8 12.6 52.7 11.8 12.5 56.7 
G739 1 4.2 11.6 36.6 12.1 12.7 79.5 
P087 2 3.3 9.1 32.6 4.7 5.1 81.2 
C789 2 3.8 11 49.8 3 3.4 72.5 
L043 2 5.1 15.2 45.8 12 12.4 68.3 
C319 2 2.6 11.9 36.9 10.6 11.5 63 
F810 3 4.8 9.2 59.7 10.7 11.1 48.1 
O523 3 2.4 6.6 46.2 1.2 1.5 65.7 
S648 3 4.4 10.5 52.7 11.4 11.9 61.5 
C241 3 3.8 11 49.8 3 3.4 72.5 
P054 3 3.4 6.1 66.3 11.3 12.1 45.7 
        
Short  
code 
Group 
CD4+ 
CD27+CD28+ 
CD4+ 
CD27-
CD28+ 
CD4+ 
CD27-
CD28- 
CD4+ 
CD27+ 
CD4+ 
CD28+ 
CD4+ 
CD45RO+CD25+ 
R771 1 91.8 3.1 4.3 92.7 94.8 18.6 
B784 1 78.6 7.9 13.1 79 86.5 23.8 
G739 1 72.6 8 18.4 73.6 80.6 42.5 
P087 2 85.8 7.5 6.3 86.2 93.3 33.4 
C789 2 65.1 5.3 27.4 67.4 70.5 13.3 
L043 2 77.3 6.7 14.2 79 84.1 20.6 
C319 2 80 3.3 16.3 80.3 83.3 41 
F810 3 78.5 5.7 15.5 78.9 84.2 20.1 
O523 3 95.4 2.1 0.2 97.7 97.4 32.3 
S648 3 76.4 9 13.4 77.6 85.4 20 
C241 3 85.3 7.9 6.5 85.5 93.3 38.3 
P054 3 83.8 3.3 12.4 84.3 87.2 14 
        
        
Short  
code 
Group 
CD4+ 
CD45RO+ 
CD25high 
CD4+ 
CD25+ 
CD4+ 
CD45RO+ 
CD4+ 
CCR7+CD45RA+ 
CD4+ 
CCR7+CD45RA- 
CD4+ 
CCR7-CD45RA- 
R771 1 0.9 35.3 33.2 48.8 35.9 11.1 
B784 1 2.8 34.9 46.5 38.2 27.4 27.2 
G739 1 2.6 51.9 67.2 16.1 41 33.3 
P087 2 2.1 39.3 72.6 16.2 53.6 26.1 
C789 2 0.6 17.8 42.7 25.4 26 26.7 
L043 2 2.8 23.3 58.1 25.9 36.5 26.6 
C319 2 2 51.1 65.9 23.9 46.6 27.7 
F810 3 1.1 32.6 36.1 45.2 28.4 16.7 
O523 3 1.1 46.5 55.5 28.7 52.5 16.1 
S648 3 1.5 37.7 29.4 47.8 9.9 15.9 
C241 3 2.7 50.7 61.6 22.6 49.1 26.3 
P054 3 2.6 23.6 37.5 49.7 27.7 18.3 
        
        
Short  
code 
Group 
CD4+ 
CCR7-
CD45RA+ 
CD4+ 
PD1+ 
CD4+PDL1+ 
CD4+ 
CCR7+CD45RA+ 
PD1+ 
CD4+ 
CCR7+CD45RA- 
PD1+ 
CD4+ 
CCR7-CD45RA- 
PD1+ 
R771 1 4.2 57.4 4.1 44 68.2 86.8 
B784 1 7.2 46.8 14.2 25.6 51.7 77.3 
G739 1 9.6 54.1 9.1 34.2 56.6 66.5 
P087 2 4.1 66.5 18.6 38.1 65.7 82.2 
C789 2 21.9 61.9 17.3 34.5 63.5 81.2 
L043 2 11 39.8 14.2 18 43 62.3 
C319 2 1.9 25.3 8.9 8.8 22.8 42.5 
F810 3 9.8 51 6.5 34.7 61.5 77.8 
O523 3 2.8 59.9 22.9 45.6 65.6 75 
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S648 3 26.4 43.2 7.1 31.8 57.7 72.7 
C241 3 2 59.5 11.6 30.1 61.8 81.2 
P054 3 4.4 44 18 27.1 54.5 75.3 
        
Short  
code 
 
CD4+ 
CCR7-
CD45RA+ 
PD1+ 
CD4+ 
CCR7-
CD45RA- 
PDL1+ 
CD4+ 
CCR7-
CD45RA+ 
PDL1+ 
CD8+ 
HLADR+CD38+ 
CD8+ 
HLADR+ 
CD8+ 
CD38+ 
R771 1 76.4 3.9 3.1 13.7 32.7 47.6 
B784 1 46.1 14.7 13.7 18.3 33.5 45.1 
G739 1 41.3 7.6 5.8 11.4 35.5 26.6 
P087 2 62.2 19.5 18 5.2 16.4 10.1 
C789 2 65.6 12.6 11.5 9.7 18.6 38.4 
L043 2 35.9 14.8 12.6 19.1 50 27.4 
C319 2 25.2 7 8.2 5 30.8 14.7 
F810 3 52.7 6.3 6.4 9.2 15.2 26.4 
O523 3 64.6 21.4 20 5.2 11.4 25.1 
S648 3 46.9 6.1 5.3 8.6 17.7 36.3 
C241 3 65.7 9.7 5.4 9.7 18.6 38.4 
P054 3 49 16 14.9 6.8 10.3 34.7 
 
Short  
code 
Group 
CD8+ 
CD57+ 
CD95+ 
CD8+ 
CD57+ 
CD8+ 
CD95+ 
CD8+ 
CD27+CD28+ 
CD8+ 
CD27+CD28- 
CD8+ 
CD27-CD28- 
R771 1 16.8 17.3 59.2 72.5 6.2 18.3 
B784 1 34.6 36.2 83.5 43.8 6.5 43.2 
G739 1 36.7 37.8 88.1 38.8 15.3 42.6 
P087 2 12.2 13.2 86 64.7 12.2 18.5 
C789 2 16.5 17 79.2 40.3 20.6 36.2 
L043 2 29.4 30.4 93.5 33.3 19.8 44.5 
C319 2 32 34 84.2 47.2 4.8 41.9 
F810 3 46.6 48.1 80.4 26.5 7.9 63.3 
O523 3 4.3 5 76.2 85.5 10.7 1.9 
S648 3 58.1 59.4 88 36.5 6.7 53.7 
C241 3 16.5 17 79.2 67.1 3.3 22.8 
P054 3 42.4 44.8 68 48 7.3 40.4 
        
Short  
code 
Group 
CD8+ 
CD27+ 
CD8+ 
CD28+ 
CD8+ 
CD25+ 
CD8+ 
CD45RO+ 
CD8+ 
CCR7+CD45RA+ 
CD8+ 
CCR7+CD45RA- 
R771 1 78.8 75.6 6.6 34.3 40.2 20.7 
B784 1 50.4 50.2 9.2 28.9 14.8 7.7 
G739 1 54 41.3 5.4 40.8 34.9 42.6 
P087 2 77 68.7 11.1 48.1 5.3 35.8 
C789 2 60.5 43.7 1 31.6 14.4 11.9 
L043 2 53.3 35.8 1.9 27.2 5 5 
C319 2 52.1 53.3 12 53.1 15.2 23.6 
F810 3 34.6 28.8 6.7 19.6 17.1 6.3 
O523 3 96.2 87.4 33.5 38.7 23.3 56 
S648 3 43.3 39.8 2.7 18 18.3 1.2 
C241 3 70.5 73.8 31.1 30.3 20 20.2 
P054 3 55.5 52.3 2.6 16.5 29.2 9.3 
        
Short  
code 
Group 
CD8+ 
CCR7-
CD45RA- 
CD8+ 
CCR7-
CD45RA+ 
CD8+ 
PD1+ 
CD8+ 
PDL1+ 
CD8+ 
CCR7+CD45RA+ 
PD1+ 
CD8+ 
CCR7+CD45RA- 
PD1+ 
R771 1 24.6 14.4 70.7 37.8 54 83.1 
B784 1 36 41.4 49.1 19 27.7 52.9 
G739 1 5.8 16.7 51 14.5 42.7 61.1 
P087 2 47.1 11.7 70.3 40.5 52.3 67.8 
C789 2 57.4 16.2 71.4 31 45.6 81 
L043 2 43.9 46.1 48.7 13.9 33.2 52.1 
C319 2 40.1 21.2 22.9 21.9 15.6 28.5 
F810 3 29.7 46.8 56.3 25.8 46.1 65.9 
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O523 3 14.3 6.4 59.5 43.2 49 58.8 
S648 3 6 74.5 55 9.3 41.6 89.7 
C241 3 45.1 14.7 62.9 24.1 43.3 63.8 
P054 3 27.5 34 44.7 16.3 35.4 65 
        
Short  
code 
Group 
CD8+ 
CCR7-
CD45RA- 
PD1+ 
CD8+ 
CCR7-
CD45RA+ 
PD1+ 
CD8+ 
CCR7+CD45RA+ 
PDL1+ 
CD8+ 
CCR7+CD45RA- 
PDL1+ 
CD8+ 
CCR7-CD45RA- 
PDL1+ 
CD8+ 
CCR7-CD45RA+ 
PDL1+ 
R771 1 86.4 73.4 39.8 26.5 4.8 3.3 
B784 1 65.6 42.1 20.1 25.6 21.3 19.7 
G739 1 53 35.4 14.5 15.8 4.9 4.2 
P087 2 76.6 61.9 52.7 49.4 31.4 30.9 
C789 2 75.1 73.5 41.1 46.1 26.6 26.1 
L043 2 62.4 38.9 27.3 38.1 11.7 9.2 
C319 2 25.5 11.9 33 31.4 17 14 
F810 3 79 49.1 55.1 51.3 25.3 13.4 
O523 3 71.7 65.3 46.7 46.5 31.6 24.5 
S648 3 86.3 56.5 14.8 23.6 8.7 7.6 
C241 3 72.8 60.6 26.1 32.8 22.1 16.9 
P054 3 51.2 36.9 18.8 22 12.7 12.5 
 
Short  
code 
Group 
CD4+ 
CD45RA+ 
CD31+ 
CD4+ 
CD31+ 
CD4+ 
PTK7+ 
CD4+ 
CTLA4+ 
TIM3+ 
CD4+ 
CD69+ 
CD4+ 
CTLA4+ 
CD4+ 
TIM3+ 
R771 1 36.7 44.5 0.5 0 1 0 0.8 
B784 1 27.9 35.8 0.5 0.1 2.3 0.1 1.3 
G739 1 13.7 40.6 1.2 0 1.2 0.1 1.4 
P087 2 7.4 21.3 0.4 0.1 1.1 0.1 1 
C789 2 30.2 44.2 0.3 0.2 2.1 0.2 2 
L043 2 23.3 37 0.7 0.1 2.2 0.5 0.8 
C319 2 15.8 27.8 0.4 0.1 1.7 0.5 1.9 
F810 3 28.8 35.6 0.3 0.1 3.8 0.1 1.8 
O523 3 19.2 44.2 0.6 0.1 0.7 0.1 1.4 
S648 3 34.9 37.2 0.8 0.1 2.2 0.6 1.7 
C241 3 14.2 42.9 0.5 0.1 1.3 0.2 1.5 
P054 3 42.6 49.4 0.5 0 0.8 0.2 1.9 
         
Short  
code 
Group 
CD8+ 
CD31+ 
CD8+ 
PTK7+ 
CD8+ 
CTLA4+ 
TIM3+ 
CD8+ 
CD69+ 
CD8+ 
CTLA4+ 
CD8+ 
TIM3+ 
 
R771 1 84.3 0.5 0.1 2.7 0.1 1.7  
B784 1 77.7 0.6 0.2 4 0.5 2.1  
G739 1 63.6 2 0.1 1.4 0.3 2.3  
P087 2 65.4 0.3 0.1 2.5 1.6 1.6  
C789 2 58.7 0.2 0 2.3 0.3 2.3  
L043 2 80.2 0.8 0 7.6 0.5 0.8  
C319 2 50.9 0.4 0 1.7 0.2 1.6  
F810 3 58.6 0.4 0 6.5 0.1 3.7  
O523 3 69.6 1.2 0.2 2.2 5.3 2.1  
S648 3 52.8 0.6 0.1 2.6 0.3 3.2  
C241 3 65.1 0.5 0.1 2.2 0.3 1.8  
P054 3 57.7 0.3 0 0.7 0.4 2.3  
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Appendix Table 5 Baseline phenotype in terms of mean fluorescence intensity (MFI). 
 
Short 
code 
Group 
CD4+ 
HLADR 
CD4+ 
CD38 
CD4+ 
CD57 
CD4+ 
CD95 
CD4+ 
CD45RO 
CD4+ 
CD25 
CD4+ 
CD28 
CD4+ 
CD27 
CD4+ 
PD1 
CD4+ 
PDL1 
R771 1 8833 2329 6571 3021 8407 857 4696 3956 492 2639 
B784 1 7081 2054 6954 3177 9399 814 4871 3411 651 2693 
G739 1 5780 1547 7608 3464 6278 601 6055 3291 571 2615 
P087 2 7969 1349 3603 2873 6291 932 5107 2493 610 2618 
C789 2 7066 1893 5710 3665 7732 1242 4936 3349 686 2648 
L043 2 6393 1122 5416 1383 9891 345 2617 2268 499 2122 
C319 2 7134 1135 8650 1254 12402 589 2603 2618 546 3075 
F810 3 7842 1689 9336 3967 5133 938 4765 3901 631 2961 
O523 3 8009 2327 1792 3516 5355 800 4740 3732 545 2470 
S648 3 7291 2234 7940 3829 4660 783 5392 2808 604 2748 
C241 3 7066 1893 5710 3665 4916 648 5186 2713 645 2403 
P054 3 6974 1153 12132 1886 10157 569 2560 2962 573 2546 
            
Short 
code 
Group 
CD8+ 
HLADR 
CD8+ 
CD38 
CD8+ 
CD57 
CD8+ 
CD95 
CD8+ 
CD45RO 
CD8+ 
CD25 
CD8+ 
CD28 
CD8+ 
CD27 
CD8+ 
PD1 
CD8+ 
PDL1 
R771 1 7910 966 6374 2013 7179 519 3181 3558 567 3321 
B784 1 7172 1045 3329 2079 9260 651 4859 2498 700 3136 
G739 1 5373 985 4850 1885 6414 493 5814 2434 564 3382 
P087 2 5942 1439 2367 1998 7075 768 4386 2114 655 3208 
C789 2 6936 1017 7361 2357 5553 1029 4724 2454 644 2826 
L043 2 6571 693 2189 1106 8347 326 2808 1568 510 2926 
C319 2 5621 550 4873 774 7917 413 2919 2033 555 3483 
F810 3 6567 1993 6371 1856 5835 834 3356 2807 855 3647 
O523 3 5461 1457 2081 2642 4287 716 4000 3113 555 2859 
S648 3 6042 984 10049 2377 5891 457 6228 2181 710 4237 
C241 3 6936 1017 7361 2357 5271 573 6429 2169 674 2589 
P054 3 7993 789 9262 1031 9773 369 2728 2290 525 3149 
            
Short 
code 
Group 
CD4+ 
CD31 
CD4+ 
PTK7 
CD4+ 
CD69 
CD4+ 
CTLA4 
CD4+ 
TIM3 
CD8+ 
CD31 
CD8+ 
PTK7 
CD8+ 
CD69 
CD8+ 
CTLA4 
CD8+ 
TIM3 
R771 1 1423 1202 4947 941 1613 2940 1870 4963 894 1465 
B784 1 1710 967 5462 741 1157 1917 760 5845 337 1088 
G739 1 1299 768 5851 609 934 1673 620 10650 541 1128 
P087 2 1993 799 6357 992 2522 2019 3355 8119 2347 2424 
C789 2 2423 914 8709 702 2843 2846 3227 9700 2924 2257 
L043 2 984 416 6917 259 688 1181 373 7546 301 580 
C319 2 1525 382 7937 250 569 1688 397 13581 333 637 
F810 3 1518 991 6027 804 1469 2610 1070 7198 1251 1119 
O523 3 1855 655 6079 867 1617 2305 1689 6348 1514 2000 
S648 3 1810 927 4648 523 970 2404 816 7006 656 797 
C241 3 1087 810 7450 596 905 1574 937 10743 1041 943 
P054 3 1151 500 6555 257 702 1694 511 8161 282 688 
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Appendix 2 Detailed statistical analysis tables for IMIRC 1003 clinical trial 
The following tables show the statistical analysis output for the IMIRC 1003 trial, evaluating 
changes from baseline to each of the study time points. For each randomisation group, mean change 
from baseline is shown, as well as the lower and upper confidence intervals. All p values are shown, 
in red where they are significant, and in blue where they are approaching significance. 
 
Appendix Table 6 Changes from baseline in patient characteristics for each group. 
Mean change (mean Δ) from baseline to each of the study time points is shown, with lower and upper confidence 
intervals (CI) and the corresponding p value. P values in red are significant (where p ≤ 0.05) and p values in blue are 
approaching significance (0.05 < p ≤ 0.1). 
 
 Group 1 Group 2 Group 3 
CD3 
count 
Mean ∆ Lower CI Upper CI P value Mean ∆ 
Lower 
CI 
Upper CI P value Mean ∆ Lower CI Upper CI P value 
Week 1 -227 -687 233 0.3355 -50 -448 348 0.8063 -54 -410 302 0.7663 
Week 2 2014 1554 2474 <.0001 -190 -589 208 0.352 2510 2154 2867 <.0001 
Week 4 102 -358 562 0.666 -80 -478 319 0.6958 654 298 1011 0.0005 
Week 6 623 163 1083 0.0096 -393 -791 6 0.0568 480 123 836 0.01 
Week 8 -22 -482 438 0.9255 -293 -692 105 0.1529 207 -149 563 0.2581 
Week 12 248 -212 708 0.2937 -349 -747 50 0.0902 375 19 732 0.0421 
Week 16 -7 -467 453 0.9763 59 -340 457 0.7742 297 -59 653 0.1064 
Week 24 74 -386 534 0.7522 -117 -516 281 0.5656 213 -143 569 0.2443 
Week 48 276 -184 736 0.243 -158 -556 240 0.4391 63 -293 419 0.729 
CD3%             
Week 1 0.60 -2.38 3.58 0.6939 -0.58 -3.15 2.00 0.6632 -1.36 -3.67 0.95 0.2512 
Week 2 4.17 1.19 7.14 0.0075 -0.60 -3.18 1.98 0.6496 3.90 1.59 6.21 0.0014 
Week 4 3.57 0.59 6.54 0.0213 0.28 -2.30 2.85 0.835 0.70 -1.61 3.01 0.5536 
Week 6 4.23 1.26 7.21 0.0066 -2.60 -5.18 -0.02 0.0515 1.80 -0.51 4.11 0.13 
Week 8 2.63 -0.34 5.61 0.0868 -1.20 -3.78 1.38 0.3644 1.80 -0.51 4.11 0.13 
Week 12 2.80 -0.18 5.78 0.069 -0.18 -2.75 2.40 0.8945 2.62 0.31 4.93 0.0288 
Week 16 3.60 0.62 6.58 0.0202 -1.10 -3.68 1.48 0.4056 1.46 -0.85 3.77 0.2183 
Week 24 2.23 -0.74 5.21 0.1454 0.30 -2.28 2.88 0.8202 1.34 -0.97 3.65 0.2582 
Week 48 2.00 -0.98 4.98 0.1917 -1.45 -4.03 1.13 0.2737 1.22 -1.09 3.53 0.3029 
CD4 
count 
            
Week 1 -58 -261 145 0.578 -52 -228 124 0.5646 -41 -198 117 0.615 
Week 2 1307 1104 1510 <.0001 -87 -263 90 0.3389 1511 1353 1668 <.0001 
Week 4 158 -45 362 0.1312 -46 -222 131 0.6142 377 219 534 <.0001 
Week 6 413 210 617 0.0001 -191 -367 -15 0.0369 239 82 397 0.0039 
Week 8 100 -103 304 0.3367 -131 -307 45 0.1498 142 -16 300 0.0812 
Week 12 206 3 409 0.0506 -155 -331 22 0.0896 216 59 374 0.0087 
Week 16 137 -66 341 0.1896 62 -115 238 0.4959 157 -1 314 0.055 
Week 24 170 -34 373 0.1061 -26 -202 151 0.7774 99 -59 256 0.2228 
Week 48 281 78 484 0.0083 -16 -192 160 0.857 83 -75 240 0.3074 
CD4%             
Week 1 2.50 -1.33 6.33 0.2047 -0.45 -3.77 2.87 0.7911 -1.20 -4.17 1.77 0.4305 
Week 2 8.30 4.47 12.13 <.0001 -0.20 -3.52 3.12 0.9063 8.20 5.23 11.17 <.0001 
Week 4 5.30 1.47 9.13 0.0082 0.95 -2.37 4.27 0.5763 3.08 0.11 6.05 0.0453 
Week 6 6.57 2.73 10.40 0.0012 -1.15 -4.47 2.17 0.499 1.86 -1.11 4.83 0.2229 
Week 8 6.67 2.83 10.50 0.001 -0.45 -3.77 2.87 0.7911 3.74 0.77 6.71 0.0156 
Week 12 4.97 1.13 8.80 0.013 0.23 -3.09 3.54 0.8946 2.74 -0.23 5.71 0.0741 
Week 16 6.93 3.10 10.77 0.0007 1.60 -1.72 4.92 0.3475 1.30 -1.67 4.27 0.3932 
Week 24 7.70 3.87 11.53 0.0002 2.73 -0.59 6.04 0.1114 1.70 -1.27 4.67 0.265 
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Week 48 5.00 1.17 8.83 0.0124 2.10 -1.22 5.42 0.2185 2.90 -0.07 5.87 0.059 
CD8 
count 
            
Week 1 -179 -436 79 0.1774 -94 -316 129 0.4134 -30 -229 170 0.7718 
Week 2 634 377 891 <.0001 -158 -381 65 0.1692 999 800 1199 <.0001 
Week 4 -26 -284 231 0.8416 -81 -304 142 0.4797 248 49 448 0.0168 
Week 6 167 -90 424 0.2071 -283 -505 -60 0.0151 221 21 420 0.033 
Week 8 -97 -355 160 0.4607 -168 -391 55 0.1429 39 -160 238 0.7024 
Week 12 4 -254 261 0.9778 -239 -462 -16 0.0387 130 -69 330 0.2042 
Week 16 -95 -352 162 0.4715 -7 -230 216 0.9493 130 -70 329 0.2063 
Week 24 -108 -365 149 0.4133 -149 -372 74 0.1931 64 -135 264 0.5284 
Week 48 42 -216 299 0.7518 -186 -408 37 0.1067 -3 -202 197 0.9781 
CD8%             
Week 1 -1.90 -4.79 0.99 0.2014 -0.75 -3.25 1.75 0.5588 -0.12 -2.36 2.12 0.9166 
Week 2 -5.17 -8.06 -2.28 0.0008 -1.03 -3.53 1.48 0.4247 -4.68 -6.92 -2.44 <.0001 
Week 4 -2.40 -5.29 0.49 0.1077 -0.18 -2.68 2.33 0.8914 -2.36 -4.60 -0.12 0.0421 
Week 6 -3.10 -5.99 -0.21 0.0387 -1.35 -3.85 1.15 0.2938 0.44 -1.80 2.68 0.7012 
Week 8 -2.93 -5.82 -0.04 0.0502 0.13 -2.38 2.63 0.9223 -1.46 -3.70 0.78 0.205 
Week 12 -2.53 -5.42 0.36 0.0898 -0.20 -2.70 2.30 0.876 -0.48 -2.72 1.76 0.6756 
Week 16 -3.60 -6.49 -0.71 0.0169 -2.40 -4.90 0.10 0.0639 0.62 -1.62 2.86 0.5889 
Week 24 -5.53 -8.42 -2.64 0.0003 -1.68 -4.18 0.83 0.1936 0.04 -2.20 2.28 0.9722 
Week 48 -3.00 -5.89 -0.11 0.0453 -2.58 -5.08 -0.07 0.0472 -0.50 -2.74 1.74 0.6629 
 
Appendix Table 7 Changes from baseline in patient characteristics for each group. 
Mean change (mean Δ) from baseline to each of the study time points is shown, with lower and upper confidence 
intervals (CI) and the corresponding p value. P values in red are significant (where p ≤ 0.05) and p values in blue are 
approaching significance (0.05 < p ≤ 0.1). 
 
 Group 1 Group 2 Group 3 
CD19 
count 
Mean ∆ Lower CI Upper CI P value Mean ∆ 
Lower 
CI 
Upper CI P value Mean ∆ Lower CI Upper CI P value 
Week 1 -19 -91 54 0.6158 18 -45 80 0.5871 -16 -72 40 0.5788 
Week 2 -41 -114 32 0.2719 -16 -79 47 0.6249 24 -32 81 0.3978 
Week 4 -131 -204 -58 0.0007 -13 -76 50 0.6922 -77 -134 -21 0.0085 
Week 6 -43 -116 29 0.2457 -17 -80 46 0.5978 -67 -123 -10 0.0229 
Week 8 -78 -151 -6 0.0376 -9 -72 54 0.7799 -63 -119 -6 0.0321 
Week 12 -47 -120 25 0.2052 -38 -100 25 0.2461 -48 -105 8 0.0956 
Week 16 -63 -135 10 0.0947 10 -53 72 0.768 -49 -105 7 0.0917 
Week 24 -12 -84 61 0.7537 -18 -81 45 0.5818 -13 -69 43 0.6569 
Week 48 10 -63 83 0.788 10 -53 73 0.7503 -24 -80 32 0.4095 
CD19%             
Week 1 0.10 -1.85 2.05 0.9203 0.48 -1.22 2.17 0.5837 -0.52 -2.03 0.99 0.5025 
Week 2 -6.33 -8.29 -4.38 <.0001 -0.20 -1.89 1.49 0.8174 -5.54 -7.05 -4.03 <.0001 
Week 4 -5.70 -7.65 -3.75 <.0001 0.15 -1.54 1.84 0.8625 -5.04 -6.55 -3.53 <.0001 
Week 6 -3.70 -5.65 -1.75 0.0004 0.55 -1.14 2.24 0.5258 -4.44 -5.95 -2.93 <.0001 
Week 8 -3.00 -4.95 -1.05 0.0035 1.20 -0.49 2.89 0.1683 -2.70 -4.21 -1.19 0.0008 
Week 12 -3.13 -5.09 -1.18 0.0023 -0.03 -1.72 1.67 0.977 -3.10 -4.61 -1.59 0.0001 
Week 16 -2.27 -4.22 -0.31 0.0256 0.28 -1.42 1.97 0.7509 -3.00 -4.51 -1.49 0.0002 
Week 24 -0.90 -2.85 1.05 0.3692 -0.40 -2.09 1.29 0.6443 -0.92 -2.43 0.59 0.2369 
Week 48 -0.77 -2.72 1.19 0.444 0.10 -1.59 1.79 0.9081 -1.00 -2.51 0.51 0.1989 
CD56 
count 
            
Week 1 -39 -192 113 0.6141 -9 -141 123 0.8969 52 -66 170 0.392 
Week 2 235 83 387 0.0033 3 -129 135 0.9646 511 393 629 <.0001 
Week 4 32 -121 184 0.6847 -18 -150 114 0.7926 187 69 305 0.0026 
Week 6 20 -133 172 0.8008 25 -107 157 0.7085 153 35 271 0.0127 
Week 8 7 -146 159 0.9318 -21 -153 111 0.7586 120 2 238 0.0496 
Week 12 27 -126 179 0.7324 -28 -159 104 0.6839 67 -51 185 0.2689 
Week 16 -22 -174 130 0.7778 6 -126 138 0.9262 58 -60 176 0.3381 
Week 24 -18 -171 134 0.8141 -24 -156 108 0.7223 -1 -119 117 0.9921 
Week 48 6 -146 159 0.9352 41 -91 173 0.5465 -10 -128 108 0.8659 
CD56%             
Week 1 -0.63 -3.63 2.37 0.6801 -0.50 -3.10 2.10 0.7069 1.52 -0.80 3.84 0.2034 
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Week 2 2.53 -0.47 5.53 0.1017 0.90 -1.70 3.50 0.499 1.70 -0.62 4.02 0.1554 
Week 4 1.33 -1.67 4.33 0.3862 -0.68 -3.27 1.92 0.6119 2.24 -0.08 4.56 0.0624 
Week 6 -0.13 -3.13 2.87 0.9308 2.23 -0.37 4.82 0.097 2.12 -0.20 4.44 0.0774 
Week 8 1.07 -1.93 4.07 0.4878 0.43 -2.17 3.02 0.7493 0.30 -2.02 2.62 0.8008 
Week 12 0.50 -2.50 3.50 0.7447 0.08 -2.52 2.67 0.955 0.20 -2.12 2.52 0.8664 
Week 16 -0.97 -3.97 2.03 0.5294 0.15 -2.45 2.75 0.9102 0.90 -1.42 3.22 0.4499 
Week 24 -0.93 -3.93 2.07 0.5436 -1.00 -3.60 1.60 0.4527 -0.16 -2.48 2.16 0.893 
Week 48 -0.33 -3.33 2.67 0.8281 1.95 -0.65 4.55 0.145 -0.28 -2.60 2.04 0.8139 
ISUM             
Week 1 -285 -874 304 0.3453 -41 -551 469 0.8745 -18 -475 438 0.9372 
Week 2 2254 1665 2843 <.0001 -203 -713 307 0.4378 3063 2606 3519 <.0001 
Week 4 2 -587 591 0.9938 -110 -620 400 0.673 764 308 1221 0.0015 
Week 6 599 10 1188 0.0496 -385 -895 126 0.1435 566 110 1023 0.0172 
Week 8 -94 -683 495 0.7561 -323 -833 187 0.2182 264 -192 721 0.2595 
Week 12 227 -362 816 0.4516 -414 -924 97 0.1161 394 -62 850 0.0944 
Week 16 -92 -681 497 0.7612 118 -393 628 0.6529 306 -151 762 0.1927 
Week 24 44 -545 633 0.8831 -159 -669 351 0.543 200 -257 656 0.3933 
Week 48 292 -297 881 0.3337 -107 -617 403 0.6821 29 -427 486 0.9005 
CD4/CD8 
ratio 
            
Week 1 0.10 -0.07 0.27 0.2603 0.03 -0.12 0.17 0.7443 -0.02 -0.15 0.11 0.7705 
Week 2 0.43 0.26 0.61 <.0001 0.03 -0.12 0.17 0.7443 0.34 0.21 0.47 <.0001 
Week 4 0.20 0.03 0.37 0.026 0.03 -0.12 0.17 0.7443 0.14 0.01 0.27 0.0437 
Week 6 0.30 0.13 0.47 0.001 0.03 -0.12 0.17 0.7443 0.06 -0.07 0.19 0.3825 
Week 8 0.30 0.13 0.47 0.001 -0.03 -0.17 0.12 0.7443 0.12 -0.01 0.25 0.0828 
Week 12 0.23 0.06 0.41 0.0098 0.05 -0.10 0.20 0.5146 0.08 -0.05 0.21 0.2451 
Week 16 0.33 0.16 0.51 0.0003 0.10 -0.05 0.25 0.1942 0.04 -0.09 0.17 0.5599 
Week 24 0.47 0.29 0.64 <.0001 0.13 -0.02 0.27 0.1056 0.06 -0.07 0.19 0.3825 
Week 48 0.27 0.09 0.44 0.0033 0.13 -0.02 0.27 0.1056 0.08 -0.05 0.21 0.2451 
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Appendix Table 8 Changes from baseline in IFN-γ ELISpot responses to peptide pools from NIBSC. 
Mean change (mean Δ) from baseline to each of the study time points is shown, with lower and upper confidence 
intervals (CI) and the corresponding p value. P values in red are significant (where p ≤ 0.05) and p values in blue are 
approaching significance (0.05 < p ≤ 0.1). 
 
IFN-γ Group 1 Group 2 Group 3 
p17 Mean ∆ 
Lower 
CI 
Upper CI P value Mean ∆ Lower CI Upper CI P value Mean ∆ 
Lower 
CI 
Upper CI P value 
Week 1 -2 -123 119 0.9743 41 -64 146 0.4459 -22 -115 72 0.6531 
Week 2 18 -103 139 0.7716 7 -98 112 0.8963 -148 -242 -54 0.0027 
Week 4 45 -76 166 0.4719 64 -41 168 0.2389 -4 -98 90 0.9336 
Week 6 25 -96 146 0.683 47 -58 151 0.3875 -54 -147 40 0.2662 
Week 8 -26 -147 95 0.6751 74 -31 179 0.1706 -16 -110 77 0.7328 
Week 12 7 -114 128 0.9144 149 44 253 0.0069 -84 -177 10 0.0846 
Week 16 -50 -171 71 0.4209 78 -27 183 0.1489 -107 -201 -13 0.0279 
Week 24 -32 -153 89 0.606 127 22 232 0.02 -119 -213 -25 0.0152 
Week 48 80 -41 201 0.1992 105 0 210 0.0532 26 -67 120 0.5828 
p24             
Week 1 11 -195 217 0.9194 -36 -214 142 0.6934 26 -133 186 0.7465 
Week 2 -168 -374 38 0.1137 -83 -261 95 0.3644 -260 -419 -100 0.002 
Week 4 108 -98 314 0.3071 -22 -200 157 0.8138 7 -153 166 0.9336 
Week 6 115 -91 321 0.2784 37 -142 215 0.6894 -12 -171 148 0.887 
Week 8 15 -191 221 0.8843 -39 -217 140 0.6733 -108 -267 52 0.1899 
Week 12 20 -186 226 0.8495 6 -172 184 0.9476 -176 -336 -17 0.0331 
Week 16 -139 -345 67 0.1885 19 -159 197 0.8351 -196 -356 -37 0.0181 
Week 24 -150 -356 56 0.1572 -21 -199 157 0.8181 -186 -346 -26 0.0249 
Week 48 201 -5 407 0.0589 -84 -262 95 0.3615 -86 -246 73 0.2916 
Nef             
Week 1 -43 -168 83 0.5081 58 -51 167 0.2998 49 -48 147 0.3253 
Week 2 -89 -214 37 0.1709 -10 -118 99 0.8647 -114 -211 -17 0.0244 
Week 4 7 -118 133 0.9093 12 -97 120 0.8366 -36 -134 61 0.4662 
Week 6 -84 -210 42 0.1943 9 -100 118 0.8718 -85 -182 13 0.0919 
Week 8 -57 -182 69 0.3799 41 -68 149 0.4683 -86 -184 11 0.086 
Week 12 -34 -160 92 0.5977 123 14 232 0.0297 -100 -197 -2 0.0485 
Week 16 -77 -202 49 0.2357 45 -64 153 0.4257 -53 -151 44 0.2877 
Week 24 -125 -250 1 0.0556 -2 -110 107 0.9785 -88 -186 9 0.0791 
Week 48 50 -76 176 0.4382 48 -61 157 0.3904 -87 -184 11 0.0846 
Tat             
Week 1 -17 -95 60 0.6619 6 -62 73 0.8726 -54 -114 6 0.0813 
Week 2 -19 -96 59 0.6377 2 -66 69 0.9651 -146 -206 -86 <.0001 
Week 4 10 -67 87 0.8007 -2 -69 65 0.9535 -50 -110 10 0.1088 
Week 6 20 -57 97 0.6139 0 -67 67 1 -79 -139 -19 0.0118 
Week 8 26 -51 103 0.5122 4 -63 71 0.9072 -92 -152 -32 0.0034 
Week 12 47 -30 125 0.2342 2 -65 69 0.9535 -112 -172 -52 0.0005 
Week 16 13 -64 91 0.7365 3 -64 70 0.9303 -120 -180 -60 0.0002 
Week 24 -11 -89 66 0.7749 -2 -69 65 0.9535 -100 -160 -40 0.0017 
Week 48 82 5 159 0.041 4 -63 71 0.9072 -53 -113 7 0.0858 
Rev             
Week 1 0 -27 27 1 1 -22 24 0.9329 -8 -28 13 0.475 
Week 2 3 -24 29 0.8458 -16 -39 7 0.1803 -23 -44 -2 0.0343 
Week 4 6 -21 33 0.6619 -10 -33 13 0.4008 -22 -43 -1 0.0409 
Week 6 0 -27 27 1 -12 -35 11 0.3138 2 -19 22 0.8803 
Week 8 1 -26 27 0.9612 3 -21 26 0.8333 0 -21 20 0.97 
Week 12 7 -20 33 0.6271 -4 -27 20 0.7683 -20 -41 0 0.0575 
Week 16 1 -25 28 0.9225 -2 -25 21 0.8663 -19 -40 2 0.0735 
Week 24 0 -27 27 1 -2 -25 21 0.8663 -27 -48 -6 0.0133 
Week 48 3 -23 30 0.808 -2 -25 21 0.8663 -18 -39 2 0.0861 
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Appendix Table 9 Changes from baseline in IL-2 ELISpot responses to peptide pools from NIBSC. 
Mean change (mean Δ) from baseline to each of the study time points is shown, with lower and upper confidence 
intervals (CI) and the corresponding p value. P values in red are significant (where p ≤ 0.05) and p values in blue are 
approaching significance (0.05 < p ≤ 0.1). 
 
IL-2 Group 1 Group 2 Group 3 
p17 Mean ∆ 
Lower 
CI 
Upper CI P value Mean ∆ Lower CI Upper CI P value Mean ∆ Lower CI Upper CI P value 
Week 1 -9 -128 111 0.8873 39 -65 143 0.4623 -20 -113 73 0.6731 
Week 2 -32 -152 88 0.6012 -23 -126 81 0.6712 -17 -110 75 0.7167 
Week 4 49 -70 169 0.4208 17 -87 121 0.7483 -11 -103 82 0.8197 
Week 6 63 -57 182 0.3071 18 -86 122 0.7341 -33 -126 59 0.4841 
Week 8 -2 -122 118 0.9739 73 -31 176 0.1736 -43 -135 50 0.3675 
Week 12 -3 -122 117 0.9652 103 -1 206 0.0557 15 -77 108 0.7484 
Week 16 -22 -142 98 0.7192 74 -30 178 0.1649 -10 -102 83 0.8394 
Week 24 73 -47 192 0.2368 125 21 228 0.0208 74 -18 167 0.1191 
Week 48 115 -4 235 0.0621 81 -23 184 0.1313 91 -1 184 0.057 
p24             
Week 1 3 -44 49 0.9112 -3 -43 37 0.8848 -20 -57 16 0.2722 
Week 2 -39 -86 7 0.1026 2 -39 42 0.9422 -1 -37 35 0.9655 
Week 4 11 -35 58 0.6356 2 -39 42 0.9422 -18 -55 18 0.3217 
Week 6 23 -24 69 0.3442 3 -38 43 0.9039 -14 -50 22 0.4503 
Week 8 -51 -97 -4 0.0365 1 -39 41 0.9615 -26 -63 10 0.1564 
Week 12 -55 -101 -8 0.0243 3 -37 43 0.8848 -20 -56 16 0.2817 
Week 16 -43 -90 3 0.0726 1 -40 41 0.9807 -22 -59 14 0.2283 
Week 24 -23 -70 23 0.3303 -7 -47 34 0.7535 -23 -59 13 0.2202 
Week 48 42 -5 89 0.0817 18 -22 58 0.3856 -18 -55 18 0.3217 
Nef             
Week 1 -5 -30 21 0.7202 -2 -24 21 0.8942 -6 -26 13 0.5264 
Week 2 -1 -26 25 0.9592 9 -13 31 0.4259 31 11 51 0.003 
Week 4 5 -20 31 0.6824 -1 -23 21 0.9294 1 -19 21 0.9368 
Week 6 -5 -31 20 0.6824 20 -3 42 0.0867 -6 -26 13 0.5264 
Week 8 -4 -29 21 0.7588 2 -21 24 0.8942 -3 -23 17 0.7512 
Week 12 -6 -31 19 0.6453 4 -19 26 0.7564 0 -20 20 1 
Week 16 9 -16 35 0.4743 1 -21 23 0.9294 0 -19 20 0.9684 
Week 24 -5 -30 21 0.7202 -3 -25 20 0.8246 -1 -21 19 0.9368 
Week 48 9 -16 35 0.4743 9 -13 31 0.4259 -2 -22 18 0.8429 
Tat             
Week 1 -1 -23 22 0.9544 1 -19 20 0.9605 4 -14 21 0.6902 
Week 2 19 -3 42 0.1 2 -18 21 0.8819 35 18 53 0.0002 
Week 4 7 -15 30 0.5298 -4 -23 16 0.7289 1 -17 18 0.9294 
Week 6 1 -21 24 0.9089 -1 -20 19 0.9605 -2 -20 15 0.7904 
Week 8 8 -15 31 0.4931 -3 -22 17 0.8044 2 -15 20 0.7904 
Week 12 2 -21 25 0.8638 1 -19 20 0.9605 3 -14 21 0.7231 
Week 16 1 -22 23 0.9544 1 -19 21 0.9211 2 -16 20 0.8247 
Week 24 3 -20 25 0.8191 -4 -23 16 0.7289 -2 -20 15 0.7904 
Week 48 -1 -24 21 0.9089 0 -20 20 1 1 -16 19 0.8943 
Rev             
Week 1 -1 -24 22 0.9104 1 -19 21 0.9223 1 -17 19 0.9305 
Week 2 30 7 53 0.013 0 -20 20 1 36 18 54 0.0001 
Week 4 -1 -24 22 0.9551 -1 -21 19 0.9223 0 -18 18 0.9652 
Week 6 -1 -24 22 0.9104 0 -20 20 1 0 -18 18 0.9652 
Week 8 -1 -24 22 0.9104 2 -19 22 0.8837 2 -16 20 0.8616 
Week 12 1 -22 24 0.9104 3 -18 23 0.8075 1 -17 19 0.9305 
Week 16 -1 -24 22 0.9104 0 -20 20 1 4 -14 22 0.663 
Week 24 0 -23 23 1 -1 -21 19 0.9223 2 -16 20 0.8616 
Week 48 -1 -24 22 0.9104 2 -18 22 0.8454 2 -16 20 0.8616 
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Appendix Table 10 Changes from baseline in IL-4 ELISpot responses to peptide pools from NIBSC. 
Mean change (mean Δ) from baseline to each of the study time points is shown, with lower and upper confidence 
intervals (CI) and the corresponding p value. P values in red are significant (where p ≤ 0.05) and p values in blue are 
approaching significance (0.05 < p ≤ 0.1). 
 
IL-4 Group 1 Group 2 Group 3 
p17 Mean ∆ Lower CI Upper CI P value Mean ∆ Lower CI Upper CI P value Mean ∆ Lower CI Upper CI P value 
Week 1 -4 -99 91 0.9343 32 -50 114 0.4475 -27 -101 46 0.4703 
Week 2 -2 -97 93 0.9671 29 -53 111 0.4911 -30 -103 44 0.4322 
Week 4 43 -52 138 0.3807 41 -41 123 0.331 -10 -84 63 0.7822 
Week 6 3 -92 98 0.9453 16 -66 98 0.7037 -12 -85 61 0.7498 
Week 8 1 -94 96 0.989 52 -31 134 0.2228 8 -65 81 0.8316 
Week 12 -3 -98 92 0.9453 100 18 182 0.0194 32 -41 106 0.3901 
Week 16 -2 -97 93 0.9671 74 -8 156 0.0813 1 -72 75 0.9745 
Week 24 4 -91 99 0.9343 85 2 167 0.0472 100 27 173 0.0092 
Week 48 111 16 206 0.024 66 -17 148 0.1221 40 -33 114 0.2845 
p24             
Week 1 -9 -20 1 0.082 -1 -10 8 0.8281 -1 -9 7 0.846 
Week 2 -9 -19 2 0.1059 -2 -10 7 0.7447 -4 -12 4 0.3328 
Week 4 -10 -20 0 0.0628 -2 -11 7 0.6642 7 -1 15 0.1015 
Week 6 -9 -20 1 0.082 -1 -9 8 0.9135 -3 -11 5 0.438 
Week 8 -9 -20 1 0.082 4 -5 12 0.4479 -5 -13 3 0.2089 
Week 12 -11 -22 -1 0.0355 3 -6 12 0.5152 -2 -10 6 0.5604 
Week 16 -11 -22 -1 0.0355 3 -6 11 0.5875 0 -8 8 1 
Week 24 -10 -20 0 0.0628 0 -9 9 1 -3 -11 5 0.4972 
Week 48 11 0 21 0.0475 11 2 19 0.0248 -1 -9 7 0.846 
Nef             
Week 1 -15 -28 -1 0.0403 0 -12 12 1 -14 -24 -3 0.0146 
Week 2 -12 -26 2 0.092 6 -6 17 0.3695 -18 -29 -7 0.0014 
Week 4 -14 -28 0 0.05 -1 -12 11 0.9348 -19 -29 -8 0.0009 
Week 6 -13 -27 0 0.0617 -2 -13 10 0.8062 -17 -28 -7 0.0023 
Week 8 -13 -27 0 0.0617 2 -10 14 0.7436 -19 -29 -8 0.0009 
Week 12 -10 -24 4 0.1592 4 -8 15 0.5674 -15 -25 -4 0.0081 
Week 16 -15 -28 -1 0.0403 3 -9 15 0.6239 -17 -28 -7 0.0023 
Week 24 -11 -25 2 0.1112 -1 -13 11 0.8701 -18 -29 -8 0.0011 
Week 48 -11 -25 2 0.1112 4 -8 16 0.5135 -18 -28 -7 0.0018 
Tat             
Week 1 -17 -51 16 0.3182 -1 -30 28 0.9468 3 -23 29 0.8346 
Week 2 78 44 112 <.0001 -1 -30 29 0.9734 -4 -31 22 0.7429 
Week 4 -18 -52 16 0.3001 -3 -32 27 0.8676 -2 -29 24 0.858 
Week 6 -15 -48 19 0.3979 2 -27 31 0.8939 13 -13 39 0.3412 
Week 8 -16 -50 18 0.3567 2 -28 31 0.9203 -2 -28 24 0.8815 
Week 12 -19 -53 14 0.266 0 -29 29 1 2 -24 29 0.858 
Week 16 -19 -52 15 0.2827 -1 -30 28 0.9468 4 -22 30 0.7656 
Week 24 -17 -50 17 0.3371 -3 -32 27 0.8676 1 -25 27 0.9287 
Week 48 -17 -51 16 0.3182 2 -28 31 0.9203 2 -24 28 0.8815 
Rev             
Week 1 -18 -27 -9 0.0003 1 -8 9 0.9047 -3 -10 4 0.454 
Week 2 -17 -27 -8 0.0005 0 -8 8 1 -7 -14 0 0.0565 
Week 4 -19 -28 -9 0.0002 -1 -9 7 0.8107 -4 -11 3 0.2857 
Week 6 -18 -27 -9 0.0003 1 -7 9 0.8107 -6 -13 1 0.1108 
Week 8 -17 -27 -8 0.0005 0 -8 8 1 -7 -14 0 0.0714 
Week 12 -12 -21 -3 0.0145 1 -8 9 0.9047 -6 -14 1 0.0893 
Week 16 -15 -25 -6 0.002 -2 -10 7 0.7194 -4 -12 3 0.2406 
Week 24 -14 -23 -5 0.0046 -2 -10 6 0.6321 -4 -11 3 0.2857 
Week 48 -19 -28 -9 0.0002 10 2 18 0.0185 -2 -9 5 0.5925 
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Appendix Table 11 Changes from baseline in perforin ELISpot responses to peptide pools from NIBSC. 
Mean change (mean Δ) from baseline to each of the study time points is shown, with lower and upper confidence 
intervals (CI) and the corresponding p value. P values in red are significant (where p ≤ 0.05) and p values in blue are 
approaching significance (0.05 < p ≤ 0.1). 
 
Perforin Group 1 Group 2 Group 3 
p17 Mean ∆ Lower CI Upper CI P value Mean ∆ Lower CI Upper CI P value Mean ∆ Lower CI Upper CI P value 
Week 1 -19 -236 198 0.8618 31 -60 62 0.7472 56 -110 111 0.5125 
Week 2 -25 -242 192 0.8195 -80 158 -156 0.4064 -56 111 -110 0.5125 
Week 4 271 54 488 0.0166 -27 53 -53 0.7789 24 -47 49 0.7767 
Week 6 17 -200 234 0.8759 29 -56 58 0.763 -25 49 -48 0.7731 
Week 8 -1 -218 216 0.9952 -19 38 -36 0.8434 163 -319 321 0.0605 
Week 12 -17 -234 200 0.8807 78 -151 153 0.4211 38 -74 75 0.6588 
Week 16 -30 -247 187 0.787 50 -97 99 0.6033 37 -72 74 0.6655 
Week 24 1 -216 218 0.9952 112 -218 220 0.2481 172 -336 337 0.0487 
Week 48 106 -111 323 0.3411 22 -42 42 0.8231 -6 12 -10 0.9481 
p24             
Week 1 -11 -165 143 0.8858 40 -94 173 0.5635 75 -44 195 0.2206 
Week 2 -21 -175 133 0.7934 -48 -181 86 0.4875 -14 -133 105 0.8188 
Week 4 -23 -177 131 0.7739 -20 -153 113 0.7698 3 -117 122 0.9635 
Week 6 -9 -163 145 0.9125 7 -126 140 0.9184 -29 -148 91 0.6376 
Week 8 0 -154 154 1 -43 -176 91 0.5344 276 156 395 <.0001 
Week 12 2 -152 156 0.9798 10 -123 143 0.8836 2 -117 121 0.9739 
Week 16 -23 -177 131 0.7675 42 -92 175 0.544 9 -110 129 0.8803 
Week 24 -25 -179 129 0.7482 20 -113 153 0.7698 55 -64 175 0.3675 
Week 48 121 -33 275 0.1268 -30 -163 103 0.6608 -6 -126 113 0.9166 
Nef             
Week 1 3 -166 171 0.9753 -65 -210 81 0.3891 53 -78 183 0.4304 
Week 2 -1 -170 167 0.9877 -96 -241 50 0.2035 -30 -160 101 0.658 
Week 4 6 -163 175 0.9446 -94 -239 52 0.213 -11 -141 120 0.8716 
Week 6 18 -151 187 0.8348 -66 -212 80 0.3782 -48 -179 82 0.4696 
Week 8 29 -139 198 0.7339 -110 -256 36 0.1436 222 91 352 0.0013 
Week 12 26 -143 195 0.7632 -20 -165 126 0.7941 31 -99 162 0.6408 
Week 16 -7 -176 161 0.9323 -53 -198 93 0.4829 -28 -159 103 0.6754 
Week 24 -11 -179 158 0.9016 -31 -177 115 0.6784 15 -116 145 0.8248 
Week 48 100 -69 269 0.2484 -72 -217 74 0.34 -14 -145 117 0.8341 
Tat             
Week 1 -36 -239 167 0.7293 -64 -240 112 0.4779 95 -63 252 0.2412 
Week 2 -52 -255 151 0.6173 -119 -295 57 0.1887 -61 -218 97 0.4511 
Week 4 71 -132 275 0.4933 -83 -259 93 0.3579 -30 -187 128 0.7134 
Week 6 -6 -209 197 0.954 -57 -233 119 0.5272 -30 -187 127 0.7097 
Week 8 -11 -214 193 0.9183 -122 -298 54 0.1779 246 89 404 0.0029 
Week 12 11 -193 214 0.9183 -24 -200 152 0.7899 29 -128 187 0.7171 
Week 16 5 -199 208 0.9642 13 -163 188 0.8896 48 -110 205 0.5549 
Week 24 -63 -266 141 0.5472 60 -116 235 0.5093 103 -55 260 0.2041 
Week 48 33 -170 237 0.7486 -73 -248 103 0.4217 -15 -172 143 0.8542 
Rev             
Week 1 -11 -138 117 0.8702 3 -107 113 0.9577 53 -46 152 0.2943 
Week 2 -12 -140 116 0.8541 -26 -136 84 0.6458 -32 -131 66 0.5222 
Week 4 -16 -144 112 0.8064 8 -103 118 0.8945 -8 -107 91 0.8743 
Week 6 -11 -139 116 0.8622 9 -102 119 0.8805 -61 -160 38 0.2312 
Week 8 7 -120 135 0.9105 -44 -154 67 0.4424 145 46 244 0.0052 
Week 12 49 -79 176 0.4567 46 -65 156 0.4218 -19 -118 80 0.7043 
Week 16 -24 -152 104 0.7132 48 -62 158 0.3969 -26 -124 73 0.6129 
Week 24 -25 -152 103 0.7056 8 -102 118 0.8875 -15 -114 84 0.7698 
Week 48 81 -47 208 0.2187 -8 -118 103 0.8945 -7 -106 92 0.893 
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Appendix Table 12 Changes from baseline in IFN-γ ELISpot responses to peptide pools from FIT Biotech. 
Mean change (mean Δ) from baseline to each of the study time points is shown, with lower and upper confidence 
intervals (CI) and the corresponding p value. P values in red are significant (where p ≤ 0.05) and p values in blue are 
approaching significance (0.05 < p ≤ 0.1). 
 
IFN-γ Group 1 Group 2 Group 3 
p17/p24 Mean ∆ Lower CI Upper CI P value Mean ∆ 
Lower 
CI 
Upper CI P value Mean ∆ 
Lower 
CI 
Upper CI P value 
Week 1 109 -129 348 0.3717 -2 -208 205 0.9887 12 -173 196 0.9024 
Week 2 -28 -267 211 0.8186 -107 -314 100 0.313 -285 -470 -100 0.0034 
Week 4 223 -16 461 0.071 -42 -248 165 0.6948 9 -176 194 0.9225 
Week 6 157 -82 395 0.2017 23 -184 230 0.8278 60 -124 245 0.5235 
Week 8 150 -89 389 0.2213 -32 -239 175 0.7622 -143 -328 42 0.1327 
Week 12 144 -95 383 0.2402 30 -177 237 0.7767 -182 -367 3 0.057 
Week 16 129 -109 368 0.2911 35 -172 241 0.7443 -106 -291 78 0.2624 
Week 24 67 -171 306 0.5816 -44 -251 163 0.6775 -237 -422 -52 0.0138 
Week 48 312 73 551 0.0122 -121 -328 86 0.2543 -150 -334 35 0.1164 
Nef             
Week 1 -39 -165 88 0.55 37 -72 146 0.509 37 -61 135 0.4629 
Week 2 19 -108 145 0.7727 -23 -132 86 0.6812 -107 -205 -9 0.0353 
Week 4 18 -108 144 0.7806 7 -102 116 0.9004 -24 -122 74 0.6318 
Week 6 10 -116 136 0.877 -3 -112 107 0.9644 -66 -164 31 0.1869 
Week 8 -90 -216 36 0.1661 20 -89 129 0.7209 -102 -200 -5 0.0433 
Week 12 -17 -143 110 0.7965 38 -71 147 0.4976 -104 -202 -6 0.0403 
Week 16 -111 -238 15 0.0877 35 -75 144 0.538 -41 -139 57 0.4113 
Week 24 -111 -237 16 0.0896 -11 -120 99 0.8512 -100 -198 -3 0.0475 
Week 48 43 -84 169 0.5096 -33 -142 77 0.5617 -70 -168 27 0.162 
Tat             
Week 1 69 -106 245 0.4406 -1 -152 151 0.9949 -19 -155 117 0.7868 
Week 2 -29 -205 146 0.7438 -9 -160 143 0.9129 -56 -192 79 0.4181 
Week 4 275 100 451 0.0028 -10 -161 142 0.9027 14 -122 150 0.8404 
Week 6 41 -134 217 0.6453 3 -149 155 0.9692 -21 -157 115 0.7648 
Week 8 -144 -319 31 0.1113 -4 -156 148 0.9589 -27 -163 109 0.6999 
Week 12 46 -129 221 0.6085 -6 -158 146 0.9385 -36 -171 100 0.6088 
Week 16 -221 -396 -45 0.0157 -4 -156 148 0.9589 -40 -176 95 0.5615 
Week 24 -157 -333 18 0.0824 1 -151 153 0.9897 -47 -183 89 0.5013 
Week 48 -191 -367 -16 0.0355 -5 -156 147 0.9538 -36 -171 100 0.6088 
Rev             
Week 1 0 -37 37 1 6 -26 37 0.7365 -27 -55 2 0.0695 
Week 2 -2 -39 35 0.9156 -13 -45 19 0.4272 -43 -71 -14 0.0043 
Week 4 1 -36 38 0.9718 -13 -45 19 0.4272 11 -18 39 0.4607 
Week 6 -3 -40 34 0.8876 -5 -36 27 0.7831 -14 -43 15 0.3395 
Week 8 -4 -41 33 0.8321 -7 -39 25 0.6685 -22 -51 7 0.135 
Week 12 -3 -40 34 0.8598 -5 -37 27 0.7597 -42 -71 -13 0.005 
Week 16 -1 -38 36 0.9437 4 -28 35 0.8304 -44 -72 -15 0.0037 
Week 24 -1 -38 36 0.9718 -9 -41 23 0.5821 -45 -73 -16 0.0029 
Week 48 0 -37 37 1 1 -31 32 0.9756 -41 -70 -13 0.0059 
CTL             
Week 1 -24 -118 70 0.6192 52 -30 134 0.2156 -30 -103 43 0.4293 
Week 2 -5 -100 89 0.912 -45 -126 37 0.2887 -54 -127 19 0.1512 
Week 4 27 -67 122 0.5715 1 -81 82 0.9905 -18 -91 55 0.638 
Week 6 18 -76 112 0.7093 35 -47 116 0.4101 -14 -87 59 0.7081 
Week 8 -21 -115 74 0.6686 3 -79 84 0.9523 -56 -129 17 0.1396 
Week 12 -5 -99 90 0.923 79 -3 161 0.0615 -82 -155 -9 0.0298 
Week 16 -25 -120 69 0.5999 8 -74 90 0.8482 -83 -156 -10 0.0283 
Week 24 -12 -106 82 0.8037 -3 -85 79 0.9428 -87 -160 -14 0.0217 
Week 48 33 -62 127 0.4991 -6 -87 76 0.8953 -90 -163 -17 0.0185 
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Appendix Table 13 Changes from baseline in IL-2 ELISpot responses to peptide pools from FIT Biotech. 
Mean change (mean Δ) from baseline to each of the study time points is shown, with lower and upper confidence 
intervals (CI) and the corresponding p value. P values in red are significant (where p ≤ 0.05) and p values in blue are 
approaching significance (0.05 < p ≤ 0.1). 
 
IL-2 Group 1 Group 2 Group 3 
p17/p24 Mean ∆ Lower CI Upper CI P value Mean ∆ Lower CI Upper CI P value Mean ∆ Lower CI Upper CI P value 
Week 1 13 -35 61 0.5866 -8 -49 34 0.7238 -23 -60 14 0.2235 
Week 2 -14 -62 34 0.568 -7 -48 35 0.7594 1 -36 38 0.9664 
Week 4 29 -19 77 0.2439 -7 -48 34 0.7415 -29 -66 8 0.1265 
Week 6 5 -43 53 0.8277 9 -32 50 0.6715 -18 -55 19 0.3336 
Week 8 -15 -63 33 0.5318 -4 -45 37 0.8505 -20 -57 17 0.284 
Week 12 -18 -66 30 0.4632 29 -12 70 0.1741 -28 -65 9 0.1427 
Week 16 -8 -56 40 0.744 -6 -47 36 0.7955 -29 -66 8 0.1265 
Week 24 -1 -49 47 0.9783 -8 -49 34 0.7238 -34 -71 3 0.076 
Week 48 79 31 127 0.0017 4 -37 45 0.8505 -24 -61 13 0.2081 
Nef             
Week 1 1 -25 26 0.9594 0 -22 22 1 -1 -21 19 0.9371 
Week 2 -5 -31 20 0.6838 0 -22 22 1 32 12 52 0.0022 
Week 4 3 -23 28 0.8386 -3 -25 20 0.8254 -2 -22 18 0.8436 
Week 6 -1 -26 25 0.9594 2 -21 24 0.8947 -4 -24 16 0.6933 
Week 8 -13 -39 12 0.3098 3 -20 25 0.8254 -2 -22 18 0.8436 
Week 12 -15 -40 11 0.2642 5 -18 27 0.6915 -3 -23 17 0.7824 
Week 16 -14 -40 12 0.2864 3 -20 25 0.8254 1 -19 21 0.9371 
Week 24 -12 -38 14 0.3604 -1 -23 21 0.9297 0 -20 20 1 
Week 48 4 -22 30 0.7599 2 -21 24 0.8947 1 -19 21 0.9058 
Tat             
Week 1 3 -21 26 0.8248 -4 -24 16 0.7014 -3 -21 15 0.7316 
Week 2 7 -16 31 0.543 -3 -23 17 0.7737 35 17 53 0.0003 
Week 4 4 -20 28 0.7398 -4 -24 17 0.7372 3 -15 21 0.7641 
Week 6 2 -22 26 0.8681 -5 -25 16 0.6663 -2 -20 16 0.8302 
Week 8 -7 -30 17 0.5802 -2 -22 18 0.8479 -2 -20 16 0.8302 
Week 12 -2 -26 22 0.8681 -2 -22 19 0.8856 -3 -21 15 0.7641 
Week 16 -5 -28 19 0.6985 -3 -23 17 0.7737 -1 -19 17 0.8976 
Week 24 -4 -28 20 0.7398 -2 -22 19 0.8856 -4 -22 15 0.6997 
Week 48 -4 -28 20 0.7398 -4 -24 16 0.7014 -4 -23 14 0.6374 
Rev             
Week 1 1 -20 23 0.9045 1 -18 20 0.9173 -1 -18 16 0.926 
Week 2 15 -7 36 0.1893 1 -18 19 0.9586 35 18 52 0.0001 
Week 4 -1 -22 21 0.9522 0 -19 19 1 -2 -19 15 0.8163 
Week 6 3 -19 24 0.8104 0 -19 19 1 -3 -20 14 0.7451 
Week 8 1 -20 23 0.9045 2 -17 20 0.8762 -3 -20 14 0.7102 
Week 12 7 -14 29 0.5099 2 -17 21 0.8354 -3 -20 14 0.7102 
Week 16 -2 -24 20 0.8572 2 -17 20 0.8762 0 -17 17 1 
Week 24 0 -22 22 1 1 -18 19 0.9586 -4 -21 13 0.6424 
Week 48 -2 -24 20 0.8572 3 -16 22 0.7553 -1 -18 16 0.8891 
CTL             
Week 1 -6 -29 17 0.6151 -2 -22 19 0.8845 -2 -20 16 0.795 
Week 2 -2 -25 21 0.8668 0 -20 20 1 34 16 52 0.0003 
Week 4 6 -17 29 0.6151 -3 -23 18 0.8087 -2 -20 16 0.8286 
Week 6 -1 -24 23 0.9554 -1 -21 19 0.9229 -2 -20 16 0.795 
Week 8 -3 -27 20 0.7799 2 -19 22 0.8845 -1 -19 17 0.931 
Week 12 -2 -25 21 0.8668 8 -13 28 0.4684 -2 -20 16 0.795 
Week 16 -9 -33 14 0.4346 3 -17 23 0.7715 -1 -19 17 0.8966 
Week 24 -3 -26 21 0.8231 -2 -22 19 0.8845 -3 -21 15 0.7618 
Week 48 15 -8 39 0.2007 0 -20 20 1 -3 -21 15 0.7291 
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Appendix Table 14 Changes from baseline in IL-4 ELISpot responses to peptide pools from FIT Biotech. 
Mean change (mean Δ) from baseline to each of the study time points is shown, with lower and upper confidence 
intervals (CI) and the corresponding p value. P values in red are significant (where p ≤ 0.05) and p values in blue are 
approaching significance (0.05 < p ≤ 0.1). 
 
IL-4 Group 1 Group 2 Group 3 
p17/p24 Mean ∆ Lower CI Upper CI P value Mean ∆ Lower CI Upper CI P value Mean ∆ Lower CI Upper CI P value 
Week 1 -7 -29 16 0.5634 6 -14 26 0.5482 12 -5 30 0.1674 
Week 2 -5 -28 17 0.6438 -2 -21 18 0.8806 0 -17 18 0.9643 
Week 4 -9 -31 14 0.4529 -1 -20 19 0.96 14 -4 31 0.1304 
Week 6 -5 -28 17 0.6438 1 -19 21 0.9202 1 -16 19 0.8931 
Week 8 -9 -31 14 0.4529 2 -18 21 0.8806 1 -16 19 0.8931 
Week 12 -7 -29 16 0.5634 2 -18 22 0.8412 4 -13 21 0.6543 
Week 16 -8 -31 15 0.4883 3 -17 23 0.7638 6 -11 24 0.4741 
Week 24 -3 -26 19 0.7725 1 -19 21 0.9202 5 -13 22 0.5911 
Week 48 -6 -29 17 0.603 38 18 58 0.0003 4 -13 22 0.6224 
Nef             
Week 1 -5 -14 5 0.3398 -7 -15 2 0.1264 1 -7 8 0.8322 
Week 2 -7 -16 3 0.1739 -7 -15 1 0.1001 -5 -13 2 0.171 
Week 4 -9 -18 1 0.0783 -8 -16 1 0.0785 5 -3 12 0.2059 
Week 6 -6 -16 4 0.2206 -7 -15 2 0.1264 -2 -10 5 0.5256 
Week 8 -7 -17 2 0.1352 -7 -15 2 0.1264 -5 -13 2 0.171 
Week 12 -7 -17 2 0.1352 -6 -14 3 0.195 -3 -10 5 0.4591 
Week 16 -7 -16 3 0.1739 -6 -14 2 0.1578 2 -5 9 0.5967 
Week 24 -5 -14 5 0.3398 -8 -16 0 0.0609 -3 -11 4 0.3978 
Week 48 -8 -18 2 0.1036 -1 -9 8 0.9057 -3 -11 4 0.3978 
Tat             
Week 1 -7 -15 2 0.1199 -2 -9 6 0.6841 -1 -7 6 0.8082 
Week 2 -1 -9 8 0.8755 -1 -8 7 0.8921 -4 -11 2 0.1842 
Week 4 -5 -14 3 0.2122 -2 -9 6 0.6841 4 -2 10 0.2269 
Week 6 -5 -13 4 0.2745 1 -6 8 0.7861 0 -7 6 0.9034 
Week 8 -6 -14 2 0.161 6 -1 13 0.1062 -2 -8 5 0.6276 
Week 12 -5 -14 3 0.2122 0 -7 7 1 -3 -9 4 0.3966 
Week 16 -5 -13 4 0.2745 3 -5 10 0.4981 2 -5 8 0.6276 
Week 24 -4 -12 4 0.3484 -1 -8 6 0.7861 -3 -9 4 0.3966 
Week 48 -4 -12 4 0.3484 9 2 16 0.0164 -1 -7 6 0.8082 
Rev             
Week 1 -7 -14 1 0.0839 -2 -8 4 0.5461 1 -5 7 0.6853 
Week 2 -7 -14 1 0.0839 -2 -8 5 0.6506 -3 -9 3 0.2814 
Week 4 -6 -13 1 0.1191 -4 -10 3 0.2919 -1 -7 5 0.787 
Week 6 -3 -11 4 0.3841 -3 -9 3 0.3659 -1 -7 5 0.6853 
Week 8 -5 -13 2 0.1653 -2 -8 5 0.6506 -3 -9 3 0.2814 
Week 12 -2 -9 5 0.601 -1 -7 5 0.7626 -3 -9 3 0.3455 
Week 16 -6 -13 1 0.1191 -3 -9 4 0.4508 -4 -9 2 0.226 
Week 24 -3 -11 4 0.3841 -4 -10 2 0.2289 -1 -7 5 0.787 
Week 48 -7 -14 1 0.0839 5 -1 11 0.1335 0 -6 6 1 
CTL             
Week 1 -5 -11 2 0.1525 1 -4 6 0.7217 1 -4 6 0.7501 
Week 2 1 -6 7 0.837 1 -5 6 0.8586 0 -5 5 0.8734 
Week 4 -5 -12 1 0.1027 -2 -7 4 0.5934 0 -5 5 0.8734 
Week 6 -4 -10 2 0.2193 1 -5 6 0.8586 0 -5 5 0.8734 
Week 8 -3 -9 4 0.4116 0 -5 5 1 0 -5 5 1 
Week 12 -6 -12 0 0.0669 1 -5 6 0.8586 3 -2 8 0.2665 
Week 16 -5 -12 1 0.1027 1 -4 6 0.7217 2 -3 7 0.3404 
Week 24 -5 -11 2 0.1525 -2 -7 4 0.5934 2 -3 7 0.5244 
Week 48 -3 -10 3 0.3053 8 2 13 0.0089 3 -2 8 0.2665 
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Appendix Table 15 Changes from baseline in perforin ELISpot responses to peptide pools from FIT Biotech. 
Mean change (mean Δ) from baseline to each of the study time points is shown, with lower and upper confidence 
intervals (CI) and the corresponding p value. P values in red are significant (where p ≤ 0.05) and p values in blue are 
approaching significance (0.05 < p ≤ 0.1). 
 
Perforin Group 1 Group 2 Group 3 
p17/p24 Mean ∆ Lower CI Upper CI P value Mean ∆ Lower CI Upper CI P value Mean ∆ Lower CI Upper CI P value 
Week 1 -6 -90 78 0.8889 -11 -84 62 0.7675 13 -52 78 0.7005 
Week 2 -17 -101 67 0.6981 -55 -128 18 0.1418 -26 -91 39 0.4283 
Week 4 -7 -91 77 0.8766 -58 -130 15 0.1248 -26 -91 39 0.4283 
Week 6 3 -81 87 0.9381 10 -63 82 0.7984 -32 -97 33 0.3315 
Week 8 27 -57 111 0.5351 -43 -115 30 0.255 10 -55 75 0.7729 
Week 12 54 -30 138 0.2108 24 -49 97 0.5192 -6 -71 59 0.8474 
Week 16 -7 -91 77 0.8766 -18 -91 55 0.6286 4 -61 69 0.9138 
Week 24 -5 -89 79 0.9012 -51 -124 22 0.1727 -24 -89 41 0.4787 
Week 48 95 11 179 0.0287 -16 -88 57 0.677 -7 -72 58 0.838 
Nef             
Week 1 -13 -120 95 0.8184 -1 -94 93 0.9916 73 -10 157 0.0895 
Week 2 -22 -130 86 0.6901 -43 -136 51 0.3747 -56 -140 27 0.1891 
Week 4 -21 -128 87 0.708 -37 -130 56 0.4394 -35 -119 48 0.4109 
Week 6 -6 -114 102 0.9134 -1 -94 92 0.9833 -78 -161 5 0.0707 
Week 8 23 -84 131 0.6724 -52 -145 42 0.2826 -24 -107 59 0.5746 
Week 12 27 -80 135 0.6204 41 -53 134 0.3975 -25 -109 58 0.5557 
Week 16 -27 -134 81 0.629 43 -50 136 0.3692 -36 -120 47 0.3952 
Week 24 -24 -132 84 0.6636 -32 -125 61 0.5035 -85 -169 -2 0.0488 
Week 48 42 -66 150 0.4471 -8 -101 86 0.8752 29 -55 112 0.5008 
Tat             
Week 1 -10 -171 151 0.9035 -1 -140 139 0.9944 111 -14 236 0.0846 
Week 2 -26 -187 135 0.7527 -51 -190 89 0.4802 -30 -154 95 0.6434 
Week 4 -13 -174 148 0.8716 -22 -161 118 0.7635 16 -108 141 0.7974 
Week 6 -8 -169 153 0.9227 9 -131 149 0.8997 -50 -175 75 0.4347 
Week 8 23 -138 184 0.7835 -46 -185 94 0.5246 164 39 288 0.012 
Week 12 55 -106 216 0.5029 10 -130 150 0.8887 21 -104 146 0.7401 
Week 16 -27 -188 134 0.7465 34 -106 173 0.6393 -38 -163 86 0.5482 
Week 24 -30 -191 131 0.7162 -13 -152 127 0.8611 -66 -191 59 0.3032 
Week 48 93 -68 254 0.2631 -11 -150 129 0.8831 -24 -149 100 0.7026 
Rev             
Week 1 -3 -112 106 0.9524 -20 -115 75 0.6795 44 -41 129 0.3108 
Week 2 -2 -111 107 0.9714 -57 -151 38 0.2449 -46 -131 38 0.2853 
Week 4 -4 -113 105 0.9429 -31 -125 64 0.5289 -57 -142 27 0.1886 
Week 6 14 -95 123 0.8022 -4 -99 91 0.9341 -71 -155 14 0.1046 
Week 8 3 -106 112 0.9619 -47 -142 48 0.3327 33 -52 117 0.4493 
Week 12 23 -86 132 0.6764 27 -68 121 0.5842 -45 -130 39 0.2979 
Week 16 -15 -124 94 0.7838 35 -60 130 0.4701 -71 -156 13 0.1027 
Week 24 -13 -122 96 0.8114 -35 -130 60 0.4701 -48 -133 37 0.2691 
Week 48 85 -24 194 0.1294 7 -88 101 0.8931 36 -49 120 0.4117 
CTL             
Week 1 -37 -186 113 0.6324 21 -109 151 0.7517 63 -53 179 0.2885 
Week 2 -41 -190 109 0.5958 -155 -284 -25 0.022 -34 -150 82 0.5716 
Week 4 -41 -191 108 0.5898 -153 -283 -23 0.0232 -42 -158 74 0.4756 
Week 6 -17 -166 133 0.8278 -114 -244 16 0.0886 -52 -168 64 0.382 
Week 8 -6 -156 144 0.9376 -148 -277 -18 0.0285 136 20 252 0.0241 
Week 12 -17 -166 133 0.8278 -86 -216 44 0.1972 -32 -148 84 0.5854 
Week 16 -43 -192 107 0.5779 -98 -228 32 0.1423 -30 -146 86 0.6087 
Week 24 -43 -193 106 0.572 -129 -258 1 0.0555 -45 -161 71 0.447 
Week 48 41 -109 190 0.5958 -63 -192 67 0.3475 -17 -133 99 0.7771 
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Appendix Table 16 Changes from baseline in markers associated with CD4 T-cell immune activation. 
Mean change (mean Δ) from baseline to each of the study time points is shown, with lower and upper confidence 
intervals (CI) and the corresponding p value. P values in red are significant (where p ≤ 0.05) and p values in blue are 
approaching significance (0.05 < p ≤ 0.1). 
 
 Group 1 Group 2 Group 3 
%CD4+HLA-
DR+CD38+ 
Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value 
Week 1 -0.63 -3.69 2.42 0.6853 0.13 -2.52 2.77 0.9264 -0.14 -2.50 2.22 0.9079 
Week 2 18.27 15.21 21.32 <.0001 4.90 2.26 7.54 0.0005 18.06 15.70 20.42 <.0001 
Week 4 1.53 -1.52 4.59 0.3277 -0.55 -3.19 2.09 0.6845 -0.12 -2.48 2.24 0.921 
Week 6 -1.00 -4.05 2.05 0.5226 -0.65 -3.29 1.99 0.6311 -1.20 -3.56 1.16 0.3228 
Week 8 -1.30 -4.35 1.75 0.4063 -0.58 -3.22 2.07 0.671 -0.84 -3.20 1.52 0.4882 
Week 12 -0.07 -3.12 2.99 0.966 -0.30 -2.94 2.34 0.8245 -0.94 -3.30 1.42 0.4381 
Week 16 -0.90 -3.95 2.15 0.5649 0.33 -2.32 2.97 0.8102 -1.58 -3.94 0.78 0.194 
Week 24 -1.70 -4.75 1.35 0.2782 0.73 -1.92 3.37 0.5923 -0.98 -3.34 1.38 0.4189 
Week 48 -1.00 -4.05 2.05 0.5226 0.95 -1.69 3.59 0.4832 -1.10 -3.46 1.26 0.3645 
%CD4+HLA-
DR+ 
            
Week 1 -1.80 -5.23 1.63 0.3068 -0.35 -3.32 2.62 0.818 -0.20 -2.86 2.46 0.8831 
Week 2 16.23 12.80 19.66 <.0001 5.40 2.43 8.37 0.0006 18.20 15.54 20.86 <.0001 
Week 4 1.60 -1.83 5.03 0.3633 -0.38 -3.35 2.60 0.8052 0.46 -2.20 3.12 0.7352 
Week 6 -1.23 -4.66 2.20 0.483 -1.03 -4.00 1.95 0.5008 -1.52 -4.18 1.14 0.2655 
Week 8 -2.10 -5.53 1.33 0.2337 -0.55 -3.52 2.42 0.7176 -1.36 -4.02 1.30 0.3187 
Week 12 -0.17 -3.60 3.26 0.9244 -0.60 -3.57 2.37 0.6932 -1.22 -3.88 1.44 0.3708 
Week 16 -1.40 -4.83 2.03 0.4261 -1.05 -4.02 1.92 0.4904 -2.42 -5.08 0.24 0.078 
Week 24 -2.73 -6.16 0.70 0.1222 0.18 -2.80 3.15 0.9084 -0.94 -3.60 1.72 0.49 
Week 48 -1.30 -4.73 2.13 0.4597 -0.85 -3.82 2.12 0.5765 -1.60 -4.26 1.06 0.2413 
%CD4+CD38+             
Week 1 3.07 -3.75 9.89 0.3807 -2.23 -8.13 3.68 0.4624 1.38 -3.90 6.66 0.61 
Week 2 19.40 12.58 26.22 <.0001 6.05 0.14 11.96 0.048 21.78 16.50 27.06 <.0001 
Week 4 -2.03 -8.85 4.79 0.5606 -2.60 -8.51 3.31 0.3908 1.84 -3.44 7.12 0.4967 
Week 6 -12.77 -19.59 -5.95 0.0004 -5.13 -11.03 0.78 0.0928 -6.38 -11.66 -1.10 0.0203 
Week 8 -10.83 -17.65 -4.01 0.0026 -6.20 -12.11 -0.29 0.0429 -6.42 -11.70 -1.14 0.0196 
Week 12 -7.87 -14.69 -1.05 0.0264 -4.58 -10.48 1.33 0.1328 -7.04 -12.32 -1.76 0.0107 
Week 16 -12.17 -18.99 -5.35 0.0008 -1.68 -7.58 4.23 0.5798 -7.14 -12.42 -1.86 0.0097 
Week 24 -13.47 -20.29 -6.65 0.0002 -3.38 -9.28 2.53 0.266 -10.62 -15.90 -5.34 0.0002 
Week 48 -8.30 -15.12 -1.48 0.0194 -3.50 -9.41 2.41 0.2488 -6.14 -11.42 -0.86 0.0254 
CD4+HLA-DR 
MFI 
            
Week 1 -58 -3476 3361 0.9737 -306 -3267 2655 0.8401 -443 -3091 2205 0.7437 
Week 2 14785 11366 18204 <.0001 3793 832 6753 0.014 16939 14291 19587 <.0001 
Week 4 107 -3312 3526 0.9512 -366 -3327 2595 0.8093 -448 -3096 2200 0.741 
Week 6 -987 -4406 2431 0.5729 -46 -3007 2915 0.9757 -165 -2813 2483 0.903 
Week 8 -628 -4047 2790 0.7196 -7 -2967 2954 0.9966 -257 -2905 2392 0.8498 
Week 12 873 -2546 4292 0.6181 433 -2528 3393 0.7754 -137 -2785 2511 0.9195 
Week 16 545 -2873 3964 0.7554 1249 -1712 4209 0.411 810 -1838 3458 0.5506 
Week 24 1153 -2266 4572 0.5105 2597 -364 5558 0.0894 1318 -1330 3966 0.3321 
Week 48 1223 -2196 4642 0.4852 3407 446 6368 0.0268 2023 -625 4671 0.1382 
CD4+CD38 
MFI 
            
Week 1 85 -351 522 0.7026 -75 -453 303 0.6975 -33 -371 305 0.8479 
Week 2 1144 707 1581 <.0001 353 -25 731 0.0711 862 524 1200 <.0001 
Week 4 -225 -662 211 0.3147 -160 -538 218 0.4093 -405 -743 -67 0.0213 
Week 6 -528 -965 -92 0.0201 -86 -464 292 0.656 -351 -689 -13 0.0452 
Week 8 -320 -756 117 0.1551 -21 -399 357 0.9126 -324 -662 15 0.0643 
Week 12 -377 -814 60 0.0944 43 -335 421 0.8252 -267 -605 71 0.1254 
Week 16 -357 -793 80 0.1132 321 -58 699 0.1005 -54 -392 284 0.7542 
Week 24 -184 -621 253 0.4112 448 70 826 0.0227 125 -213 463 0.4701 
Week 48 -468 -905 -31 0.0387 -14 -392 364 0.9423 -346 -684 -8 0.0484 
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Appendix Table 17 Changes from baseline in markers associated with CD8 T-cell immune activation. 
Mean change (mean Δ) from baseline to each of the study time points is shown, with lower and upper confidence 
intervals (CI) and the corresponding p value. P values in red are significant (where p ≤ 0.05) and p values in blue are 
approaching significance (0.05 < p ≤ 0.1). 
 
 Group 1 Group 2 Group 3 
%CD8+HLA-
DR+CD38+ 
Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value 
Week 1 -1.47 -6.32 3.38 0.555 0.60 -3.60 4.80 0.7802 -0.20 -3.96 3.56 0.9171 
Week 2 30.90 26.05 35.75 <.0001 7.28 3.08 11.47 0.0011 13.86 10.10 17.62 <.0001 
Week 4 6.20 1.35 11.05 0.0142 0.08 -4.12 4.27 0.9722 -0.06 -3.82 3.70 0.9751 
Week 6 -1.00 -5.85 3.85 0.6871 -2.55 -6.75 1.65 0.2375 -1.58 -5.34 2.18 0.4121 
Week 8 -1.60 -6.45 3.25 0.5196 -0.85 -5.05 3.35 0.6926 -1.44 -5.20 2.32 0.4546 
Week 12 -1.43 -6.28 3.42 0.564 -0.03 -4.22 4.17 0.9907 -1.90 -5.66 1.86 0.3244 
Week 16 -1.03 -5.88 3.82 0.6773 2.58 -1.62 6.77 0.2329 -2.24 -6.00 1.52 0.2459 
Week 24 -3.53 -8.38 1.32 0.1571 0.83 -3.37 5.02 0.7012 -1.80 -5.56 1.96 0.3504 
Week 48 -1.27 -6.12 3.58 0.6101 1.35 -2.85 5.55 0.5304 -3.00 -6.76 0.76 0.1214 
%CD8+HLA-
DR+ 
            
Week 1 -2.20 -7.49 3.09 0.4177 -3.55 -8.13 1.03 0.133 -0.44 -4.54 3.66 0.8339 
Week 2 19.20 13.91 24.49 <.0001 3.38 -1.21 7.96 0.1529 10.38 6.28 14.48 <.0001 
Week 4 5.57 0.27 10.86 0.0425 -2.75 -7.33 1.83 0.2431 -1.28 -5.38 2.82 0.5423 
Week 6 2.13 -3.16 7.43 0.4319 -3.13 -7.71 1.46 0.1853 -2.24 -6.34 1.86 0.2875 
Week 8 0.20 -5.09 5.49 0.9412 0.25 -4.33 4.83 0.9151 -2.24 -6.34 1.86 0.2875 
Week 12 0.13 -5.16 5.43 0.9607 -0.80 -5.38 3.78 0.7332 -1.90 -6.00 2.20 0.3665 
Week 16 0.00 -5.29 5.29 1 -1.45 -6.03 3.13 0.537 -2.34 -6.44 1.76 0.2666 
Week 24 -2.40 -7.69 2.89 0.3768 -0.88 -5.46 3.71 0.7093 -0.44 -4.54 3.66 0.8339 
Week 48 4.43 -0.86 9.73 0.1046 0.60 -3.98 5.18 0.7982 -2.62 -6.72 1.48 0.214 
%CD8+CD38+             
Week 1 -0.17 -9.01 8.67 0.9706 0.30 -7.36 7.96 0.939 2.26 -4.59 9.11 0.5195 
Week 2 35.50 26.66 44.34 <.0001 12.73 5.07 20.38 0.0016 41.46 34.61 48.31 <.0001 
Week 4 7.23 -1.61 16.07 0.1127 1.58 -6.08 9.23 0.6878 10.30 3.45 17.15 0.0042 
Week 6 -8.37 -17.21 0.47 0.0672 -6.28 -13.93 1.38 0.1121 -3.52 -10.37 3.33 0.3167 
Week 8 -5.77 -14.61 3.07 0.2047 -3.93 -11.58 3.73 0.318 -2.86 -9.71 3.99 0.4154 
Week 12 -5.23 -14.07 3.61 0.2493 -1.25 -8.91 6.41 0.7498 -4.36 -11.21 2.49 0.2156 
Week 16 -7.60 -16.44 1.24 0.0958 5.43 -2.23 13.08 0.1687 -1.52 -8.37 5.33 0.6647 
Week 24 -12.77 -21.61 -3.93 0.0059 -0.55 -8.21 7.11 0.8884 -6.96 -13.81 -0.11 0.0497 
Week 48 -8.43 -17.27 0.41 0.0651 -2.28 -9.93 5.38 0.5619 -8.78 -15.63 -1.93 0.0139 
CD8+HLA-DR 
MFI 
            
Week 1 -332 -3228 2564 0.8226 140 -2368 2648 0.9133 -115 -2358 2129 0.9205 
Week 2 6605 3709 9501 <.0001 3305 797 5813 0.0116 11214 8971 13457 <.0001 
Week 4 -668 -3564 2228 0.6524 183 -2325 2691 0.8868 -28 -2271 2215 0.9805 
Week 6 -1201 -4097 1695 0.4187 516 -1992 3024 0.688 197 -2046 2440 0.8636 
Week 8 -1064 -3960 1832 0.4737 64 -2445 2572 0.9605 -120 -2363 2123 0.9166 
Week 12 798 -2098 3694 0.5908 95 -2413 2603 0.9408 -359 -2603 1884 0.7543 
Week 16 50 -2846 2946 0.9731 966 -1542 3474 0.4525 556 -1687 2799 0.6285 
Week 24 429 -2467 3325 0.7723 1873 -635 4381 0.1471 1464 -780 3707 0.2046 
Week 48 377 -2519 3273 0.7993 1503 -1005 4011 0.2435 130 -2113 2374 0.9096 
CD8+CD38 
MFI 
            
Week 1 84 -429 598 0.7485 -77 -522 368 0.7345 -88 -486 310 0.6673 
Week 2 2056 1543 2570 <.0001 620 175 1064 0.0078 1445 1047 1843 <.0001 
Week 4 120 -393 634 0.6474 -96 -541 349 0.6735 -145 -543 253 0.4778 
Week 6 -49 -563 465 0.8522 42 -403 487 0.8545 -216 -614 182 0.2896 
Week 8 20 -494 533 0.9404 34 -411 478 0.883 -220 -618 178 0.2809 
Week 12 25 -488 539 0.9232 18 -427 463 0.937 -210 -608 188 0.305 
Week 16 -30 -543 484 0.9102 99 -346 544 0.6639 -199 -597 199 0.3294 
Week 24 169 -345 683 0.5209 250 -195 695 0.274 -35 -433 363 0.8651 
Week 48 -31 -544 483 0.9071 130 -315 575 0.5684 -299 -697 99 0.1452 
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Appendix Table 18 Changes from baseline in markers associated with CD4 T-cell immune senescence and apoptosis. 
Mean change (mean Δ) from baseline to each of the study time points is shown, with lower and upper confidence 
intervals (CI) and the corresponding p value. P values in red are significant (where p ≤ 0.05) and p values in blue are 
approaching significance (0.05 < p ≤ 0.1). 
 
 Group 1 Group 2 Group 3 
%CD4+CD57+ 
CD95+ 
Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value 
Week 1 -0.60 -3.65 2.45 0.7013 0.90 -1.75 3.55 0.5068 1.12 -1.25 3.49 0.3563 
Week 2 -2.27 -5.32 0.79 0.1497 1.43 -1.22 4.07 0.2942 -2.06 -4.43 0.31 0.0918 
Week 4 -3.53 -6.59 -0.48 0.0261 0.43 -2.22 3.07 0.7537 -3.20 -5.57 -0.83 0.0097 
Week 6 -1.77 -4.82 1.29 0.2603 0.10 -2.55 2.75 0.9411 -1.88 -4.25 0.49 0.1233 
Week 8 -3.07 -6.12 -0.01 0.0525 0.70 -1.95 3.35 0.6054 -2.16 -4.53 0.21 0.0773 
Week 12 0.17 -2.89 3.22 0.9151 0.65 -2.00 3.30 0.6314 -1.18 -3.55 1.19 0.3313 
Week 16 -2.83 -5.89 0.22 0.0728 -1.10 -3.75 1.55 0.4175 -1.14 -3.51 1.23 0.3478 
Week 24 -2.93 -5.99 0.12 0.0634 -0.15 -2.80 2.50 0.9118 0.16 -2.21 2.53 0.8949 
Week 48 -2.93 -5.99 0.12 0.0634 -2.73 -5.37 -0.08 0.0468 -2.84 -5.21 -0.47 0.0211 
%CD4+CD57+             
Week 1 -0.67 -3.90 2.57 0.6871 0.95 -1.85 3.75 0.5079 1.18 -1.32 3.68 0.3584 
Week 2 -2.60 -5.83 0.63 0.1188 1.48 -1.32 4.27 0.3048 -2.32 -4.82 0.18 0.0731 
Week 4 -3.70 -6.93 -0.47 0.0276 0.38 -2.42 3.17 0.7936 -3.32 -5.82 -0.82 0.0111 
Week 6 -1.73 -4.97 1.50 0.2964 0.13 -2.67 2.92 0.9305 -1.96 -4.46 0.54 0.1289 
Week 8 -3.10 -6.33 0.13 0.0638 0.68 -2.12 3.47 0.6378 -1.68 -4.18 0.82 0.1922 
Week 12 0.23 -3.00 3.47 0.8878 0.73 -2.07 3.52 0.6131 -1.20 -3.70 1.30 0.3504 
Week 16 -3.00 -6.23 0.23 0.0726 -1.18 -3.97 1.62 0.4131 -1.16 -3.66 1.34 0.3666 
Week 24 -3.07 -6.30 0.17 0.0666 -0.05 -2.85 2.75 0.9722 0.20 -2.30 2.70 0.876 
Week 48 -2.97 -6.20 0.27 0.0758 -2.90 -5.70 -0.10 0.0456 -2.98 -5.48 -0.48 0.0221 
%CD4+CD95+             
Week 1 -2.13 -6.80 2.53 0.373 2.20 -1.84 6.24 0.2893 -1.28 -4.90 2.34 0.4898 
Week 2 18.57 13.90 23.23 <.0001 6.05 2.01 10.09 0.0044 17.20 13.58 20.82 <.0001 
Week 4 12.57 7.90 17.23 <.0001 0.43 -3.62 4.47 0.8373 7.32 3.70 10.94 0.0002 
Week 6 9.53 4.87 14.20 0.0001 2.33 -1.72 6.37 0.263 4.60 0.98 8.22 0.0147 
Week 8 7.10 2.43 11.77 0.0038 2.50 -1.54 6.54 0.229 4.14 0.52 7.76 0.0275 
Week 12 5.93 1.27 10.60 0.0148 3.88 -0.17 7.92 0.0639 4.68 1.06 8.30 0.0131 
Week 16 7.77 3.10 12.43 0.0016 2.55 -1.49 6.59 0.2199 3.30 -0.32 6.92 0.0774 
Week 24 6.77 2.10 11.43 0.0057 2.30 -1.74 6.34 0.2681 4.76 1.14 8.38 0.0117 
Week 48 3.33 -1.33 8.00 0.1654 -0.40 -4.44 3.64 0.8467 0.50 -3.12 4.12 0.7871 
CD4+CD57 
MFI 
            
Week 1 -12 -2184 2161 0.9916 824 -1058 2706 0.3933 866 -817 2549 0.3164 
Week 2 -2193 -4366 -21 0.0513 -230 -2111 1652 0.8115 -2216 -3899 -533 0.0117 
Week 4 -2587 -4760 -415 0.0221 1646 -236 3527 0.0903 -2136 -3819 -453 0.0149 
Week 6 -1527 -3699 646 0.1723 847 -1035 2728 0.3804 -49 -1732 1634 0.9546 
Week 8 -1222 -3394 951 0.2737 966 -915 2848 0.3172 3 -1680 1686 0.9974 
Week 12 1065 -1108 3237 0.3397 970 -912 2852 0.3153 -22 -1705 1661 0.9796 
Week 16 -1956 -4129 216 0.0814 -757 -2638 1125 0.4329 -738 -2421 945 0.3926 
Week 24 -804 -2977 1368 0.4702 1593 -288 3475 0.1009 949 -734 2632 0.2722 
Week 48 -1940 -4113 232 0.0838 -1130 -3011 752 0.2428 -942 -2625 741 0.2761 
CD4+CD95 
MFI 
            
Week 1 257 -862 1377 0.6536 15 -955 985 0.9759 -91 -958 777 0.8379 
Week 2 3750 2630 4869 <.0001 790 -179 1760 0.1141 4068 3200 4935 <.0001 
Week 4 63 -1057 1183 0.9125 -62 -1032 907 0.9002 -121 -989 746 0.7849 
Week 6 -471 -1591 648 0.4118 109 -861 1078 0.827 -96 -963 771 0.8288 
Week 8 7 -1113 1127 0.9903 123 -846 1093 0.8039 97 -770 964 0.8271 
Week 12 -219 -1339 901 0.7025 103 -867 1072 0.836 -135 -1002 733 0.7618 
Week 16 486 -634 1605 0.3978 55 -914 1025 0.9114 -214 -1081 654 0.6306 
Week 24 -623 -1743 497 0.2787 855 -115 1824 0.0879 594 -274 1461 0.1836 
Week 48 -1562 -2682 -442 0.0077 -739 -1709 230 0.139 -1675 -2542 -808 0.0003 
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Appendix Table 19 Changes from baseline in markers associated with CD8 T-cell immune senescence and apoptosis. 
Mean change (mean Δ) from baseline to each of the study time points is shown, with lower and upper confidence 
intervals (CI) and the corresponding p value. P values in red are significant (where p ≤ 0.05) and p values in blue are 
approaching significance (0.05 < p ≤ 0.1). 
 
 Group 1 Group 2 Group 3 
%CD8+CD57+ 
CD95+ 
Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value 
Week 1 -0.73 -8.07 6.60 0.8451 -0.10 -6.45 6.25 0.9755 5.20 -0.48 10.88 0.0766 
Week 2 -3.60 -10.94 3.74 0.3389 -1.75 -8.10 4.60 0.5907 -6.06 -11.74 -0.38 0.0397 
Week 4 -5.47 -12.80 1.87 0.148 -0.20 -6.55 6.15 0.9509 -5.46 -11.14 0.22 0.0632 
Week 6 -0.10 -7.44 7.24 0.9787 -1.65 -8.00 4.70 0.6121 -5.26 -10.94 0.42 0.0733 
Week 8 -3.40 -10.74 3.94 0.3663 -1.40 -7.75 4.95 0.6669 -7.84 -13.52 -2.16 0.0083 
Week 12 3.70 -3.64 11.04 0.3258 0.45 -5.90 6.80 0.8899 -5.12 -10.80 0.56 0.0811 
Week 16 -3.80 -11.14 3.54 0.313 -4.25 -10.60 2.10 0.1935 -5.18 -10.86 0.50 0.0777 
Week 24 -2.73 -10.07 4.60 0.4673 0.10 -6.25 6.45 0.9755 -1.94 -7.62 3.74 0.5053 
Week 48 -4.03 -11.37 3.30 0.2844 -6.15 -12.50 0.20 0.0613 -10.52 -16.20 -4.84 0.0005 
%CD8+CD57+             
Week 1 -0.97 -8.37 6.44 0.7987 -0.20 -6.61 6.21 0.9514 5.00 -0.73 10.73 0.0913 
Week 2 -4.10 -11.50 3.30 0.281 -1.90 -8.31 4.51 0.563 -6.70 -12.43 -0.97 0.0246 
Week 4 -5.33 -12.74 2.07 0.1618 -0.25 -6.66 6.16 0.9393 -5.76 -11.49 -0.03 0.0524 
Week 6 0.00 -7.40 7.40 1 -1.53 -7.94 4.89 0.6424 -5.52 -11.25 0.21 0.0628 
Week 8 -3.43 -10.84 3.97 0.3661 -1.30 -7.71 5.11 0.6921 -7.90 -13.63 -2.17 0.0084 
Week 12 3.77 -3.64 11.17 0.3217 0.35 -6.06 6.76 0.9151 -5.20 -10.93 0.53 0.0793 
Week 16 -3.87 -11.27 3.54 0.3091 -4.18 -10.59 2.24 0.2055 -5.14 -10.87 0.59 0.0828 
Week 24 -2.80 -10.20 4.60 0.4607 0.10 -6.31 6.51 0.9757 -2.24 -7.97 3.49 0.4462 
Week 48 -3.80 -11.20 3.60 0.3174 -6.68 -13.09 -0.26 0.0446 -10.40 -16.13 -4.67 0.0006 
%CD8+CD95+             
Week 1 -0.57 -6.78 5.65 0.8587 -2.35 -7.74 3.04 0.3949 1.04 -3.78 5.86 0.6733 
Week 2 6.00 -0.22 12.22 0.0622 2.15 -3.24 7.54 0.4362 -1.22 -6.04 3.60 0.6209 
Week 4 4.13 -2.08 10.35 0.1963 1.35 -4.04 6.74 0.6245 -0.42 -5.24 4.40 0.8647 
Week 6 3.67 -2.55 9.88 0.2512 1.20 -4.19 6.59 0.6634 2.82 -2.00 7.64 0.2545 
Week 8 1.97 -4.25 8.18 0.5371 1.03 -4.36 6.41 0.7101 -2.04 -6.86 2.78 0.4089 
Week 12 3.87 -2.35 10.08 0.2265 3.70 -1.69 9.09 0.1818 1.54 -3.28 6.36 0.5326 
Week 16 3.10 -3.12 9.32 0.3314 0.50 -4.89 5.89 0.856 0.22 -4.60 5.04 0.9289 
Week 24 3.30 -2.92 9.52 0.3014 1.30 -4.09 6.69 0.6374 4.98 0.16 9.80 0.046 
Week 48 -0.37 -6.58 5.85 0.9083 -0.18 -5.56 5.21 0.9494 -3.64 -8.46 1.18 0.1424 
CD8+CD57 
MFI 
            
Week 1 171 -1328 1669 0.824 258 -1040 1556 0.6981 637 -524 1798 0.2855 
Week 2 -566 -2065 933 0.4613 241 -1057 1539 0.7166 -163 -1324 998 0.7841 
Week 4 -1831 -3329 -332 0.019 169 -1129 1466 0.7998 -1229 -2390 -68 0.0412 
Week 6 -407 -1905 1092 0.5963 -176 -1473 1122 0.7917 -724 -1885 437 0.2249 
Week 8 -936 -2434 563 0.2246 316 -982 1614 0.6343 -1275 -2436 -114 0.0343 
Week 12 -189 -1687 1310 0.8057 79 -1219 1377 0.9053 -1049 -2210 112 0.0803 
Week 16 -1244 -2743 254 0.1076 -256 -1553 1042 0.7006 -1020 -2181 141 0.0888 
Week 24 -338 -1837 1161 0.6597 872 -426 2170 0.1916 -242 -1403 919 0.6839 
Week 48 -1524 -3023 -25 0.0496 -604 -1902 694 0.3646 -1640 -2801 -479 0.007 
CD8+CD95 
MFI 
            
Week 1 258 -721 1237 0.6069 35 -813 882 0.9366 -35 -793 724 0.9286 
Week 2 1903 924 2882 0.0003 463 -385 1311 0.2876 2848 2089 3606 <.0001 
Week 4 79 -900 1058 0.8752 27 -821 875 0.9499 148 -611 906 0.7034 
Week 6 -215 -1194 764 0.6685 79 -769 927 0.856 252 -507 1010 0.517 
Week 8 32 -947 1011 0.9485 90 -758 937 0.8366 545 -213 1304 0.1626 
Week 12 -21 -1000 958 0.9671 19 -829 867 0.9646 141 -617 900 0.7161 
Week 16 566 -413 1545 0.2608 24 -824 872 0.9559 25 -733 784 0.9482 
Week 24 -290 -1269 689 0.5636 520 -328 1368 0.2326 707 -51 1466 0.0712 
Week 48 -874 -1853 105 0.0838 -525 -1373 323 0.2286 -919 -1677 -160 0.0199 
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Appendix Table 20 Changes from baseline in markers associated with early, intermediate and late CD4 T- cells. 
Mean change (mean Δ) from baseline to each of the study time points is shown, with lower and upper confidence 
intervals (CI) and the corresponding p value. P values in red are significant (where p ≤ 0.05) and p values in blue are 
approaching significance (0.05 < p ≤ 0.1). 
 
 Group 1 Group 2 Group 3 
%CD4+CD27+ 
CD28+ 
Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value 
Week 1 2.33 -2.12 6.79 0.3079 -1.73 -5.58 2.13 0.3837 -2.12 -5.57 1.33 0.2323 
Week 2 -1.97 -6.42 2.49 0.3897 -2.75 -6.61 1.11 0.1664 2.70 -0.75 6.15 0.1292 
Week 4 0.13 -4.32 4.59 0.9534 1.45 -2.41 5.31 0.4637 0.70 -2.75 4.15 0.6921 
Week 6 0.57 -3.89 5.02 0.8038 -0.83 -4.68 3.03 0.6764 3.60 0.15 7.05 0.0442 
Week 8 2.27 -2.19 6.72 0.3218 -1.55 -5.41 2.31 0.4335 2.46 -0.99 5.91 0.1664 
Week 12 0.47 -3.99 4.92 0.8379 -2.35 -6.21 1.51 0.2362 1.58 -1.87 5.03 0.3724 
Week 16 2.57 -1.89 7.02 0.2624 0.05 -3.81 3.91 0.9798 -0.10 -3.55 3.35 0.9549 
Week 24 3.67 -0.79 8.12 0.1108 0.13 -3.73 3.98 0.9495 1.46 -1.99 4.91 0.4096 
Week 48 0.70 -3.76 5.16 0.759 0.93 -2.93 4.78 0.6398 0.68 -2.77 4.13 0.7005 
%CD4+CD27-
CD28+ 
            
Week 1 -0.67 -2.19 0.85 0.3921 0.53 -0.79 1.84 0.4363 -0.32 -1.50 0.86 0.5954 
Week 2 5.30 3.78 6.82 <.0001 0.95 -0.37 2.27 0.1607 2.22 1.04 3.40 0.0004 
Week 4 2.17 0.65 3.69 0.0065 0.40 -0.92 1.72 0.5528 1.90 0.72 3.08 0.0022 
Week 6 1.73 0.21 3.25 0.028 0.43 -0.89 1.74 0.5283 0.16 -1.02 1.34 0.7905 
Week 8 1.37 -0.15 2.89 0.0816 0.45 -0.87 1.77 0.5044 0.06 -1.12 1.24 0.9206 
Week 12 0.20 -1.32 1.72 0.797 1.40 0.08 2.72 0.0401 0.02 -1.16 1.20 0.9735 
Week 16 0.97 -0.55 2.49 0.2158 0.83 -0.49 2.14 0.2225 -0.30 -1.48 0.88 0.6186 
Week 24 0.97 -0.55 2.49 0.2158 1.03 -0.29 2.34 0.1306 -0.04 -1.22 1.14 0.947 
Week 48 -0.17 -1.69 1.35 0.8302 1.00 -0.32 2.32 0.1401 0.18 -1.00 1.36 0.765 
%CD4+CD27-
CD28- 
            
Week 1 -1.63 -5.67 2.40 0.4298 1.15 -2.34 4.64 0.5207 2.48 -0.64 5.60 0.1237 
Week 2 -3.37 -7.40 0.67 0.1058 1.83 -1.67 5.32 0.309 -4.70 -7.82 -1.58 0.0042 
Week 4 -2.47 -6.50 1.57 0.2343 -1.80 -5.29 1.69 0.3156 -2.58 -5.70 0.54 0.1095 
Week 6 -2.33 -6.37 1.70 0.2603 0.50 -2.99 3.99 0.7798 -3.62 -6.74 -0.50 0.0258 
Week 8 -3.63 -7.67 0.40 0.0813 1.10 -2.39 4.59 0.5389 -2.26 -5.38 0.86 0.1602 
Week 12 -0.87 -4.90 3.17 0.6748 1.00 -2.49 4.49 0.5763 -1.40 -4.52 1.72 0.3825 
Week 16 -3.57 -7.60 0.47 0.0869 -0.78 -4.27 2.72 0.6649 0.44 -2.68 3.56 0.7833 
Week 24 -4.60 -8.63 -0.57 0.0282 -1.10 -4.59 2.39 0.5389 -1.28 -4.40 1.84 0.4244 
Week 48 -0.77 -4.80 3.27 0.7105 -1.83 -5.32 1.67 0.309 -0.82 -3.94 2.30 0.6084 
CD4+CD27 
MFI 
            
Week 1 182 -333 698 0.49 30 -417 476 0.8972 29 -370 428 0.8871 
Week 2 168 -347 684 0.5238 -137 -583 310 0.5498 743 344 1143 0.0005 
Week 4 -309 -824 206 0.2433 -17 -463 430 0.9424 -341 -740 58 0.0979 
Week 6 -583 -1099 -68 0.0293 -35 -481 411 0.8782 -85 -484 314 0.6775 
Week 8 -449 -964 66 0.0915 -216 -662 230 0.3456 -285 -684 114 0.1652 
Week 12 -85 -601 430 0.7463 -411 -857 35 0.0748 -307 -706 92 0.1358 
Week 16 -273 -788 242 0.3022 -21 -468 425 0.9259 115 -284 514 0.5732 
Week 24 -80 -596 435 0.7607 -86 -533 360 0.7058 206 -194 605 0.3157 
Week 48 -349 -865 166 0.1877 34 -412 480 0.8817 -255 -654 144 0.2138 
CD4+CD28 
MFI 
            
Week 1 229 -974 1433 0.7098 -128 -1170 915 0.8111 262 -671 1194 0.5836 
Week 2 498 -706 1701 0.4201 281 -762 1323 0.599 914 -18 1846 0.0582 
Week 4 -274 -1478 929 0.6563 -149 -1191 894 0.7804 35 -897 968 0.9412 
Week 6 -980 -2183 224 0.1145 518 -525 1560 0.3332 92 -841 1024 0.8474 
Week 8 -251 -1455 953 0.6838 -151 -1194 891 0.7768 445 -488 1377 0.3527 
Week 12 -510 -1713 694 0.409 -68 -1110 975 0.8993 354 -578 1286 0.4589 
Week 16 722 -482 1925 0.2434 162 -881 1204 0.7622 854 -79 1786 0.0765 
Week 24 -1084 -2288 119 0.0812 228 -815 1270 0.6696 2092 1160 3025 <.0001 
Week 48 -2341 -3544 -1137 0.0003 -1126 -2168 -83 0.0373 -1876 -2808 -943 0.0002 
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Appendix Table 21 Changes from baseline in markers associated with early, intermediate and late CD8 T- cells. 
Mean change (mean Δ) from baseline to each of the study time points is shown, with lower and upper confidence 
intervals (CI) and the corresponding p value. P values in red are significant (where p ≤ 0.05) and p values in blue are 
approaching significance (0.05 < p ≤ 0.1). 
 
 Group 1 Group 2 Group 3 
%CD8+CD27+ 
CD28+ 
Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value 
Week 1 5.73 -1.43 12.89 0.1205 2.58 -3.63 8.78 0.4181 -5.84 -11.39 -0.29 0.0423 
Week 2 -0.87 -8.03 6.29 0.8131 0.95 -5.25 7.15 0.7648 4.12 -1.43 9.67 0.1493 
Week 4 -0.57 -7.73 6.59 0.8771 7.98 1.77 14.18 0.0137 4.78 -0.77 10.33 0.0951 
Week 6 1.20 -5.96 8.36 0.7434 3.18 -3.03 9.38 0.3186 8.16 2.61 13.71 0.005 
Week 8 1.53 -5.63 8.69 0.6758 6.70 0.50 12.90 0.0373 7.44 1.89 12.99 0.0102 
Week 12 -1.57 -8.73 5.59 0.6692 6.30 0.10 12.50 0.0498 7.46 1.91 13.01 0.0101 
Week 16 3.47 -3.69 10.63 0.3455 3.78 -2.43 9.98 0.2363 3.02 -2.53 8.57 0.2891 
Week 24 5.33 -1.83 12.49 0.1482 6.73 0.52 12.93 0.0366 4.72 -0.83 10.27 0.0992 
Week 48 2.73 -4.43 9.89 0.4566 5.23 -0.98 11.43 0.1025 6.74 1.19 12.29 0.0196 
%CD8+CD27+ 
CD28- 
            
Week 1 -1.03 -2.81 0.75 0.2587 -2.58 -4.12 -1.03 0.0016 0.10 -1.28 1.48 0.8874 
Week 2 -1.53 -3.31 0.25 0.0953 -1.90 -3.44 -0.36 0.018 0.06 -1.32 1.44 0.9323 
Week 4 -0.17 -1.95 1.61 0.8549 -3.15 -4.69 -1.61 0.0001 -2.08 -3.46 -0.70 0.0041 
Week 6 -0.80 -2.58 0.98 0.3812 -1.25 -2.79 0.29 0.116 -0.94 -2.32 0.44 0.1854 
Week 8 -0.97 -2.75 0.81 0.2905 -4.48 -6.02 -2.93 <.0001 -1.20 -2.58 0.18 0.092 
Week 12 0.87 -0.91 2.65 0.343 -2.58 -4.12 -1.03 0.0016 -1.20 -2.58 0.18 0.092 
Week 16 -0.40 -2.18 1.38 0.6609 -1.60 -3.14 -0.06 0.0453 -0.14 -1.52 1.24 0.8428 
Week 24 -1.43 -3.21 0.35 0.1185 -1.98 -3.52 -0.43 0.0141 -0.40 -1.78 0.98 0.5713 
Week 48 -0.60 -2.38 1.18 0.5109 -3.43 -4.97 -1.88 <.0001 -1.20 -2.58 0.18 0.092 
%CD8+CD27-
CD28- 
            
Week 1 -5.13 -12.57 2.30 0.1799 -0.43 -6.87 6.02 0.8974 5.80 0.04 11.56 0.0519 
Week 2 -2.73 -10.17 4.70 0.4734 0.23 -6.22 6.67 0.9456 -8.12 -13.88 -2.36 0.0071 
Week 4 -0.83 -8.27 6.60 0.8267 -5.68 -12.12 0.77 0.088 -3.12 -8.88 2.64 0.2916 
Week 6 -1.07 -8.50 6.37 0.7794 -1.93 -8.37 4.52 0.5597 -7.68 -13.44 -1.92 0.0107 
Week 8 -1.43 -8.87 6.00 0.7066 -5.38 -11.82 1.07 0.1058 -7.38 -13.14 -1.62 0.014 
Week 12 0.57 -6.87 8.00 0.8817 -4.43 -10.87 2.02 0.1819 -6.58 -12.34 -0.82 0.0279 
Week 16 -3.77 -11.20 3.67 0.3238 -2.18 -8.62 4.27 0.5099 -2.90 -8.66 2.86 0.3268 
Week 24 -4.70 -12.14 2.74 0.2191 -5.28 -11.72 1.17 0.1123 -4.38 -10.14 1.38 0.1401 
Week 48 -2.17 -9.60 5.27 0.5696 -1.68 -8.12 4.77 0.6116 -5.46 -11.22 0.30 0.0669 
CD8+CD27 
MFI 
            
Week 1 221 -190 633 0.2951 -3 -359 354 0.988 21 -298 339 0.8996 
Week 2 47 -365 459 0.8235 -62 -418 295 0.7351 437 118 756 0.0088 
Week 4 -270 -682 141 0.2017 67 -290 424 0.7136 -235 -554 84 0.1528 
Week 6 -372 -784 40 0.0803 -19 -376 338 0.9171 -109 -428 209 0.5032 
Week 8 -251 -662 161 0.2362 -81 -438 275 0.6563 -250 -569 69 0.1286 
Week 12 -61 -472 351 0.7734 -289 -645 68 0.1166 -174 -493 145 0.2885 
Week 16 -102 -514 310 0.6285 49 -308 406 0.7883 107 -212 426 0.5126 
Week 24 70 -342 482 0.7398 3 -354 360 0.9869 83 -236 402 0.6113 
Week 48 -202 -614 209 0.3382 145 -211 502 0.4269 -76 -394 243 0.6434 
CD8+CD28 
MFI 
            
Week 1 256 -1197 1709 0.7307 -471 -1729 788 0.4655 237 -888 1362 0.6809 
Week 2 155 -1298 1608 0.8352 -280 -1538 979 0.6642 631 -494 1757 0.2749 
Week 4 99 -1354 1552 0.8941 -419 -1677 839 0.5158 206 -919 1332 0.7204 
Week 6 -302 -1755 1151 0.6845 24 -1234 1282 0.9703 333 -793 1458 0.564 
Week 8 -20 -1473 1433 0.9785 -394 -1652 864 0.5411 490 -635 1616 0.3956 
Week 12 431 -1022 1884 0.5623 344 -915 1602 0.5941 1057 -68 2183 0.0693 
Week 16 2038 585 3491 0.0074 995 -264 2253 0.1252 1881 756 3007 0.0015 
Week 24 73 -1380 1526 0.9214 670 -589 1928 0.2999 3432 2307 4558 <.0001 
Week 48 -1723 -3176 -270 0.0226 -783 -2041 476 0.2264 -1456 -2581 -330 0.0132 
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Appendix Table 22 Changes from baseline in markers associated with a regulatory T-cell phenotype. 
Mean change (mean Δ) from baseline to each of the study time points is shown, with lower and upper confidence 
intervals (CI) and the corresponding p value. P values in red are significant (where p ≤ 0.05) and p values in blue are 
approaching significance (0.05 < p ≤ 0.1). 
 
 Group 1 Group 2 Group 3 
%CD4+CD45RO+ 
CD25high 
Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value 
Week 1 -0.43 -3.02 2.16 0.7437 -0.10 -2.34 2.14 0.9306 0.26 -1.75 2.27 0.8 
Week 2 6.97 4.38 9.56 <.0001 0.05 -2.19 2.29 0.9652 10.98 8.97 12.99 <.0001 
Week 4 0.23 -2.36 2.82 0.8602 0.38 -1.87 2.62 0.7439 1.92 -0.09 3.93 0.0642 
Week 6 -0.27 -2.86 2.32 0.8405 0.43 -1.82 2.67 0.7112 1.32 -0.69 3.33 0.2007 
Week 8 -0.37 -2.96 2.22 0.782 -0.03 -2.27 2.22 0.9826 0.36 -1.65 2.37 0.7259 
Week 12 0.13 -2.46 2.72 0.9198 0.65 -1.59 2.89 0.5714 0.96 -1.05 2.97 0.3509 
Week 16 0.10 -2.49 2.69 0.9398 0.70 -1.54 2.94 0.5423 0.50 -1.51 2.51 0.6264 
Week 24 0.00 -2.59 2.59 1 0.80 -1.44 3.04 0.4863 0.74 -1.27 2.75 0.4716 
Week 48 0.17 -2.42 2.76 0.8999 0.50 -1.74 2.74 0.6632 0.84 -1.17 2.85 0.4141 
%CD4+CD45RO+ 
CD25+ 
            
Week 1 -1.03 -7.79 5.72 0.765 3.68 -2.17 9.52 0.2217 -0.12 -5.35 5.11 0.9643 
Week 2 16.20 9.45 22.95 <.0001 4.80 -1.05 10.65 0.1116 20.20 14.97 25.43 <.0001 
Week 4 10.40 3.65 17.15 0.0034 1.45 -4.40 7.30 0.6284 9.76 4.53 14.99 0.0005 
Week 6 4.20 -2.55 10.95 0.2264 3.23 -2.62 9.07 0.283 3.64 -1.59 8.87 0.1764 
Week 8 4.63 -2.12 11.39 0.1825 5.08 -0.77 10.92 0.0929 3.54 -1.69 8.77 0.1885 
Week 12 1.20 -5.55 7.95 0.7286 8.98 3.13 14.82 0.0035 5.80 0.57 11.03 0.0327 
Week 16 3.07 -3.69 9.82 0.3761 7.23 1.38 13.07 0.0177 4.20 -1.03 9.43 0.1195 
Week 24 4.67 -2.09 11.42 0.1794 4.93 -0.92 10.77 0.1027 -0.22 -5.45 5.01 0.9345 
Week 48 10.00 3.25 16.75 0.0048 6.95 1.10 12.80 0.0224 5.78 0.55 11.01 0.0333 
%CD4+CD25+             
Week 1 -0.77 -8.69 7.16 0.8501 4.10 -2.76 10.96 0.2451 0.18 -5.96 6.32 0.9543 
Week 2 16.97 9.04 24.89 <.0001 4.05 -2.81 10.91 0.2509 26.06 19.92 32.20 <.0001 
Week 4 12.17 4.24 20.09 0.0035 3.30 -3.56 10.16 0.3488 13.80 7.66 19.94 <.0001 
Week 6 5.67 -2.26 13.59 0.1649 4.78 -2.09 11.64 0.1765 9.90 3.76 16.04 0.0022 
Week 8 7.23 -0.69 15.16 0.0774 5.48 -1.39 12.34 0.1219 7.04 0.90 13.18 0.0273 
Week 12 2.20 -5.73 10.13 0.5879 10.78 3.91 17.64 0.0029 9.12 2.98 15.26 0.0046 
Week 16 3.13 -4.79 11.06 0.4407 9.63 2.76 16.49 0.0074 7.54 1.40 13.68 0.0184 
Week 24 2.10 -5.83 10.03 0.605 6.00 -0.86 12.86 0.0905 -1.34 -7.48 4.80 0.6699 
Week 48 5.27 -2.66 13.19 0.1965 8.33 1.46 15.19 0.0198 4.20 -1.94 10.34 0.1837 
%CD4+CD45RO+             
Week 1 -1.50 -7.13 4.13 0.6033 2.18 -2.70 7.05 0.3849 0.98 -3.38 5.34 0.661 
Week 2 11.73 6.10 17.37 0.0001 3.20 -1.68 8.08 0.2023 13.52 9.16 17.88 <.0001 
Week 4 8.27 2.63 13.90 0.0052 -1.33 -6.20 3.55 0.596 7.80 3.44 12.16 0.0008 
Week 6 5.63 0.00 11.27 0.0535 0.68 -4.20 5.55 0.787 2.32 -2.04 6.68 0.3006 
Week 8 4.53 -1.10 10.17 0.1187 1.03 -3.85 5.90 0.6816 5.70 1.34 10.06 0.0123 
Week 12 3.70 -1.93 9.33 0.2017 1.65 -3.23 6.53 0.5094 5.30 0.94 9.66 0.0197 
Week 16 7.70 2.07 13.33 0.009 -0.30 -5.18 4.58 0.9044 3.34 -1.02 7.70 0.1375 
Week 24 10.27 4.63 15.90 0.0006 3.43 -1.45 8.30 0.1727 7.26 2.90 11.62 0.0016 
Week 48 8.97 3.33 14.60 0.0025 1.85 -3.03 6.73 0.4596 6.64 2.28 11.00 0.0038 
CD4+CD25 MFI             
Week 1 25 -280 330 0.8711 -137 -401 128 0.3143 14 -222 251 0.9066 
Week 2 1197 892 1502 <.0001 -83 -347 181 0.5411 1404 1168 1641 <.0001 
Week 4 211 -94 516 0.1798 -174 -438 90 0.1999 221 -16 457 0.0708 
Week 6 20 -285 325 0.8981 -141 -405 123 0.2988 76 -160 313 0.5282 
Week 8 5 -300 310 0.9728 -147 -411 117 0.2788 -7 -243 229 0.9539 
Week 12 -103 -408 202 0.5101 -156 -420 108 0.2499 -71 -308 165 0.5554 
Week 16 -92 -397 213 0.5562 -155 -419 109 0.2529 -31 -267 206 0.7991 
Week 24 -115 -420 190 0.4609 -196 -460 68 0.1499 -97 -333 140 0.4254 
Week 48 -94 -399 211 0.5477 -252 -516 12 0.0652 -99 -336 137 0.4131 
CD4+ 
CD45RO MFI 
            
Week 1 -487 -4554 3581 0.8152 -411 -3933 3112 0.8198 980 -2171 4130 0.5439 
Week 2 1341 -2727 5408 0.5201 178 -3345 3700 0.9216 3493 343 6643 0.0327 
Week 4 -675 -4743 3392 0.7457 229 -3294 3751 0.8991 327 -2824 3477 0.8395 
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Week 6 -2999 -7066 1069 0.1523 1273 -2249 4796 0.4807 -230 -3380 2921 0.8868 
Week 8 -527 -4595 3540 0.8 -38 -3561 3484 0.9831 2122 -1029 5272 0.1905 
Week 12 1234 -2834 5301 0.5538 409 -3114 3931 0.8208 972 -2178 4123 0.547 
Week 16 1845 -2222 5912 0.3766 3098 -425 6620 0.0886 2593 -557 5744 0.1105 
Week 24 2460 -1607 6528 0.2392 2760 -762 6283 0.1284 4792 1642 7942 0.0038 
Week 48 3244 -823 7311 0.1219 3042 -481 6564 0.0944 4194 1043 7344 0.0108 
 
Appendix Table 23 Changes from baseline in markers associated with CD4 T-cell differentiation/maturation. 
Mean change (mean Δ) from baseline to each of the study time points is shown, with lower and upper confidence 
intervals (CI) and the corresponding p value. P values in red are significant (where p ≤ 0.05) and p values in blue are 
approaching significance (0.05 < p ≤ 0.1). 
 
 Group 1 Group 2 Group 3 
%CD4 Naïve Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value 
Week 1 4.37 -0.55 9.29 0.0857 -2.88 -7.14 1.39 0.1897 1.78 -2.03 5.59 0.3627 
Week 2 -6.97 -11.89 -2.05 0.0068 -3.50 -7.76 0.76 0.1113 -6.94 -10.75 -3.13 0.0006 
Week 4 -9.97 -14.89 -5.05 0.0002 2.30 -1.96 6.56 0.2932 -5.66 -9.47 -1.85 0.0047 
Week 6 -5.77 -10.69 -0.85 0.0242 -1.10 -5.36 3.16 0.6142 -0.32 -4.13 3.49 0.8697 
Week 8 -1.07 -5.99 3.85 0.672 -1.75 -6.01 2.51 0.4232 -0.34 -4.15 3.47 0.8616 
Week 12 -2.73 -7.65 2.19 0.2794 -1.85 -6.11 2.41 0.3973 -0.58 -4.39 3.23 0.7662 
Week 16 -1.90 -6.82 3.02 0.4513 -0.13 -4.39 4.14 0.9543 -0.72 -4.53 3.09 0.7121 
Week 24 -3.30 -8.22 1.62 0.1924 -1.55 -5.81 2.71 0.4779 -0.24 -4.05 3.57 0.9021 
Week 48 -5.77 -10.69 -0.85 0.0242 -0.73 -4.99 3.54 0.7396 -0.58 -4.39 3.23 0.7662 
%CD4 TCM             
Week 1 -2.40 -8.66 3.86 0.4544 1.00 -4.42 6.42 0.7186 -3.36 -8.21 1.49 0.1781 
Week 2 -1.63 -7.89 4.62 0.6104 6.85 1.43 12.27 0.0153 1.34 -3.51 6.19 0.5895 
Week 4 4.70 -1.56 10.96 0.1449 1.03 -4.39 6.44 0.7118 4.64 -0.21 9.49 0.0643 
Week 6 0.00 -6.26 6.26 1 2.75 -2.67 8.17 0.3229 2.46 -2.39 7.31 0.3229 
Week 8 1.67 -4.59 7.92 0.6031 0.63 -4.79 6.04 0.8218 2.26 -2.59 7.11 0.3636 
Week 12 -2.57 -8.82 3.69 0.4238 -1.05 -6.47 4.37 0.7052 -1.70 -6.55 3.15 0.4938 
Week 16 0.83 -5.42 7.09 0.7948 0.15 -5.27 5.57 0.9569 3.24 -1.61 8.09 0.1939 
Week 24 6.07 -0.19 12.32 0.061 3.83 -1.59 9.24 0.1704 0.86 -3.99 5.71 0.729 
Week 48 6.17 -0.09 12.42 0.0569 6.20 0.78 11.62 0.0277 1.42 -3.43 6.27 0.5675 
%CD4 TEM             
Week 1 -0.40 -5.83 5.03 0.8855 1.38 -3.32 6.07 0.5679 -0.64 -4.84 3.56 0.7661 
Week 2 8.70 3.27 14.13 0.0023 -3.88 -8.57 0.82 0.11 4.72 0.52 8.92 0.0306 
Week 4 5.20 -0.23 10.63 0.064 -3.13 -7.82 1.57 0.1962 0.32 -3.88 4.52 0.8818 
Week 6 6.53 1.11 11.96 0.0207 -1.45 -6.15 3.25 0.5471 -1.64 -5.84 2.56 0.4467 
Week 8 0.57 -4.86 5.99 0.8383 1.23 -3.47 5.92 0.6108 -1.62 -5.82 2.58 0.4522 
Week 12 4.17 -1.26 9.59 0.1362 2.18 -2.52 6.87 0.3671 -0.12 -4.32 4.08 0.9555 
Week 16 1.80 -3.63 7.23 0.5175 0.28 -4.42 4.97 0.909 -3.34 -7.54 0.86 0.1233 
Week 24 -0.87 -6.29 4.56 0.7551 -1.85 -6.55 2.85 0.4426 -2.62 -6.82 1.58 0.2254 
Week 48 0.80 -4.63 6.23 0.7734 -3.45 -8.15 1.25 0.1541 -1.12 -5.32 3.08 0.6029 
%CD4 TEMRA             
Week 1 -1.57 -4.58 1.45 0.3115 0.40 -2.21 3.01 0.7647 2.12 -0.22 4.46 0.079 
Week 2 -0.03 -3.05 2.98 0.9828 0.50 -2.11 3.11 0.7084 0.84 -1.50 3.18 0.4828 
Week 4 0.07 -2.95 3.08 0.9655 -0.20 -2.81 2.41 0.881 0.64 -1.70 2.98 0.5926 
Week 6 -0.77 -3.78 2.25 0.6195 -0.25 -2.86 2.36 0.8516 -0.56 -2.90 1.78 0.6396 
Week 8 -1.10 -4.11 1.91 0.4766 -0.10 -2.71 2.51 0.9403 -0.38 -2.72 1.96 0.7506 
Week 12 1.13 -1.88 4.15 0.4634 0.70 -1.91 3.31 0.6007 2.30 -0.04 4.64 0.0571 
Week 16 -0.70 -3.71 2.31 0.6503 -0.28 -2.89 2.34 0.837 0.76 -1.58 3.10 0.5254 
Week 24 -1.93 -4.95 1.08 0.2124 -0.45 -3.06 2.16 0.7364 1.98 -0.36 4.32 0.1004 
Week 48 -1.23 -4.25 1.78 0.425 -2.05 -4.66 0.56 0.1277 0.22 -2.12 2.56 0.854 
Appendix Table 22 continued 
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Appendix Table 24 Changes from baseline in markers associated with CD8 T-cell differentiation/maturation. 
Mean change (mean Δ) from baseline to each of the study time points is shown, with lower and upper confidence 
intervals (CI) and the corresponding p value. P values in red are significant (where p ≤ 0.05) and p values in blue are 
approaching significance (0.05 < p ≤ 0.1). 
 
 Group 1 Group 2 Group 3 
%CD8 Naïve Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value 
Week 1 2.17 -7.48 11.81 0.6609 -0.05 -8.40 8.30 0.9907 10.32 2.85 17.79 0.0083 
Week 2 -4.33 -13.98 5.31 0.3812 1.10 -7.25 9.45 0.797 12.88 5.41 20.35 0.0011 
Week 4 -5.47 -15.11 4.18 0.2699 3.28 -5.08 11.63 0.4445 10.54 3.07 18.01 0.007 
Week 6 -5.50 -15.15 4.15 0.267 2.58 -5.78 10.93 0.5474 9.70 2.23 17.17 0.0128 
Week 8 -2.97 -12.61 6.68 0.5483 0.80 -7.55 9.15 0.8516 11.10 3.63 18.57 0.0046 
Week 12 -2.33 -11.98 7.31 0.6367 2.85 -5.50 11.20 0.5056 12.58 5.11 20.05 0.0014 
Week 16 -4.87 -14.51 4.78 0.3257 4.50 -3.85 12.85 0.2942 10.34 2.87 17.81 0.0082 
Week 24 -7.60 -17.25 2.05 0.1264 4.70 -3.65 13.05 0.2734 9.32 1.85 16.79 0.0167 
Week 48 -3.13 -12.78 6.51 0.5261 3.90 -4.45 12.25 0.3629 10.64 3.17 18.11 0.0065 
%CD8 TCM             
Week 1 2.60 -4.81 10.01 0.4934 0.68 -5.74 7.09 0.8371 -5.82 -11.56 -0.08 0.0501 
Week 2 3.10 -4.31 10.51 0.4144 2.88 -3.54 9.29 0.3823 -3.74 -9.48 2.00 0.205 
Week 4 2.30 -5.11 9.71 0.5444 0.38 -6.04 6.79 0.9091 -1.86 -7.60 3.88 0.5269 
Week 6 3.63 -3.77 11.04 0.3392 -0.38 -6.79 6.04 0.9091 -1.40 -7.14 4.34 0.6337 
Week 8 3.13 -4.27 10.54 0.4094 1.90 -4.51 8.31 0.5631 -0.80 -6.54 4.94 0.7853 
Week 12 -0.80 -8.21 6.61 0.8329 0.55 -5.86 6.96 0.8669 -2.56 -8.30 3.18 0.3844 
Week 16 1.30 -6.11 8.71 0.7317 -2.65 -9.06 3.76 0.4204 -6.90 -12.64 -1.16 0.0208 
Week 24 2.20 -5.21 9.61 0.562 0.58 -5.84 6.99 0.861 -5.12 -10.86 0.62 0.084 
Week 48 1.43 -5.97 8.84 0.7054 2.90 -3.51 9.31 0.3781 -5.70 -11.44 0.04 0.055 
%CD8 TEM             
Week 1 -0.47 -8.96 8.03 0.9145 0.30 -7.06 7.66 0.9365 2.04 -4.54 8.62 0.5451 
Week 2 5.37 -3.13 13.86 0.2191 -7.83 -15.18 -0.47 0.0402 7.42 0.84 14.00 0.0299 
Week 4 3.80 -4.69 12.29 0.3831 -6.73 -14.08 0.63 0.0769 2.80 -3.78 9.38 0.4066 
Week 6 2.57 -5.93 11.06 0.5553 -6.00 -13.36 1.36 0.1138 5.70 -0.88 12.28 0.0933 
Week 8 -0.07 -8.56 8.43 0.9878 -4.23 -11.58 3.13 0.2636 3.10 -3.48 9.68 0.3585 
Week 12 3.70 -4.79 12.19 0.3957 -7.93 -15.28 -0.57 0.0378 3.50 -3.08 10.08 0.3002 
Week 16 2.83 -5.66 11.33 0.5151 -8.53 -15.88 -1.17 0.0258 6.66 0.08 13.24 0.0506 
Week 24 6.20 -2.29 14.69 0.1564 -8.13 -15.48 -0.77 0.0333 4.80 -1.78 11.38 0.1566 
Week 48 3.13 -5.36 11.63 0.4717 -5.90 -13.26 1.46 0.1198 5.72 -0.86 12.30 0.0922 
%CD8 TEMRA             
Week 1 -4.23 -15.11 6.65 0.4478 -0.93 -10.35 8.50 0.8479 -6.50 -14.93 1.93 0.1344 
Week 2 -3.97 -14.85 6.91 0.4769 3.88 -5.55 13.30 0.4225 -16.56 -24.99 -8.13 0.0002 
Week 4 -0.57 -11.45 10.31 0.9189 3.13 -6.30 12.55 0.5174 -11.46 -19.89 -3.03 0.0093 
Week 6 -0.67 -11.55 10.21 0.9047 3.83 -5.60 13.25 0.4285 -13.98 -22.41 -5.55 0.0017 
Week 8 0.00 -10.88 10.88 1 1.50 -7.92 10.92 0.7558 -13.34 -21.77 -4.91 0.0026 
Week 12 -0.50 -11.38 10.38 0.9284 4.60 -4.82 14.02 0.3414 -13.50 -21.93 -5.07 0.0024 
Week 16 0.87 -10.01 11.75 0.8763 6.75 -2.67 16.17 0.164 -10.08 -18.51 -1.65 0.0215 
Week 24 -0.73 -11.61 10.15 0.8952 2.88 -6.55 12.30 0.5514 -8.94 -17.37 -0.51 0.0407 
Week 48 -1.33 -12.21 9.55 0.8108 -0.90 -10.32 8.52 0.8519 -10.60 -19.03 -2.17 0.0158 
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Appendix Table 25 Changes from baseline in PD-1 expression on CD4 T-cell differentiation/maturation subsets. 
Mean change (mean Δ) from baseline to each of the study time points is shown, with lower and upper confidence 
intervals (CI) and the corresponding p value. P values in red are significant (where p ≤ 0.05) and p values in blue are 
approaching significance (0.05 < p ≤ 0.1). 
 
 Group 1 Group 2 Group 3 
%CD4 Naïve 
PD-1 
Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value 
Week 1 -2.43 -16.61 11.74 0.7374 -2.85 -15.13 9.43 0.6503 -5.46 -16.44 5.52 0.3326 
Week 2 -11.97 -26.14 2.21 0.1019 5.75 -6.53 18.03 0.3613 5.56 -5.42 16.54 0.3239 
Week 4 -14.23 -28.41 -0.06 0.0525 0.13 -12.15 12.40 0.9841 -0.60 -11.58 10.38 0.915 
Week 6 -19.50 -33.68 -5.32 0.0085 4.70 -7.58 16.98 0.4552 -0.38 -11.36 10.60 0.9461 
Week 8 -8.30 -22.48 5.88 0.2545 5.78 -6.50 18.05 0.3593 -10.14 -21.12 0.84 0.074 
Week 12 0.80 -13.38 14.98 0.9122 1.60 -10.68 13.88 0.799 -1.82 -12.80 9.16 0.7461 
Week 16 -11.90 -26.08 2.28 0.1038 -0.60 -12.88 11.68 0.9239 -11.12 -22.10 -0.14 0.0505 
Week 24 -11.60 -25.78 2.58 0.1126 -0.45 -12.73 11.83 0.9429 -14.00 -24.98 -3.02 0.0145 
Week 48 -19.67 -33.84 -5.49 0.008 -15.20 -27.48 -2.92 0.0175 -18.14 -29.12 -7.16 0.0017 
%CD4 TCM 
PD-1 
            
Week 1 -1.87 -16.97 13.24 0.8092 -4.20 -17.28 8.88 0.5309 -4.60 -16.30 7.10 0.4432 
Week 2 -4.80 -19.91 10.31 0.5351 6.80 -6.28 19.88 0.3113 4.58 -7.12 16.28 0.4452 
Week 4 -19.33 -34.44 -4.23 0.0141 4.25 -8.83 17.33 0.5261 -11.80 -23.50 -0.10 0.0515 
Week 6 -23.80 -38.91 -8.69 0.0028 7.43 -5.66 20.51 0.2692 -7.80 -19.50 3.90 0.195 
Week 8 -13.60 -28.71 1.51 0.0814 5.00 -8.08 18.08 0.4559 -15.18 -26.88 -3.48 0.0129 
Week 12 -2.07 -17.17 13.04 0.7893 3.95 -9.13 17.03 0.5556 -6.48 -18.18 5.22 0.2809 
Week 16 -12.03 -27.14 3.07 0.1223 2.20 -10.88 15.28 0.7425 -14.46 -26.16 -2.76 0.0177 
Week 24 -15.23 -30.34 -0.13 0.0515 2.43 -10.66 15.51 0.7173 -20.10 -31.80 -8.40 0.0012 
Week 48 -19.57 -34.67 -4.46 0.013 -20.68 -33.76 -7.59 0.0027 -23.66 -35.36 -11.96 0.0002 
%CD4 TEM 
PD-1 
            
Week 1 -1.83 -14.19 10.52 0.7719 -3.25 -13.95 7.45 0.5533 -4.94 -14.51 4.63 0.3147 
Week 2 -0.37 -12.72 11.99 0.9538 4.80 -5.90 15.50 0.3819 6.36 -3.21 15.93 0.1964 
Week 4 -16.13 -28.49 -3.78 0.0124 3.35 -7.35 14.05 0.5412 -11.96 -21.53 -2.39 0.0165 
Week 6 -19.37 -31.72 -7.01 0.0029 3.55 -7.15 14.25 0.5174 -5.36 -14.93 4.21 0.2756 
Week 8 -12.03 -24.39 0.32 0.0598 4.30 -6.40 15.00 0.4332 -12.76 -22.33 -3.19 0.0107 
Week 12 -2.20 -14.56 10.16 0.728 2.45 -8.25 13.15 0.6548 -4.76 -14.33 4.81 0.3326 
Week 16 -8.23 -20.59 4.12 0.1952 2.55 -8.15 13.25 0.6417 -11.04 -20.61 -1.47 0.0264 
Week 24 -14.10 -26.46 -1.74 0.0281 2.83 -7.88 13.53 0.6062 -16.02 -25.59 -6.45 0.0015 
Week 48 -15.20 -27.56 -2.84 0.0182 -18.30 -29.00 -7.60 0.0012 -19.86 -29.43 -10.29 0.0001 
%CD4 TEMRA 
PD-1 
            
Week 1 -3.27 -17.40 10.86 0.6517 -4.00 -16.24 8.24 0.5236 -7.16 -18.11 3.79 0.2035 
Week 2 -3.27 -17.40 10.86 0.6517 3.30 -8.94 15.54 0.5986 5.90 -5.05 16.85 0.2939 
Week 4 -12.77 -26.90 1.36 0.0804 2.60 -9.64 14.84 0.6782 -9.26 -20.21 1.69 0.1012 
Week 6 -21.00 -35.13 -6.87 0.0046 5.73 -6.51 17.96 0.3619 -4.24 -15.19 6.71 0.4499 
Week 8 -9.93 -24.06 4.20 0.1721 3.38 -8.86 15.61 0.5903 -12.56 -23.51 -1.61 0.0272 
Week 12 -2.60 -16.73 11.53 0.7193 2.00 -10.24 14.24 0.7495 -4.06 -15.01 6.89 0.4693 
Week 16 -8.63 -22.76 5.50 0.2346 1.90 -10.34 14.14 0.7617 -10.86 -21.81 0.09 0.0553 
Week 24 -13.53 -27.66 0.60 0.0641 -0.90 -13.14 11.34 0.8857 -16.66 -27.61 -5.71 0.0038 
Week 48 -16.70 -30.83 -2.57 0.0231 -17.80 -30.04 -5.56 0.0055 -20.80 -31.75 -9.85 0.0004 
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Appendix Table 26 Changes from baseline in PD-1 expression on CD8 T-cell differentiation/maturation subsets. 
Mean change (mean Δ) from baseline to each of the study time points is shown, with lower and upper confidence 
intervals (CI) and the corresponding p value. P values in red are significant (where p ≤ 0.05) and p values in blue are 
approaching significance (0.05 < p ≤ 0.1). 
 
 Group 1 Group 2 Group 3 
%CD8 Naïve 
PD-1 
Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value 
Week 1 0.23 -16.90 17.36 0.9788 5.75 -9.09 20.59 0.4497 1.00 -12.27 14.27 0.8829 
Week 2 -4.83 -21.96 12.30 0.5818 10.83 -4.01 25.66 0.1565 8.62 -4.65 21.89 0.2066 
Week 4 -15.10 -32.23 2.03 0.0879 1.88 -12.96 16.71 0.805 3.70 -9.57 16.97 0.5862 
Week 6 -14.83 -31.96 2.30 0.0935 5.20 -9.64 20.04 0.494 0.36 -12.91 13.63 0.9577 
Week 8 -6.73 -23.86 10.40 0.4433 5.60 -9.24 20.44 0.4615 -5.80 -19.07 7.47 0.3941 
Week 12 3.90 -13.23 21.03 0.6566 6.53 -8.31 21.36 0.3912 -3.46 -16.73 9.81 0.6107 
Week 16 -10.20 -27.33 6.93 0.2466 5.98 -8.86 20.81 0.4322 -7.58 -20.85 5.69 0.2662 
Week 24 -15.67 -32.80 1.46 0.0768 3.43 -11.41 18.26 0.6521 -9.40 -22.67 3.87 0.1688 
Week 48 -20.87 -38.00 -3.74 0.0193 -18.10 -32.94 -3.26 0.0191 -15.50 -28.77 -2.23 0.0247 
%CD8 TCM 
PD-1 
            
Week 1 2.53 -13.63 18.70 0.7595 4.38 -9.62 18.37 0.5419 -6.08 -18.60 6.44 0.344 
Week 2 1.43 -14.73 17.60 0.8624 9.63 -4.37 23.62 0.1815 1.00 -11.52 13.52 0.876 
Week 4 -16.07 -32.23 0.10 0.0548 2.90 -11.10 16.90 0.6858 -5.88 -18.40 6.64 0.36 
Week 6 -13.80 -29.96 2.36 0.0981 7.78 -6.22 21.77 0.2795 -7.82 -20.34 4.70 0.2244 
Week 8 -8.53 -24.70 7.63 0.3038 0.63 -13.37 14.62 0.9305 -15.50 -28.02 -2.98 0.0175 
Week 12 1.73 -14.43 17.90 0.834 6.18 -7.82 20.17 0.3898 -9.66 -22.18 2.86 0.1344 
Week 16 -7.20 -23.36 8.96 0.3852 7.95 -6.05 21.95 0.2689 -13.96 -26.48 -1.44 0.0317 
Week 24 -16.87 -33.03 -0.70 0.0441 2.78 -11.22 16.77 0.6986 -16.70 -29.22 -4.18 0.0107 
Week 48 -18.57 -34.73 -2.40 0.0271 -19.88 -33.87 -5.88 0.0067 -25.04 -37.56 -12.52 0.0002 
%CD8 TEM 
PD-1 
            
Week 1 0.03 -14.93 15.00 0.9965 -0.93 -13.88 12.03 0.8891 -10.76 -22.35 0.83 0.0725 
Week 2 0.70 -14.26 15.66 0.9272 9.45 -3.51 22.41 0.1567 -3.06 -14.65 8.53 0.6062 
Week 4 -13.57 -28.53 1.40 0.0793 3.25 -9.71 16.21 0.6243 -15.70 -27.29 -4.11 0.0095 
Week 6 -16.70 -31.66 -1.74 0.0316 6.10 -6.86 19.06 0.3589 -13.80 -25.39 -2.21 0.0221 
Week 8 -11.47 -26.43 3.50 0.137 4.25 -8.71 17.21 0.5221 -21.26 -32.85 -9.67 0.0006 
Week 12 -1.23 -16.20 13.73 0.8721 4.63 -8.33 17.58 0.4862 -14.42 -26.01 -2.83 0.0169 
Week 16 -6.37 -21.33 8.60 0.4067 5.48 -7.48 18.43 0.41 -21.14 -32.73 -9.55 0.0006 
Week 24 -15.93 -30.90 -0.97 0.04 -0.80 -13.76 12.16 0.904 -23.12 -34.71 -11.53 0.0002 
Week 48 -18.93 -33.90 -3.97 0.0152 -20.88 -33.83 -7.92 0.0022 -26.92 -38.51 -15.33 <.0001 
%CD8 TEMRA 
PD-1 
            
Week 1 1.40 -14.42 17.22 0.8627 1.50 -12.20 15.20 0.8306 -6.28 -18.53 5.97 0.318 
Week 2 -3.87 -19.68 11.95 0.6331 7.88 -5.82 21.57 0.2631 1.82 -10.43 14.07 0.7716 
Week 4 -15.03 -30.85 0.78 0.0661 0.68 -13.02 14.37 0.9233 -10.94 -23.19 1.31 0.0838 
Week 6 -16.87 -32.68 -1.05 0.0397 7.43 -6.27 21.12 0.2911 -7.66 -19.91 4.59 0.2239 
Week 8 -6.97 -22.78 8.85 0.3905 4.88 -8.82 18.57 0.4874 -12.34 -24.59 -0.09 0.0518 
Week 12 3.93 -11.88 19.75 0.6272 2.28 -11.42 15.97 0.7456 -9.54 -21.79 2.71 0.1308 
Week 16 -7.60 -23.42 8.22 0.3491 2.25 -11.45 15.95 0.7483 -13.70 -25.95 -1.45 0.0313 
Week 24 -12.97 -28.78 2.85 0.1119 -1.65 -15.35 12.05 0.8139 -15.46 -27.71 -3.21 0.0155 
Week 48 -17.70 -33.52 -1.88 0.0311 -21.58 -35.27 -7.88 0.0028 -21.72 -33.97 -9.47 0.0008 
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Appendix Table 27 Changes from baseline in PD-L1 expression on CD4 T-cell differentiation/maturation subsets. 
Mean change (mean Δ) from baseline to each of the study time points is shown, with lower and upper confidence 
intervals (CI) and the corresponding p value. P values in red are significant (where p ≤ 0.05) and p values in blue are 
approaching significance (0.05 < p ≤ 0.1). 
 
 Group 1 Group 2 Group 3 
%CD4 Naïve 
PD-L1 
Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value 
Week 1 0.63 -5.38 6.65 0.837 0.90 -4.31 6.11 0.7357 1.24 -3.42 5.90 0.6033 
Week 2 -2.20 -8.21 3.81 0.4755 6.00 0.79 11.21 0.0266 2.06 -2.60 6.72 0.3887 
Week 4 0.17 -5.85 6.18 0.9568 1.10 -4.11 6.31 0.68 -1.84 -6.50 2.82 0.4411 
Week 6 -1.93 -7.95 4.08 0.5304 1.88 -3.33 7.08 0.4825 -1.30 -5.96 3.36 0.5859 
Week 8 -2.47 -8.48 3.55 0.4238 4.23 -0.98 9.43 0.1157 -1.90 -6.56 2.76 0.4264 
Week 12 -0.27 -6.28 5.75 0.931 0.25 -4.96 5.46 0.9253 -1.50 -6.16 3.16 0.5298 
Week 16 -1.27 -7.28 4.75 0.6808 -2.35 -7.56 2.86 0.3791 -5.20 -9.86 -0.54 0.0316 
Week 24 -2.07 -8.08 3.95 0.5025 -0.05 -5.26 5.16 0.985 -2.18 -6.84 2.48 0.3618 
Week 48 2.87 -3.15 8.88 0.353 -2.58 -7.78 2.63 0.3354 2.02 -2.64 6.68 0.3979 
%CD4 TCM 
PD-L1 
            
Week 1 0.33 -7.37 8.03 0.9326 -0.23 -6.89 6.44 0.9474 0.86 -5.10 6.82 0.7782 
Week 2 0.17 -7.53 7.87 0.9663 6.35 -0.32 13.02 0.0656 5.08 -0.88 11.04 0.0989 
Week 4 -1.00 -8.70 6.70 0.7997 1.25 -5.42 7.92 0.7143 -4.58 -10.54 1.38 0.1362 
Week 6 -1.77 -9.47 5.93 0.6541 2.38 -4.29 9.04 0.4871 -2.50 -8.46 3.46 0.4138 
Week 8 -4.20 -11.90 3.50 0.2882 3.43 -3.24 10.09 0.3171 -3.70 -9.66 2.26 0.2276 
Week 12 -0.13 -7.83 7.57 0.973 1.43 -5.24 8.09 0.6764 -2.50 -8.46 3.46 0.4138 
Week 16 -1.37 -9.07 6.33 0.7288 -1.45 -8.12 5.22 0.6711 -8.02 -13.98 -2.06 0.0101 
Week 24 -3.17 -10.87 4.53 0.4226 1.13 -5.54 7.79 0.7418 -3.36 -9.32 2.60 0.2728 
Week 48 5.73 -1.97 13.43 0.1483 -3.53 -10.19 3.14 0.3033 2.96 -3.00 8.92 0.3336 
%CD4 TEM 
PD-L1 
            
Week 1 0.53 -6.41 7.48 0.8808 -1.18 -7.19 4.84 0.7029 0.50 -4.88 5.88 0.856 
Week 2 1.00 -5.95 7.95 0.7786 3.55 -2.47 9.57 0.2509 3.06 -2.32 8.44 0.2684 
Week 4 -0.70 -7.65 6.25 0.844 0.15 -5.87 6.17 0.9612 -4.26 -9.64 1.12 0.1247 
Week 6 -1.80 -8.75 5.15 0.613 0.85 -5.17 6.87 0.7826 -1.62 -7.00 3.76 0.5569 
Week 8 -3.43 -10.38 3.51 0.3357 2.83 -3.19 8.84 0.3602 -2.54 -7.92 2.84 0.3577 
Week 12 -0.23 -7.18 6.71 0.9477 0.90 -5.12 6.92 0.7702 -1.72 -7.10 3.66 0.5328 
Week 16 -1.27 -8.21 5.68 0.7218 -2.60 -8.62 3.42 0.3995 -6.92 -12.30 -1.54 0.0137 
Week 24 -3.17 -10.11 3.78 0.3743 -0.48 -6.49 5.54 0.8774 -3.00 -8.38 2.38 0.2778 
Week 48 3.83 -3.11 10.78 0.2827 -3.43 -9.44 2.59 0.2679 3.20 -2.18 8.58 0.2473 
%CD4 TEMRA 
PD-L1 
            
Week 1 2.10 -4.29 8.49 0.5212 -2.40 -7.93 3.13 0.3977 1.12 -3.83 6.07 0.6585 
Week 2 0.10 -6.29 6.49 0.9756 5.43 -0.11 10.96 0.0581 1.06 -3.89 6.01 0.6757 
Week 4 -0.37 -6.76 6.02 0.9107 2.38 -3.16 7.91 0.4026 -3.16 -8.11 1.79 0.2143 
Week 6 -1.87 -8.26 4.52 0.5684 2.43 -3.11 7.96 0.3928 -1.26 -6.21 3.69 0.6191 
Week 8 -2.67 -9.06 3.72 0.4157 3.65 -1.88 9.18 0.1997 -1.36 -6.31 3.59 0.5916 
Week 12 0.13 -6.26 6.52 0.9675 -0.90 -6.43 4.63 0.7507 -0.92 -5.87 4.03 0.7165 
Week 16 -0.53 -6.92 5.86 0.8704 -3.20 -8.73 2.33 0.2603 -5.84 -10.79 -0.89 0.0233 
Week 24 -2.30 -8.69 4.09 0.4824 -1.55 -7.08 3.98 0.5844 -2.68 -7.63 2.27 0.2916 
Week 48 4.50 -1.89 10.89 0.1712 -2.28 -7.81 3.26 0.4226 2.92 -2.03 7.87 0.2508 
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Appendix Table 28 Changes from baseline in PD-1 expression on CD8 T-cell differentiation/maturation subsets. 
Mean change (mean Δ) from baseline to each of the study time points is shown, with lower and upper confidence 
intervals (CI) and the corresponding p value. P values in red are significant (where p ≤ 0.05) and p values in blue are 
approaching significance (0.05 < p ≤ 0.1). 
 
 Group 1 Group 2 Group 3 
%CD8 Naïve 
PD-L1 
Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value 
Week 1 7.83 -13.22 28.89 0.4679 -3.93 -22.16 14.31 0.6742 -0.34 -16.65 15.97 0.9675 
Week 2 4.20 -16.85 25.25 0.6968 3.70 -14.53 21.93 0.6919 18.66 2.35 34.97 0.0276 
Week 4 8.73 -12.32 29.79 0.4186 -2.55 -20.78 15.68 0.7847 -0.76 -17.07 15.55 0.9274 
Week 6 3.40 -17.65 24.45 0.7524 -4.88 -23.11 13.36 0.6017 4.82 -11.49 21.13 0.564 
Week 8 5.53 -15.52 26.59 0.6079 -12.73 -30.96 5.51 0.1751 0.32 -15.99 16.63 0.9694 
Week 12 -2.57 -23.62 18.49 0.8117 -8.70 -26.93 9.53 0.3524 -12.94 -29.25 3.37 0.1238 
Week 16 1.30 -19.75 22.35 0.904 -9.35 -27.58 8.88 0.3178 0.08 -16.23 16.39 0.9924 
Week 24 5.23 -15.82 26.29 0.6274 -1.18 -19.41 17.06 0.8998 -3.10 -19.41 13.21 0.7104 
Week 48 5.73 -15.32 26.79 0.595 -7.90 -26.13 10.33 0.3982 0.08 -16.23 16.39 0.9924 
%CD8 TCM 
PD-L1 
            
Week 1 15.67 -2.88 34.21 0.1016 -1.08 -17.13 14.98 0.8959 0.02 -14.34 14.38 0.9978 
Week 2 14.00 -4.54 32.54 0.1428 4.98 -11.08 21.03 0.5454 19.12 4.76 33.48 0.0108 
Week 4 10.07 -8.48 28.61 0.2904 0.10 -15.96 16.16 0.9903 -4.38 -18.74 9.98 0.5517 
Week 6 8.57 -9.98 27.11 0.3679 -3.03 -19.08 13.03 0.7129 0.42 -13.94 14.78 0.9544 
Week 8 11.47 -7.08 30.01 0.229 -12.65 -28.71 3.41 0.1265 -0.40 -14.76 13.96 0.9566 
Week 12 7.03 -11.51 25.58 0.4594 -5.85 -21.91 10.21 0.4773 -12.10 -26.46 2.26 0.1026 
Week 16 9.40 -9.14 27.94 0.3234 -5.08 -21.13 10.98 0.5374 -1.76 -16.12 12.60 0.8108 
Week 24 13.63 -4.91 32.18 0.1534 0.80 -15.26 16.86 0.9225 -3.20 -17.56 11.16 0.6635 
Week 48 12.80 -5.74 31.34 0.1798 -7.53 -23.58 8.53 0.3611 0.54 -13.82 14.90 0.9414 
%CD8 TEM 
PD-L1 
            
Week 1 12.53 1.63 23.44 0.027 1.25 -8.20 10.70 0.796 -1.32 -9.77 7.13 0.7602 
Week 2 10.80 -0.11 21.71 0.0558 6.85 -2.60 16.30 0.1591 15.44 6.99 23.89 0.0006 
Week 4 8.33 -2.57 19.24 0.1382 2.85 -6.60 12.30 0.556 -2.56 -11.01 5.89 0.5543 
Week 6 4.67 -6.24 15.57 0.4042 0.18 -9.27 9.62 0.9711 -0.56 -9.01 7.89 0.897 
Week 8 9.10 -1.81 20.01 0.1059 -1.58 -11.02 7.87 0.7447 0.22 -8.23 8.67 0.9594 
Week 12 4.20 -6.71 15.11 0.4526 0.38 -9.07 9.82 0.9382 -5.90 -14.35 2.55 0.1749 
Week 16 2.53 -8.37 13.44 0.6502 -2.45 -11.90 7.00 0.6126 -5.34 -13.79 3.11 0.219 
Week 24 7.10 -3.81 18.01 0.2057 1.30 -8.15 10.75 0.7881 -3.94 -12.39 4.51 0.3635 
Week 48 8.87 -2.04 19.77 0.115 -3.30 -12.75 6.15 0.4955 0.90 -7.55 9.35 0.8352 
%CD8 TEMRA 
PD-L1 
            
Week 1 9.63 -1.00 20.26 0.0795 2.65 -6.56 11.86 0.5742 -0.52 -8.75 7.71 0.9018 
Week 2 5.17 -5.46 15.80 0.3436 6.05 -3.16 15.26 0.2014 14.46 6.23 22.69 0.0009 
Week 4 6.53 -4.10 17.16 0.2319 2.03 -7.18 11.23 0.6675 -2.46 -10.69 5.77 0.5598 
Week 6 2.97 -7.66 13.60 0.5859 0.63 -8.58 9.83 0.8945 0.22 -8.01 8.45 0.9584 
Week 8 7.23 -3.40 17.86 0.186 0.30 -8.91 9.51 0.9492 3.66 -4.57 11.89 0.3862 
Week 12 4.07 -6.56 14.70 0.4555 0.23 -8.98 9.43 0.9619 -2.66 -10.89 5.57 0.5284 
Week 16 4.03 -6.60 14.66 0.4592 -3.58 -12.78 5.63 0.4488 -1.40 -9.63 6.83 0.7398 
Week 24 6.03 -4.60 16.66 0.2692 -0.15 -9.36 9.06 0.9746 -0.68 -8.91 7.55 0.8718 
Week 48 8.67 -1.96 19.30 0.1139 -4.03 -13.23 5.18 0.394 4.34 -3.89 12.57 0.3046 
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Appendix Table 29 Changes from baseline in CD27, CD28, PD-1 and PD-L1 expression on CD4 T cells. 
Mean change (mean Δ) from baseline to each of the study time points is shown, with lower and upper confidence 
intervals (CI) and the corresponding p value. P values in red are significant (where p ≤ 0.05) and p values in blue are 
approaching significance (0.05 < p ≤ 0.1). 
 
 Group 1 Group 2 Group 3 
%CD4+CD27+ Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value 
Week 1 2.23 -2.13 6.60 0.319 -1.63 -5.41 2.16 0.4021 -2.18 -5.56 1.20 0.2101 
Week 2 -1.97 -6.33 2.40 0.3799 -2.75 -6.53 1.03 0.1579 2.50 -0.88 5.88 0.1512 
Week 4 0.33 -4.03 4.70 0.8814 1.53 -2.26 5.31 0.4315 0.76 -2.62 4.14 0.6608 
Week 6 0.67 -3.70 5.03 0.7655 -0.90 -4.68 2.88 0.6421 3.48 0.10 6.86 0.047 
Week 8 2.23 -2.13 6.60 0.319 -1.45 -5.23 2.33 0.4545 2.28 -1.10 5.66 0.1901 
Week 12 0.70 -3.67 5.07 0.7541 -2.30 -6.08 1.48 0.2366 1.44 -1.94 4.82 0.4064 
Week 16 2.60 -1.77 6.97 0.2466 0.03 -3.76 3.81 0.9897 -0.10 -3.48 3.28 0.9539 
Week 24 3.60 -0.77 7.97 0.11 0.05 -3.73 3.83 0.9794 1.32 -2.06 4.70 0.4465 
Week 48 0.93 -3.43 5.30 0.6763 0.85 -2.93 4.63 0.6607 0.66 -2.72 4.04 0.7031 
%CD4+CD28+             
Week 1 1.70 -2.41 5.81 0.4203 -1.23 -4.79 2.34 0.5023 -2.44 -5.63 0.75 0.1373 
Week 2 3.37 -0.75 7.48 0.1126 -1.85 -5.41 1.71 0.3118 4.88 1.69 8.07 0.0036 
Week 4 2.33 -1.78 6.45 0.2695 1.78 -1.79 5.34 0.3317 2.56 -0.63 5.75 0.1192 
Week 6 2.43 -1.68 6.55 0.2497 -0.43 -3.99 3.14 0.8157 3.74 0.55 6.93 0.024 
Week 8 3.70 -0.41 7.81 0.0817 -1.15 -4.71 2.41 0.5287 2.48 -0.71 5.67 0.131 
Week 12 0.70 -3.41 4.81 0.7396 -1.00 -4.56 2.56 0.5837 1.62 -1.57 4.81 0.322 
Week 16 3.60 -0.51 7.71 0.0901 0.85 -2.71 4.41 0.6413 -0.40 -3.59 2.79 0.8063 
Week 24 4.73 0.62 8.85 0.0268 1.10 -2.46 4.66 0.5467 1.46 -1.73 4.65 0.3718 
Week 48 0.57 -3.55 4.68 0.7878 1.85 -1.71 5.41 0.3118 0.80 -2.39 3.99 0.624 
%CD4+PD-1+             
Week 1 -1.13 -14.80 12.53 0.8712 -3.13 -14.96 8.71 0.6061 -4.44 -15.02 6.14 0.4133 
Week 2 -0.57 -14.23 13.10 0.9354 5.63 -6.21 17.46 0.3542 7.98 -2.60 18.56 0.1433 
Week 4 -10.63 -24.30 3.03 0.131 1.80 -10.03 13.63 0.7663 -5.70 -16.28 4.88 0.2942 
Week 6 -17.37 -31.03 -3.70 0.0148 8.35 -3.48 20.18 0.1704 -4.04 -14.62 6.54 0.4565 
Week 8 -10.30 -23.96 3.36 0.1434 4.90 -6.93 16.73 0.4193 -12.22 -22.80 -1.64 0.0263 
Week 12 1.47 -12.20 15.13 0.8339 4.63 -7.21 16.46 0.4458 -4.26 -14.84 6.32 0.4324 
Week 16 -8.50 -22.16 5.16 0.2262 0.50 -11.33 12.33 0.9342 -13.08 -23.66 -2.50 0.0176 
Week 24 -11.97 -25.63 1.70 0.0898 2.65 -9.18 14.48 0.6618 -15.90 -26.48 -5.32 0.0042 
Week 48 -15.43 -29.10 -1.77 0.0296 -19.03 -30.86 -7.19 0.0023 -20.02 -30.60 -9.44 0.0004 
%CD4+PD-L1             
Week 1 0.87 -6.12 7.85 0.8086 -0.70 -6.75 5.35 0.8212 -0.36 -5.77 5.05 0.8966 
Week 2 -0.33 -7.32 6.65 0.9257 4.98 -1.08 11.03 0.111 2.40 -3.01 7.81 0.3874 
Week 4 -0.07 -7.05 6.92 0.9851 -0.10 -6.15 5.95 0.9742 -3.96 -9.37 1.45 0.1555 
Week 6 -1.60 -8.59 5.39 0.6548 0.73 -5.33 6.78 0.815 -2.42 -7.83 2.99 0.3835 
Week 8 -3.60 -10.59 3.39 0.3156 2.05 -4.00 8.10 0.5086 -3.42 -8.83 1.99 0.2192 
Week 12 0.07 -6.92 7.05 0.9851 0.20 -5.85 6.25 0.9485 -3.02 -8.43 2.39 0.2774 
Week 16 -1.37 -8.35 5.62 0.7025 -3.03 -9.08 3.03 0.3302 -6.60 -12.01 -1.19 0.0192 
Week 24 -1.20 -8.19 5.79 0.7373 -0.58 -6.63 5.48 0.8527 -3.54 -8.95 1.87 0.2036 
Week 48 5.00 -1.99 11.99 0.1646 -4.23 -10.28 1.83 0.175 1.40 -4.01 6.81 0.6136 
CD4+PD-1 MFI             
Week 1 -25 -120 70 0.6124 44 -39 126 0.3034 3 -70 77 0.9281 
Week 2 90 -5 185 0.0671 18 -64 100 0.6693 105 31 179 0.0065 
Week 4 -23 -118 72 0.6317 3 -80 85 0.948 -39 -113 34 0.2973 
Week 6 -30 -125 65 0.5334 38 -45 120 0.3714 -39 -112 35 0.3047 
Week 8 -45 -140 50 0.3597 12 -71 94 0.7849 -40 -113 34 0.2925 
Week 12 -31 -126 64 0.5245 78 -4 160 0.0669 -67 -141 6 0.0765 
Week 16 -7 -102 88 0.891 59 -24 141 0.1674 26 -48 100 0.4908 
Week 24 55 -40 150 0.2601 21 -61 104 0.6142 43 -30 117 0.2535 
Week 48 22 -73 117 0.6464 123 40 205 0.0046 17 -57 91 0.6521 
CD4+PD-L1 MFI             
Week 1 550 -59 1159 0.0806 -146 -673 382 0.5901 6 -466 477 0.9815 
Week 2 170 -439 779 0.5865 -27 -554 501 0.9218 483 11 954 0.0482 
Week 4 -128 -737 481 0.6822 178 -350 705 0.5113 272 -200 743 0.2624 
Week 6 -56 -665 553 0.8574 77 -451 604 0.7769 130 -341 602 0.59 
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Week 8 258 -351 867 0.4081 25 -502 552 0.9262 172 -299 644 0.4758 
Week 12 440 -169 1049 0.1608 433 -94 960 0.1114 221 -251 692 0.3616 
Week 16 653 44 1262 0.0388 385 -142 912 0.1563 736 264 1208 0.003 
Week 24 881 272 1490 0.0058 275 -253 802 0.3106 529 57 1001 0.0308 
Week 48 434 -175 1043 0.1666 876 349 1403 0.0017 407 -64 879 0.0943 
 
Appendix Table 30 Changes from baseline in CD27, CD28, PD-1 and PD-L1 expression on CD8 T cells. 
Mean change (mean Δ) from baseline to each of the study time points is shown, with lower and upper confidence 
intervals (CI) and the corresponding p value. P values in red are significant (where p ≤ 0.05) and p values in blue are 
approaching significance (0.05 < p ≤ 0.1). 
 
 Group 1 Group 2 Group 3 
%CD8+CD27+ Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value 
Week 1 4.63 -2.29 11.56 0.1935 0.05 -5.95 6.05 0.987 -5.74 -11.11 -0.37 0.0391 
Week 2 -2.50 -9.43 4.43 0.4813 -0.80 -6.80 5.20 0.7945 4.10 -1.27 9.47 0.1381 
Week 4 -0.63 -7.56 6.29 0.8582 4.78 -1.22 10.77 0.1226 2.66 -2.71 8.03 0.3341 
Week 6 0.40 -6.53 7.33 0.9102 1.98 -4.02 7.97 0.5206 7.20 1.83 12.57 0.0102 
Week 8 0.60 -6.33 7.53 0.8656 2.23 -3.77 8.22 0.4693 6.16 0.79 11.53 0.0271 
Week 12 -0.67 -7.59 6.26 0.8508 3.75 -2.25 9.75 0.224 6.14 0.77 11.51 0.0276 
Week 16 3.07 -3.86 9.99 0.3881 2.28 -3.72 8.27 0.4594 2.80 -2.57 8.17 0.3094 
Week 24 3.90 -3.03 10.83 0.2731 4.85 -1.15 10.85 0.1169 4.26 -1.11 9.63 0.1236 
Week 48 2.07 -4.86 8.99 0.5603 1.85 -4.15 7.85 0.5472 5.40 0.03 10.77 0.052 
%CD8+CD28+             
Week 1 6.13 -1.65 13.92 0.1264 3.20 -3.54 9.94 0.3549 -5.94 -11.97 0.09 0.057 
Week 2 4.50 -3.28 12.28 0.2605 1.90 -4.84 8.64 0.5822 8.08 2.05 14.11 0.0103 
Week 4 1.37 -6.42 9.15 0.7316 8.90 2.16 15.64 0.0114 5.16 -0.87 11.19 0.0973 
Week 6 2.03 -5.75 9.82 0.61 3.10 -3.64 9.84 0.3701 8.68 2.65 14.71 0.006 
Week 8 3.00 -4.78 10.78 0.4522 9.70 2.96 16.44 0.006 8.74 2.71 14.77 0.0057 
Week 12 -1.20 -8.98 6.58 0.7633 6.90 0.16 13.64 0.0482 7.68 1.65 13.71 0.0146 
Week 16 4.40 -3.38 12.18 0.2712 3.85 -2.89 10.59 0.2663 3.08 -2.95 9.11 0.3197 
Week 24 6.50 -1.28 14.28 0.1056 7.38 0.63 14.12 0.035 4.74 -1.29 10.77 0.1272 
Week 48 2.97 -4.82 10.75 0.4572 5.13 -1.62 11.87 0.1401 6.62 0.59 12.65 0.0344 
%CD8+PD-1+             
Week 1 -0.33 -15.98 15.31 0.9668 0.83 -12.72 14.37 0.9053 -2.76 -14.88 9.36 0.6565 
Week 2 0.43 -15.21 16.08 0.9568 4.58 -8.97 18.12 0.51 6.18 -5.94 18.30 0.3205 
Week 4 -13.07 -28.71 2.58 0.1055 1.18 -12.37 14.72 0.8655 -3.80 -15.92 8.32 0.5405 
Week 6 -15.17 -30.81 0.48 0.061 6.73 -6.82 20.27 0.3335 -5.14 -17.26 6.98 0.4082 
Week 8 -9.63 -25.28 6.01 0.231 0.45 -13.10 14.00 0.9483 -12.10 -24.22 0.02 0.0538 
Week 12 3.00 -12.65 18.65 0.708 4.83 -8.72 18.37 0.4872 -6.22 -18.34 5.90 0.3174 
Week 16 -7.83 -23.48 7.81 0.3293 3.18 -10.37 16.72 0.6473 -11.06 -23.18 1.06 0.0774 
Week 24 -12.80 -28.45 2.85 0.1127 0.93 -12.62 14.47 0.8939 -15.26 -27.38 -3.14 0.0157 
Week 48 -17.17 -32.81 -1.52 0.0345 -20.33 -33.87 -6.78 0.0043 -20.44 -32.56 -8.32 0.0014 
%CD8+PD-L1             
Week 1 5.50 -8.84 19.84 0.4545 -2.23 -14.65 10.20 0.7264 0.20 -10.91 11.31 0.9719 
Week 2 1.90 -12.44 16.24 0.7958 6.88 -5.55 19.30 0.2812 18.94 7.83 30.05 0.0013 
Week 4 2.27 -12.08 16.61 0.7576 1.58 -10.85 14.00 0.8044 -3.24 -14.35 7.87 0.5692 
Week 6 -2.63 -16.98 11.71 0.7199 -1.33 -13.75 11.10 0.8349 2.38 -8.73 13.49 0.6757 
Week 8 2.83 -11.51 17.18 0.6996 -5.30 -17.72 7.12 0.4055 2.62 -8.49 13.73 0.6452 
Week 12 -2.00 -16.34 12.34 0.7853 -0.83 -13.25 11.60 0.8967 -6.50 -17.61 4.61 0.2549 
Week 16 -0.73 -15.08 13.61 0.9204 -4.15 -16.57 8.27 0.5144 -0.28 -11.39 10.83 0.9607 
Week 24 0.33 -14.01 14.68 0.9638 1.68 -10.75 14.10 0.7922 -1.66 -12.77 9.45 0.7704 
Week 48 1.33 -13.01 15.68 0.8559 -2.10 -14.52 10.32 0.7412 5.38 -5.73 16.49 0.3454 
CD8+PD-1 MFI             
Week 1 -12 -138 114 0.8526 19 -90 129 0.7308 -25 -123 73 0.6176 
Week 2 43 -83 169 0.5062 18 -92 127 0.7511 51 -46 149 0.3058 
Week 4 -9 -136 117 0.8851 10 -99 120 0.8546 -80 -178 18 0.1135 
Week 6 -25 -151 102 0.7027 93 -16 202 0.0992 -61 -159 36 0.2219 
Week 8 -37 -163 90 0.5707 47 -62 157 0.3993 -66 -164 32 0.1908 
Week 12 -49 -175 77 0.4489 77 -32 187 0.1698 -84 -182 14 0.096 
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Week 16 -3 -130 123 0.9588 48 -62 157 0.3944 8 -90 106 0.8761 
Week 24 43 -83 170 0.5029 16 -93 125 0.7749 31 -66 129 0.5308 
Week 48 36 -90 162 0.5777 126 17 235 0.0265 1 -97 98 0.9904 
CD8+PD-L1 MFI             
Week 1 974 128 1819 0.0267 -427 -1160 305 0.2563 -8 -663 647 0.98 
Week 2 -39 -884 807 0.9288 -79 -811 654 0.8336 535 -120 1190 0.1135 
Week 4 -404 -1249 442 0.3523 70 -662 802 0.8519 -9 -664 646 0.9795 
Week 6 -377 -1222 469 0.3853 108 -624 841 0.7728 -143 -798 512 0.6699 
Week 8 -531 -1376 315 0.2223 -116 -848 616 0.757 -421 -1076 234 0.2119 
Week 12 86 -760 932 0.8425 385 -348 1117 0.3066 -110 -765 545 0.7438 
Week 16 442 -403 1288 0.3084 449 -283 1182 0.2328 351 -304 1006 0.2965 
Week 24 382 -463 1228 0.3782 92 -640 824 0.8061 204 -451 859 0.5441 
Week 48 282 -564 1127 0.5157 833 100 1565 0.0286 147 -508 802 0.6621 
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Appendix Table 31 Changes from baseline in CD25 and CD45RO expression on CD8 T cells. 
Mean change (mean Δ) from baseline to each of the study time points is shown, with lower and upper confidence 
intervals (CI) and the corresponding p value. P values in red are significant (where p ≤ 0.05) and p values in blue are 
approaching significance (0.05 < p ≤ 0.1). 
 
 Group 1 Group 2 Group 3 
%CD8+CD25+ Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value 
Week 1 0.67 -5.50 6.83 0.8327 2.65 -2.69 7.99 0.3336 0.30 -4.48 5.08 0.9023 
Week 2 2.27 -3.90 8.43 0.4732 2.18 -3.16 7.51 0.427 13.56 8.78 18.34 <.0001 
Week 4 2.07 -4.10 8.23 0.513 3.80 -1.54 9.14 0.1669 10.94 6.16 15.72 <.0001 
Week 6 2.40 -3.77 8.57 0.4477 2.55 -2.79 7.89 0.352 12.30 7.52 17.08 <.0001 
Week 8 2.03 -4.13 8.20 0.5198 4.65 -0.69 9.99 0.0917 10.46 5.68 15.24 <.0001 
Week 12 -0.03 -6.20 6.13 0.9916 3.60 -1.74 8.94 0.1901 11.28 6.50 16.06 <.0001 
Week 16 2.60 -3.57 8.77 0.4109 4.13 -1.21 9.46 0.1339 9.20 4.42 13.98 0.0003 
Week 24 1.30 -4.87 7.47 0.6805 2.05 -3.29 7.39 0.4539 5.28 0.50 10.06 0.0332 
Week 48 2.73 -3.43 8.90 0.3875 1.98 -3.36 7.31 0.4706 7.86 3.08 12.64 0.0018 
%CD8+CD45RO+             
Week 1 -0.10 -8.18 7.98 0.9807 2.18 -4.83 9.18 0.5443 1.76 -4.50 8.02 0.5832 
Week 2 8.17 0.08 16.25 0.0511 -1.43 -8.43 5.58 0.691 11.36 5.10 17.62 0.0006 
Week 4 4.57 -3.52 12.65 0.2715 3.53 -3.48 10.53 0.3266 4.06 -2.20 10.32 0.2074 
Week 6 -1.00 -9.08 7.08 0.809 1.28 -5.73 8.28 0.722 3.96 -2.30 10.22 0.2187 
Week 8 1.47 -6.62 9.55 0.7231 3.28 -3.73 10.28 0.3619 7.02 0.76 13.28 0.0308 
Week 12 0.13 -7.95 8.22 0.9743 4.68 -2.33 11.68 0.1943 8.32 2.06 14.58 0.0109 
Week 16 3.37 -4.72 11.45 0.4167 3.43 -3.58 10.43 0.3405 6.56 0.30 12.82 0.0433 
Week 24 5.83 -2.25 13.92 0.1611 9.63 2.62 16.63 0.0086 10.50 4.24 16.76 0.0015 
Week 48 5.77 -2.32 13.85 0.1659 5.03 -1.98 12.03 0.1633 10.72 4.46 16.98 0.0012 
CD8+CD25 MFI             
Week 1 31 -185 247 0.7792 -119 -306 68 0.217 25 -143 192 0.7722 
Week 2 392 176 608 0.0006 -88 -275 99 0.3579 523 355 690 <.0001 
Week 4 165 -51 381 0.139 -177 -364 10 0.0669 181 13 348 0.0375 
Week 6 -14 -230 202 0.8968 -162 -349 26 0.0945 33 -135 200 0.7036 
Week 8 33 -183 249 0.7677 -195 -382 -8 0.044 -1 -168 167 0.9925 
Week 12 -72 -288 144 0.5154 -154 -341 33 0.11 -7 -174 160 0.9349 
Week 16 -62 -278 154 0.5732 -143 -330 44 0.1373 21 -146 188 0.8063 
Week 24 -31 -247 185 0.7769 -167 -354 20 0.0835 -109 -276 59 0.2061 
Week 48 -46 -262 170 0.6753 -198 -385 -10 0.0417 -102 -269 65 0.2356 
CD8+CD45RO 
MFI 
            
Week 1 -358 -3763 3046 0.8371 -145 -3093 2804 0.9237 907 -1731 3544 0.5023 
Week 2 1530 -1875 4934 0.3812 381 -2567 3330 0.8006 1992 -646 4629 0.1427 
Week 4 -347 -3752 3058 0.8422 -450 -3399 2499 0.7656 -126 -2763 2511 0.9256 
Week 6 -2720 -6125 685 0.1213 687 -2261 3636 0.649 -792 -3429 1846 0.5579 
Week 8 -510 -3915 2895 0.7698 -527 -3475 2422 0.7273 737 -1900 3375 0.5853 
Week 12 2196 -1209 5600 0.2099 -154 -3102 2795 0.9188 189 -2449 2826 0.8888 
Week 16 1834 -1570 5239 0.2941 474 -2475 3422 0.7536 1892 -745 4529 0.1635 
Week 24 1191 -2214 4595 0.495 356 -2593 3304 0.8137 4207 1570 6845 0.0025 
Week 48 2652 -753 6057 0.1307 1148 -1800 4097 0.4475 2560 -77 5197 0.0607 
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Appendix Table 32 Changes from baseline in markers associated with recent thymic emigrants on CD4 T cells. 
Mean change (mean Δ) from baseline to each of the study time points is shown, with lower and upper confidence 
intervals (CI) and the corresponding p value. P values in red are significant (where p ≤ 0.05) and p values in blue are 
approaching significance (0.05 < p ≤ 0.1). 
 
 Group 1 Group 2 Group 3 
%CD4+CD45RA+ 
CD31+ 
Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value 
Week 1 1.00 -2.27 4.27 0.55 1.03 -1.80 3.85 0.4795 0.28 -2.25 2.81 0.8288 
Week 2 -6.30 -9.57 -3.03 0.0003 1.28 -1.55 4.10 0.3795 -5.92 -8.45 -3.39 <.0001 
Week 4 -4.33 -7.60 -1.07 0.0111 -0.30 -3.13 2.53 0.8358 -3.70 -6.23 -1.17 0.0053 
Week 6 -7.17 -10.43 -3.90 <.0001 -1.60 -4.43 1.23 0.2708 -2.14 -4.67 0.39 0.1011 
Week 8 -4.90 -8.17 -1.63 0.0043 1.43 -1.40 4.25 0.3263 -3.84 -6.37 -1.31 0.0039 
Week 12 -3.73 -7.00 -0.47 0.0278 0.48 -2.35 3.30 0.7429 -3.02 -5.55 -0.49 0.0217 
Week 16 -4.73 -8.00 -1.47 0.0057 -0.60 -3.43 2.23 0.6786 -5.06 -7.59 -2.53 0.0002 
Week 24 -6.40 -9.67 -3.13 0.0002 -1.78 -4.60 1.05 0.2222 -1.40 -3.93 1.13 0.2812 
Week 48 -4.70 -7.97 -1.43 0.006 -1.40 -4.23 1.43 0.3348 -1.02 -3.55 1.51 0.4316 
%CD4+CD31+             
Week 1 -0.27 -7.47 6.94 0.9424 3.10 -3.14 9.34 0.3332 -0.86 -6.44 4.72 0.7635 
Week 2 -10.27 -17.47 -3.06 0.0065 3.98 -2.27 10.22 0.2155 -10.36 -15.94 -4.78 0.0005 
Week 4 -1.33 -8.54 5.87 0.7178 -3.60 -9.84 2.64 0.2616 -6.12 -11.70 -0.54 0.0346 
Week 6 -10.73 -17.94 -3.53 0.0045 -3.28 -9.52 2.97 0.3068 -8.10 -13.68 -2.52 0.0056 
Week 8 -0.97 -8.17 6.24 0.7933 6.53 0.28 12.77 0.0437 -5.22 -10.80 0.36 0.0705 
Week 12 -2.27 -9.47 4.94 0.5393 10.10 3.86 16.34 0.0021 -4.40 -9.98 1.18 0.1263 
Week 16 -1.97 -9.17 5.24 0.5942 0.40 -5.84 6.64 0.9003 -11.10 -16.68 -5.52 0.0002 
Week 24 -4.03 -11.24 3.17 0.2759 0.83 -5.42 7.07 0.7962 -3.54 -9.12 2.04 0.2175 
Week 48 -7.60 -14.81 -0.39 0.0419 -1.30 -7.54 4.94 0.6842 -6.52 -12.10 -0.94 0.0247 
%CD4+PTK-7+             
Week 1 -0.20 -0.47 0.07 0.1536 0.00 -0.24 0.24 1 -0.06 -0.27 0.15 0.5784 
Week 2 -0.33 -0.61 -0.06 0.0186 0.05 -0.19 0.29 0.6786 -0.08 -0.29 0.13 0.4591 
Week 4 -0.47 -0.74 -0.19 0.0012 0.08 -0.16 0.31 0.5345 -0.10 -0.31 0.11 0.3552 
Week 6 -0.27 -0.54 0.01 0.0583 -0.03 -0.26 0.21 0.8358 -0.04 -0.25 0.17 0.7109 
Week 8 -0.07 -0.34 0.21 0.6324 0.03 -0.21 0.26 0.8358 0.10 -0.11 0.31 0.3552 
Week 12 -0.33 -0.61 -0.06 0.0186 0.03 -0.21 0.26 0.8358 0.00 -0.21 0.21 1 
Week 16 -0.33 -0.61 -0.06 0.0186 -0.03 -0.26 0.21 0.8358 0.10 -0.11 0.31 0.3552 
Week 24 -0.33 -0.61 -0.06 0.0186 0.10 -0.14 0.34 0.408 0.20 -0.01 0.41 0.0665 
Week 48 -0.37 -0.64 -0.09 0.0099 -0.08 -0.31 0.16 0.5345 -0.04 -0.25 0.17 0.7109 
CD4+CD31 MFI             
Week 1 204 -250 657 0.3812 -271 -663 122 0.1803 147 -205 498 0.4157 
Week 2 572 119 1025 0.0155 -306 -698 87 0.1309 415 64 767 0.023 
Week 4 200 -253 653 0.3898 -597 -989 -204 0.0038 -283 -634 69 0.1187 
Week 6 62 -391 516 0.7883 -366 -758 27 0.0729 165 -187 516 0.361 
Week 8 140 -313 594 0.5458 -364 -757 29 0.0729 -11 -363 340 0.9494 
Week 12 119 -334 573 0.6074 -679 -1071 -286 0.0011 28 -323 379 0.8771 
Week 16 70 -383 523 0.763 -103 -496 289 0.6077 74 -277 425 0.6799 
Week 24 318 -135 771 0.173 -177 -570 215 0.3789 215 -136 567 0.2328 
Week 48 -183 -636 271 0.4321 -532 -924 -139 0.0096 -105 -457 246 0.558 
CD4+PTK-7 MFI             
Week 1 -5 -279 269 0.9715 93 -144 330 0.4442 114 -98 326 0.296 
Week 2 -38 -312 235 0.7844 48 -189 285 0.6925 -8 -220 204 0.9398 
Week 4 33 -241 307 0.8138 70 -167 307 0.563 5 -207 217 0.9662 
Week 6 20 -253 294 0.8846 -50 -287 188 0.6835 17 -195 229 0.8755 
Week 8 -118 -392 155 0.3994 142 -96 379 0.2455 167 -45 379 0.1266 
Week 12 -184 -458 89 0.1906 6 -231 243 0.9606 -91 -303 121 0.4017 
Week 16 -150 -424 124 0.2861 116 -122 353 0.3425 -65 -277 147 0.5497 
Week 24 -238 -511 36 0.0927 -114 -351 123 0.3477 56 -156 268 0.6062 
Week 48 -357 -631 -83 0.0125 -151 -388 87 0.217 -327 -539 -115 0.0034 
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Appendix Table 33 Changes from baseline in markers associated with recent thymic emigrants on CD8 T cells. 
Mean change (mean Δ) from baseline to each of the study time points is shown, with lower and upper confidence 
intervals (CI) and the corresponding p value. P values in red are significant (where p ≤ 0.05) and p values in blue are 
approaching significance (0.05 < p ≤ 0.1). 
 
 Group 1 Group 2 Group 3 
%CD8+CD31+ Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value 
Week 1 -0.57 -6.60 5.46 0.8543 3.65 -1.57 8.87 0.1745 -0.90 -5.57 3.77 0.7067 
Week 2 1.77 -4.26 7.80 0.5674 3.80 -1.42 9.02 0.1576 10.76 6.09 15.43 <.0001 
Week 4 -4.23 -10.26 1.80 0.1726 1.55 -3.67 6.77 0.5623 -0.22 -4.89 4.45 0.9267 
Week 6 -7.70 -13.73 -1.67 0.0143 1.05 -4.17 6.27 0.6945 -2.30 -6.97 2.37 0.3373 
Week 8 -6.07 -12.10 -0.04 0.052 4.90 -0.32 10.12 0.0696 -1.56 -6.23 3.11 0.5146 
Week 12 -6.17 -12.20 -0.14 0.0484 3.68 -1.55 8.90 0.1716 -4.28 -8.95 0.39 0.0762 
Week 16 -1.87 -7.90 4.16 0.5457 0.90 -4.32 6.12 0.7364 -5.08 -9.75 -0.41 0.0361 
Week 24 -4.60 -10.63 1.43 0.1387 2.25 -2.97 7.47 0.4009 -3.82 -8.49 0.85 0.1128 
Week 48 -4.80 -10.83 1.23 0.1226 -2.58 -7.80 2.65 0.3367 -2.76 -7.43 1.91 0.2502 
%CD8+PTK-7+             
Week 1 0.43 -0.60 1.47 0.4147 0.28 -0.62 1.17 0.5497 0.74 -0.06 1.54 0.0744 
Week 2 1.13 0.10 2.17 0.035 0.38 -0.52 1.27 0.4151 0.58 -0.22 1.38 0.1604 
Week 4 -0.23 -1.27 0.80 0.6601 0.40 -0.50 1.30 0.3848 0.16 -0.64 0.96 0.697 
Week 6 1.80 0.76 2.84 0.001 1.05 0.15 1.95 0.0244 0.16 -0.64 0.96 0.697 
Week 8 0.57 -0.47 1.60 0.2869 1.05 0.15 1.95 0.0244 0.04 -0.76 0.84 0.9224 
Week 12 -0.23 -1.27 0.80 0.6601 0.30 -0.60 1.20 0.5141 -0.06 -0.86 0.74 0.8839 
Week 16 0.10 -0.94 1.14 0.8504 0.23 -0.67 1.12 0.6244 0.32 -0.48 1.12 0.4368 
Week 24 -0.53 -1.57 0.50 0.316 0.23 -0.67 1.12 0.6244 0.02 -0.78 0.82 0.9612 
Week 48 -0.47 -1.50 0.57 0.3799 0.05 -0.85 0.95 0.9133 0.04 -0.76 0.84 0.9224 
CD8+CD31 MFI 543 -379 1464 0.2517 303 -495 1101 0.4592 489 -224 1203 0.1827 
Week 1 1476 554 2397 0.0024 -170 -968 628 0.6769 2054 1340 2768 <.0001 
Week 2 266 -656 1187 0.5735 -485 -1282 313 0.2375 -303 -1016 411 0.4081 
Week 4 25 -896 946 0.9577 -330 -1128 468 0.42 263 -451 977 0.4722 
Week 6 62 -859 983 0.8954 -348 -1146 450 0.3952 -259 -972 455 0.4796 
Week 8 -114 -1035 807 0.809 -615 -1413 183 0.1348 -211 -924 503 0.5646 
Week 12 -46 -967 875 0.9223 54 -744 852 0.8948 630 -84 1343 0.0876 
Week 16 285 -636 1206 0.546 -81 -878 717 0.8437 -60 -773 654 0.8704 
Week 24 -307 -1228 614 0.5155 -319 -1116 479 0.4363 -312 -1025 402 0.3943 
Week 48             
CD8+PTK-7 MFI             
Week 1 -423 -2278 1432 0.9715 -869 -2475 738 0.4442 -73 -1510 1364 0.296 
Week 2 16 -1839 1871 0.7844 -903 -2509 704 0.6925 3450 2013 4887 0.9398 
Week 4 -248 -2103 1607 0.8138 -1104 -2711 503 0.563 88 -1349 1525 0.9662 
Week 6 272 -1583 2127 0.8846 -1239 -2845 368 0.6835 78 -1359 1515 0.8755 
Week 8 -336 -2191 1519 0.3994 301 -1306 1908 0.2455 1698 261 3135 0.1266 
Week 12 -593 -2448 1262 0.1906 -1246 -2853 360 0.9606 -372 -1809 1065 0.4017 
Week 16 -525 -2380 1330 0.2861 -1067 -2674 540 0.3425 -147 -1584 1290 0.5497 
Week 24 -450 -2305 1405 0.0927 -1331 -2937 276 0.3477 -88 -1525 1349 0.6062 
Week 48 -593 -2448 1262 0.0125 -1250 -2856 357 0.217 -552 -1989 885 0.0034 
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Appendix Table 34 Changes from baseline in expression of the negative inhibitory marker CTLA-4 and the exhaustion 
marker TIM-3, on CD4 T cells. 
Mean change (mean Δ) from baseline to each of the study time points is shown, with lower and upper confidence 
intervals (CI) and the corresponding p value. P values in red are significant (where p ≤ 0.05) and p values in blue are 
approaching significance (0.05 < p ≤ 0.1). 
 
 Group 1 Group 2 Group 3 
%CD4+ 
TIM-3+CTLA-4+ 
Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value 
Week 1 0.03 -0.03 0.09 0.2895 0.00 -0.05 0.05 1 0.00 -0.05 0.05 1 
Week 2 0.07 0.01 0.13 0.036 -0.03 -0.08 0.03 0.3585 0.00 -0.05 0.05 1 
Week 4 0.07 0.01 0.13 0.036 -0.03 -0.08 0.03 0.3585 0.02 -0.03 0.07 0.4113 
Week 6 0.07 0.01 0.13 0.036 -0.05 -0.10 0.00 0.0684 -0.02 -0.07 0.03 0.4113 
Week 8 0.03 -0.03 0.09 0.2895 -0.10 -0.15 -0.05 0.0004 -0.04 -0.09 0.01 0.1025 
Week 12 0.03 -0.03 0.09 0.2895 -0.05 -0.10 0.00 0.0684 -0.04 -0.09 0.01 0.1025 
Week 16 0.03 -0.03 0.09 0.2895 -0.08 -0.13 -0.02 0.007 0.00 -0.05 0.05 0.9985 
Week 24 0.03 -0.03 0.09 0.2895 -0.08 -0.13 -0.02 0.007 -0.04 -0.09 0.01 0.1025 
Week 48 0.00 -0.06 0.06 1 -0.05 -0.10 0.00 0.0684 -0.06 -0.11 -0.01 0.0153 
%CD4+TIM-3+             
Week 1 0.07 -0.67 0.81 0.8605 0.33 -0.32 0.97 0.3239 0.12 -0.45 0.69 0.6831 
Week 2 1.07 0.33 1.81 0.006 0.20 -0.44 0.84 0.5431 1.40 0.83 1.97 <.0001 
Week 4 -0.13 -0.87 0.61 0.7253 0.08 -0.57 0.72 0.8194 -0.22 -0.79 0.35 0.4548 
Week 6 0.07 -0.67 0.81 0.8605 -0.13 -0.77 0.52 0.7037 -0.24 -0.81 0.33 0.415 
Week 8 -0.07 -0.81 0.67 0.8605 -0.20 -0.84 0.44 0.5431 0.02 -0.55 0.59 0.9457 
Week 12 0.17 -0.57 0.91 0.6605 1.05 0.41 1.69 0.0019 -0.02 -0.59 0.55 0.9457 
Week 16 0.10 -0.64 0.84 0.7921 0.28 -0.37 0.92 0.4035 0.18 -0.43 0.79 0.5622 
Week 24 -0.23 -0.97 0.51 0.5389 0.28 -0.37 0.92 0.4035 -0.16 -0.73 0.41 0.5864 
Week 48 0.30 -0.44 1.04 0.4299 -0.05 -0.69 0.59 0.879 -0.22 -0.79 0.35 0.4548 
%CD4+CTLA-4+             
Week 1 0.07 -0.19 0.32 0.6071 -0.03 -0.24 0.19 0.8237 0.16 -0.04 0.36 0.1136 
Week 2 0.13 -0.12 0.39 0.3049 -0.05 -0.27 0.17 0.656 0.04 -0.16 0.24 0.6903 
Week 4 0.10 -0.15 0.35 0.441 0.05 -0.17 0.27 0.656 0.04 -0.16 0.24 0.6903 
Week 6 0.20 -0.05 0.45 0.1254 0.25 0.03 0.47 0.0282 0.04 -0.16 0.24 0.6903 
Week 8 0.13 -0.12 0.39 0.3049 -0.03 -0.24 0.19 0.8237 -0.02 -0.22 0.18 0.842 
Week 12 0.23 -0.02 0.49 0.0745 0.28 0.06 0.49 0.0161 0.06 -0.14 0.26 0.5503 
Week 16 0.23 -0.02 0.49 0.0745 -0.10 -0.32 0.12 0.3739 0.18 -0.02 0.39 0.0871 
Week 24 0.13 -0.12 0.39 0.3049 -0.10 -0.32 0.12 0.3739 0.10 -0.10 0.30 0.3204 
Week 48 0.10 -0.15 0.35 0.441 0.08 -0.14 0.29 0.5044 -0.06 -0.26 0.14 0.5503 
CD4+TIM-3 MFI             
Week 1 146 -449 741 0.6326 -264 -779 251 0.3177 186 -275 646 0.4322 
Week 2 317 -278 912 0.2989 -206 -721 309 0.4349 360 -101 820 0.1301 
Week 4 263 -332 858 0.3888 -252 -767 263 0.3406 188 -273 648 0.4272 
Week 6 127 -468 722 0.6767 -531 -1046 -15 0.0469 -64 -524 397 0.7874 
Week 8 -111 -706 484 0.7163 -596 -1111 -81 0.0261 -183 -644 277 0.4376 
Week 12 -150 -745 445 0.6217 -897 -1412 -382 0.001 -272 -733 189 0.2504 
Week 16 -152 -747 443 0.6179 -785 -1300 -269 0.0038 -221 -713 270 0.3804 
Week 24 -37 -632 558 0.9033 -753 -1268 -238 0.0053 -41 -502 420 0.862 
Week 48 -458 -1053 137 0.1352 -812 -1327 -297 0.0028 -396 -857 64 0.0957 
CD4+CTLA-4 MFI             
Week 1 -13 -252 225 0.913 103 -103 310 0.3299 61 -124 245 0.5205 
Week 2 -117 -355 122 0.3403 -79 -285 128 0.4569 -72 -257 113 0.447 
Week 4 -76 -314 163 0.5356 21 -186 227 0.8462 37 -148 222 0.6955 
Week 6 -176 -414 63 0.1525 -17 -223 190 0.8759 -45 -230 139 0.6327 
Week 8 -184 -422 54 0.1342 -44 -250 163 0.6807 -67 -252 117 0.4777 
Week 12 -307 -545 -68 0.0137 -229 -435 -22 0.033 -189 -374 -4 0.0482 
Week 16 -265 -504 -27 0.0321 94 -113 300 0.3761 -127 -324 70 0.2097 
Week 24 -247 -485 -9 0.0456 -187 -393 20 0.0804 -121 -306 63 0.202 
Week 48 -431 -669 -193 0.0007 -238 -444 -32 0.0266 -295 -480 -110 0.0024 
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Appendix Table 35 Changes from baseline in expression of the negative inhibitory marker CTLA-4 and the exhaustion 
marker TIM-3, on CD8 T cells. 
Mean change (mean Δ) from baseline to each of the study time points is shown, with lower and upper confidence 
intervals (CI) and the corresponding p value. P values in red are significant (where p ≤ 0.05) and p values in blue are 
approaching significance (0.05 < p ≤ 0.1). 
 
 Group 1 Group 2 Group 3 
%CD8+ 
TIM-3+CTLA-4+ 
Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value 
Week 1 0.00 -0.08 0.08 1 0.03 -0.04 0.09 0.4778 0.02 -0.04 0.08 0.5254 
Week 2 -0.03 -0.11 0.05 0.4127 0.00 -0.07 0.07 1 -0.02 -0.08 0.04 0.5254 
Week 4 -0.07 -0.15 0.01 0.1035 0.05 -0.02 0.12 0.1577 -0.04 -0.10 0.02 0.2057 
Week 6 0.00 -0.08 0.08 1 0.00 -0.07 0.07 1 -0.02 -0.08 0.04 0.5254 
Week 8 -0.07 -0.15 0.01 0.1035 -0.03 -0.09 0.04 0.4778 -0.04 -0.10 0.02 0.2057 
Week 12 0.00 -0.08 0.08 1 0.00 -0.07 0.07 1 0.00 -0.06 0.06 1 
Week 16 -0.03 -0.11 0.05 0.4127 0.00 -0.07 0.07 1 0.00 -0.07 0.06 0.9485 
Week 24 -0.07 -0.15 0.01 0.1035 0.03 -0.04 0.09 0.4778 -0.02 -0.08 0.04 0.5254 
Week 48 -0.13 -0.21 -0.05 0.0015 -0.03 -0.09 0.04 0.4778 -0.08 -0.14 -0.02 0.0126 
%CD8+TIM-3+             
Week 1 1.27 0.29 2.24 0.0127 0.35 -0.49 1.19 0.4186 -0.32 -1.07 0.43 0.4084 
Week 2 2.23 1.26 3.21 <.0001 0.33 -0.52 1.17 0.4524 0.56 -0.19 1.31 0.1497 
Week 4 0.10 -0.87 1.07 0.8411 0.28 -0.57 1.12 0.5247 -0.62 -1.37 0.13 0.1113 
Week 6 0.03 -0.94 1.01 0.9467 0.10 -0.74 0.94 0.8169 -0.60 -1.35 0.15 0.1231 
Week 8 -0.37 -1.34 0.61 0.4629 1.10 0.26 1.94 0.0125 0.20 -0.55 0.95 0.6049 
Week 12 0.03 -0.94 1.01 0.9467 1.23 0.38 2.07 0.0056 -0.10 -0.85 0.65 0.7957 
Week 16 0.27 -0.71 1.24 0.5931 0.65 -0.19 1.49 0.135 0.11 -0.70 0.91 0.7982 
Week 24 0.40 -0.57 1.37 0.4233 0.45 -0.39 1.29 0.299 -0.44 -1.19 0.31 0.2565 
Week 48 0.50 -0.47 1.47 0.3175 0.50 -0.34 1.34 0.2489 -0.74 -1.49 0.01 0.0582 
%CD8+CTLA-4+             
Week 1 0.63 -0.28 1.55 0.1791 0.13 -0.67 0.92 0.7582 0.06 -0.65 0.77 0.8687 
Week 2 0.53 -0.38 1.45 0.2571 0.08 -0.72 0.87 0.8534 -0.88 -1.59 -0.17 0.0173 
Week 4 -0.07 -0.98 0.85 0.8869 -0.23 -1.02 0.57 0.5797 -0.80 -1.51 -0.09 0.0299 
Week 6 0.07 -0.85 0.98 0.8869 0.15 -0.64 0.94 0.7118 -0.96 -1.67 -0.25 0.0096 
Week 8 0.03 -0.88 0.95 0.9433 0.18 -0.62 0.97 0.6665 -0.76 -1.47 -0.05 0.0389 
Week 12 0.27 -0.65 1.18 0.5698 -0.10 -0.89 0.69 0.8054 -0.86 -1.57 -0.15 0.0199 
Week 16 0.07 -0.85 0.98 0.8869 -0.33 -1.12 0.47 0.4242 -0.87 -1.63 -0.12 0.0261 
Week 24 0.03 -0.88 0.95 0.9433 -0.38 -1.17 0.42 0.3568 -0.88 -1.59 -0.17 0.0173 
Week 48 -0.17 -1.08 0.75 0.7222 -0.28 -1.07 0.52 0.4987 -1.02 -1.73 -0.31 0.0061 
CD8+TIM-3 MFI             
Week 1 -167 -684 350 0.5275 -76 -524 371 0.7393 214 -186 614 0.298 
Week 2 2 -515 519 0.995 -164 -612 283 0.4741 399 -1 800 0.0542 
Week 4 188 -329 705 0.4788 -319 -766 129 0.167 164 -236 565 0.4239 
Week 6 39 -478 556 0.8838 -499 -946 -51 0.0319 -23 -423 378 0.9114 
Week 8 -15 -532 502 0.9538 -674 -1122 -226 0.0042 -149 -549 252 0.4691 
Week 12 -79 -596 438 0.7643 -788 -1236 -341 0.0009 -202 -603 198 0.3252 
Week 16 -220 -737 297 0.4073 -683 -1130 -235 0.0037 -175 -602 252 0.4246 
Week 24 -228 -745 289 0.3898 -600 -1048 -153 0.0103 -48 -448 353 0.8156 
Week 48 -485 -1002 32 0.0698 -769 -1216 -321 0.0012 -339 -740 61 0.1007 
CD8+CTLA-4 MFI             
Week 1 -18 -2050 2014 0.9859 -298 -2058 1462 0.7411 -38 -1612 1536 0.9628 
Week 2 252 -1780 2284 0.8083 -390 -2149 1370 0.6656 3546 1972 5120 <.0001 
Week 4 249 -1783 2281 0.8111 -997 -2906 913 0.3095 -8 -1582 1566 0.9919 
Week 6 84 -1948 2116 0.9354 -494 -2254 1266 0.5839 -196 -1770 1378 0.8076 
Week 8 524 -1508 2556 0.6149 622 -1138 2381 0.4908 1396 -178 2970 0.0861 
Week 12 -91 -2123 1941 0.9303 -935 -2695 825 0.301 -373 -1947 1201 0.6436 
Week 16 -66 -2098 1966 0.9497 -976 -2735 784 0.2806 -422 -2098 1253 0.6226 
Week 24 -95 -2127 1937 0.9272 -1036 -2795 724 0.2523 -338 -1912 1236 0.6752 
Week 48 -183 -2215 1849 0.8603 -1107 -2867 653 0.2212 -588 -2162 986 0.4661 
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Appendix Table 36 Changes from baseline in CD69 expression on CD4 and CD8 T cells. 
Mean change (mean Δ) from baseline to each of the study time points is shown, with lower and upper confidence 
intervals (CI) and the corresponding p value. P values in red are significant (where p ≤ 0.05) and p values in blue are 
approaching significance (0.05 < p ≤ 0.1). 
 
 Group 1 Group 2 Group 3 
%CD4+CD69+ Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value Mean ∆ 
Lower 
CI 
Upper 
CI 
P value 
Week 1 0.20 -0.62 1.02 0.6339 0.00 -0.71 0.71 1 0.18 -0.46 0.82 0.5802 
Week 2 0.03 -0.79 0.85 0.9367 0.18 -0.54 0.89 0.6304 -0.04 -0.68 0.60 0.9021 
Week 4 0.07 -0.75 0.89 0.8738 -0.13 -0.84 0.59 0.731 -0.52 -1.16 0.12 0.1125 
Week 6 0.27 -0.55 1.09 0.5257 0.08 -0.64 0.79 0.8365 -0.78 -1.42 -0.14 0.0184 
Week 8 -0.07 -0.89 0.75 0.8738 0.50 -0.21 1.21 0.1714 -0.42 -1.06 0.22 0.1987 
Week 12 -0.13 -0.95 0.69 0.7508 -0.13 -0.84 0.59 0.731 -0.64 -1.28 0.00 0.0517 
Week 16 -0.30 -1.12 0.52 0.4754 0.28 -0.44 0.99 0.4501 -0.32 -1.00 0.36 0.3596 
Week 24 -0.27 -1.09 0.55 0.5257 0.23 -0.49 0.94 0.5364 -0.36 -1.00 0.28 0.27 
Week 48 -0.17 -0.99 0.65 0.6914 0.23 -0.49 0.94 0.5364 -0.28 -0.92 0.36 0.3902 
%CD8+CD69+             
Week 1 2.33 0.39 4.27 0.0208 0.80 -0.88 2.48 0.3533 0.56 -0.94 2.06 0.4671 
Week 2 -0.07 -2.01 1.87 0.9464 0.35 -1.33 2.03 0.684 -0.74 -2.24 0.76 0.3372 
Week 4 0.37 -1.57 2.31 0.7119 0.88 -0.80 2.55 0.3102 -0.12 -1.62 1.38 0.876 
Week 6 0.50 -1.44 2.44 0.6147 0.48 -1.20 2.15 0.5809 -0.88 -2.38 0.62 0.2543 
Week 8 -0.83 -2.77 1.11 0.4022 1.08 -0.60 2.75 0.2133 -0.90 -2.40 0.60 0.2437 
Week 12 -0.07 -2.01 1.87 0.9464 -0.93 -2.60 0.75 0.2836 -1.10 -2.60 0.40 0.1551 
Week 16 -0.50 -2.44 1.44 0.6147 0.23 -1.45 1.90 0.7935 -1.46 -3.06 0.14 0.0781 
Week 24 -0.63 -2.57 1.31 0.5239 -1.55 -3.23 0.13 0.0742 -1.00 -2.50 0.50 0.1957 
Week 48 -0.87 -2.81 1.07 0.3837 -1.43 -3.10 0.25 0.1002 -1.16 -2.66 0.34 0.1341 
CD4+CD69 MFI             
Week 1 -93 -2515 2329 0.9402 -317 -2415 1780 0.7676 1483 -393 3359 0.1252 
Week 2 764 -1658 3185 0.5383 -40 -2137 2057 0.9703 1525 -351 3401 0.115 
Week 4 365 -2056 2787 0.7682 -256 -2353 1842 0.8117 499 -1377 2374 0.6038 
Week 6 66 -2356 2488 0.9575 -614 -2711 1484 0.5679 -49 -1924 1827 0.9596 
Week 8 494 -1927 2916 0.6902 -580 -2678 1517 0.5891 687 -1189 2563 0.4748 
Week 12 1961 -461 4383 0.1164 263 -1835 2360 0.8067 333 -1542 2209 0.7285 
Week 16 3062 641 5484 0.0153 191 -1906 2289 0.8586 4833 2833 6832 <.0001 
Week 24 2603 182 5025 0.0383 -139 -2236 1959 0.8973 2785 909 4661 0.0047 
Week 48 3069 648 5491 0.0151 1952 -146 4049 0.0719 1329 -547 3204 0.1689 
CD8+CD69 MFI             
Week 1 -300 -3666 3065 0.8616 -1533 -4448 1382 0.3057 993 -1614 3600 0.4576 
Week 2 1028 -2337 4394 0.551 -313 -3228 2602 0.8338 3644 1037 6251 0.0076 
Week 4 165 -3201 3530 0.9238 -1596 -4510 1319 0.2866 -738 -3345 1869 0.5808 
Week 6 -171 -3537 3195 0.9209 -2230 -5145 685 0.1376 -684 -3291 1923 0.6083 
Week 8 1402 -1964 4768 0.4167 -1388 -4302 1527 0.3536 530 -2077 3137 0.6911 
Week 12 1403 -1963 4768 0.4164 901 -2014 3816 0.5464 50 -2557 2657 0.9703 
Week 16 3779 413 7144 0.0307 398 -2517 3313 0.7895 6678 3897 9458 <.0001 
Week 24 3550 184 6915 0.042 2764 -151 5679 0.0667 3670 1063 6277 0.0072 
Week 48 3208 -158 6574 0.0654 6478 3563 9392 <.0001 2281 -326 4888 0.0902 
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Appendix 3 Preparation and validation of procedures and materials for the IMIRC 
1003 clinical trial – testing of peptides for ELISpot assays 
The preparation of peptide antigens from NIBSC and FIT Biotech was carried out as described in 
the Materials & Methods section 2.16.3. The pooled peptides were run in ELISpot assays (detailed 
in section 2.17) on PBMC from both seronegative donors and from HIV-1-infected individuals. 
 
Appendix Figure 1 IFN-γ production in response to HIV-1 peptides in HIV-1+ persons and healthy donors. 
IFN-γ response to overlapping peptide pools of Gag p17, Gag p24, Nef, Tat, Rev (from NIBSC) and sub-pools of Gag 
p17/p24, Nef, Tat, Rev and CTL, in addition to FEC (healthy donors only), PHA and TCM (negative control). HIV-1
+
 
individuals are represented with red circles (●) and healthy controls with blue circles (●). Data represent mean values of 
duplicate wells with <10% variation among duplicates. The threshold of 50 SFC/10
6
 PBMC is marked with a dotted 
line. Box plots show the median and IQR while whiskers represent the 10
th
 and 90
th
 percentiles. 
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Appendix Figure 2 IL-2 production in response to HIV-1 peptides in HIV-1
+
 persons and healthy donors. 
IL-2 response to overlapping peptide pools of Gag p17, Gag p24, Nef, Tat, Rev (from NIBSC) and sub-pools of Gag 
p17/p24, Nef, Tat, Rev and CTL, in addition to FEC (healthy donors only), PHA and TCM (negative control). HIV-1
+
 
individuals are represented with red circles (●) and healthy controls with blue circles (●). Data represent mean values of 
duplicate wells with <10% variation among duplicates. The threshold of 50 SFC/10
6
 PBMC is marked with a dotted 
line. Box plots show the median and IQR while whiskers represent the 10
th
 and 90
th
 percentiles. 
 
 
Appendix Figure 3 IL-4 production in response to HIV-1 peptides in HIV-1
+
 persons and healthy donors. 
IL-4 response to overlapping peptide pools of Gag p17, Gag p24, Nef, Tat, Rev (from NIBSC) and sub-pools of Gag 
p17/p24, Nef, Tat, Rev and CTL, in addition to FEC (healthy donors only), PHA and TCM (negative control). HIV-1
+
 
individuals are represented with red circles (●) and healthy controls with blue circles (●). Data represent mean values of 
duplicate wells with <10% variation among duplicates. The threshold of 50 SFC/10
6
 PBMC is marked with a dotted 
line. Box plots show the median and IQR while whiskers represent the 10
th
 and 90
th
 percentiles. 
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Appendix Figure 4 Perforin production in response to HIV-1 peptides in HIV-1
+
 persons and healthy donors. 
Perforin response to overlapping peptide pools of Gag p17, Gag p24, Nef, Tat, Rev (from NIBSC) and sub-pools of Gag 
p17/p24, Nef, Tat, Rev and CTL, in addition to FEC (healthy donors only), PHA and TCM (negative control). HIV-1
+
 
individuals are represented with red circles (●) and healthy controls with blue circles (●). Data represent mean values of 
duplicate wells with <10% variation among duplicates. The threshold of 50 SFC/10
6
 PBMC is marked with a dotted 
line. Box plots show the median and IQR while whiskers represent the 10
th
 and 90
th
 percentiles. 
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Appendix 4 Adverse events for IMIRC 1003 clinical trial 
The adverse events (AE) reported for patients enrolled on the IMIRC 1003 clinical trial are 
summarised here. Appendix Table 37 gives an overview of the adverse events per treatment group, 
defined by grade and the likelihood of their relation to the study drugs. Appendix Table 38 gives a 
more detailed outline of the types of adverse events reported for patients in each of the three 
treatment groups. All patients, apart from one (P054, in group 3), reported at least one AE during 
the course of the study, however there was only one serious adverse event (SAE), and this was for 
patient C241 (who had been randomised to group 3). This individual received one dose of rhGH 
and was admitted to the hospital with headaches. The subject received no further rhGH but 
remained in the study on an observational basis. 
 
Appendix Table 37 Adverse events for the IMIRC 1003 clinical trial. 
 
 Group 1 (n = 3) Group 2 (n = 4) Group 3 (n = 5) 
Adverse Events 
Vaccine + IL-2/GM-CSF + 
rhGH 
Vaccine IL-2/GM-CSF + rhGH 
Total AEs 31 24 64 
Patients reporting no AEs 0 0 0 
SAE 0 0 1 
    
Grade 3 0 0 5 
Definitely 0 0 1 
Probably 0 0 0 
Possibly 0 0 2 
Unlikely/not related 0 0 2 
    
Grade 2 and 1 30 22 53 
Definitely 9 0 13 
Probably 15 0 9 
Possibly 2 3 18 
Unlikely/not related 3 19 13 
    
Ungraded 1 2 6 
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Appendix Table 38 Adverse events in detail for the IMIRC 1003 trial. 
 
 Group 1 (n = 3) Group 2 (n = 4) Group 3 (n = 5) 
AE reported 
Vaccine + IL-2/GM-CSF + 
rhGH 
Vaccine IL-2/GM-CSF + rhGH 
Total Grade 3 AE 
definitely, probably or 
possibly attributed to study 
0 0 3 
Fatigue 0 0 1 
Headache 0 0 1 
Transaminitis 0 0 1 
    
Total Grade 2 and 1 
definitely, probably or 
possibly attributed to study 
27 3 39 
Erythema at injection site; 
lumps at injection site; 
blisters 
5 0 5 
Generalised erythamous 
rash; rash 
1 0 3 
Itching 2 0 3 
Nausea; vomitting 1 0 4 
Diarrhoea; abdominal 
cramps; loose stools; blood 
in stool 
2 0 5 
Muscle pains; joint aches 2 0 1 
General malaise; fatigue; 
lethargy; loss of appetite; 
fevers 
3 1 4 
Headache 1 0 0 
Dizziness 0 0 1 
Sore throat; nasal 
congestion; congestion; 
earache 
4 0 4 
Dry mouth; dry skin; dry 
lips 
3 0 3 
Rigors 2 0 2 
Insomnia 1 0 1 
Myalgia right and left arm 0 1 0 
Blurred vision 0 1 0 
Hiccups 0 0 1 
Swelling of ankles 0 0 1 
Photophobia 0 0 1 
 
